<SEC-DOCUMENT>0001558370-22-008847.txt : 20220516
<SEC-HEADER>0001558370-22-008847.hdr.sgml : 20220516
<ACCEPTANCE-DATETIME>20220516070928
ACCESSION NUMBER:		0001558370-22-008847
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220516
DATE AS OF CHANGE:		20220516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		22925401

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20220331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/16/2022 11:04:53 AM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 52acaa1e-9e31-42b5-ac54-a812ed9780c3 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" xs:nil="true" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_DC-WlNaYwUe4_Y9IUplLqQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" xs:nil="true" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_FSf8QzRRF0y1vbPqC_PdxQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_-kAnU6UZEUeayl0wjoSMrQ">0.05</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" sign="-" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_wTNccG_X4E22ngVLWu0dAw">0.14</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_S9q7KewJekShrqi_MJYrWg">45843563</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Sf_oIWLKaEqHrgCEmqHDqA">39933972</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityCentralIndexKey" id="Tc_tDJCeFDWwkKr7NBGTLPObA_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:CurrentFiscalYearEndDate" id="Tc_9Cl0h81Hg0uqJ349_PUA-Q_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentFiscalYearFocus" id="Tc_LKk6Ia9au0-LBHhy8K4B8g_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentFiscalPeriodFocus" id="Tc_13ZRTmHelkGUQFaH0_h_Qw_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:AmendmentFlag" id="Tc_u-P20IIakEiFlCeVv4jykA_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-25</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ipOEoOOBwEqJNxqVYD1F_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tWPPUkvGKEK_RWlQ1tQ97w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HBV2SgD3KU-05oHsFRVGVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B5yak48wUUafPhw4EIHy6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AqmwNqv8vkWAh_7muHfOwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gvkx-vnKf0Wu9yKA-z9U8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1yHZ2g1o_EW2u2UToeG0rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8IQ8YzoFvU2yjxQe73qorw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_86wb_A24g0O9P6vNpbYVDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_uft0WkxfTECQKQCU4pZbsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_S21-ZapyUEi0AfHd0ZmzGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Cs1RmaB2dk2-zzlPaX739Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yDiuB0IrXUGmEWzXQrmjvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v7ZxPQ9J60mXrkEKrBuF-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_v1cxXGJXc0O9MyYD4oL8bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_elDf2ZxouEeDMOgwfencjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_3xzulSOt60KM80hUQQxNuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8zRl47LpDUWLgsLuXBCfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BOmkiauMyU-HVMlM8M_LMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_j2CUvjm09keHknkDWIvMIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e09An94TDkebg9LA56J2sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kSc5Ga3WDkWOtVnhp3oTgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2-Rf8ep840CPArFgmLRo6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_25Q10gL8H0ejcvFB3qy2aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_qujldeuPW0iQr0wx-0hqGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_oryUP8iiq0yLMk4y318KNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_yI08emDAWU6kcLogTQGSFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Xd_TT8X3jEGIRtcxZqdgfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6kbZygJL5UGCoK2CMw5wLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2022_To_5_10_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_letqXd_CLESNLLjD9nX3rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_13_2022_To_4_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_QQ3bC0ekv0uTXXOWJ2xaAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-13</xbrli:startDate><xbrli:endDate>2022-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8P6P2mP_x0aZdoJRwGajdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_yGfuKJ8Y0U6-4sMMOBEt2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MVMnGHuu4U2rlaci2l_31w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3TlFp6KPJ0O_taG6Nu2ZJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_JFg0AHq1C0mWxuNhSH7UZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d3VeMhBTD0ySWJQLs_isIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_5E9e4OgdikqRj2Wn6sSnbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2022_wuiTkkd39E-ICmFp5ELdlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_4CakW3DMrUShwcChN38RSg"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_Y3YGIoGOL0-P28Oze-2O3w"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gFsSd6wNLE2dyPmazIX7-A_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MuvEekivCEKppyszPy-1jQ_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kxeunX7HskqujxoxGB5SUg_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qb3IYo9alEyPI7QEX2vE5w_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_RJQOws5VPUGxUtZyrh2dSA_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_E5bj0evlnUiJARjI729_tw_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_o1dU5w4--U2sE9K77mUxhA_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">fFFAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_93340c33_7625_4d4c_8f6f_e18378327f0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentType" id="Narr_nx5iqfTKa0ufVGr4Fm3iFQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentQuarterlyReport" id="Narr_B3Q1rsEP10KSxVnkNgbGcg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentPeriodEndDate" id="Narr_qXEJ0BOYE0y7gb7zXhg52Q"><b style="font-size:8pt;font-weight:bold;">March&#160;31, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:DocumentTransitionReport" id="Narr_9rToRBWTX0mqf4ddbBqRfQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityFileNumber" id="Narr_tF95KsqQckWRak6IXH8CdQ"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityRegistrantName" id="Narr_dHbJmZNI-EKngZMhHhKyJA"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_VohTO611Sk6lEy0zDt_GzA_1_1"></a><a id="Tc_NTdSWVBvGUuRoBw2_Nmwlw_2_0"></a><a id="Tc_D8vfi-z8O0iTjx_QZsXC9A_2_1"></a><a id="Tc_KGEMUOgJyEGgwbAdJD1GWA_4_0"></a><a id="Tc_Lr9g8W-2U02Y2aWGDaqbGA_5_0"></a><a id="Tc_p7zoTV5Qm0ugFI-oQc6IFQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityIncorporationStateCountryCode" id="Tc_tvEPeMu46kSog3EiQugjpw_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityTaxIdentificationNumber" id="Narr_qZB0ReNfHUesO3tYRhwZ2Q"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityAddressAddressLine1" id="Narr_V9W3wgdOW0Sp7PBS8IAmXQ"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityAddressAddressLine2" id="Narr_GfMgzkr_CEeuOuoLmO_2zA"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityAddressCityOrTown" id="Narr_39zIztcwwkWyzJtkMP8AfA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityAddressStateOrProvince" id="Narr_paVxdPBZ2EG7KpV55aSetw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityAddressPostalZipCode" id="Tc_0AsuQehQNUOwZnsG7Wq12Q_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:CityAreaCode" id="Narr_B_tl_xAtQ0ehL-mkVmevIg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:LocalPhoneNumber" id="Narr_vvUfXiXYVkeiLyjXdHYyIw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_M5R-3mj5GEeXhSbBh4mU_w_1_0"></a><a id="Tc_oT6TcWA9BUqWjECt_V85Kg_1_2"></a><a id="Tc_TPJ_9eeEl0qUIHoRzhW68A_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:Security12bTitle" id="Tc_CvlmUqZop0uLAzCYKLYw2A_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:TradingSymbol" id="Tc_OjzWYsK6NE2SdxYnX3jEwA_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:SecurityExchangeName" id="Tc_liVvyo4r4ESJJvT2psmvsQ_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityCurrentReportingStatus" id="Narr_2JCBt4ta8k-bavCNVY-_cg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityInteractiveDataCurrent" id="Narr_vLeNdtWdu0mNCGBR-AG-Vw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_Hhe6n55GekuR2ERe6rt4Gg_1_0"></a><a id="Tc_HjKEumqbgEynBaCyujHidQ_1_1"></a><a id="Tc_b4zYwo61k0u91p1G-dTSsg_1_2"></a><a id="Tc_yhW8MxsU-E-PrgUlh_sHmw_1_3"></a><a id="Tc_xwXBgF-zP0q8HnIpo_oOCg_2_1"></a><a id="Tc_8OqielXM1EuFirAli6WWlQ_2_2"></a><a id="Tc_6Y_BKtB5KUqHSmuksPqYHw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityFilerCategory" id="Tc_JCl2Hs-3oESCzrnfw4bSSg_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntitySmallBusiness" id="Tc_qpKGmVjyLUW1uOAW4alpZw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityEmergingGrowthCompany" id="Tc_Q9TwR4LKWEa9B15Cpr1Bbw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="dei:EntityShellCompany" id="Narr_z3ib1EGXJ06vYDorvonhgg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On May&#160;10, 2022, approximately <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_10_2022_wuiTkkd39E-ICmFp5ELdlA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_86DK45m0YEmWF_NFvJnhFQ">47,063,300</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9944cb5a_dfb1_4dbb_bd8e_22e46e05caf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of March&#160;31, 2022 and December&#160;31, 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Three Months ended March&#160;31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f275c393_200f_4cab_af06_1e5a9312cf62"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_ygMPnoEF-E69rgEL2wfm6g_1_2"></a><a id="Tc_hqCVtvZdNE6soyYs-tmBdw_1_5"></a><a id="Tc_26NB6ogvmEuTunwqpseRHA_3_0"></a><a id="Tc_3ZYVGKEviUGMGGVeiUl44Q_5_0"></a><a id="Tc_EiELEjCOLUq7eyATkwnoSw_6_0"></a><a id="Tc_XgmOPlpz0E2_AXv5UwoQnQ_6_2"></a><a id="Tc_3fb4dgieKEy0WKOHUX-mNw_6_5"></a><a id="Tc_HnTxvV85cUSj-TVsGl457g_7_0"></a><a id="Tc_bCgZtEgVS0SC9U7O3XbzbQ_8_0"></a><a id="Tc_6FS5B2YImkifBza7twcWwQ_9_0"></a><a id="Tc_tIfH-JsBXEy5gDeerK9dwQ_10_0"></a><a id="Tc_8fgmQSPMlU2EeaYx3DszvQ_11_0"></a><a id="Tc_-GTgNE0cNkOFXosQWwKpdg_11_2"></a><a id="Tc_fDcMM6szkEKmOI-hD7gXKw_11_5"></a><a id="Tc_2yw1LbuH_UebhKVui4QOXQ_13_0"></a><a id="Tc_zs0oeBhNR0mPTQfhhIMorw_14_0"></a><a id="Tc_7tE7ss_1pUWhRBdtlSF3tA_14_2"></a><a id="Tc_WP2mxJke9U6XR_xQxCsMpg_14_5"></a><a id="Tc_HFcSjrAFjUC8a-smN1OBMQ_15_0"></a><a id="Tc_M9WP1M1p4UyEg6kOh1C3fA_16_0"></a><a id="Tc_a3kgFiVUp06HlV2nUvrB3w_17_0"></a><a id="Tc_4BWA0j0nRkKVmH5Wd6EGYA_17_2"></a><a id="Tc_MVdtUVhGHUm0FkyYtj4q5w_17_5"></a><a id="Tc_vPE0pbNoiU-qsehCXdAJhg_19_0"></a><a id="Tc_mli7p2A5I0KbRxCdCkcglQ_21_0"></a><a id="Tc_aSUYXWR_80ew6efc9Bv5fA_22_0"></a><a id="Tc_OCvW-xeXnEq_R3yaKB8Hpg_23_0"></a><a id="Tc_fU4A5jGUfU6dFHUUTF3Meg_23_2"></a><a id="Tc_jXyTRKfJyEyarWL-NKltmA_23_5"></a><a id="Tc_tdORsxjKxUKjZv5x1vVMqg_24_0"></a><a id="Tc_alnRQCL8ZUeTH_XMUzVvFQ_25_0"></a><a id="Tc_tcDfmG84v0mm3Y0IUII95w_26_0"></a><a id="Tc_Um9frAP9oEyG4BAwcQ5-7w_27_0"></a><a id="Tc_GJO75x2UiEe7dQQqEeBKfQ_27_2"></a><a id="Tc_CpWATwK2hEyapBniNe5jOQ_27_5"></a><a id="Tc_iKLNNF-Zw0yPpCsMgApX9A_29_0"></a><a id="Tc_uix25lRj6Eu506duoGxeFg_30_0"></a><a id="Tc_L429AWhKG0ChVvtIkllAvg_30_2"></a><a id="Tc_mPkXNOtFS06nUvCytJccBQ_30_5"></a><a id="Tc_q1g_dEySyEWR3kViYljqUw_31_0"></a><a id="Tc_dk6RjrkFNE2aoXrSIR4C0A_32_0"></a><a id="Tc_r1LyeTcfNUy0eoP6wrItjg_33_0"></a><a id="Tc_I9KZ0zPZKkGAgOKHnnIOqw_34_0"></a><a id="Tc_hTXu7CBhDEyCdEKo0s3kRw_34_2"></a><a id="Tc_ANDQkfRFU025sZumuyFSVg_34_5"></a><a id="Tc_0O-DT4MzTU6kJdHCNiPgHg_35_0"></a><a id="Tc_p5TQr8pXq0KpmDhDRA98Lg_35_2"></a><a id="Tc_A3_KUeUKdked2SWJnLZF0Q_35_5"></a><a id="Tc_y0LHRpx7aEq5JDjDtVKTAQ_37_0"></a><a id="Tc_3vjNSI8Ng0iTwg-WWtDu5w_39_0"></a><a id="Tc_B0xlbOH7c0mOIknZ73oRmA_40_0"></a><a id="Tc_lZ0sqpkiYECjLLs_yv-eBA_40_2"></a><a id="Tc_GnDmn12Y1kODNITwdbEWMg_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_VKFYOm_P_UuwyJkSLnIyEQ_6_3">16,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_NF47gr059EqqCNJkSIsgSQ_6_6">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_GVgaIiEskkWjWpYTDOWu8w_7_3">16,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_aAx3yszuUUisNL37QmS_Cw_8_3">5,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_f3lTkQeJe0WaWZYO_yfsoA_8_6">3,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_tHqaFQAEyk-BY012JK95Qg_9_3">1,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_9F0Tdt2l0U6C46tHmgon3Q_9_6">1,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_SsrsY7u5PU6SopXnLHv3mQ_10_3">16,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_zZ-6jPKdyUuKASNjAUfR6w_10_6">17,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_-mSrXLERnkWv5OlfPM9T4A_11_3">56,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_MwE9y2f3k0CldsLpDKHFvg_11_6">61,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_jy9BhTZj-U2IlFOGAUhWTw_14_3">2,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_6p9O9eXca0a8UnmCoR2jBg_14_6">2,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_TJC-O6R52UiO1u9lFxdh5w_15_3">4,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZQrBUI_u0UuBRY6TcNqN1g_15_6">4,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_TiUwMTpQzkidme_lr7CXBA_16_3">4,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_4LtpSum7hkuVtg0TMQQZiw_16_6">4,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_ALZ0LD90x0qASe3E2xEtpg_17_3">68,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_OC9O_Un0IE2ykhF4tWf09g_17_6">73,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_1vkaf5WeY0GoTgs2JW0f1g_23_3">7,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc__2MTER9ACkC8MgIyH7pxvw_23_6">6,986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_tPduboA9FUOc27Gy_jOr7Q_24_3">14,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_KLJHxrEfzkShlgXh-j9_yQ_24_6">16,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_xvd90WZeykedYr0VJGkPsQ_25_3">1,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_eVPdGcBVsEyl9O3dj2EIoA_25_6">1,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_YvhbgjY4QUaEw_-6RZy4HA_26_3">11,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_j81XOv0kMkWouWRf6rslpg_26_6">8,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_RjTnqG6-mEWgTn2IX5a9Vg_27_3">35,331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_v_PQ8tzfwk-QLyfEPQ_hYQ_27_6">33,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_58FdIZhak0aa_a_i--WV1g_30_3">27,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_skYM21bubU6hrY6dUjUnQg_30_6">27,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_opIPyn6QJUOeQfHJYw5obQ_31_3">5,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_Ij2Oo7wg0U-btxW8mBjM_A_31_6">11,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_N3Ow_cVAhkCnG8nYBOei0g_32_3">2,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_JkjtcZyJXEi0FbDD_u8JoQ_32_6">2,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_qWW0bwg_gUGWEx0xOcXBmw_33_3">4,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Tx_JQTRrLUGO9yQeF0ZFbQ_33_6">4,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_kIBzFB6TBEuP4FKt-q4faA_34_3">40,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_8elEjhWtcEyAMWIujCnRqQ_34_6">46,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_-BvVk5sxDk-t1bUl7G3fYQ_35_3">75,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_jIq8d2viwkqgKPZdMvdh8A_35_6">79,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tq_Qbk2DwkSEo0yxg3GVRQ_39_3">7,486</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BnbkK1U8nUO5WJ_FGsaHKA_39_6">6,036</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_veq-7kmWN0G-DYf8tf_mWQ_40_3">68,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_S82lX0M0206mBPssfEvTfw_40_6">73,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8488e67_cd30_41d6_985c_7b2b2667ccf1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_ndu8GvvzhUiATjJF488IFA_0_0"></a><a id="Tc_XtcbPpBuQ06Roe-Y718ebg_1_2"></a><a id="Tc_oaHqQNnpYkiMd2MN_rZl6w_2_2"></a><a id="Tc__3oLd5M3Ik65v_jBWLTt9g_2_5"></a><a id="Tc_Dwo3V50XuUC00v46gnPo-g_3_0"></a><a id="Tc_O4iEnssIoUak9qrSHr9lAg_3_2"></a><a id="Tc_QNDkVzu2H0q4PvwwAIm2jQ_3_5"></a><a id="Tc_lYZSAchkzEWgz3fQuNUG2g_4_0"></a><a id="Tc_nrHO-sAVfE2upzaQ7OhHLw_5_0"></a><a id="Tc_W0r2bvOPeUuIgtNkUkL4BA_6_0"></a><a id="Tc_qlDRG2EDY0O-MfACMgkmZA_7_0"></a><a id="Tc_TraEYayRtEGV3_9GuaaXiw_8_0"></a><a id="Tc_kSa9LChAJ0-Gk_HgOUz_pQ_9_0"></a><a id="Tc_9Elk1oD6t0S63Wt034698A_10_0"></a><a id="Tc_SzptUom90EmKW9s8B8QKqw_11_0"></a><a id="Tc_xYocdbA2t0qhl-xb1J_D-w_12_0"></a><a id="Tc_yiTwWTtdLkGB4KOaq4Akfw_13_0"></a><a id="Tc_786aXPq7bUCNbMwCOsoOiw_14_0"></a><a id="Tc_Zde4XOoZskGq5DJaMnwSGg_14_2"></a><a id="Tc_nWmhel9pI0OeuqITPNBp6w_14_5"></a><a id="Tc_VZKfpTivCEa_Jvs3BiU32g_15_0"></a><a id="Tc_IzxPc2lqR0maSL3TPL8z0w_16_0"></a><a id="Tc_Gx-ZVNUV8EqvDRQFJ47tBA_17_0"></a><a id="Tc_NmoQc9U_GEi_vHM-LXlpRw_18_0"></a><a id="Tc_qIBGObmopU2UGVj-fjDxEw_18_2"></a><a id="Tc_kjYU62VQ3kSgdJRwzbKtzQ_18_5"></a><a id="Tc_QKX4y9-El06fHNNI8dZuow_19_0"></a><a id="Tc_gIDFYgvICk-RaAjpXeu_hQ_19_2"></a><a id="Tc_AheHpH8MM0am79vnbzjKQQ_19_5"></a><a id="Tc_Dt4vHhcuOUC3zgpZz3Dm6w_20_0"></a><a id="Tc_a7pVtGiTa0m906fI8tzTJg_20_2"></a><a id="Tc_z2V3FbJQQEKNXQgslFEohw_20_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt 0pt 0.05pt 0pt;">yyyyyyyyyyyyyyyyyyyy</p></div></div></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6tJAUrb9HEe0Nrz43VtVuA_3_3">9,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kTiWFWJDJ0ufD8UEaJqf-A_3_6">4,511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_m5yDuzEcyEqblXW6cUHbIQ_4_3">7,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qktQWDHMCEe1SEnCnz6Emw_4_6">6,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_CWftXDvMyU-UeUvokrL1FA_5_3">16,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Mwl02EU-Lk2akS26sDuJHg_5_6">11,320</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_RJQOws5VPUGxUtZyrh2dSA_6_3">6,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_qb3IYo9alEyPI7QEX2vE5w_6_6">4,765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3">8,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_E5bj0evlnUiJARjI729_tw_7_6">7,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_o1dU5w4--U2sE9K77mUxhA_8_3">3,154</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6">3,138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_L8KcmSasV0-YdlJBL53QJQ_9_3">1,870</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_VXDh26oMXEqKSAXPi5ALZw_9_6">3,705</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_S-fEy3nczkaC5tv-qhpSHw_10_3">618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_NNqDqLX9ckSMS6kP_WTbkQ_10_6">2,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_CGHOPlHJX0ue2ZhGa3m4qA_11_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Xe_9yGBOU0qmiTsMPw9B2g_11_6">335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES &#8211; NET</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_JzCaVR78AkCGvujh_n-_7g_12_3">416</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_UdV55qgPxEm0Mip1M05TPA_12_6">1,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_r91IiyhdfEygSLk9RYIELQ_13_6">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HEiKBiV-m0CkyviHf0k_4w_14_3">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_N1_iDizrO0yNnuDHpjv1PQ_14_6">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-kAnU6UZEUeayl0wjoSMrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_mIco-pHDnU6IpN6VTFDSJg_15_3">0.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wTNccG_X4E22ngVLWu0dAw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_eZBqTZ-qRECE3wuCMPiD0A_15_6">0.14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_9sIrSPv0mEaFpMVkRRnthQ_17_3">45,843,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hdeS6r91gkucpxzu1Pjz2A_17_6">39,933,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_XnHOJIVKdku-bvE15B5dbA_18_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_qujldeuPW0iQr0wx-0hqGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0JCIYCF4pEaKc6tF06pQ9g_18_6">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kSc5Ga3WDkWOtVnhp3oTgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_LEn45Ss40Ea_nhsGJwyrpA_19_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_25Q10gL8H0ejcvFB3qy2aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EsE74qczDUGHKEOZJ6pIVQ_19_6">210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e09An94TDkebg9LA56J2sA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Qod_BACx0EaZrNFkbcBrLQ_20_3">766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2-Rf8ep840CPArFgmLRo6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ro6TEY7un0iyGGZu26D9Kg_20_6">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89eec5e_357a_4111_86ce_812eb43d3102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_J9K6qs4ilkeeLMiBCoFPbQ_1_7"></a><a id="Tc_HYPtm00mykeDVdAaAV-aBQ_2_2"></a><a id="Tc_Lis74UI0DEi1baoucqhywg_2_4"></a><a id="Tc_8SFVq3IRz0iaL6qRK9uYrw_2_7"></a><a id="Tc_AKvcs0ekNEakS3ld1se-Hw_2_10"></a><a id="Tc_VYI_lEBRAEa4wTY8nLT18w_3_2"></a><a id="Tc_22paX9wSPkSG2BfJ316wJw_3_4"></a><a id="Tc_ku5fJmeYUU-EoB8wAdMf_w_3_7"></a><a id="Tc_Okdov68htkWTgcxa1X72yg_3_10"></a><a id="Tc_PnpDuz44ykWw-bdMOpJbHQ_3_13"></a><a id="Tc_GSCgAti3l0GwPyLIsgD83w_4_2"></a><a id="Tc_vdHRAkMeKEicyYtJbXR_cA_5_2"></a><a id="Tc_xSA4Itaa6EehGe-MdInD-g_5_4"></a><a id="Tc_A9LLXZXZDkSxIpNphAxl7w_6_0"></a><a id="Tc_-1j-GitF7EO92fUI_TGXvg_6_4"></a><a id="Tc_fL3EiSgOdkqvHYHAH7CdFg_6_7"></a><a id="Tc_UkhkUMvWR0eghjug3YbxGw_6_10"></a><a id="Tc_Y33ARMKepkiBce6_TL1JxA_6_13"></a><a id="Tc_ZBrH24mLpkaEIkc4x5jN3g_7_0"></a><a id="Tc_xsF6C5ldz0aMiJyaakbGMg_8_0"></a><a id="Tc_hxSfWh5f3EueeAOFmI21cw_9_0"></a><a id="Tc_UtiN3lrD0EOaq3Dl994uCQ_10_0"></a><a id="Tc_G6lag1GAL0W6ybvwvLHS0w_11_0"></a><a id="Tc_ZR4tv9F3YkqnEyOJv_gSBQ_12_0"></a><a id="Tc_em1i8-SBdEuTtY2dUsre1A_13_0"></a><a id="Tc_DOObFEG5z0OKVJj5dwf54w_13_4"></a><a id="Tc_XKLo8oImJ06briO6Tn59fQ_13_7"></a><a id="Tc_hRYV8Oh730eHFoHKGTUGTA_13_10"></a><a id="Tc_RjHFQJSsv0eZBkANHTVQ6w_13_13"></a><a id="Tc_g3L3mQrjEkSuF-QEZep0-A_14_0"></a><a id="Tc_hWPaxm4JUUCianmPVSv5og_14_4"></a><a id="Tc_V_-6btnSGEiiMd112J9PJg_14_7"></a><a id="Tc_uyyS9132606bfVnlT9eEPA_14_10"></a><a id="Tc_OiG-tpJzNkCEDwVhwtL8bg_14_13"></a><a id="Tc_GimD3-2hMkWGrGI-BQJdlg_15_0"></a><a id="Tc_lFt4jJnzUU-ezkNz3D9HMQ_16_0"></a><a id="Tc_1PPgLj9qdUaC308zTuNYzQ_17_0"></a><a id="Tc_XWYR41qn4EaT3GobG4mCoQ_18_0"></a><a id="Tc_SItWYn6IpEe3jdhQ0pIcUA_19_0"></a><a id="Tc_JX8XZoCXKUqGrD95uU9YxA_19_4"></a><a id="Tc_ksQACwF8pUaRyUSSenXibw_19_7"></a><a id="Tc_kDp3b7krs06u4GGtegTrDg_19_10"></a><a id="Tc_i9NhxUPJ0kukylDKMPpx7w_19_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_MuvEekivCEKppyszPy-1jQ_6_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TkZGETImrEmQD7XWNKa90g_6_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8IQ8YzoFvU2yjxQe73qorw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_R-dXJiWDNE2C8Ng-BtuUhQ_6_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1yHZ2g1o_EW2u2UToeG0rQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ekutbg20zEyOYTQTu8kLSA_6_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i8CxtXPR-0uhkzHngYAabA_6_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_qrq73xVa90S2RIUQ_noXeA_8_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_LgYur5HB0kKJtbQJVokatA_8_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_-Jl06tjAe0KVd98q3mZaqw_8_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc__yhwq8Ghf0eVQkoePgRHUQ_9_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_l-6_C-sz5kS43bvrDrba6g_9_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_coZZHuD2KkmQRPXHen9tiA_9_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_nRUwAAqTG0GfspP9trq7XQ_10_8">510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CglUhRUHjU2Twr5uyvIA1A_10_14">510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_O4BMRTvXQEqqDtSfLwGMdA_11_8">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_VUmYKBdyJ0Wmf-KVNhXY-g_11_14">306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v7ZxPQ9J60mXrkEKrBuF-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Q7LWMxP_ok-cGOdkUhRYrQ_12_11">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_b8xhQt99X0GxLFcgY7rbAQ_12_14">5,475</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2">45,382,831</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qRgywLMj4UC8US0AeA9kcA_13_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gvkx-vnKf0Wu9yKA-z9U8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zgCNu-89fUW_NNZESrmO3g_13_8">367,285</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AqmwNqv8vkWAh_7muHfOwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HiU7xk6CvkemCn0kn8hmUQ_13_11">352,827</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CrKi08qWZEmV10KV0SjL0Q_13_14">14,504</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0gItQ4XhT06POAvCfEebZw_14_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B5yak48wUUafPhw4EIHy6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JM-1cuZ6fEqkQ46Wn3eAow_14_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HBV2SgD3KU-05oHsFRVGVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_TWI7lXq62kqcyJmnBD9-gw_14_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_sBPJzE1_V0OE8fi_Qa-D-g_14_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ENbCBaRIikKWnpIr1drYfg_16_8">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_5zDDlygavkGkDBr-IF3B2Q_16_14">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Xd_TT8X3jEGIRtcxZqdgfw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_gFsSd6wNLE2dyPmazIX7-A_17_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_FUS-akZTnU28m7bMw4u5wg_17_8">687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_pW1kBdk_60Of_uj_erIugg_17_14">687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yDiuB0IrXUGmEWzXQrmjvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hy8t91ApqEGU7EuPwutrcg_18_11">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DEI179JujkijLTJ-r-iQGw_18_14">2,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_kxeunX7HskqujxoxGB5SUg_19_2">46,316,129</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qdOEKEcM80e5Ex63DqRgeA_19_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tWPPUkvGKEK_RWlQ1tQ97w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_G33HJiaWoE67oefSIGEjTA_19_8">369,688</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ipOEoOOBwEqJNxqVYD1F_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_m2BSVNhmIkS9YyTqB1519w_19_11">377,220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5x8_EBzaTE6nr5nSjaVaVg_19_14">7,486</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Represents an amount equal to less than $1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_jA1NqXXhhEWVuJN-DQWa2A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_2o_iiWMr8EixYw23S0pqNg">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of March&#160;31, 2022 and 2021 - <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_iwuBfgsfAUSRkRoRaTeHag"><ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_WCqigvJ1mkG0i3-B5VflFw">120,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1969ae3b_b04b_4ede_8d7d_86a45b16dd76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc__8IYy6AFbU2GQYvmK0Jebw_1_2"></a><a id="Tc_WN4MtGsMBUW92KWYEE9K8g_2_2"></a><a id="Tc_ELRXJN9WzU2piwmUkCJi8Q_2_5"></a><a id="Tc_cEAuzQ_BX0GmLgLj7itOjg_3_0"></a><a id="Tc_Za7oVi4QiEKgyGPl4Ha2tg_4_0"></a><a id="Tc_fdeBEAVIDEO1PHMG_qIoqw_4_2"></a><a id="Tc_hyBGErIHRUer-6B-qiYJyg_4_5"></a><a id="Tc_7cF1xxEWJEKpbfcRLXegNQ_5_0"></a><a id="Tc_sfh6DbCNyk-pyeTWUFG3eg_6_0"></a><a id="Tc_ofjt_l4j-kGEW7il9lWxAw_7_0"></a><a id="Tc_t1W-e5AIm0SJhc6NbKi_mg_8_0"></a><a id="Tc_uu_mxq93uk2hC_ju9bV1pQ_9_0"></a><a id="Tc_osoA45MtskaRh2VNcHpmzQ_10_0"></a><a id="Tc_34PhjCu9N0yvBm0LQnUv5g_11_0"></a><a id="Tc_kMWhgIztYUaBvLb8q3TzPQ_12_0"></a><a id="Tc_deZiQY9agk2Mb_SGdSj0Ag_13_0"></a><a id="Tc_s2QKPaifW0OoWvcVEycJYA_14_0"></a><a id="Tc_MxpMmKRTTUy-X7adyBQNWQ_15_0"></a><a id="Tc_F8CqXBYOlEC4MO6W_iK3Hg_16_0"></a><a id="Tc_rqNk0cSz20-UfLmqsjSpGQ_17_0"></a><a id="Tc_5VZJmFs6q023ELqxu5Fh8g_18_0"></a><a id="Tc_59KSANoeNEaKR_YJCzbrKw_19_0"></a><a id="Tc_DHcWv1BxeU6ixGBFCAMICw_20_0"></a><a id="Tc_uIdOCib78Eilp5Jgvkj_bw_20_2"></a><a id="Tc_F9Z6sSB3dUGD2AqpTDNPhw_20_5"></a><a id="Tc_dsWBxFZCW0qfBcI6XgFFNA_22_0"></a><a id="Tc_vM9pLRjSjEW4M_NZkDSzsw_23_0"></a><a id="Tc_bTVULBmjvUGcE6c1BB8XCA_23_2"></a><a id="Tc_k8NmEZbwckCABz_yUbSUgw_23_5"></a><a id="Tc_x1kULSyMcEqBBahd6ZSwug_24_0"></a><a id="Tc_Ep4ft3uxBEqo54hQQWAwzQ_25_0"></a><a id="Tc_cud6Cj2XS0yBGXYBDFFAAQ_26_0"></a><a id="Tc_mwqr_INnJEq6GL-T0pm0pA_27_0"></a><a id="Tc_I5BqnnH5ZUWnL3SxyPntUA_28_0"></a><a id="Tc_vxVKrQmDjkWaMsRfKBWfOg_29_0"></a><a id="Tc_BncbT5p7j0mNtQb5IlSJSw_29_2"></a><a id="Tc_S0EkfNQGYUOHXJ4Q70cGQA_29_5"></a><a id="Tc_lqxXKKvlRk-sw_SCOD_cSg_31_0"></a><a id="Tc_0tC7rwgc10OJHZUmVWQswA_32_0"></a><a id="Tc_1pEB-z6dNUqyFSn1FqR5wA_32_5"></a><a id="Tc_trWPnFxYI0aipolHdoWh2g_33_0"></a><a id="Tc_A6p_cx0LwUihqTMkgqYf9Q_34_0"></a><a id="Tc_YIYtuZdwuUOBcMh3b6thQA_35_0"></a><a id="Tc_p1NhXXYOyUSR3m_tzrnOJQ_35_2"></a><a id="Tc_LnyxKuEU4k69PoLGR90emw_35_3"></a><a id="Tc_V0iugbj77UuPlzMJX7YxGQ_35_5"></a><a id="Tc_7dL6X4Qp4Um7bm7l_3eFwQ_36_0"></a><a id="Tc__b8ivuQoc0aubl_1XG3JAA_36_2"></a><a id="Tc_-w_SnFWGjEC7i591erAmBA_36_5"></a><a id="Tc_RKPKDQq6BkeE8WcsAm5nnw_37_0"></a><a id="Tc_p2Opn0Ay3keSJF2xiZjN5A_38_0"></a><a id="Tc__5rf_x48R0GVCW5qEmPrJw_39_0"></a><a id="Tc_v2e1yNHUG0mrPFFEjAlPjw_39_2"></a><a id="Tc_RqJsoQRyA0CTtr_I91MUUA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_er09fJFvhUO4LMZqYhNj5Q_4_3">2,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9iJroCv9tkSU5X2ZmmlYtQ_4_6">5,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Mc7_FvC2R0afhlTCLdiexg_6_3">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_uuFIOIOadU2uUfPJScSj-g_6_6">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_DDUj_xtxg0q04QSzYBBPzQ_7_3">270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_OVZkn3c35ky-cgHNR8gcMA_7_6">286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_7XJ65M5MjkO8_WCwOarNMg_8_3">198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_sxdzHp4ZckWxG3qlS5dMog_8_6">168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_qwikmqh6M02CFGhkIzTjXw_9_3">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_rUuVzXWs7EKIhZ2mo16JJw_9_6">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_-2NH-QdsTUmjEW3tYBqbbg_10_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_SCq3fOj7bUeo0eDm1JmGaw_10_6">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_b-G3AUFqhEeRUzz942Qajw_11_6">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_kpEkwf2ySEiM4yMgv75V2A_12_3">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_JUMna6Lk7UuFwtxLW-l04Q_12_6">945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_xOs_PQ2ca0u28IJhCUl4CA_14_3">2,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_UuQkgu_G50yaav1cWZrLvQ_14_6">3,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_aXYszJ08zEODGwtUCt_Uqg_15_3">2,314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc__wt6lkSpNU2w6Xm44HzJJA_15_6">2,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_lq0gAsKVdU6gq_b4eb_FrQ_16_3">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_gQugblfKnUW_7UWZUC9UfQ_16_6">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_SS2Hvn52VEKgAtWDzo2Mdg_17_3">1,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_1POLpt8bMkqvPLfyNeCv_Q_17_6">833</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_LXRVGK4PLkyvRaqxlXBnmg_18_3">1,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_ZIU_8hX32kWTaE8CKWLw_A_18_6">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_GDvnlBnRZku4LAVkfX2b6g_19_6">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_QN3vdPXlSEyGaBzPd_1Seg_20_3">5,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_qFVp7YZCkEWzcCAuw2zVjQ_20_6">9,834</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_NIJBi75CkUmVy0IiLwkw-w_23_3">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_N_mh67PBLUm7FL7nasHNaA_23_6">37,835</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_iQ38IDZu_0GJgK3fZYqyGQ_24_6">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_VXK1_OV_rUmMM3XK8SjjYQ_25_3">229</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Uoncq-b5VUq3TV_KH7MuTw_25_6">386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_yrgCchJ4V0KqvWfLkCR28w_26_6">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_hCLYdDphDEmbY3xn8eiVEw_27_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_A24KZrobUE-3FSkyS5xBvA_28_3">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_TBMxeej_uUml9P_ZOjAlCw_28_6">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Kqlz-R1WOE6ZFxKktePOug_29_3">16,257</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_5RmnZIb1WUCWb3pom7NxQQ_29_6">30,684</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_FAW0457PPEadSd39tVfBCQ_32_6">4,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_no0v9dNGUkKMgAk9S4vX5Q_33_6">37,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_fWiSrZxEmUWjXZVHn9NfCA_34_6">8,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_-oDxNKIGH0eCvPGi7YcNIA_35_6">42,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_NGWVI8NZw02Cz9EvcbRAXg_36_3">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_9NzQNhblG0mfnZ-jqvwEFw_36_6">31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_deAJkhfdz0S_VkdQyQSSmg_37_3">22,097</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_3Es-Urbu6UKUzaH9ZYz3XQ_37_6">1,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_QOXPiMoOyEGb2Lsx70IoDQ_38_3">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_dtfCj0RpZ0aF4b34QMaPWA_38_6">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_UGFrVkfb80KHHtaFCc0-bA_39_3">16,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_HQqne0AofkO-F2fGLmXe1g_39_6">19,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_B57EH6-7iEi8l-vFvMqV1g_1_2"></a><a id="Tc_0C88eF3i1E-bot11REY03Q_2_2"></a><a id="Tc_jnsBroku7U6YSz7QC9gPKw_2_5"></a><a id="Tc_YmOinH8-2UGcXKJRXHZ-fg_3_0"></a><a id="Tc__BjjRORQ8UyVNYADGrUAcQ_4_0"></a><a id="Tc_ksi6imcv90G_YID3-6XxOw_4_2"></a><a id="Tc_rMcXR47BaU29RGHHju8Vjw_4_5"></a><a id="Tc_B5rcw_gAvEuk0u4kr2fMWA_5_0"></a><a id="Tc_wxatvdjDrUWKq8PUd03IUQ_5_2"></a><a id="Tc_Xi9F_qTg9keCADqzVkfLAg_5_5"></a><a id="Tc_UnKJsC1kVkizXp0EAkVR3Q_7_0"></a><a id="Tc_PNgc78cyMEqpmEjsCsR2SQ_8_0"></a><a id="Tc_4hVi8Vjw20il5kI22TKU3w_8_2"></a><a id="Tc_yad7qxLFC0qjyPJMEfOwAg_9_0"></a><a id="Tc_7JUjHNZW_ECkqQr713-izA_9_2"></a><a id="Tc_iwQPfsZBKEOgpupgR9FJ0A_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_5oj6RzF1j0S0r30L2PMoGA_4_3">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_TX0SVaTfCUG45YchNwnoUA_4_6">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_ZP6LbJMreUuYC2Hk7r2ZQg_5_3">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_DBitXD3BKkuA0_mrOUlSlQ_5_6">122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_nefZAgYIDkCepQkDnv2jew_8_3">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_6cOCTAXa6kaF42LYEjqLuw_9_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_QYI9JAhOY0uUOOAHQk_9sA_9_6">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_hEcggLMKO0y3LvdytY20zA" continuedAt="Tb_hEcggLMKO0y3LvdytY20zA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_5GY229hNgk6rVVnTm7vytg" continuedAt="Tb_5GY229hNgk6rVVnTm7vytg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hEcggLMKO0y3LvdytY20zA_cont1" continuedAt="Tb_hEcggLMKO0y3LvdytY20zA_cont2"><ix:continuation id="Tb_5GY229hNgk6rVVnTm7vytg_cont1" continuedAt="Tb_5GY229hNgk6rVVnTm7vytg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_j2CUvjm09keHknkDWIvMIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_lbQwoXNs90CYcdU7gTufuw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_lrwJhCuCXUascmBgLL81fQ">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_s3ZZqU9fV0eh823IophcWg">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_c6y-Uko4y0OX5ic5QH08OA">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_yI08emDAWU6kcLogTQGSFw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_yWPWxEiJ5USqUdhnKIhqBA"><ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_oryUP8iiq0yLMk4y318KNA" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_qmcROuzHeUGz9fS3njuefw">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_UBWNDWXmB0y5Q-gobYSmOg">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_-EGsAXXohEKuQa9I9p0eIw">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_0l4Oa6OyLUifRhSbkuCI8A">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_pWwrgqp2aE-ytBPsQ_pgKA">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_fM2Dtvd7yEyy8aQnHWEflg">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_BaUNMIH4yU6ZDnrQVMWFzw">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MVMnGHuu4U2rlaci2l_31w" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_l9Fj1VYtm0aLZJMQbdXHcQ">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3TlFp6KPJ0O_taG6Nu2ZJQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_lvYq8_c_e0WQt9H7brIfXA">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8P6P2mP_x0aZdoJRwGajdg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_2pkG2f53akeOf0pblZHcnQ">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_yGfuKJ8Y0U6-4sMMOBEt2Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_btQoQ-s3m0K7kKoh2VISlw">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hEcggLMKO0y3LvdytY20zA_cont2" continuedAt="Tb_hEcggLMKO0y3LvdytY20zA_cont3"><ix:continuation id="Tb_5GY229hNgk6rVVnTm7vytg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_5E9e4OgdikqRj2Wn6sSnbA" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_lrJH2KCyI0yy-LhGbvLOPA">10.0</ix:nonFraction>&#160;million payment to the Company in the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d3VeMhBTD0ySWJQLs_isIw" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_3I7zw1Vpt0S40nSJi5VZAg">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_JFg0AHq1C0mWxuNhSH7UZQ" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_HZc0_5_Jq0SUq1MrBFgmzA">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_1teeMAb7jUKdKERzEeKKTg">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_5BfrsCR3zEKmBDJzhHi37w">7.5</ix:nonFraction></span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_aw785iRfQUmWDw4Pa4lObQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and y Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_tzB1vxOA-kmA5Ks4J1rlng" continuedAt="Tb_tzB1vxOA-kmA5Ks4J1rlng_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hEcggLMKO0y3LvdytY20zA_cont3" continuedAt="Tb_hEcggLMKO0y3LvdytY20zA_cont4"><ix:continuation id="Tb_tzB1vxOA-kmA5Ks4J1rlng_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_6jlsSsW6gketmz0cA7LHjg">33,004,217</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022, and <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_w8phlz5rI0Wi8LDT1gznog">26,769,693</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BOmkiauMyU-HVMlM8M_LMw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_KUqR1dwcgEW_GXwUrg2dEg">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three months ended March&#160;31, 2021, because their effect would be anti-dilutive.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_r3OV8P154060a-hrIdJ1Qg" continuedAt="Tb_r3OV8P154060a-hrIdJ1Qg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_4CakW3DMrUShwcChN38RSg" contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6kbZygJL5UGCoK2CMw5wLQ" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_vsdivaSWGE2LBtlVgj7VMg">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hEcggLMKO0y3LvdytY20zA_cont4"><ix:continuation id="Tb_r3OV8P154060a-hrIdJ1Qg_cont1"><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_6ifVJfZDFk2vkoQYHiiv3w_1_2"></a><a id="Tc_wqUehchdLUaULBRif8Nkzg_1_5"></a><a id="Tc_4KswJh1ZdE-REtUQzA6asA_2_0"></a><a id="Tc__I1V4cR2TEKWvUCI0_ag5A_2_2"></a><a id="Tc_VoukhixjhEKwO_G7g9yQDg_2_5"></a><a id="Tc_oywNZ2kEaE2KlRCi1MzvmA_3_0"></a><a id="Tc_BtsQtg_sAUqTp3JWPFm3RA_3_2"></a><a id="Tc_YQM8M6TSm0mVlnEz23C4rQ_3_5"></a><a id="Tc_5xy7N983DU2qgGXTIYC3ZQ_4_0"></a><a id="Tc_aNWWG4ZUT0ChP0L3MCGrmA_5_0"></a><a id="Tc_FbHvsZ_fZ0OrA42J0DrYFw_6_0"></a><a id="Tc_Y99b8vfawEOv5DepHpzaQw_6_2"></a><a id="Tc_VfAALK6pyECwRaI5igRGZA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_Y3ZxNhYUrEuEOimR4jGGeA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_JgqhkkzNIEiIPBK9_bVwJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_IN8gLXCIbUmlQgNq-24HMQ_3_3">3,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_C8e57PaI-kadXCL97GCSLg_3_6">3,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_w5llgLQ0RESglK66Svpviw_4_3">3,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_dWP4p0efBUWor8dOUxITlA_4_6">3,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_InsYJ_pIFk68wij5QfCZFg_5_3">10,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_eDANZeCpqEO9_QWvjbkReQ_5_6">11,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_oJQJWgXTp0epzSeDnbHm4g_6_3">16,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_LYAuPgjfMUus4TNFq2UzMw_6_6">17,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_d002d227_bf39_47c7_97b0_43f3ca0805ef"></a><a id="Tc_Prb-K5DDGE-9pbiLaPXpGA_1_5"></a><a id="Tc_bqdCzpOPKUi7QZkH-752pA_2_0"></a><a id="Tc_74Sluoms40eux18HJdzlgw_3_0"></a><a id="Tc_21LAfMU8WEi753ZClZkdQw_4_0"></a><a id="Tc_YEMQmasVbEiGBaUAgctdhQ_4_6"></a><a id="Tc_G0PEfbpsIUuO2i4pBYWiNg_5_0"></a><a id="Tc_osv_sVrC1EaCdAbZJ9AAbg_5_6"></a><a id="Tc_ABbCJ40o_0qeKnC76EEV4A_6_0"></a><a id="Tc_yqlC0Nve8kSrQgt2eCektg_6_6"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_WbMguMynD0eRFUIAFbzKyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of March&#160;31, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of March&#160;31, 2022, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_aF0Wk0sgCkCg0sNCmX2SwA">28.75</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_1gW6yLh-xUyRxcB09KpK7A">33.8</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_ANmzZNTd0k66qmaTPy9Adg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_TFE4vlbPi0yeS40NhO5UgA_2_5">1.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_Y3YGIoGOL0-P28Oze-2O3w" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_3xzulSOt60KM80hUQQxNuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_6k7QL3chX0y6BAgkHI3AlA_3_5">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_v1cxXGJXc0O9MyYD4oL8bQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_gVCp-qaHWEyqRwHdk1bOBg_4_5">2.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_elDf2ZxouEeDMOgwfencjw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_slmCPFLqJUu_baK0Gc7uKA_5_5">80.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8zRl47LpDUWLgsLuXBCfPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_acaOXC3_KEyWwMF-anPgjg_6_5">10.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_bq-bLYZkzEmnekHTR2tBHQ_1_2"></a><a id="Tc_RgIxUA0Po0yYw38sc5YuWQ_2_0"></a><a id="Tc_1av4iWVibkiBQ52KStOqHg_2_2"></a><a id="Tc__Oftm0a9f0Kfa0cgwP-JPQ_2_5"></a><a id="Tc_gA6iKW8njUyhA78fGUWzcw_3_0"></a><a id="Tc_OW0a2jmsb0CD513V3OcSiw_3_2"></a><a id="Tc_yZbALBARw0uGStnn1fC1Ow_3_5"></a><a id="Tc__uIC-YO76kCZRcqH-kMzLw_4_0"></a><a id="Tc_cYxCkWbR-EKnaN8XgJ9-Pw_4_2"></a><a id="Tc_r3BKYco6UEebghZ7fvRmrg_4_5"></a><a id="Tc_dtYQoCcwW02XhTtZVYkRtA_4_6"></a><a id="Tc_vH5ANMYPx0KSyZzK_Ma_lg_5_0"></a><a id="Tc_xcvPw1GjIE-7JrrNrFKqUg_5_2"></a><a id="Tc_nqvTpce4AUel_M9OwYMZVA_5_5"></a><a id="Tc_8klcoZqQN0GBlbGvHvufFA_5_6"></a><a id="Tc_rnTwuHsYbE69z8IilvYdBA_6_0"></a><a id="Tc_rsUVW0_M8UqFR1lx0FV6UA_6_2"></a><a id="Tc_g6hTHSF3tky57DpTDAAsnw_6_5"></a><a id="Tc_3BFatA6WJ0mgNZ3LY1oxPQ_7_0"></a><a id="Tc_Fs76Sk2yB0eXCZYcHp_Z_g_7_2"></a><a id="Tc_oO2Tnz88C0mxdBE65bemsg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="plx:RevenueDisclosureTextBlock" id="Tb_SUDBqRW5-EaIPNLElIXQMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_TeK6djP6iE6GsgJbqZPbpg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_86wb_A24g0O9P6vNpbYVDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Sph0jgYwhUaDZ8TSk4vO_Q_3_3">3,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Cs1RmaB2dk2-zzlPaX739Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MtTHcP8PFUKHiW54Rq_tzA_3_6">4,511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_S21-ZapyUEi0AfHd0ZmzGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_UpQuJm8HXk2pU5FXZyUL4Q_4_3">5,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_uft0WkxfTECQKQCU4pZbsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__uowG6K4skyNkAPwfdHguA_5_3">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_XeVk5pPYw0GYiWFUVpkB7g_6_3">9,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ghbY-hqOj0e-YsHfdxOdzw_6_6">4,511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tfqt1-V71kudSA40_Vo07g_7_3">7,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vFeR9-g5q06wpQ-rokci_w_7_6">6,809</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_EQpnTLuB5kmHDu9je4tCqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span><ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_N0WLZMBvvEKsDk2yyQIaMQ">637,531</ix:nonFraction> shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_Y7zqgkDc0UiQjkmr9C8_7A">523,000</ix:nonFraction>.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span><ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_cXJ2pwmPOUqmnEbCQqQnsg">121,951</ix:nonFraction> shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_ca8ydwL9nUC_5za3Jv6FrA">100,000</ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_8FMp8zF-QEKmxiMoEw0y-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During April and May 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw" contextRef="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Narr_anB22yu0bU6SUuY7yjDF-g">746,171</ix:nonFraction> shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ" decimals="0" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="0" id="Narr_M9H00TPIM0-mc1JGNxyhSQ">886,000</ix:nonFraction> in connection with such sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On April&#160;13, 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_4_13_2022_To_4_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_QQ3bC0ekv0uTXXOWJ2xaAQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_QMArHEPafUy15SjkjKEwQA">1.2</ix:nonFraction>&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On May&#160;10, 2022, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g" contextRef="Duration_5_10_2022_To_5_10_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_letqXd_CLESNLLjD9nX3rA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_TwSZEDy5f0SwwPxQFyxmew">3.6</ix:nonFraction>&#160;million from sales of alfataliglicerase to Fiocruz.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d30392ac_01a9_43ad_9a1c_c82bad98e7fb"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2021. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing and progress of the preparation of an updated Biologics License Application, or BLA, for PRX-102 addressing the Complete Response Letter, or CRL;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the U.S.&#160;Food and Drug Administration, or the FDA, and the European Medicines Agency, or the EMA, of a resubmitted Biologics License Application, or BLA, and of a Marketing Authorization Application, or an MAA, respectively, for PRX-102, and, if approved, whether the use of PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug product to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>and the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On April&#160;4, 2022, we, together with Chiesi, announced topline&#160;results from the <i style="font-style:italic;">BALANCE</i> pivotal Phase&#160;III clinical trial evaluating PRX&#8211;102, 1&#160;mg/kg, administered every two weeks, compared to agalsidase beta for the treatment of Fabry disease. </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On March&#160;18, 2022, we, together with Chiesi, announced final results from our phase&#160;III <i style="font-style:italic;">BRIGHT </i>clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIGHT</i> study, designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 treatment, 2&#160;mg/kg every four&#160;weeks, in up to 30&#160;patients with Fabry disease previously treated with a commercially available enzyme replacement therapy, or ERT (agalsidase alfa &#8211; Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> or agalsidase beta).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On February&#160;24, 2022, we, together with Chiesi, announced that the PRX-102 MAA was submitted to the EMA following the October&#160;8, 2021 meeting we, together with Chiesi, held with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102, and that the submission was subsequently validated by the EMA. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete two of the trials and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic and its variants on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.26pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20220331x10q005.jpg" alt="Graphic" style="display:inline-block;height:207.26pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell in Suspension Expression System for Therapeutic Proteins Development and Industrial Production: Executive Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220331x10q006.jpg" alt="Graphic" style="display:inline-block;height:233.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20220331x10q007.jpg" alt="Graphic" style="display:inline-block;height:144.7pt;width:532.52pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease is forecasted to be approximately $1.9&#160;billion and $2.1&#160;billion in 2021 and 2022, respectively (Global Data) and to grow at a CAGR of approximately 10% from 2020-2027 (Global Data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential treatment for Fabry disease. The submission is supported by the 12&#8211;month interim data analysis generated from our phase&#160;III </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">BALANCE</i> clinical trial of PRX-102, which was released in June 2021. Data generated from the completed phase&#160;III <i style="font-style:italic;">BRIDGE</i> clinical trial, the phase&#160;1/2 clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the filing. In addition, the MAA includes data from the completed 12&#8211;month switch&#8211;over phase&#160;III <i style="font-style:italic;">BRIGHT</i>&#160;clinical trial of patients treated with the 2&#160;mg/kg every 4&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The initial BLA submitted on May&#160;27, 2020 included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta, a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021 to discuss the FDA&#8217;s requirements for a BLA resubmission. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the clinical data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. We intend to continue to work collaboratively with the FDA resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given the changed regulatory landscape in the United States, the planned data package for the PRX-102<span style="direction:rtl;"> </span>BLA resubmission is expected to include the final two-year analyses of the <i style="font-style:italic;">BALANCE </i>study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January&#160;2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our clinical development program is designed to show that PRX-102 has a potential clinical benefit in adult Fabry patient populations when compared to currently marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed enhanced activity in Fabry disease target organs, reduction of the accumulated substrate, significantly longer half-life due to higher enzyme stability, and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of antibodies. Providing a meaningful improvement in the health and quality of life for Fabry patients being treated with PRX-102 represents a significant potential market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. In the phase&#160;III clinical program, we are studying two potential dosing regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients that completed the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Currently, 126 subjects that participated in the our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term extension studies; 10 subjects that completed an extension study from the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial, 18 subjects that completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects that completed the <i style="font-style:italic;">BALANCE</i> study; and 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study. Of the 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study that are enrolled in a long-term extension study, 27 of them are being treated with 2&#160;mg/kg of PRX-102 every 4 weeks and two are being treated with 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The pivotal </span><i style="font-style:italic;">BALANCE</i> s<span style="background:#ffffff;">tudy is a 24</span>-<span style="background:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background:#ffffff;">102 in adult Fabry patients with deteriorating renal function that was </span>designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta (Fabrazyme)<span style="background:#ffffff;">. The study</span> has been completed and topline results from the final analysis are now available. A total of 78 patients who were previously treated with agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for at least one year with an estimated glomerular filtration rate (eGFR) slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. The last patient in the study received the final dose in October 2021. <span style="background:#ffffff;">The study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of estimated Glomerular Filtration Rate, or eGFR, slope between agalsidase beta and PRX-102. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters being evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the September 2021 Type A End-of-Review meeting, the FDA, in principle, agreed that <span style="letter-spacing:-0.1pt;background:#ffffff;">the proposed analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study demonstrating non-inferiority to agalsidase beta to be included in the data package for the PRX-102 BLA resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. Given the changed regulatory landscape in </span>the United States with the full approval of agalsidase beta in March 2021<span style="letter-spacing:-0.1pt;background:#ffffff;">, the primary analysis of the </span><i style="font-style:italic;letter-spacing:-0.1pt;background:#ffffff;">BALANCE</i><span style="letter-spacing:-0.1pt;background:#ffffff;"> study was changed from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. </span>The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study compared the eGFR annualized changes (slope) between the two treatment arms in the ITT analysis set (77 patients). The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The median (95% confidence interval) of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.788, -1.240) and -2.155 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359 mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). The prespecified non-inferiority margin was met. Topline results in the PP&#160;analysis set (72 patients) are consistent with the ITT results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>approximately six years. At baseline, mean (SD) eGFR was 73.33&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (19.82) and median eGFR was 74.51&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.21&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year&#160;(5.88) and median eGFR slope was -7.32&#160;ml/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one adverse event compared to 24 (96.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (4<span style="direction:rtl;">0</span>.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assessment of anti-PRX-102 antibodies or anti-agalsidase beta antibodies, respectively, in the study indicated that, for the PRX-102 arm, 18 (34.6%) patients were anti-drug antibody- (ADA-) positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA-positive at baseline, of which seven (87.5%) had neutralizing antibody activity. At the end of the two-year study, 11 (23.4%) patients receiving PRX-102 were ADA-positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment-related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 69 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every other week in a long-term open-label extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, in planned to include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa (Replagal; marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc)) for at least two years and on a stable dose for at least six months. The trial was completed in December 2019. Patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE </i>study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.<span style="font-size:12pt;"> </span>In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">et</span>. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">al</span>., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of treatment <span style="letter-spacing:-2.9pt;"> </span>emergent adverse events were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate treatment emergent adverse events were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent antidrug antibodies over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt 5.2pt 0pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;margin:0pt 5.2pt 10pt 0pt;">and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> study, which were first announced in February 2020, were used to support the PRX-102 BLA filing with the FDA, and we anticipate that the final analysis will be used to support the planned MAA submission to the EMA and the BLA resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The </span><i style="font-style:italic;">BRIGHT</i> study was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four&#160;weeks for 52 weeks (a total of 14 infusions). The trial, which was completed in June 2020, enrolled 30&#160;adult patients (24&#160;males and 6&#160;females) with mean (SD) age of 40.5&#160;(11.3)&#160;years, ranging from 19 to 58&#160;years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without anti-drug antibodies, or ADAs, at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30&#160;patients received at least one dose of pegunigalsidase alfa, and 29&#160;patients completed the one-year study. Of these 29&#160;patients, 28 received the intended regimen of 2&#160;mg/kg every 4&#160;weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg pegunigalsidase alfa every two weeks per protocol at the 11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Overall, 33 of 183 total treatment-emergent adverse events (TEAEs) reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs lead to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36&#160;nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05)&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every 2&#160;weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every 4&#160;weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (NCT03614234) of the 2&#160;mg/kg PRX-102 every 4&#160;weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. We were able to complete two of the trials and the last patient in the <i style="font-style:italic;">BALANCE</i> study received the final dose in the study in October 2021. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45 million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We Company received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $1.5&#160;billion and $1.6&#160;billion in 2021 and 2022, respectively, and to grow at a CAGR of approximately 8.6% from 2020-2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed in Brazil as BioManguinhos alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2020, we generated $8.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-size:10pt;">, currently the only commercially available DNase therapy), even more so in the presence of actin. We are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. Refractory gout patients are those whom, despite treatment with existing ULTs, have high flare frequency, consistent tophi, and the inability to maintain therapeutic goals of urate levels. An estimated approximately 2% of the gout population is considered to have chronic refractory disease and are in need of other therapeutic options. One option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for treatment of chronic gout refractory to conventional therapy (no longer approved in the European Union) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of March&#160;31, 2022, we hold a broad portfolio of over 80 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;">On November&#160;22, 2021, Dr. Ales Linhart, of Charles University in Praha, Czech Republic, a principal investigator in our phase&#160;III clinical trials of PRX-102, delivered a virtual presentation entitled &#8220;</span>Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study.<span style="letter-spacing:-0.1pt;">&#8221; The presentation was delivered at the </span>14th International Congress of Inborn Errors of Metabolism 2021 (ICIEM) meeting which took place from November 21-23, 2021 virtually and in Sydney, Australia<span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;">On February&#160;9, </span>2022, Mr.&#160;Myrl D. Holida, PA, of the University of Iowa Health Care in Iowa City, Iowa, a principal sub-investigator in certain of our <span style="letter-spacing:-0.1pt;">phase&#160;III clinical trials of PRX-102</span>, delivered a poster presentation entitled &#8220;Safety and Efficacy of Pegunigalsidase Alfa Administered Every 4&#160;Weeks in Patients with Fabry Disease: Results from the Phase 3, Open-label, BRIGHT Study&#8221; as part of the 18th Annual WORLD<i style="font-style:italic;">Symposium</i> which took place February 7&#8211;11, 2022 in San Diego, CA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;">On February&#160;9</span>, 2022, Dr. Derralynn Hughes of University College London in London, UK, a principal<span style="letter-spacing:-0.1pt;"> investigator in our phase&#160;III clinical trials of PRX-102, delivered a </span>poster presentation entitled &#8220;Long-Term-Safety and Efficacy of pegunigalsidase alfa: A Multicenter Extension Study in Adult Patients with Fabry Disease&#8221; as part of the 18th Annual WORLD<i style="font-style:italic;">Symposium</i> which took place February 7&#8211;11, 2022 in San Diego, CA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">In March&#160;2022, John A. Bernat, M.D., Ph.D., of the University of Iowa Hospitals and Clinics, a principal investigator in our phase&#160;III clinical trials of PRX-102, delivered an eposter presentation entitled </span>&#8220;Long-term safety and efficacy of pegunigalsidase alfa: a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">multicenter extension study in adult patients with Fabry disease&#8221; (ePoster) as part of the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting which took place March 22&#8211;26, 2022 in Nashville, TN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="letter-spacing:-0.1pt;">In March&#160;2022, John A. Bernat, M.D., Ph.D., of the University of Iowa Hospitals and Clinics, a principal investigator in our phase&#160;III clinical trials of PRX-102, delivered an eposter presentation entitled </span>&#8220;Safety and Efficacy of Pegunigalsidase Alfa, Every 4&#160;Weeks, in Fabry Disease: Results from the Phase 3, Open-label, BRIGHT Study&#8221; (ePoster) as part of the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting which took place March 22&#8211;26, 2022 in Nashville, TN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended March&#160;31, 2022 compared to the three months ended March&#160;31, 2021 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $9.0&#160;million during the three months ended March&#160;31, 2022, an increase of $4.5&#160;million, or 100%, compared to revenues of $4.5&#160;million for the three months ended March&#160;31, 2021. The increase of $5.4&#160;million in sales to Brazil, resulting from timing differences, was partially offset by a decrease of $1.1&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $7.1&#160;million for the three months ended March&#160;31, 2022 and $6.8 million for the three months ended March&#160;31, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $6.0&#160;million for the three months ended March&#160;31, 2022, an increase of $1.2&#160;million, or 25%, from cost of goods sold of $4.8&#160;million for the three months ended March&#160;31, 2021. <span style="background:#ffffff;">The increase in cost of goods sold was primarily the result of higher sales.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $8.8&#160;million for the three months ended March&#160;31, 2022, an increase of $1.7&#160;million, or 24%, compared to $7.1&#160;million of research and development expenses for the three months ended March&#160;31, 2021. The increase is primarily the result of subcontractors costs related to the completion of our phase III clinical trials of PRX-102 and maintaining our related extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.2&#160;million for the three months ended March&#160;31, 2022, an increase of $0.1&#160;million, or 3%, compared to $3.1&#160;million for the three months ended March&#160;31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $0.4&#160;million for the three months ended March&#160;31, 2022 and $1.8&#160;million for the three months ended March&#160;31, 2021. <span style="background:#ffffff;">The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92&#160;million 2021 Notes to an aggregate principal amount of $28.</span>75&#160;million<span style="background:#ffffff;"> 2024 Notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity include our cash balances and bank deposits. At March&#160;31, 2022, we had $32.9&#160;million in cash and cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of March&#160;31, 2022, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $5.8&#160;million for the three months ended March&#160;31, 2022. The net loss for the three months ended March&#160;31, 2022 of $2.3&#160;million was increased by a $2.6&#160;million decrease in contracts liability, a $2.3&#160;million increase in accounts receivable and other assets and $1.0&#160;million decrease in account payable and accruals, and was partially offset by a $1.4&#160;million decrease in inventories and a $0.8&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2022 was $16.3&#160;million and consisted primarily of investment in bank deposits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $9.8&#160;million for the three months ended March&#160;31, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the three months ended March&#160;31, 2021 of $5.5&#160;million was increased by a $3.7&#160;million decrease in contracts liability, a $2.3&#160;million increase in accounts receivable and other assets and a $0.8&#160;million increase in inventories, partially offset by an increase of $0.6&#160;million in accounts payable and accruals, $0.9&#160;million amortization of debt issuance costs and debt discount and $0.8&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2021 was $30.7&#160;million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $42.1&#160;million resulting from the sale of common stock under our ATM program and from our public offering of common stock, net of the promissory note payment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160; payment of interest on our outstanding 2024 Notes. We believe that our cash and cash equivalents and short term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program, as amended on May 2, 2022, pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the three months ended March&#160;31, 2022 and March&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of March&#160;31, 2022 and March&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9b4c0d00_75a4_4f05_9aa8_2e415e016c80"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and approximately 65% of our expenses and capital expenditures, as well as the repayment of our 2021 Notes in 2021, are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 31% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.197</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.268</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.176</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.110</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a32759e_5a74_480e_8c2b_45fce53eb63c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&#160;31, 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b630537_1066_49ba_916f_ffdd013d7a89"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d06ddd6e_f9f5_47bb_a0a1_6ec9d55b2394"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt 18pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_f9ad971f_2b7a_4e22_a819_fe4e9ed02dfb"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eec34dc_1253_475d_a1be_0c42559aa930"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966e3751_9a3a_4eca_8883_8a8569ef5519"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_456f122b_a221_47f7_9a57_c06b953e1e11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_11a4c9d6_778c_4de5_9fb0_1794b2af99ac"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022006566/plx-20220502xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Amendment dated May&#160;2, 2022</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">May&#160;2, 2022</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb42ea3a_7937_40ba_a34c_13018e511030"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20220331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/16/2022 11:05:18 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20220331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/16/2022 11:05:21 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20220331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/16/2022 11:05:23 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20220331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/16/2022 11:05:26 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;16, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20220331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $B!"L# 2(  A$! Q$!_\0
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MQ9_T"]-_)O\ &O1_VU?^1#T;_K__ /9#7QK0!]!_\-H^+/\ H%Z;^3?XT?\
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M (;1\6?] O3?R;_&C_AM'Q9_T"]-_)O\:^?** /H/_AM'Q9_T"]-_)O\:/\
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MF_QH_P"&T?%G_0+TW\F_QKY\HH ^@_\ AM'Q9_T"]-_)O\:?#^V9XLGE2/\
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M'Q9_T"]-_)O\:^?** /H/_AM'Q9_T"]-_)O\:/\ AM'Q9_T"]-_)O\:^?**
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MYU4!% _=A@!]T-M]JA^+<GB1/@MJT?BN]M+K4CKJM"+>:.1A!M&W=L/3T!Y
MQFI;LG_75?HRDM;>OZ_Y'D'@OX27_C70+G64UK0]&T^WG%LTNL7AMP7(R #M
M(_6LGQKX!U;P'KC:7J*12R^6LT<UH_F12QM]UU;'(/T%>C>!/$ECX<^!.KS7
MFD6.N@ZS&!9WS-M_U?WL*0>*VOA_\5M2UQO'NOLMKIUS9Z (K&W@4". (?D"
M YSCK^%.5DW;I_E<F.J5^O\ G8\ %O*0Q$3D+][Y3Q]:1(9)%++&S*.I ) K
MZ^^&'BM-0^'FFWT$%IJDTSW$FO2W6J):(KG)W3H49G!'3:#CZ<U@:'<:O?>
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MCR)3)Y?EOYG]W:<_E7UQH$IU_P 4Z7KIU"+^WF\+)*RQ&&.XNI2Y!VO)\J,
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M7PAX(\6^)]=GNH(KJ,:-;FP5&N09.79 Q X ')/8T)K6_:_W[+[P:T5N]O\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G;]M7_ )$/1O\ K_\
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M_P!]'_&C^Q[/_GB/^^C_ (U<HH I_P!CV?\ SQ'_ 'T?\:/['L_^>(_[Z/\
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M+G_P!F_^)K2-.<E>*N>5BLUP&"G[+$UXPEO9R2=OF>@_\*Q\)?\ 0N:;_P"
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M'_"L?"7_ $+FF_\ @,O^%>??\-??#'_H,7/_ ( S?_$T?\-??#'_ *#%S_X
MS?\ Q-'L:G\K#_6#*/\ H+I_^!Q_S/0?^%8^$O\ H7--_P# 9?\ "C_A6/A+
M_H7--_\  9?\*\^_X:^^&/\ T&+G_P  9O\ XFC_ (:^^&/_ $&+G_P!F_\
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M%>??\-??#'_H,7/_ ( S?_$T?\-??#'_ *#%S_X S?\ Q-'L:G\K#_6#*/\
MH+I_^!Q_S/0?^%8^$O\ H7--_P# 9?\ "C_A6/A+_H7--_\  9?\*\^_X:^^
M&/\ T&+G_P  9O\ XFC_ (:^^&/_ $&+G_P!F_\ B:/8U/Y6'^L&4?\ 073_
M / X_P"9Z#_PK'PE_P!"YIO_ (#+_A1_PK'PE_T+FF_^ R_X5Y]_PU]\,?\
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MFCV-3^5A_K!E'_073_\  X_YGH/_  K'PE_T+FF_^ R_X4?\*Q\)?]"YIO\
MX#+_ (5Y]_PU]\,?^@Q<_P#@#-_\31_PU]\,?^@Q<_\ @#-_\31[&I_*P_U@
MRC_H+I_^!Q_S/0?^%8^$O^A<TW_P&7_"C_A6/A+_ *%S3?\ P&7_  KS[_AK
M[X8_]!BY_P# &;_XFC_AK[X8_P#08N?_  !F_P#B:/8U/Y6'^L&4?]!=/_P.
M/^9Z#_PK'PE_T+FF_P#@,O\ A5'2/ASX7N;:5Y= T^1A<3("UNI(59651TZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_<G^%1M^QOXE'_,:TW_OB3_"CZS2_F#_ %/SW_H&?WQ_S/ **]\/['?B4?\
M,9TX_P# )/\ "F']C_Q,/^8QIW_?$G^%'UFE_,/_ %/SW_H&?WQ_S/!J*]V/
M[(?B8?\ ,7T[_OB3_"F']D?Q,/\ F+:=_P!\2?X4?6:7\P?ZGY[_ - S^^/^
M9X917N)_9*\3#_F*Z=_WQ)_A3&_9-\3#_F*Z=_WS)_A1]9H_S!_J?GO_ $#/
M[X_YGB-%>RI^RUXE>[FMQJ6G[HT5R=LF#NW>W^S4A_93\3#_ )B>G?\ ?,G^
M%'UFC_,'^IV>_P#0,_OC_F>+45[.?V5O$P_YB>G?]\R?X4A_99\3#_F):?\
M]\R?X4?6:7\P?ZG9[_T#/[X_YGC-%>R?\,M^)O\ H):?_P!\R?X4G_#+GB;_
M *".G_E)_A1]9I?S#_U.SW_H&?WQ_P SQRBO8C^R]XG'_,1T_P#[YD_PI/\
MAE_Q/_T$=/\ ^^9/\*/K-+^8/]3L]_Z!G]\?\SQZBO8/^&7_ !/_ -!#3_\
MOF3_  H_X9?\3_\ 01T_\I/\*/K-+^8/]3L]_P"@9_?'_,\?HKV'_AE_Q/\
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ML=^)C_S&=.'_  "3_"CZS2_F#_4_/?\ H&?WQ_S/ Z*]_7]C?Q,W_,:TT?\
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M_P"@9_?'_,^8J*^G?^&$?$7_ $,VF?\ ?J3_  H_X81\1?\ 0S:9_P!^I/\
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M .!'_P!C1]JO_P#GQC_\"/\ [&@"]15'[5?_ //C'_X$?_8T?:K_ /Y\8_\
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M^V:G_P! V+_P*_\ L:/MFI_] V+_ ,"O_L: +9M$/:FFR3TJM]LU/_H&Q?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!ME_R,-G_UPF_FE=+7DGQ-\9WO@9=-O[%(I)G,D1$HR,$*?Z5P
M_P#PT9XB_P"?:S_[X/\ C0!])T5\V?\ #1GB+_GVL_\ O@_XT?\ #1GB+_GV
ML_\ O@_XT ?2=%?-G_#1GB+_ )]K/_O@_P"-'_#1GB+_ )]K/_O@_P"- 'TG
M17S9_P -&>(O^?:S_P"^#_C1_P -&>(O^?:S_P"^#_C0!])T5\V?\-&>(O\
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MM0WG_'I/_N-_*O(?^%I:[_?@_P"_5))\3];EC="\&&!!_=4!<]9T;_D#V/\
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M_P#79_\ T$5Y%X?TE=<U:"Q-P+9ILJCLN07P2J]1U.!GWKUW]H'_ )!.D_\
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M,_(OTIX-11_<7Z4Z@!X-.!I@-+0(>#2YI@-*#0!(#3@:C!I0: )0:4-48:G
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M7OL-M_S[Q?\ ? H^Q6__ #PB_P"^!1<5CR0/3PU>L?8K?_GA%_WP*7[%;_\
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M-Z7_ ,^$'_? H_X1O2_^?"#_ +X% &AY8]*3RE]!5#_A&]+_ .?"#_O@4?\
M"-Z7_P ^$'_? H O^4I[4GDKZ"J/_"-Z7_SX0?\ ? H_X1O2_P#GP@_[X% %
MWR%]!1Y"^@JE_P (WI?_ #X0?]\"C_A&]+_Y\(/^^!0!=^SIZ"D^S)Z"J?\
MPC>E_P#/A!_WP*/^$;TO_GP@_P"^!0!#:VR?V_J''_+"#^<E:/V1/05B6WA_
M33KE\ALH2BPPD#9T),F?Y"M#_A&]+_Y\(/\ O@4 6OLB?W11]C3^Z*J_\(WI
M?_/A!_WP*/\ A&]+_P"?"#_O@4 6OL<?]T4GV*/^Z*K?\(WI?_/A!_WP*/\
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M"#_O@4?\(WI?_/A!_P!\"@#2HK-_X1O2_P#GP@_[X%'_  C>E_\ /A!_WP*
M-*BLW_A&]+_Y\(/^^!1_PC>E_P#/A!_WP* -*BLW_A&]+_Y\(/\ O@4?\(WI
M?_/A!_WP* -*BLW_ (1O2_\ GP@_[X%'_"-Z7_SX0?\ ? H TJ*S?^$;TO\
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M^2%K_P#&J/\ AJ#XF_\ 0S?^2%K_ /&J/JL^Z#^V,/\ RO\ #_,^^J*^!?\
MAJ#XF_\ 0S?^2%K_ /&J/^&H/B;_ -#-_P"2%K_\:H^JS[H/[8P_\K_#_,^^
MJ*^/?!W[0?C?6M++7&N![B-BK-]D@&?3@)6]_P +I\9?]!C_ ,E8?_B*AT)+
M0Z(YE1DKI/\ #_,^I**^7!\:?&1_YC'_ )*P_P#Q%+_PNCQE_P!!C_R5A_\
MB*7L9%?VA2[/\/\ ,^D+7_D8-0_ZX0?SDK2KY>'Q<\6(3<KJN)I?D=OLT7(7
MH,;/]H_G2CXS^,?^@Q_Y*P__ !%+V,F-X^DNC_KYGU!17S"/C-XP_P"@Q_Y+
M0_\ Q%*/C+XP_P"@O_Y+0_\ Q%/V,A?VA2[/\/\ ,^G:*^8Q\9/%_P#T%_\
MR6A_^(I?^%Q^+_\ H+_^2T/_ ,11[&0_K]+L_P"OF?3=%?,H^,?B_P#Z"_\
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M5_T%?_)>+_XFCV,@^O4^S_KYGT56;H/_ !YS?]?=Q_Z.>O"/^%L>*C_S%?\
MR7B_^)IL'Q.\2VBE(M2VJS-(1Y$1^9B68_=]2:7LI%?7:=KV?]?,^BZ*^>?^
M%K>*3_S%/_)>+_XFE'Q6\4=]4_\ )>+_ .)I^RD+Z[3[/^OF?0M%?/@^*OB@
M_P#,4_\ )>+_ .)I?^%I^*/^@G_Y+Q?_ !-+V4@^NT^S_KYGT%17S^/BGXG/
M_,3_ /)>+_XFG#XH^)O^@G_Y+Q?_ !-'LI#^NT^S_KYGOU%>!CXH>)O^@G_Y
M B_^)I1\3_$I_P"8E_Y B_\ B:/92#Z[3[/^OF>]T5X,/B=XE_Z"7_D"+_XF
MG#XF^)/^@E_Y B_^)H]E(?URGV9[O17A/_"S/$G_ $$O_($?_P 32CXF>(_^
M@C_Y C_^)H]E(/KE/LSW6BO#!\2O$9_YB/\ Y C_ /B:4?$GQ%_T$?\ R!'_
M /$T>RD'URGV9[E17AX^)'B+_H(_^0(__B:</B/XA_Z"'_D"/_XFE[-A];I]
MF>W5#>?\>D_^XW\J\9'Q&\0'_F(?^08__B:)/B%K[QNK7^5((/[F/_XFCV;'
M];AV9[!HW_('L?\ KA'_ .@BKE>)6OC[78+:*-+["(@51Y,?  _W:F'Q"U__
M )__ /R#'_\ $T>S8_K4.S/9Z*\;'Q!U[_G_ /\ R#'_ /$TO_"?Z]_S_P#_
M )!C_P#B:/9L/K4.S/8Z*\>'C_7?^?[_ ,@Q_P#Q-.'C[7?^?[_R#'_\31[-
MA]:AV9Z_17D0\>:X?^7[_P @Q_\ Q-.'CO6_^?W_ ,A)_P#$T>S8_K,.S/6Z
M*\F'CK6O^?W_ ,A)_P#$TX>.-:_Y_?\ R$G_ ,31[-A]9AV9ZO17E7_";ZT?
M^7W_ ,A)_P#$TH\;:S_S^?\ D)/_ (FER,?UF'9GJE%>6CQKK/\ S^?^0D_P
MIX\::N?^7S_R$G^%'(P^L0[,]/HKS(>,M7_Y^_\ R$G^%.'C'5_^?O\ \AI_
MA1R,/K$#TNBO-AXOU8_\O?\ Y#3_  IP\7:K_P _7_D-/\*.1C^L1/1ZS8_^
M1CN/^O2/_P!#>N,_X2S53_R]?^0T_P *K)XGU(:K+)]I^<PHI/EKT#-[>]'(
MQJO%GIU%>?#Q5J9_Y>O_ "&O^%.'BG4N]S_Y#7_"CD8>WB=_17"#Q/J)_P"7
MG_QQ?\*</$NHG_EY_P#'%_PHY&'MXG<T5P__  DFH_\ /Q_XXO\ A3AXDU#_
M )^/_'%_PI<C'[:)VU%<8OB*_/\ RW_\<7_"GCQ!?'_EO_XXO^%'(Q^UB=A1
M7(C7KT_\M_\ QQ?\*>-=O?\ GM_XXO\ A1R,/:Q.KHKEAK=Y_P ]O_'1_A3A
MK5W_ ,]O_'1_A1RL/:Q.GHKFAK%W_P ]?_'1_A3QJ]U_SU_\='^%+E8_:(Z*
MBN?&JW)_Y:_^.C_"G#5+C_GI_P".C_"CE8^=&]16&-3N#_RT_P#'13QJ,_\
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MUH=JX,;1,#A<]"I!]\TDH:W\OT_X(Y2Q-UR)VL][>=OT.AN/C!86'@Y]>O\
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MC[1J/_/E!_X$G_XBKU% %'[1J/\ SY0?^!)_^(H^T:C_ ,^4'_@2?_B*O44
M4?M&H_\ /E!_X$G_ .(H^T:C_P ^4'_@2?\ XBKU% %'[1J/_/E!_P"!)_\
MB*/M&H_\^4'_ ($G_P"(J]10!1^T:C_SY0?^!)_^(H^T:C_SY0?^!)_^(J]1
M0!1^T:C_ ,^4'_@2?_B*/M&H_P#/E!_X$G_XBKU% %'[1J/_ #Y0?^!)_P#B
M*/M&H_\ /E!_X$G_ .(J]10!1^T:C_SY0?\ @2?_ (BC[1J/_/E!_P"!)_\
MB*O44 4?M&H_\^4'_@2?_B*/M&H_\^4'_@2?_B*O44 4?M&H_P#/E!_X$G_X
MBC[1J/\ SY0?^!)_^(J]10!GVEQJ(UZT(LH"_DRX7[2<$93/.RN@^U:M_P!
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M%7* ,S[5JW_0/MO_  +/_P ;H^U:M_T#[;_P+/\ \;K3HH S/M6K?] ^V_\
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M_0/MO_ L_P#QNM.B@#,^U:M_T#[;_P "S_\ &Z/M6K?] ^V_\"S_ /&ZTZ*
M,34;G5#I]T&L+8+Y39(NR<<'_IG6AI18Z7:%U"MY*9 .0.!WI=3_ .0;=_\
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MO0Z5%IM2[!&MB$TG'J[Z/\'_ %H>A:5X^T#6K.[NK344:"T7?.TJ-$8U]2'
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M\N)_[^__ %JXP=*>.E+V%/L/V]3N=B/'RG_ER/\ W]_^M3AX[5O^7(_]_?\
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M #_ E8F*32CV_3_+\3UU=&M[$ZS>27TUQJ4EM:S6\UIID;7"1,6#;H"Z@/\
M*N3DG!SWJ*XEL+#7M16'2M2MFFM;8S7MK:Q/-;S%<LQA#LJA^"5W CD5Y*NH
M72W!N!<S"<]91(=Q_'K1%J%U;S-+%<S1RO\ >=)"&/U-'L'U8/$QZ1_K^O\
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M P.(D4*IX]>3BNDHJO:2:LWTL1[*"=TNM_Z^\****R-@HHHH **** "BBB@
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M/Q?^9\]?\,DK_P!#4?\ P7__ &VC_ADE?^AJ/_@O_P#MM?0M%'U[$?S?@O\
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M%2Z/_P _-]_W\3_XB@?"72!_R\WO_?:?_$5VU%+ZQ5_F#ZM2_E.*'PGT@?\
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MX6&>4/4T>6!ZT^BBX6&[![T;![TZBBX6&A *7;2T4AB;:-M+10 FV@#%+10
M4444 5=3_P"0;=_]<7_]!-+IW_(/M?\ KDO\A2:G_P @V[_ZXO\ ^@FET[_D
M'VO_ %R7^0H SI]!TR6>5WTZT=W8LS- I)/J3BF?\(]I?_0-L_\ OPG^%%%
M!_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?
M\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%%
M!_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?
M\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%%
M!_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?
M\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%%
M!_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?
M\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%%
M!_PCVE_] VS_ ._"?X4?\(]I?_0-L_\ OPG^%%% !_PCVE_] VS_ ._"?X4?
M\(]I?_0-L_\ OPG^%%% !_PCVE9S_9EGG_K@G^%']@:7_P! VT_[\+_A110
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MH.F8_P"0=:?]^%_PHHH D&@Z9G_D'6G_ 'X7_"GC0=,S_P @ZT_[\+_A110
MO]@:9_T#K3_OPO\ A3QH&F8_Y!UI_P!^%_PHHH /[ TS_H'6G_?A?\*<- TO
M'_(-M/\ OPO^%%% !_8&E_\ 0-M/^_"_X4?V!I?_ $#;3_OPO^%%% !_8&E_
M] VT_P"_"_X4?V!I?_0-M/\ OPO^%%% !_8&E_\ 0-M/^_"_X4?V!I?_ $#;
M3_OPO^%%% !_8&E_] VT_P"_"_X4?V!I?_0-M/\ OPO^%%% !_8&E_\ 0-M/
M^_"_X4?\(_I><_V;9Y]?(3_"BB@ _L#2_P#H&VG_ 'X7_"C^P-+_ .@;:?\
M?A?\*** #^P-+_Z!MI_WX7_"C^P-+_Z!MI_WX7_"BB@ _L#2_P#H&VG_ 'X7
M_"C^P-+_ .@;:?\ ?A?\*** #^P-+_Z!MI_WX7_"C^P-+_Z!MI_WX7_"BB@
M_L#2_P#H&VG_ 'X7_"C^P-+_ .@;:?\ ?A?\*** #^P-+_Z!MI_WX7_"C^P-
M+_Z!MI_WX7_"BB@ _L#2_P#H&VG_ 'X7_"C^P-+_ .@;:?\ ?A?\*** #^P-
M+_Z!MI_WX7_"C^P-+_Z!MI_WX7_"BB@ _L#2_P#H&VG_ 'X7_"C^P-+_ .@;
M:?\ ?A?\*** #^P-+_Z!MI_WX7_"C^P-+_Z!MI_WX7_"BB@ /A_2R/\ D&VG
;_?A?\*V+:)(+>..)%CC50%1!@ >@%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20220331x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220331x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &?!#@# 2(  A$! Q$!_\0
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M0!C7/^OD^M15+<_Z^3ZU%0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117$_$
M?XR>%OA3=:%;^(KR:VEUJZ%I:+# TF7]6Q]U1QS^E'D!VU%%>-?M"^-;SPG=
M^$((_%>I^$-/O[N6.[OM(TY;Z?:L3,H$9AE.,@<A:3=AI7/9:*\,^$/Q)U34
MD\17MOJ^O?$;PI9VZO::I/HJVMY-<AL/;QHL<0D '?:-IX)]-.3]I&QTZP\0
M/K'A76=(U+1H(KJ72WFMKB66*1]BLC0R,N<_PD@U5A;GL%%>0ZQ\;5DT36HK
MW2/$7@[5K$03K!,ELUQ+!)(%66,[GCP2<,K?,N>@-9OQ#^.=\D+0^'M'UF"S
MCU>WTYO$8BA:T>3S566(*6+XP2-^S;G@&BUVD'2Y[A17'_$;XD1_#Z;1X!HF
MI:]=ZM<M:VMKI@0R%PI89WLH XQDG ZGBN8E_:#M5L],2'PGKL^N7M_)IC:&
M/(2YM[E$WE79G\O:1@APVW%):[ ]-SU>BO+'^/MG#?L9/#&N)H$-RMC=>( (
M6M+>Y. 8RH?S&"L0ID52H/>L+X@_'.^51#X>T?6(+%-8M]./B/RH6M))/-59
M8@I8OC!(W[=N> :%JTN_]?J&Q[A17GZ_&;3)/#\VL#3KP01ZT=$\HLF[S!($
MW]<;<G/K69-\>(9=1NH-/\*Z[?::D\MC!K<4<1M)KM <Q ;]ZC(QYC*$SQFC
M^OR_S0>7]?UHSU.BO-_A=\2M3\1_"%/%GB'2IK"ZCBGFE@#19E5&;E C$#@8
MY.<@UG6GQ^?4M*TNXLO GB*ZO]64S:=I:/:B:X@"Y:<DRA8T&<?.02<8'--J
MSL"U5SUFBO#_ !!\9+O67L;O0+FYTV!]+U%[FSN84$T%U"!A7!!PRGT.#[UZ
M19^+(]&^&=CXEUN60Q)IL5U<S+'EG8Q@G '4DG@#UHV5W_6_^0[:I=_^!_F=
M117E!_:"MK"PU&;6_">N^';JWLCJ-O9ZAY&^]MP0"T;([*K#(RC$,*=\4OC-
M/X2T748]'TBYOM871#K$'S1>6J[E&&#,,D;L_A2>G]?UV8)7V_K;_-'JM%<O
MIOBV\'P]LM?O=%U"2^>SCGDTNTC2:X9RH^50K;>>O7 !YKA9?VD['3M+UZ;5
MO"NLZ7J>CB%YM*::UN)I$E;:C(\4C(3G^$D$4VK-Q$M5<]BHKR^'X\V4%EK+
M:QX:UO0M3TTQ8TFZ6&2XN1*<1>48W93N/&"1CO3/AM\0];\7_$CQ1I^I:9J.
M@06-G:NFD:DL)D@D<G<P>,L'!&.0Q'TH2N'2YZG17B?Q5^.%[INGZQ;^'='U
MC98W<5E+XBBBA:TBG+KNCVLV\\'!<(5&>M:6I_M'Z!I7B633)+*ZFL+:=;.[
MUA;FU6*&8X&WR6E$S@$C+*A S26NP/0]:HK@V^+^F)8><UE=+<C53I)LRR>8
M)!R7SG&S;\WTK TC]H[0]?UQ=-AL;NUM;MI(-/U66YM6CN95!X$*RF9,D'!=
M #0!ZW17C/ASXVWT/A;0H3H6L>-?$=Q:R7EW%I2P1F&%9&7S'+LB]L!1R<<"
MK5Q^T78W-Q%%H/A3Q!XF+6"ZC(;!(4\F+<5?>)'7#*0<J,DXXS0]/Z_KL!ZY
M17D^K_M$:?:7$<>E>&=<\1(VF)J[RV"Q*L5N3AB_F.N"N#E>2<8&:DLOVA='
M<W<VI:+K.A:>FG_VI:7M_%&%O8,@$HJN60Y(&UPI-']?U]S^YA_7]?>CU2BO
M';;]IK17TC6;N[T74+&YTZU%\MA]JM+F6Y@+!=R&&5U!R1E&(8>E4_%/[0>H
MVWA#Q+-9>#=8TGQ!I]C'?VMGJ9MCYT#L )AME*X&>5)##TH!:GMU%9?A;4KK
M6/#>F7U[:26%W<6\<LMM*R,R,5!()0E?R-:E-JSL).ZN%%%%(84444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QKG_7R?6HJEN?\
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M5<#"\G ZUH77[.?A"^TF3SM-@B\0RZ>EC)KD ?S<J@4.%+%?X0<$5ZE11O\
MU_7<=SQZ3X):]XI2]?QGXJM-4N?[,DTNQ;3---LD*/C,LBL[;Y#M&<$+UP*J
MK\#/$VKOJ$WB+Q;87UQ<:"VB1_8=,:".(;@5DVF1BQ^4;N>>V*]KHH_K\_\
M-B6G]>G^2.!\1?#S5?%'PE7PI>:Q;0:G]FC@>^M;9UMY"F.&B+[MC  ,N[)Y
MYKS?1?V7=1L#K<DNL>'[1M3CM5-MHNB-9VT)AE#_ "KYC,VX#&6).?:OH:BG
M=J7-U%;3EZ'F7C/X-R^+/$.LZM'K"V$]U;VRV;K!O:VG@<NKL"<.I/!7CZU;
M^'_@#Q%H'BW6_$?B37['6K_5+>"$II]BUK%#Y9/W0SL2#GN<UZ%126FP6/&_
M%/P2\1:H=8TW2/%=EIWAG5+Q=1ELKC33+<),&4LJRAP!&VWH5)'8U3G_ &;A
M#XQN]1LG\*MIE[>"^G;4_#$-YJ43\;EAN'. IQ_$I*]J]PHH6EK?U_5AO4\Z
MG^#\5S\49/%$NH;M,>U*?V.(\*+DJ4,^[UV'&,5RG@O]G%O!VNPM%)X4?2;5
MY'MYH_"\*ZJV[.%DNB3D#/WE4,?6O<** >IXY:?!7Q)X8ATZY\+>*=/T[5H[
M)M/O9+_3&N8)XC(SJR*)%977=QDD'N*YO3?A-XJ\.>.+G2_"VN)IMLNB1V]Q
MJ>J:6;B.Y9Y&,C)M90L@+$@9('<&OH>EH_K\_P#,/Z_+_(\NTGX)KH<MZMIJ
M:FVGT :,BRQ$N'R296(.#DDG:*AU_P"!,?B?3-.TZ_U*,VMMH;:1)L@R7?((
MD 8D8!'W3G->K44/7?\ K?\ S8?U^7^2/"],_9TO8?#VLZ?<7/A&RGO+=+6&
M;0/"\=A\JN&WS,&+NQQR%(7GI74>,_@_-XMO]4N%U6*U6\T$:.H,!8HX<,)#
MR,KQ]WK[UZ910]06FW];?Y&;X:LK[3?#^GVFI3V]U?00)%+-:1-'$Y48RJL2
M0..A)K2HHIMW=Q)65@HHHI#"BBB@ HHHH ?%_K%^M;0Z5BQ?ZQ?K6T.E "T4
M44 %(2!S2TUC@T 1W$ICB9AC@9YKR'6;B>^U:669\L6P%'I7J^HX-G*/;M7F
MU]IP5R1@$MN)/>O-QE]$CKH63;+%SID,MLAE5%; VL ":YS4-"96EG (781R
M !^5=E$<6VU<$ =&ZBLB[NU2-D(RIZ@FN1V3NSI3;6A\>_%C4M0T[Q-;6=F\
M(B60%PT><*>>_4>U>M?"RW&J:692=QNEW.PYW=@,^U7_ !U\$M-\:Z@+Z*YG
MM)G*^:T=RR;U'8@']:[#PQX>LO!UA!:6T:)Y2!51.@_&N2',IMO8]"JZ3HQ4
M/BZCM(\+S6FU71PG]X2@DUU5OI\ MS'"C!@<EG.>:JPW32,K2?*#Z=OK6O;:
MK:(5C+!6[;>0:Z::3>AY\Y.QTWAB_6>R6$N?-CX/'%;R@CJ0:YS1)$:Y?:N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M12RJG04(P=TI<SO:[^Y);Z[=#SS6_#4FM>(/%NF/(D$VJ6<$MI,_(S'Q@CN
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M:ZYK7B&UO]?;5H-1NY;:R:"W*1*56&)"[,O7[S,36K??":>[T_6+8:G"IO\
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M4 %%%% !1110 4444 %%%% !1110!C7/^OD^M15+<_Z^3ZU%0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!C7/^OD^M15+<_Z^3ZU%0 4444 %&:KZC*\&GW4
MD9VND,C*?0A20:^)OA!>_M)?&;X?2>+]&^*6GV]ND\\*V-[I\0D=HNHW+ 5
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M<V&A_%KX ZOXQ,:^"(M'BC6:[&;6&[,2[3)G@?P\GT]JVUU/1O%_[;'AR_\
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M_FW]YJT444""BBB@ JIJ&CV&K-;F^L;6]-O()H3<PK)Y3CHZ[@=K#U'-6Z*
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M3]Q5BC=W..^W'JW2G6G[0DNHQWMW;: G]G6MO9R!I;TK-++<JOEQA/+( #.
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MNBZE::1;VK1RM?1LH(.0W!')SM_[Z%;FM_&R"*_L+6YDFMPBQH_F0MD;7ZX
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M/N!P#UQ26F_]:H9Y!_PN'Q7KB:G";;3]/CL=!GU"XBGMW:2=T>5, I,/+4[
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M69@JCJ6.!7S9K7QL^(%KXIO-,T72+_6(M#:*UN$L?"LMTFH2;07)G68"WZ\
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MQ["_<'J<]MS?^.UP8IS7PLZ*$8ROS&UX\^()\0)I[./*\R6%A$LY/3<3NX[
M#%<[X&\7/)JOAW<D<D,FMQ75Q$$ XB&Q>0/5^?4\URFKV"P:=IM_)<JDA"6Z
M1X[,FQ<<]3U_&K/@FUBM+SPX(Y683:K';Q&7Y<IN61CQQG*8]>:RIR<59]?^
M :RLW>/];GUQ\9=7%S9WL:GA6A'YLU>)^?\ 9)YBP_=--&6."<;=S_\ LM>O
M^/5AE\-:I,RAI6D@VL>H&6KY_P#B!XA:TTJZL(H5$@664W!!W#<A7"D>P/YU
MV8J:C!39S8>/-/E.AN%FU7X>>!I[=/,G?Q%><'N7M^!^8Q6M\/K(CXH:1!/=
M0)-97D4D\*ARX6*/YP1MX(P>I%<GX+\6W%UX2O\ 38(S')X=:UU.WN?-#YD:
M3:V5/89&,_C72^$_$5SX?-_XANH8KO4M<O'MXWN%PN%C+RR@ C^+:!VS^5>-
M4O/%4DX^[:]];W/4C.4:-2V]['D6H:[)K7QMU_5KK5XOM$FHW2/91B43,@1E
MV ^7L "@?Q=J^@O!_AR'QAXSU:QO;BR6VAB,X:>T67E'(4$2/MXY/2OFCX%>
M)KCQ?K^O7-WIFERW]_>),9A9J)8W9R&\IB24#9RV.M>P^)=%?Q)XWO--@0$S
MZ@RK\N0BB20EC[ 9/X5Y^91JU*$Z6'ERRE)I/?6V^IOA]:G[S9)$_B;Q=>Z5
MI%X%6WLYKR<V\,EM8Q0K)&/+RP4#'0$9[XQ6C^R[K5S/X>\0ZA?^3!;?N528
M6\=O'D(2P!55!QQZXR*XWXOZU#<7]C;VHQ:V$SVD9!^^L:1C=^))-8GPCD>7
MP!J*F:14CE1Q&96"_P"K.<+T)Z?E7?1K3IXB,&[J/ZK_ #)K4T\-*5K-O]3)
MT;Q%<:.]X]X@2\:[>.WBD@C!)9R VWRP0%!W;B>2 .].\.>,+\V=B\DC>>Q$
M1F5(AYA/)) 08PH/3KFN%TXM+J$3,[,WVL<LQ)^_[UMZ &2XT:$C!C"L?JRY
M_EBN-XF7,K=_\CLE0BT[]4=)XVN[;4_&&JW>F+]CT][$310%$8AO*0MDE<D;
MBW!-9EKJU_!H%K'*;.Y5UN<">QB(7 7!&%!!]3GTIK$3,SCY@=)_7 %1S_+H
MMI@Y(2Z/Z+6D:TG4_KN92II1M_6Q5^-$EE_PJGX>)-=26J;!L\FV,BL=A[%P
M0.?4U>^,]GI3:YX>2_U.XM'72X-J06(G!&>Y\Q<?2N<^.^!\,OAM$#DCC'I^
M['^-:/QU8'QKHR'@)IL _4U[M6R@Y/R/+HW;C\SG]0BT9=<N9%U6[\S?,,'3
MP,'YLC/FG./UJWI]MH8T]4BU>Y\U9]P#::<$[3@9$O\ 2N?8";59G7[K-.>O
MLQK0T6S+21-C(-PJ_H:\3F3>W?\ 0]%II;GZ4_\ !/%XV\%>)EC.X+=QY;RR
MA;.\YP?R_"OK:OD#_@G1+N\*^,4'1+R#I[J]?7]?3T/X<3PJGQ,*,9HHK<S"
MLO4O#.G:OJ^DZG=0L]YI;O):N)"H1F4JV0.&X)ZUJ44 <SJWPU\.:[JFHW]]
MIPN)]1LO[/O$:1A'<0@Y = <$@]&ZC/!K#L?@)X+L=(U+3C87MY!?HL4TNH:
MI<W,ZHIRJQRNY:,*0" I&"*]"HH \ZTC]G[P1HZZN$TZ[OFU>V%I?R:GJ5Q>
M27,8.1O>1R2P/1LY%+;_   \%6NBSZ:ME?LL\\5R][+JEQ)>F2(YC/VAG,@"
M]@#@5Z)10!P2_ SP8/$XU[^S)FO!,+HP-?3&T:<=)S;[O+,G'W]N:O3_  F\
M,W/AB[T"2RF_LVZNWOG"7<J2K.S;C(DJL&0[N1@\5U]%'D'F<_X-\!Z-X"L9
M[728KC_2)/-GN;Z[EN[B=L8!DEE9G; X&3Q7/6_P%\%6GB.+6X=-N4O(;K[;
M#']OG-O#,<[FCA+[$W9.[ &>]>@T4=;ATL<+HOP0\'>'_$HURRTR9+Q)'FAA
MDO9I+6VD;[TD,#,8XV.3DJHZUTUSX9TZ[\16>N2PLVI6D$EO#*)&"JCXW#;T
M/0<FM2B@#@=4^!?@[5],L[&6QO(%LY)98+FRU&>VN8S*Q:11-&P?:Q)RN<5H
M0_"CPQ:3>'I;2PDL'T#<+#['<R0A WWE<*W[P'J0^<GFNNHH6FP/7<QY?"6E
MS>()]:>!SJ,]F;!Y/-;!A)SMVYP#GOUKEM3^ O@S5+#2[5[*]METV$V]O-8Z
MG<6L_E$[C&\D;JSH2?NL2*]!HH'<X/7_ ('>#O$2:>LVGW-D;"#[+"^EZA/9
M.8?^>3M$ZET/=6S1XA^!O@OQ,MDMWI4L*VEM]C1;&]FM1)!_SRD$;CS$[X?/
M/-=Y10(Q$\%Z,OA%/##V*S:&EL+/[),Q<&(# 4D\GZ]:Y6T_9]\#6FC7VF_V
M7<W45X4,EQ>:A<3W2[.8PD[N70)_"%(QVKT6BAZNX>1Q&C_!CPGH=I:P6UC<
M,UO?+J(N;B]FGN);A>%>65V+28'&&)%:5Q\.=!N[>_@EM96BOKY-1G G<;IU
M(PPYX' X'%=+13O_ %_7H@_K^OO/)/!/[/NCZ3JUWK&N6XO=4;59]0A6*]G-
MK\S QN\!(C:1?[Q4X]:Z^'X5^&8;F&?[ TCQ27$JK).[(6G&)<J3@@CL>G:N
MLHI=+!NVSS6T_9T\ V=G>VRZ1<2QW48AW7&HW$KV\8;<$MV9R8%!Y CQBG:?
M^SUX(TVUUF%+&_G.L0+;W\]WJMS//.JG*DRNY;<#T8'(KTBB@#SW4/@+X-U2
M_M[RYL]0>>...*7;JMRBW:I]S[2JN!.1ZN":=XF^ W@KQ=JDU_J.F3^=,J+-
M':WTT$$Q3&QGB1@C,N.&()%>@44 9&K>$],US^ROMD+R?V7<)<VNV5EV2*,*
M3@_-QV-49_ASH-S;WD$EK(8[N_74Y@)W&Z=2"&'/ X' XKI:*/Z_K[@\CA&^
M"'@UO%9\0G2Y3>F?[7]G^V3?8_/_ .>WV;=Y7F?[6W-:0^&7AY=)BTP6DOV.
M*_\ [31/M#Y%QNW;LYSC/;I74T4; ]=6<6?@[X6_XEQ6SN8FT^\EOK=XKV5&
M$DO^L#$-\R-W0Y'M531O@1X*T'59M0L],G$SK(D<4U]/+!:B0$/Y$3.4AW9.
M=@%=_10!Q&J_!KPOJ_A_2='D@O[:VTD%;*:PU*XM;F$'J!-&ZO@]P3S72>&O
M#6F^$=&M]*TFV%K8P [$WLY)/)9F8DLQ/))))K3HHN 4444 %%%% #XO]8OU
MK:'2L6+_ %B_6MH=* %HHHH **** &%4\S)"[\8SWQ3)+2"5</#&XW;\,H(S
MZ_6O"OB_K.K>%?B1>:KI5W.;U= 46]F\D8A8_:,.P5EY*J2W7CJ>*RM)\>>*
M];U;2=)A\221V%UJ20-?6]Q:W<[*82SIYB0^5UP1@%AT-"U5_P"M[ ]'_7:Y
M[UXC\+Z;XKT]K/4K<3PEE;ABK JP888<CD"KZV=NC%A#'N(P6VC)[<GO7S/+
M\3/%^F>%H]0;Q//-<7.GZ@Q>6W@VPM ZA)%4(.<$YSD'T%6]4^*/B73H1#H^
MO-XBTJ46AN];,EM&;)Y%8R()-GEKT7[X.W=@]J?I_7]6!H^D/)CVLNQ=K=1@
M8/UH2**&$1HB)$HP%  4#Z5\\^'?'WBC6_$.GVEQK\\>GQ6M]=!K#R+E[M86
M&S>ZQ!7/4'RL!O6N0\1?$?6O$^BZAITOB&::UO=,6_D,-S;O+;,ER@.?+CQ"
M-O)1F<C')H2N[?UU_P F+^OZ^\^M3!$P'R*>,#@=*YS2_A[I.EZRVIAKR[N<
M,(OMMW).L(;[P0.3C.!^5>+S_%K5],LY;!?$2-?IXBCM8(W\EI7LC$S*<!>5
M. =^.?6JA^(?B^T\/>%;BYUVY-MJUE+>3ZG-<6=H%F4X6)6DBV!<<[<%CZT;
M:_UM<-]#Z6:"-\_* <8R!R*SM!\/6/ABSFBM0^))&GFFGE,DDCDY+,S<FL[X
M?^(+C7O"VF3:C+;'5WMDEN(K=\XST." 0#[@5X')\0M9UCPE>;_$S:]=7L>J
M6U_I12 "T@C23:^U$#+@@+ECALTI7C?R''WK'TWMM_.6;$?FN-HDXW,/3/>E
MCM((EVI%&B[MV%4 9]?K7@&F6VOQ+\(7U&_TJXL3<+Y45K9212K_ *.V,NTS
M@\>BBKOQN^)VJ^%];U"#3M7.FMIVGI>I%+)#!'.Q;& '1WGXXP@4+W;TJ2Y7
M;SL)>\K^1[F]K#+]^)'YW?,H//K220V\KQHZ1LR?,BL 2/<5\^6WQ%\5B*ZU
MM-8FO&3Q"VF1:48H5@>(QLRID)NW;@,-N]N:L_#S6CX@^*GAJ^N?$9U?5)M$
MN'N[)O*_T-S(N4 104QTVMD\4DKO^NUQO^OOL>[RSVMO/&DDD4<TA.P,0&8]
M\=S3)A864(AE%O!%*VT1OM57)[8/4UXM"WA4ZSXW7X@FT&I&_?[/]N_U_P!D
MP/)^S?Q=,8\KG=[T^R/A@>+?$Q\<BU$12#^RO[=''V/RA_JO-_CW;MVWYL]>
MU+H&W]?U_5CVB[T^WNM/FM7#102(5;R7,3 >H92"I]P:R/#7@C3/#+SS6WGW
M5S<;?,NKV=IY6"_=&YNPSVKS[X4>+KC3/"F@Z-X@L-487[R0VMW<VY,7E,7,
M,<C,=VXQKSP?<@UTWP9NYKGPC-%(QD@M+^YM;:0_Q0I*RH?R IVLV'0[C[/%
MYWG>6OFXV^9M&['IGTI1$@((1>#D<=Z?12 B6VA0L5B12V=Q"@9SUS3GACDB
M,;HK1D8*$9!'IBGT4 0M:0.L:M"C",Y0%1\I]O2G^2G/R+R=QX'7UI]% $(M
M( SL(8PS_>.T9;Z^M*+:(2&01H)#U8*,G\:EHH ACM(8EVI#&B[MV%4 9]?K
M1+9P3@"2&.0!MX#(#\WK]?>IJ* &O&K@!E# =,C-(L2*00H! P"!T'I3Z* (
M_L\7FF7RT\P]7VC/YTU[2"0('AC8(VY<J#M/J/0U-10!'-!%<(4EC21#U5U!
M'ZT&",@@QJ05VD$#IZ?2I** (X[>*)45(T14&%"J %'H/2D6UA1Y&6) TGWV
M"C+?7UJ6B@"!;*W2 PK!&L)&TQA %QZ8]*=]FBS&?+3,8PAVCY1[>E2T4 11
M6L,"(D<21HARJJH !]O2JVIZ+::N]F]S&6DM)A<0.K%61P",@CU!((Z$&KU%
M $/V*W_>_N8_WO\ K/D'S_7U_&N>N?AYI-YX@35KAKR>1)5G2UENY&MDD485
MQ$3M!'4 <9YQGFNGHH\P\B@^AV+ZA;7IMT^TVRR+$P&-F\@O@>IVCFK]%% !
M1110 4444 %%%% !1110!C7/^OD^M15+<_Z^3ZU%0!\$?\%/(9+G7/AM%#')
M-(8;Y@D:EF(#1YX%?%]MH\4'AFUN=3FAM52ZN;B.U8F2692(<?*GW0,$D,5.
M"/6OMG_@IMXAU;0;WX?KIL\EM'<17<<TD.%?EHP%W]0#DC (SWKX/!LM&T"U
M/G3W,Z:E<#_1F$2(_EQ;AN*DL,8]._7BO!Q$8^VFVOZT/5I2DZ<8IV_/J:?A
M+XA:?I]YJ%OIT]UIEG/%$)/M4,'E2 /^\W*D3%% 8D-NW=!S7MGQF'B0ZRMO
MKUWYEG:P"731:A85VF55D\P(!O.0/O9 [5Y/X*BL/B_JL/A2U\/V&C7"_,=4
M&UI&7DD.%C3=D*1R>]>@_$F9K+XA^([>[D>2&*TM$MT9R56/";=G. N0< <5
M6+G_ ,)UXMO1KR6C%0@OKOO)='Y]$>H_LZ^)=)N;^T\-Z[<-%;71BN;1U8C9
M<).Q3'N>>O%>9_$:WMKSQ3<ZU%?"8W&L:PT5BXDCFMU9R-TJ,!]X , 1QNXK
M/\&2WD?BGPS/:(_R/"V_RR5 %RW7C&*Z_P#:"TNVT_Q)9ZS;I/+-JES>?:#A
M51KE0%;'7:-H'&.H/2N>G*I/ 2B^C7D54Y%BU)=4SS'XB7L%[XV\%7\ERVCQ
MKX08?:],;SI#(KN@CD4$%58?+G_:/7%5_AIK4DEAJ'A6W$*OJ-HS6TSC=+'-
M'+O"JQZ!Q'M)//W3S@UW,?AWP;J^B:6A,[:W<>&&,<09F>)4ED=9''"GYUD
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M 6>H^/O"*17$%L=+B5+A'?YG8 #"YZL01P*Y(M<J7=G1U?DCZ:\:W_F:+>Q
M]7A/7W:O ?B'YA-QYF%B:%U0CJQ .[\LBO6_$DS3/?0EN"UO@?@QKS#QFT45
MS:RW%NMY;#S0\)8KD%23@@C' KJQJO12.3#.U0/@W>/+\0],TW45OK_1=0T.
MZL;Z5(XT\F&+<Z,KE06*MC/4;BM:9\83:YXYT]="A2UTR,MIME9Z@OF(B/$W
M[UMN#YG4Y!QR<@BCQ-I6E>'KNVOM/BEMHK+PX\.YF=T^T7<PR!W)\M6/MD5/
M\,/"=CJVLW]P-9LI;G3D^VVT,1F#2.J\HP\O/0D?UQ7+64_;480?:[.RFX>S
MJ3DCE?AO#JOP^^)MG87G@_3?#UE<74,D+6<,@%R(RA$F#*^T,&8\8SG'M7N'
MQ9L])^%3:PECJ":MK6J%@9(CM-I;NS$#OAF!Q^%?-_P>6>]^--W?M/'-)-?F
M/R[B[1KF-1,I53&&+!1^0'IFN^^)'B%_$?BCQ+>2!<O>J@V] JY48R<XXK+,
M:JIT;P6MW;[M6;8.#G5Y6]+*_P#D<EXLD$SP%!LC$LAVYSSB/)S_ $KJ?V:[
M_4(?A7XBTT:=#JD\LF7O2YB8*8R%4+T&!GGOWKD?$N$EME!Z^:V/J4_PKT']
ME><)X%\2#C<3'C/_ %S:N?!2?UFWIT_NG3BX)X5M]'^IXG87&GW=TA2TFL6\
MU1&HF,P+A^^0#S[=*T]%4IJUEN'S!A^D=8>CQC]U.TAC47.Y& R68,< #Z]3
M6OX=?[1)I4^=Y8-O.,?,$/\ 2O.E=R7J=UU%OT-!(A#\@Z?V7S^.#5.X<#2H
MQG@17)'Y#_"K-W,8[A@.VFHI]N!65<S!M+([K;W!_G6T5[Z_KJ<\W=,H?'F4
M'P3\.$ P ^/_ "&O^-2?&.[%WXZMFR?DM($..W)IWQMTZYU/1?AE:01EF:41
MYZ*I*1_>/8>]5OBOI&H6?Q!NK9K*XD:W$,3F"%Y$!SG&Y017T==7A9>1XU%K
MF7S_ #,.Q02W(/\ #MD;/_ 6K;T$*PL4SPUXIS^&/ZUDZ3'-$S"2WE5TMW)#
M1L#G&.X]ZU=&66+^S7:*4 W3-CRFR -OM7A*+O\ UW/4DU;^NQ^A7_!-F>"X
M\)>-S&7,JZA LA;&W_5DKM_,Y_"OLFOB[_@F5;M#X)\;.ZLK2:A;-AAC_ED:
M^T:^IHZ4XW/!G\3"BBO/OBMJ'Q'L;OPV/ 6EZ9J-O)?*NK-J#A6BM^Y3)'XD
M9/H#6W5(@]!HI:\M^*-_XFN?'?A#P_H'B.3PY!J4=XUU<0VL4\F(X]R[!(I
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M5((IU>3_ +-ME=Z/\(+-KK4KS6F::XD3S8HPZCS&&U0@4'/7GUZUW'_"7/\
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M8((5E! /TJ,ZC:+:&Z-S"+8#/G&0;,?[V<5&NLV#/L%[;%\$[1,N< X/?L:
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M>N4$DD"J#LZGY1R 2*XJW4#58@'\Y1-(1(3G<!O^;\>M6-(?RY;8Y)Q#(?\
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M(+:8GR'8O+,.>HP<*/?\Z\"$5?5_U<]63>UC]$/^"9LS7'P[\82,!EM67H,
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MWD_QK*JT\$TEH[_E?]"TG]:3>]B!]>GN=&MPMK;QI<075C&D462B;5XWMEL
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M_P"[ )$@E<V\87/+@8;L!7/>%?$7B;XH:U\/99_$KZ#K3IJ=HVJK:VSW#*C
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M5MP:IJD*9N=)!3KFTN!*0/<$+D_3-2:/X=ATR5IVDEO+V3B2YN&W.?8=E'L
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M5];^']&<G0=%M[F&)@V1/,8W,LIX[MD#V%.^%/[CX0^*\#JLW?\ Z9"N76W
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M<>$?$5U',]QI\_ABZU&^E$;8#I:JP\J-N"6=^,X&:'[M_N_/_@D_%_7I_P
M],TCX,^!= U+4-0T[PGI5E>WZ/'<3PP89U;[P'/R@Y.=N,ULIX+T.+^RBNE6
MP&EPM;665)$$;+M9%R>A7CG->,>&/BYXX^)UAX9L-!ETG0-9NM,GU*^N]1L'
MF0^5*8A&D6]=FXC+$L=GO6'<^//&7ACQYXGU^\O]+NWCT&S5=*ME,MHD\DK1
M@B</RH?YB0N2/EXQFG9[?UI?_@H=]+_UK8]K\._!SP/X2OI+S1O"NF:==2+(
MC2P0X)63[ZG)QM/IT],5'HWP4\!^'HM3BTWPEI5DFIH8[L0PX\U#U7.<A?9<
M"O-?&7Q,^('PRM=:TO5;_1-:UA-.74K&_MM.:VC0^:J/%)$9&R/FX<$$]Q3/
M'?Q!^)?@#4=-34K^SCT<0">?78?"\]U9RR,V3%+Y4I>V55P/,VMNZX%+?\@/
M9[[P1H&INK7>DVUR5LVT\>8I/^CL #%U^Z<#\JI>&OAQHGA#53>:1:)8(MC'
MI\=M"#L2)&+ <DD\D_2G^(/B%HGA+PS:ZYJUVXT^<1[)K"TGNPY<9!58D9MI
M]2/K6%\5?'U_H?PIN/$GA=H7O)!"UHU_;N$(=P/GC;:PX/0X(IZI_P!?UU!6
M:_K^NAJ:O\(?!6O>*(?$>H^%],O-<A(*7TL&9,C[I/9B.Q8'%+<?"3P7=^+5
M\43>%],E\0*0PU!H 9-PZ,>Q8?WB,^]>:ZI\4O&_@>ZU[0]7N=&UO6E6S;3[
MR"R>U@C-Q)Y>V5/,8L$/.006]J[+P'XB\46?C35/"/BN]T[6;RVLX[^#4M.L
MS:!D9MI1X2[X(/0@\BA+:W]=Q-[W_KL0^!/@7X;\)ZM-K%YIVF:EXD-[<746
MJ?9]LL:R-N"\D\@?Q=?3%:)^!7P];7Y-</@[2?[7DF%R;P0D2"4'(<<X4Y[C
M&>]87CC37^%5IXA\=6NH7>I7>US%IUTL8MUDE**,L%WA00._0D5S_BKQE\4/
M!%A:V=[JOAB_U#4+ZSAM;Z&S:/RUF;:ZO;>820N?ED##=W H6MDO)?\  &^I
MZ?J7PO\ ">K^&IO#][X?L;G199FN'LI$)0RLVYG'.0Q/.015&V^"/@*RT.[T
M>W\):9;Z7=O'+/:Q1%4D=/N.<'[P]>M<#J7C?XB1KXFO++5M":S\(%8;V&YT
MMU?5) @>1@PE_P!'7!PN _/6J6I_&?Q=8^.K"74/)\->$KL6S6KWVASW%M=1
MRJ"2U]$Y$,@)P%9-O')H2OHNMO\ @?\  !Z;_P!=SU*7X/\ @B?Q1#XCD\+:
M7)KD079?/!F0%1A3Z%@!PQ!/O5#QK\+%\2Z5#HFGR6.E>'KB\^UZM;&T:66Z
M.X-A&WX0E@,D@\=,5Q.F_%7Q?9_%G^R/$TD&@:5<WK6UG97>ASB*YC_@>'4$
M=D:1O[CJH[9S6M\43KT?Q?\ A\]AKD&G:<!=O/;3VID5]L>26;>,#'&<';UY
MI+:+_KN#W?D>L3V=O<V;VLT$4MJZ&-X9%!0IC&T@\8Q7):'\(O >@Z1J.DZ7
MX8TBWT[4AF[M8X599Q_M DDCT'0=L5X_8?&OQ+>^+K33KG4;;6]"UN*[B1[7
MPY<V-O 4C8J8KN5O](Z<_*.Y%<CX9\=7?@GQ/X;CL(%CN=3\.VMDNI7,)>TL
M=UP?WDV.W8#@$D9(II7^>GY_Y _=7I_P#Z3T7X3>"M T<:/IGAS3K/3TN$NC
M;0IQYRG*NQSN)';)J[K7P]\->(DU5-3T6TOEU146]$RD^>$^YNY[=L8KQS7?
M&_BK2/'.I:/X>.B6NIWFMV>G3:C<:8"95: EI) K@LP(X&>!Q5VU^)GC>>5?
M"/V[1SXK;67TO^VSI[BV$:Q^9YGV;S.7QQMWX]Z-9?UZ?YH6B_KU_P F>K6_
M@?PSI6E7^FII-A#I^HG-W;2@&.X.T+\P<G/  JCHGPA\%>'-%FTG2_#.G66F
MSRK/+!#&0)'4Y5F.<G!Z<X%<)X:T&Y^,<6MV'CPZ??W?A_59+.&6PLU2-E,8
MRVU]Q!.>F?SKV>W@2V@BAC&$C0(H] !@?RH\_3_-#\CF=<^%?A#Q+I5SINJ^
M';"_L;BX-W)#-&2#,>L@.<ACCJ"*COOA'X*U/PS:>'KGPOI<NB6CB2WL3;@1
MQ,/XEQ@@^ISSWS76T4@.2LOA;X=TBZT232]-@TJ'29I9[>WM4VH'D&&[\ ^E
M6_%WPZ\,>/A:#Q'H5CK7V1_,@-W%N,9[X/!Q[=#7144/7<#E?^%4^#OL L3X
M;TY[,6IL1;O%NC$!;<8]I.,9YKF-;_9\\+2^&;/0="TC3-$TQ-2BOKJW%N76
MY5,Y1LG))!ZDD"O4:*//^NX;'*6GPH\&V/A2?PS;^&=-CT"=BTNG^0#'(Q_B
M;/)/OG-5_P#A3/@4>$CX8_X132_[ +^;]A\CY-_]_.=V[_:SGWKLZ* .'O?@
M;\/]1\/V.AW'A#2I=)L7,EM:F'"Q,>I!!SD]\DY[TRY^!'P\N]*ATV7P=I+Z
M?"9#%;>20D1?E]H!^7..U=W10!AVO@;P]8QV,=OHME#%8V[VEM&D0"10MPR!
M>F#WR*H^$/A7X/\  %W=W7ASPWIVC7-T?WTUK#AF'IDDX'L,#VKJJ*/,5N@4
M444#'Q?ZQ?K6T.E8L7^L7ZUM#I0 M%%% !1110 5Y5\:/'L7A&T<,"TL<?G1
M1[L"68G"!AW48)/;I7JM?,_[4ES]M\3:/8(B[HH&D+8Y.X],^E;T:?M)J)E4
MERQN?.FLW=YXAUBZU*_G:>ZN&W23OC+M[5";>,J$2-I #T'3\ZZRX\)O!:M*
MZL%;(3C  K$E@D0B.(*BJ.I'\A7K5<%2<-%L<5/$5(/7J8][8FXB"D^6I;YQ
MGDCTK%N]-0!S)B.$?=BC.T >IQUKH)OM(D?8Z3)_MY'\A5GPA\,-0^*&N+;*
MUG80Q_?N[B7RU5>Y!."Y'HOXU\/B\)-MPAMY;GUV%Q4(Q4YK[]C@1%:PC>46
M-<_*2?\ $U],?LK^%8+73M6UO7+^5-/FV+'$'"+(BDG,@'+#/0=_0UM:)\"/
MAOX<NK*TM-4O/$WB-P0Z6NVX5_7@JR0@?WB<U[9X'^%&A^%3'/%HEE:W6=P$
M8,BQ_0MR6]6_+ K' 9-]4J_6*DVWV+Q^=?6Z+PU*%EW.OT2X-U8)*(3;Q-S$
MCIM;;V)'8^U:5( !T%+7T)X"V"DVTM% "=*6BB@ HHHH **** "FLP3&X@9.
M.33JP?&^C?VYX9O8%98YT43P2MQLD0[E.>W(_(FCU(FY1BW%7?8VWFCC#%G5
M0O7) Q0\R1[=SJNXX&3C-?-_B;PYKGBKPWI?B-]/>\M]0N);J\LCIBZGC(58
M<P>8F\!5ZY.,].]97B_P/XAN= TRQO-!U/4;J+32+*YATJ*>5),L0C%I66V*
M_+@KEC_>R *W5)=6?+U,[K1YG##MJR:=][VMTTNG]Z:/J4S(K[2ZAL9P3SCU
MJEH6O6/B33DOM/F%Q;.2JN 1D@X/!^E>#_\ ")ZG_P +)TV^'A^^OKB<0_:)
M=2T\-&D?EA7*7:R!D &<PNI!.>*ZSP9X4O=/^#NL:-I6ER:'JY^TQA#%Y!DD
M).&5NX8<!J4H*,;W.FAF=>M5<?8VBN;O=VLU;2VNNAZP)XRC.'4JO4Y&!65K
M?B[3/#Q47LS)N@DN04C+Y1,;CQ_O#CO7A>L^$GO_  >T7AKP5J/AZUBN8GU*
MVNK 3"]VHP)%KYR^;AL$G(W=?FQ5C1_!NO0>%(XFL+UT:SU 06YT\6ODJYCV
M1K"LDFP'#84MGV%#II7=_P"K&/\ :N(D^2-'HG?5K>UK-1>WEOY:GN=_X@L]
M-2Q:=V O)!%#M0MN8J6QQTX4U-I^K6^HV4%U&6C290RK.AC?GH"K8(/L:Y;Q
M?IEW=V?AE8+:69H+I6E"+G8/(D&3Z<D#\:\K3X7RZIH&H3:AX>GFU*TT*T73
MVDB/F17"AB?+]'!V\CFIBD[W.S$8W$49J-.GS73[KHGO9^?0^AS(H<(6 <C(
M7/.*194=F56!9>H!Y%?.=YX(\3R_$U+J:VN3<O>Q7$&HQZ,LK1P#;E/M;3KY
M2XRICV<\\'.:V?AAX9U'0?B??/#H=Y':R";[5?:E8+!*"6RN+E)"MT"<XRN5
M ZU?LU:]^AS0S:M*JJ;P[2YN6]_QLE\[=M=KM>[4445@?2A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!C7/^OD^M15+<_P"OD^M1
M4 ?!?_!4VP:6V^&UXHX@N+J,G_?5<?\ H%?"JV<ES9:M'&A:1C9[1Z_OFK])
M?^"@VFZ??>'?#TNI74%E:VC-<--/;-<*N'4?<4CGYL9)P.]? 4OQ$\(^&+?4
M4TG1I/$$UP\<+7>KDV]L0NYR%@@92P^[]Y_3KDUY.)IWJ<S>Z/0H5/<Y4KZF
M!X>7_BZ7AV.)MZPR1C*\_P#+0$G_ #VKW[XG:5I,/BNXUS6]1-MI\%B4D2*/
M+?Q<M(?E0= ,!B2>@ZUXIX;\:76O>*M'A=88X!<*ZV]G:I;PQ@..0B#/7C+$
MG /K7;?M4>)M-T[4+72M2;Y;I!+$T@Q$C*6!+?WNO / QFNC#T%*ERRUUN<^
M(JM5.:/:PGPJ\6V_Q%G\8P:1IR:1HRZ),;*65?\ 3)&C )=FW'=GD>@W <FO
MH+0M-/BJQT^!T6"#5=$,,LD2 O&<J\>#T^4LV..M?,?[.,ME;^.=7D5##!>>
M'KDF0@GS6) !'J/3'%?77PPEC7PWX9MS+%]I%M&WEALL44(I('H"1S[BO4BE
M&-H:(X')S=Y=3<^'WA"W\,Z+;6$#33I;+L\VY?S)')))+,>IR3_*NXMK+GI3
M].TX0KA5.,FMJVL\'W^E)('8;96F%&!6U;P87.#265J,=./4\5IB( #O5VL2
MT9LD!8DD?E4?V?/0?IS6GY)R>.GO2B$$X('M2!&<+<8X-2"T^7@$CKFKZP #
MTYJ1(,9P./6E<#+:TR,XZU UF<FMTP\<C%0M;@DX% '.W%GN4\<5AZCIYDCR
MH^8'D5W36VX#BLJ^TW:=RCGZ4FBDSPOXD_"'0O';1OK&F1:@B(T?ENS+E3U4
MX(R/8UXK+\/;#P+XQM8K'3X+"U2*9H&5"6QY; Q;CV&<KGW&:^QKG3ED1N.O
M!%>*?&Z[T[P]911W$<PO+A7^SLL!9.%^;+C@'!X%0]-AV5SR#]G;X@ZQ<> K
M*UGMQ"MM>+IT-]/!_I#P[7D(5\DD#C' XKPW0=5U3P%XLUFRU:YL[ZV?49_/
MLKIW8S R,0Z]UD&<@@Y()'I7K/[/VKC4O"$-JX9+&*\%W;:@(<QL1&T<D3GJ
M"-RD'VK@?B?\-+[QQXHU;7-#MK.^M)Y0\,Z2[!/\HW8# $'(Z_\ ZZEQ]HN5
MK1C4G!\R.U,OAJ;3$NK/5CIBWEO(+>'5-TL#!PRG]_&"0 Q/WD_'O7:^'_#T
MUI\&O$J)+;WK/'.T36$RSI(#&,;2O7/IUKP"X\+FQC>V_MJ"\OX+>(2Z>I'G
MQR#C<N.6P,9Z]_6O<OAK#<1_LZ>(04:&<_:\B4%2K;5]??FO+A@_857IT9ZD
ML5[6G%-ZW1X8VEW6FR6T5S9W%G="U*NDL#HP/R]01Q6JKWOVB\!GN6"VQ$>2
MV 2ZC^M8VA>-M6T^UGEEU[5[."-1'"D-U*0TA.=NW=C@ G\*D7XG>(;QLW.L
M7\J=?+\]QQ[X/?\ PKP98>UGJ>U[>[:=OZL7&@N[S3;\W$EQ<'S%.""0IZ<$
MGIZU@:OXHL=)UK2M,\Z*ZU"ZN+>)88I>(1D#+],]?NC\3VKJ)-:U/7?#TLD=
MW%'!)(A19F,K,!RP/<'''J,\UXEH?AU?^%HZ&MQ$UO<#4XF7>22?W@QSWKUL
M#@E&TZBV/&Q6*YN:,6>X>/H5B_:)T",V[B6#1Y<SA\JPR^%V]B.>?>G^(/!>
MD^*+K1[+5_$<WAGS=,9K6^,;/ D_F,2)2>"I7(X.0>>E3_$#48)/V@%#02+=
MQZ1N#D?*5)?(]B*SO%3O:MI.H+!>7R?8(UA2SD92[9;.0 01[FO=W3L>6M]2
M(^)/&GPQU+1V?5X=)TO3TVIKWA]HIK'4 "-JW(4[6Z=U\SG!!ZU]O^$;W1_B
M=X-M[F7[%J"W$(\\1*/+<D<G;DD ^F?Q-?"2V<VLV;_;/#7D[R"O]HW4?DJ>
MQ90BD_B:]$^'VC^*]&=;O1=2^SW4B\/8QA8V7& ,L0F .!V^M=*FM$C.Q]P?
ML01+%X<\5QH (XK\0H%& %7< /P  _"OIBOE[]@AY9? GB-YB6F-^OF$@ EM
MIR>..3SQ7U#7,]S:.P4444B@KD_''PM\/?$2>PGUJWNGN+ 2?99[.]FM9(2X
MPS*\;*0<=\\5UE% ''V?PC\)V%MI=O#I*BWTZ&>"")I796688E\S)/F%N<LV
M3DYK+TGX >"-%M-1M[?3;J1+ZU:Q<W6HW%PT-NW6&%I')B3I\J8'%>B44 <?
MXH^$WAKQ?I^EVE_;749TR,16=U87TUI<P(%"[5FB97P0 ",\]ZSM4^ G@K5K
M+3;5M/O+./3XVAB;3]3N;61XV.725XW#2JQY(<G)KT&B@#SF?]GSP/-X?TK1
MDTV[M+/2_,%FUGJ5Q!-$CG+QB5'#E&SRA)%7G^"?@QIU<:.(X1IW]E-:13R)
M;26W9'B#;6())#'D$YS7<44 >>Z?\ _!>FZ3J.GI87EQ'J"I'<3WNI7%S<-&
MAW)&)9'+*@(X4$"KOBSX.>%_&NJ1ZAJ<%^MRL0@D^Q:G<6J7$0Z1S)&ZB5?9
M@:[6BC<".SMXM/MH;>U06\$*"...+Y510, #'8"L_P 3^&=/\8:3+IFJQ/<6
M<C*[(LC(258,/F'/4"M2BCS YG7/AKX<\2W6IW&IZ<+U]2M4L[D22-M:)6W*
M  ?E(/.X8-,\#_#/P_\ #Q+K^Q[>Y^T717S[R_O);RYE"_=5I969BH[#.!74
MT4+38"GK&CV7B#2[K3=2MH[RQNHS%-!*,JZGJ#7$:3\ O!6C1H(-/NY94N8;
MH7-WJ,]Q/NB.8E\R1RWEKV3.WVKT.BA:.Z!ZJQPWB?X*>$/&'B ZSJFG3R7D
MFW[0D-]-#!=A3E1/$CA)<=MX--U/X(^$-7\1'6;FQN_/9TDEM(M1N([*9T^X
MTELKB)R,#&5[5W=%"TV#<X:U^"GA*T\4?V]'9WANA.;I;5]2N&LDF_YZK;%_
M*#_[06MCQ5X!T7QG=:9<ZI!-)/ITC2V[P7,D)!8896V$;U(."IR#70T4>0>9
MYII?[.O@;1]7M=3M['4&N[0O]E-QJUS,ELK@AHXD=RJ(03\J@"M:+X-^$HK:
M:W_LUWAFT\:6Z27#L#;AMP7D\$'G=UKM:*/(/,X^U^$OAFTU&"_2UN7NX;B*
MZ666[D<F2--B,<GG"^O7J:YWXF?"'^W-'O!X?T_39]0O+];^X75+VZMBT@7:
M&AN(#OMW [J"/:O4J*'K_7]=@6G]?UW///@C\,)?A?X:O;6Y:#[;?WCWL\=K
M/-/%$S #:))CYDG3EFY)/05Z'113;N)*P4444AA1110 4444 %%%% !1110
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M)]1O3+'#]BF49V]?,!(X[#"X&/ISZS\9O".I^.?'&F:;9ZLVEVAL&EFE)^1
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M^GM5JSTZUT^(16MO%;QCHD2!1^E6:*!604444#"BBB@ HHHH **** "BBB@
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MOXFZ=XEMO"NC:AX@URYM=,75)]0T^'28I9F<\*ZW)11"O3Y!NYY:C;^NU_\
M(7]?E_F?2M5QJ-H;XV0NH3>B/S3;"0>8$SC=MSG&>_2O.M>\>>(-*^"">(;B
M"VT_Q"UO&LN6CFAMY&;:9"48H5'WN&(]Z\G\4^(?$OPJ\7>*=0_X2 ^--7@\
M/0?9[J:VMXI8_,G ^94VQD#.5S@8ZD]:'H[?UL"U5_ZW/J6J]YJ5GIQ@%W=P
M6IGD$,0FE5/,<]%7)Y8^@YKYXTGQ3\7K;0O$5E/%>17OV6.?3[SQ'<Z0EUO9
M@&6-;>0QD$?<,B@9P"33-)^)>OQVNFZ=J6HZQ<ZU::[;QW5GXBT>U@O8XG5B
M%+0YBD!(XDC"FG;7^N]A-Z7_ *VN?25%?-O_  G?C1;3PEXE;QL)+;Q!JDD$
MFA)96ZQV\:[\)&^WS"1M&[<3^%7_ (=^*?'$%Q\/M6UOQ=+K=IXGEFMI],DL
M((HH,!BCHZ*'W?+SDD'T%"38WIJ?0=4KW7=-TR1H[S4;2TD6/S2D\ZH0F<;L
M$],D#/2O+/C;XLUBQU*STK0=;URQOOLLEY+:^'M+M;B<HO1Y);IO+CCSP1C)
M]17E%_XKU#QUX6L=:U4J^H7/A:03.JJ Q6[5<X7*Y..W'I26O]>O^0WI_7I_
MF?6RL&4$$$$9!'>EKYZU?QMXM>P\4^)[3Q:FCV?ABYCM(_#S6<#PW2A4SYSL
M/,#/N^781CT-;-]\5]<\.2)9W3K/-:7 U&_DN% 9-,900< #D$[<^U,E:GME
M,GGCM89)II$AAC4L\DC!54#J23P!7SMXS\7?$9X=/U;3-1U6/0[E)K]U\/VM
ME<WMO%N_=&2"?#/#M&3L^8YZBNL^+-^_C7]F[4]0T_6IHUNM-2;[;;VRQF89
M&X&-PVP'G(ZCUI.Z392UDEW/5-(UK3_$%A'?:7?VNIV4N?+N;.99HGQP<,I(
M/YU<KYNTZ_\ %=GHNM6^F^-QH-KX.TVWE6V;3;3;?EHMY>X&P;4/W1Y83UR3
M74_#'Q1XH\?_ ! U*ZNM>GL-&L;:SG718;:'9(TL6Y@\C*7V@\@ @^]5;6R(
MOI=GL":E9R7\MBEW ][$@DDMEE4RHIZ,5SD ^IJQ7S9\0?%NJ^%_V@=3BL"^
MG6>H6%A;7NOB-9!IR&0X;8W4L?E#$%5SDU'XA^)'Q-O/&VOCP[::M/IF@7B6
M8C232DLIA@;FNFGD68%@208]H],U*U2\RGI<^EZ*^9=4^*/Q0UGQAK5UH>F:
MFNFZ/?):&TBETI-/884O]H>>59]QR<%,#@8W5>O?&WC4?\)?XC3QHEO:Z!K"
M6T?AYK.W>.9&*@Q228W[CN.TJ1T[T+6W]=O\P>G]?UV/H.SU.SU!IUM+N"Z:
MWD,,PAE5S$XZHV#PP]#S5FOG)O%OC#7?$\6CZ3X@;P[]N\37-I+<06-N\B0+
M"K!0&3!8$_>;)]<U9TGQIXRUJXTSP:_BQ[#46U:\L9?$BV,'VB:.$ JJQLOE
M"1L\G;T' %"U_KT_S!_U^/\ D?0E%><? [Q#K'B#0-8.MZPFN75GJUQ9I>1Q
M)$KHAP/E3BO1Z!#XO]8OUK:'2L6+_6+]:VATH&+114<_F>2_E;?-VG;OSMSC
MC..U $E(3@9-<?\ "\>.!H,__">'2#JWVJ7RO[&W^5Y&[Y,[OXL=:Z/6_P#D
M#WW_ %PD_P#032EHKC2N[%HW$2Q>:9$$?]\L,?G3P01D&OGWPOXZT^Q_9UL8
M-,UC3GU>WMH_]&66&9T_?@-F(Y['N.*K:/XH\6:K/HSR^+KV*/4]3OK)XH8+
M8+%%$,IL_=<,/4YSZ53T;$M3Z(\^/S"F]=X&2N1D#Z5)7R=K/B_6/%MIH\FH
MZL]NB+IMS-<VZ0PMGSY%+.^S[IP."<9/05KV/Q<\<-=7,L+QW.HC[4KZ1)<0
MOY:(#L9(4C\U2, DNV&S]*+:7]?P';]/Q/I@2*7*;AN SMSSBE# ]"*\1^%5
M_!J?Q3U&YB\2GQ+-)H=LTTC&(F%S(Q*9C4 8.>#R*YGPUXAN]%U&\TJY\5W6
MAZ;/J^I27.I3RP%X9%<&.'+H0@8$MAAENU)Z.WK^#%Y^GXJY]*TE>+:OX[\3
M2_"/PQJ9NWTO5;_4K:UEN8X$#/$[D%@K@@%@ >G&>*R%\>ZU%XBNO#^J^*IM
M(T>SO;N Z_(+=)F*!3'$[,GE@X8G[H+8IVM?^NW^8=$_ZZ_Y'T#17S'8?$SQ
MGJ=AK^I7.N3V3Z1I]E=Q6D=M"L<I=L,SAD+8=>< C&>*]%\6^-O$*0:0EU ?
M"NE7=VL=SK:W,,GEQ%"P(W K'N.!EP?3J:&K"N>J^8H<+N&XC(&>:=7R[I/B
MO7M6U&TUBUUM]8O]/BU I>&&(&YMHKD H0J@<Q@\@9R!6Y_PLW6=:O;6^N_$
MTGA;PUJ=O<:A87IMX^BMMBB(=26^4;B@^9MV 126J3*:LSZ&HKP&X^).O'4)
MITUUAJT>J16=MH#6R(MS:MC,YB9?-Y7+[@V%QBJ^G?$3Q$KZG''KTVKZA91K
MJ,K6,EK=6,D*/B5!L19(25R0CY/R\'K0(^A-ZAPNX;B,XSS2D@8R<9KYHU7Q
M_J+:A%XO-U*@O-,N)M/*PQY@MGN$6/[V /E.2SY"YR<XQ6>WC35M=US38Y]>
MENX]&U^-8)X+V&19M]FSK&\JQ(CY<[1@?Q8!)YH>F_\ 6MA_U^%SZHIHD5F9
M0P++U /(KYBTKXN^-I-/DN$NXY[N6T,U];M<03MI[>8BETBCCW1A59R5F)/R
M]\&N]^#<]K<^/?&TMKX@/B1&^QYO6:)B3Y"_+NC4*<?3VII7);L>OR2I"A=W
M5$'5F. *<"",@U\W:[\2M9TY=?M9]>&K7C1EXFLGM+JRB"SQC#Q&/S(6 ;&)
M-P)S@Y%6M%\2^*]7O]$\WQ;?10ZIJ^H6#PP06P$4,6XQ[,Q$AA@?,<_2ETN/
MK8^B*:LBL2 P)!P<'H:^9H?BOKFH16SWWC,Z1,OAH:A! D5NOVV[$DJC.Y#N
MW;%!1<9SQBJZ^.O$.E:G=*K'1H-2U*:74+I+JWMFBF6&$K%YLZLBYW,<$9.W
MCH:=OZ^=@_K\+GU'29KQGQ'X]\06OP.TK79]4AT?5)[BSCFU""-9$6-YU1G
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M_P OO';5Q^7Y?UZ'HFN_#?PGXAL-2L]6T*PO;74IQ<74=RF1-* %#Y)R&P
M1@UH^&?">C>"]'BTK0M,MM)TZ/)6WM8]BY/4GN2?4Y-?.(^)6N^+M,U/2/$#
MF\ET?6]*DAO9-%DTF29))<_-;.[%<%>#GFM;PS\=O'GB/QC%<P>'-4NO#EQJ
M$EG]FA\,S"*&)9"GG_;_ #2&(QDKY8';--+I_6R_S$W^'_!_R/<-*\">']#N
MEN;#2+:TN%CEB62,'(21M\@Z]&;DTRV^'OANQ6!8-%M81!;RVL856^2*4[I$
M'/1B<FO'O#/Q+^(<\?A_6]3U+0Y-%U?6IM&6PM],99HAYCI'-YOF8)!493:
M1WKI/V=X_$+?#O5&U/68M4O7U2^6WF^RF/RR)6'(+MN&<$#C XI6TO\ UZ?B
M4]'\_P#/7\#K]>^$7@SQ/H>F:-JWAK3[_3-, %G;31DK;@# "G.0,=L\]ZHZ
MA\"OAU?:'!I-UX/T<Z5;2M/#;F'8D+M]XJ005S@9 .#Z5P6H_'G6K31+:6&W
MM)M2TVRN9M:@:/"K,C^5&O!^0,Y5N_RU0^('B/QCH^@ZUX;\77^DZW_:FBR:
MA;76F6+6AMRC+NB92[[U^;A^"<<BA]_Z?]6%Y?U_6IZY?_"?P;JG]G_:?#>G
MR"PMVM+4+&4$4+##1KM(^4CM4_B3X9^%/&%AIUCK?A^QU2TTXJ;2*YCW"#:,
M#:<Y P ,9Y[UYO<_%/7M+\(_$2[5K5'\.FVBT\O;_*%:%"=_/S<D^E9.L_%'
MXBPR>)-5L+O0?[)T74;:S6PN;%S+<B5$SF57&S:6R,*2>G%-K6W]?UJ*^B9Z
MAJGP8\"ZWHMEI%]X4TNZTVRD:6VMGA^6%F.6*X.0">HSCVJ_=?#7PK?:A;WT
M_A^PENK>T:PB<PX"V[#!BVC@KCL17D7B3XQ>-? 5EXBTO419^(->M[^TM+*Z
MTK29",7 )YMA(3(4VG #C=WQ7:_!+QKXJ\50:G;^*-)U&UDM)$^SZC?:(^D_
M:U;K^X:1\%3W#$&A:W_KI_DQO0T]*^"/P_TFQN+/3_"FEVUK/$;>:.!#ATW!
MMK?-D\@'VQ6CXP^%OA'Q^EFOB/P[8:S]C_X]S=1Y:,>@((...G3VKQ[3O&?C
M"^\5+X=\*R:!H#7^L:DD]W+I7F@")5(D**Z[W)/))Y_"O3/AOXYU#7/AY<:O
MK202ZEI\ES!<FR0I',T)(W*I)*[@.F3BIO>/,_4+6=O.W]?<=@=$T]M(.E&Q
MMO[,,7D?8_*7R?+QC9LQC&.U<WX?^#G@?PK!=0Z3X5TRPBNH3;W"1PY66(G)
M1@2<C/K7DWPU^./CKQ1KUC=WV@Z@?#FI+(Y>7PW-9VVGH 2DAO#*PF7@9)1?
M:HM$^/?B2V\9V*7M[;Z_H>H0W4BFT\.7-A#$8D9U$-S*W^D XQG:/44WYAY(
M]:TKX+^ ?#VB:CI5EX3T>UTS4!_I<!@!28=@Q8DX'89P.V*GT+X1^#/#.FV]
MEI'ARPT^V@N!>1+ A^68?=DR222.V2:\=\4>(_'FN_"34M7UJ\\/7.B:]I#W
M5M9V\36]Q9-D%$R6;[0"/O'"D'M7<_#3Q'XJLO%T7ACQ+>Z9J<4VC1:E:2Z=
M9-;& ?*IB;+MOZCYN#[4TG=KK_P_Y6$[63_KI_F8FC_LU!/B,OB76)_#MRD-
MR]TDFFZ(;2]N&(( GD\TQX //EHI;O7JT/@O0+*VTF*/3+:&#1V,EB.0MLQR
M"5R>.IZ^M>/_ !I^,/B3P=K>I_V#JUI+%I422S:9;^'+G4'?/)$]RK+';\=,
M;CW-9OQ+\8>+_'G@OQM/IMQI&G^']+LXHKFPNK5Y9[II(U=F$P<",#. -K9[
MTD_=TZ%6][7J>R>,_ACX/^(+VD_B;0-.UEK/F"2\3.P'J,Y&0?0Y%):_"KP?
M9Z?'96_AVQALT@:V2"-"$6)FWE ,\+NP<"O$O'?B+Q=XI^'?BD:;=:39^&]$
MM;>QGL;JT=[BZ)CC9G$P<"/&1@;2#WI=1^.7CA?$D]EX;T#4K_3=&,%JUI:>
M&I;U;P^6I;==+*H@Z\ (WO3M9V7]>?\ 7<71-GM.K?"CP5JWB.U\1:CX:TNY
MUBU"B*^GA&]<?=SS@X[%@<=JW[S0--U"6XEN;&WGDN8/LTSR("9(LYV$]U]J
M^?/BQXH\7^-?!?C"\MIM,T[PUIMS%8RZ5=6;M=RMN1F<S;P$()P$V$''6OHR
MR_X\K?\ ZY)_Z"*+:?UU%U_KH<SXL^$W@WQVMB/$'AK3M6^P@+;&XBYB4=%!
M!!V\?=/'M6W>>'=+U#0WT:XL()-)>(0FSV[8M@Z+@8P.!TK1HI#.2\0_"3P7
MXKU'3[_6/#&FZE>V"JEM/<0[FC5?NKU^8# P&R*W+#P[IFEZE>ZA:64-M>WN
MS[3-&,-+M&%SVX' Q6C10!B:AX)T'5KG4;B\TFVN9]1MUM+MY5),\(.0C<]
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M/5UB4$_CBIQ"@QA%XY' XK#C\>^'9=<_L==:LFU/.W[,)AN+?W?][VZUO9H
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M)+L#Z^9Y?\(='U6#2?$5_J']H'6I]2ODB.HS3%?+$S^3M1V(5,8QM'3UK@;
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M((?L\"N'VK%'A2S%1N<G)KT+Q;X1L_&7ABZT.]>6.">,)YT#;9(V7!5U/J"
M:V\BC(HW5@V=SR$?L_S:FVM3>(O&FJ>(+W5--&FM<R6L%N855PZ.BH-NX$#.
M0<]:BF_9YGU2'6GUKQKJ.LZAJMA#82W<ME#'L6.3>I1$PHZ8(_'->QY%&10&
MW]?UV/./&7P5M?&.LRZA+JUQ:M):6]H8XX%8 12B0-DGJ2N,=JSOBK\,&U+_
M (2#Q!9PZEJFIW4%JL%GIKPQ3P/ Y=98FD^5G!/W6P#C&>:]8R*,BC4:9XU\
M!?#'BJVU[Q-XF\4OJ[7&J)!#$-=@MK>Z(CSDF&W9DC7G@;B3R:Z*Z^#=K=:#
MK>EG59U35-7&KM*(5)C8,I\L#/(^7J>>:]"! I<BG?\ K\?S)_K]#RJY^ XN
M-4GB'BK4X_",][_:,WAI88?+:?<&.)\>8(RPR4'YU>D^"UJ_@_4M &KW"1WN
MJG53<"!=T;%P^P#.".,9KT?(HR*6W]>G^2&]=_Z_JYXSX1^ >N>%-5U.4?$*
MXU#3M5N9)]2M;K0[5IKQ6S^[>X),F #@8Z#I5[3/@(]O-;1:EXPU36=(TV.2
M/2-.N+>%%LMZE=S.@#3%0<+NQCWKUC(HR*.E@ZW. A^$%I%:>#[9M2G=/#EO
M+;(?*4&X#QF,EN?E(!SQFN-;]F69;;24@\;7<,^GP2V27$FD6DY^S,VX(HD#
M"-QG'F+R>XKW'(HR*'KN!YY\.O@Y;_#R326BUBYU(Z?I\FGJ;B%%:16E\S>Q
M4_>SQP,&J7C[X)2_$+7DGU#Q5=G0_-29M'ET^UFV.I!'DW#)YD()'.TY]"*]
M0R*,BFW=W8;7/+V^![PZ[=26/B_6=,\-W=U]MN-!M!&BO-C!(N /,5#C)0'!
M/>N?T3]F)=&UK2KO_A+[R6QTJ[>YM+!=+M8A\X8$2R(H>5OF.&8Y]C7N&11D
M4M@/)I/@+)86VE/H'BR\T'5;*V:SDODL+>Y%S"7+[6BE!4$$\,#D>]=E;_#?
M0?+LY=0T^UUK5K:#R!K-_:0O>D$$$B0("O4\+@"NGR*,BE)*2M)7-(5)TGS4
MY-/;1VT/%5_9]NM*BM9?^$MU36;?1HKH:5I<UK B1K+&P\LLH!<Y/#-SVJ?X
M0_![5-&T[PM?>)->U.^?2;;_ $/1+N&%$L96!#%G0;I"!P-QX]Z]CR*,BJ3:
M,FKA11D49%(8449%&10 449%&10 449%&10 449%&10 ^+_6+]:VATK,LK8R
MN'/"BM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20220331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '3!#@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]1[Z[>V9
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M_MO^;^XF4Z\;\JOOT?\ >M^27S/3-8^*WA70?$!T6^U58+Y72.7]S(T4#O\
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M_3[C2A^)WBBQ\27&@^#]&T&&_P!7\;:SIDDVHO<M$H@@67[2X#DEB1RB[5/
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MRP1*3E9@(W!D8[#\N$Y./1?&7PCT3QSJ-W>ZC+>I-=6,.GN+>557RXKE;E2
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MHLF@S?9I53%N\HD)7*G#[AUY&.U0ZA\%] U/PWXQT2:6^%GXJNQ>W[),H=9
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M C E=C*P(ZY(!K:\!_#33/AKH6J:;H\U]<1W]Y<:A+)J-SY\K3S ;R7(!()
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M5-1GM8K.^1([>"Y6[EMBEO,LH8A8W/WF4+\P_AW+ZU\BZ]X?\)>)-!^(]EX
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M;G*.JK"S*V&&.F2:T:M)KLVON3_R,UK%/ND_O:_S/K/MGM5'7-3_ +#T>ZU
MV5[?K;IO^SZ?;F:>3D#"(/O'GI]:\H^!.M:A\1]8\0>-]5MY+2=(8/#L5N^0
MJ26^6O64>AN690>XB%>5>/\ PE8WNG_M&>))H9YM9T^^%I83M-)BWBDMK4R"
M- =HW'J<9.!4O1V\K_E;[[HJ*NTGW2_S^ZS/KM59P"%.#W(K \%>--.\?:--
MJ>E>>;6*\N;%C/%Y;>9!*T4G&3QN4X/<5\L:E=6/AW]IP7<-U!XJU^XUV!1I
M[/J-CKEE"^Q66+&;>XLD'S8*JI7<2Q(J7X*Q7NF^)XY_$TLDOAV]UCQ!;>&I
M;1'_ .)?J0O+@R-(G22:6/<8G/ V%0,MDB=U?U_"W^=O4+:?=^-_\ON/L J1
MU!'U%%?(?[*EWI^C_$N72=)ELO$WGV$QO]>TJ74+>=)$9"O]J6ER61;ER2 Z
ML&SO&T"OKRG;1/N)Z-H****0@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** +.G?\?:_0T4:=_P ?:_0T5$MS>&Q+JOWX_H:HU>U7[\?T-4:I
M;&4OB9Q'CGX+^#OB1J<&H>(M(.H7<,/D1R"YECPF2<81@.I-2:)\'?"/AVST
MFUT_2C!!I5Z^HV:?:)6\J=EVL^2QSQQ@Y'M79T5LJM11Y5)V,'1IN7.XJ_>Q
MYSXY^$EMJ_A?6[#0K738;O5K]=2NQJHFEBFF&,L"CAHFX&&3IZ5D>!_@/;V-
MGXHC\316,\6O26YDT_399_)B6'[O[UR)'8M\Q8\D^M>NT52KU(QY4_ZT_P D
M3*A3E)2:_K7_ #9S-[\./#NHKXD%Q8>8/$2)'J?[YQYZJNU1P?EP./EQ5+7_
M (/>#_%$]K-J>C+<26]NEH"L\L?F0K]V.7:P\Q1CH^179T5"J36J;+=.#5G%
M?UK^9Q_B7X1^$?%U[#=ZIHT<\T<*V_[N62%9(E.5CD5& D0=E8$5L:?X2TG2
MM?O-:M+00:C>00VTTJLVTQ19\M0N=H R>@%;%%+GDU9O0:IP3NDKG+:7\,?#
M6BR:(]GIQA;199YK ^?(WDM-GS3RWS9R>N<=L5S?CCX.P:AX5?2O#EIID/FZ
MH=5FBU0W#+)*QR[)+&XDA<GHR].1CFO3:*I59IWO_6_YDNE"2<;?U:WY'GOP
M?^&EQ\/+?79;R2S^V:O>"Z>WT\2>1;A4"*BM)\[GC)9N22:]"HHI3FZDN:15
M.$:<>6(4445F6%%%% !1110 4444 %%%% !1110 4444 9NO'%DG_75?ZTNF
MG]V*9XC.+!/^NJ_UI=*.8A0!IT444 '2E+$]23]3244 *6+=23]32444 +N;
M&-QQZ9I*** "N'\=_":P\>:G;W\NN^)=#N$A^S3#0=7DM$N8<D[)5 (/)/S
M!N?O5W%%#5]QIM;%+1-&LO#FCV.E:;;K::?8PI;V\$?2.-1A0/H!5+QMX3L?
M'_A/5?#NJM/_ &=J4!MYS;R;)-I()VL0<'@<X-;5%-N^K$M-@7*JJY)"@ 9-
M%%% ;!0#CI112 7<V<Y.?K0'8$G<<GOFDHH *"<T44 *&*]"1]*3.3GO110
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MG9F9BQZDFMBBBFW<0NXXQDX],TE%%(!2[-U8GZFDHHH **** "BBB@ HHHH
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M )Y+1]B@_P">2U/11=A9$'V*#_GDM'V*#_GDM3T47861!]B@_P">2T?8H/\
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M7861!]B@_P">2T?8H/\ GDM3T47861!]B@_YY+1]B@_YY+4]%%V%D0?8H/\
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MWJL?%/Q]XH\+_%'X<:3I-A#<:+JMQ<C499+I(CL2$L>&4G"+F3@C=MV]Z/\
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MNTU_5[?\ \UTK]G'5XO#WB+1]6\;1:C;:CI,^D6IMO#]K:-"LJ;/-E9/FFD
M_NF-3DY7D8Z#Q3\!-/\ &47AZVU/4))+#3-!O-!F@2(*US'<111EPV?D*^5D
M<'D^W/J(<$9SQ5'7]?T_POH]YJNJ726>GV<1FGGD^[&@ZDTGK>_];_YL26JM
MT_X'^2/&K#]G#5V\,^)M%U?QO%J,&J:1/I%L]KX>M;-H$E39YLI3YII /1HU
M.3\O3'3^+/@5IWC34K235+Z233X_#5WX:GM$B"F:.<PDRA\_*R^2,#!Y.<\<
M^EK*KJK \,,BG%@"!GDTV[[_ -;K]6-.UK?UM_DCPZ3]G'5_$6@WNG>+_B)J
M/B(K#!%I;QV,5O'9/#*LL4[Q9=)YMR*"[  KD!1N-6[+]GS4+GPGJFG:[XO%
MYJEQ/;W-EJ.DZ+;:<NGS02>9#(D:[B[;P-V]R"!@!<FO9@02?:C<,XSS1=O^
MOQ]?/<5OZ_KIY;'FGPS^$^L>#?%>O^)-?\6MXIU?6;2TM9G%@MI%%Y!EQY:*
M[84^;T))R"<G.!4L?@/'9>-+;Q!_;;N8/$UYXC^S_9@ 3/9_9O)W;NB_>W8Y
MZ8'6O5@P)QGFD#@G /-%];_UO?\ ,.EOZVM^1Y!>?L_W U=-5TWQ,;'48_%L
MOB>-Y+!9D"RP""6V*EQG*;L29!!(.TXYJ^%/V=+KP;XKAGTWQ5'%X4@O7OH=
M&_L.U:Y5FD:0Q?;&!8Q;F.!M#@8&_BO9;J[2TMIYV#NL2%V6)"[$ 9P%')/L
M.M1:9J<6JZ=:7L:311W,2S)'<0M%(H8 @,C ,K<\@@$=Z2TM;I_DE^@WKOU_
MS;_4\NTCX 1Z5X1\+:&-<>4:%XF?Q&)_LH!G+3S2^3MW_*/W^-V3]W..:S_B
M!^S8/&UQXDNXO$"6=WJFL6>LPI=::EW;126]MY 2:%W G0C+8)7#;2/NUZW8
M^(=.U/5-3TZUNDFO=-9$NX5SF%G0.H/N5(/XBKX<$9SQ1LK?UT_R0/5\SW_X
M?_-GA'@G]EV3PI<R7%SXK_M&:7Q%9^(G\O2HK6,/!;F'R42-@JH1@C@E<<[B
M<UV'Q/\ @RGQ)U4WK:LVGD^'M3T'8MN).+P1 RYW#[GE?=[[NHQ7;ZWXBT[P
M[9)=ZC=):V[SQ6RN^?FDD<1QJ,=RS #ZUHD@#/:AOF5G_6EOR!:._P#6]_S/
M-];^"UOKVHZ3<3ZI(L5CX<O/#KQ)" 94N%B4RAL_*0(NF#][KQSPY_9@U>VM
M=$N+#QM:P>(+/3(='O=0N?#D%S#>6T+,8"(7<^5*BN5WAB#U*G@#VK6_%6G>
M'KO1[:]E:.75KO[#:A8V;=+Y;R8) X&V-CD\<>]:VX<>].[>O]=7_P"W/[Q+
M1<O]=/\ )?<>;:3\$[2Q\5W^K7FI2:G;WWAJ#PW/:36Z1F1(Y)6:5C'M4%_.
M(*JB@8X]*Y;1/V<=9L=:\.W&I_$"ZUG3/#D%W9Z58RZ;%&T=O-;^0HED5LR2
M(N/GP,@8V@DM7N08'.#TH# C(/%)ZII]?^#_ )O[RDVG=?UT_1'SSXE_9/O/
M$G@[P]X3F\903>'-.TFWTJXM;[P_;74A\I AFM96.ZVD8 '/[S!"D8QST6J?
ML_ZFOB74;KP[X[U+PSH>LO;S:QIUM;J\\\D2)'OAN2P:%G2-%<X8G&1M)S7L
M8<'&#UK)U+Q7IVE>(-'T6XE9;_5?.^RH(V(;RD#OE@,# (Z]:J[;OUW)MI8\
M#\3? [Q+I/Q"\(?\(QKES8R-J/B'5I-;73EGALGNQ&R0RQLV'4G<OWE)VY!%
M=5_PS7"=,LXI/$=S<:AY6L&_OY[92]Y<ZA$(Y)MJD! N!M0<8 &>,U[,\R(K
M.S *@))/85BZ+XUTOQ$^G'37GO+74+(W]O>Q6TAMWBRH'[W&T,=P(4G)&2!@
M&IZ<OE;Y?TOP'M9]G?YW_P"#^)YWI'[.\>E>%/&^B#7GE'B;0[713/\ 9 /L
MXAL?LGF ;_FW??VY&.F3UKD/'O['K^,KS5S;^,(M.M=7TN#3;PRZ%;W=TGE6
MX@!MYY&S"A R4 /+,0RELU]'AP03GBE#!LX/2G)N3;?7^OU&FU:W3_@?Y(\R
M\,_#H?"RZ\9^)GN+GQ ^I65EYFGV=E^\/V2U\G;&N\[VDQD+Q@G&3UJA^S3\
M/)_ _@B[NKZUNK&^UF\DNULKX@SV5H/DM+9\9 ,<*H"N3@DCM7KE9'BGQ5IW
M@SP]>ZUJDK0Z?9J'E=(V<@%@O"@9/)'2FY-MR?7^OZ_X)*6BBNAYSJ7P*U7_
M (3'5;_0_'5_X=\/:U?QZGJNCVEJAEFN%"!C#<[@T*R") X"MGYL%<FN.MOV
M0I[3Q58ZC'XPA73K#Q"GB"&W&@VXNYG$[2M'<W>[S)A\[!3\N/ESNQBOHT."
M0,\FC>,XSS4K1IKI_P #_)#?O)I]?Z_4^;OA#\#/$E_I&G'Q)X@O[+P]:>(;
MW5QX5FL$1VF74)I8&,^=QA/R2A-N2<?-CBGZ?^Q_-I_BC2]03QC$=/TSQ NO
MP6XT& 7<[B5I&2ZO-WF3??8!OEQQD-C%?1Q8+QG%!< XSS0M+6Z?\#_)#D^9
MROU_X/\ FSPWPQ^S7J.B7.EV5_XZN=4\):?JTNN1Z'_9T<1:Z-R]Q&#,&+>4
MCN#LQDLH.['RU)+^S'%+H#Z8?$;C=INO:=YOV,?\Q.<2E\;_ /EGC&/XNN5K
MU_2_$.G:U<:E!9727$NG7'V6Z5,_NI=BOL/OM=3^-7]XV[L\4K)K^NJM^07=
M[^?XK_@GB>K?LW3:CJ>N2Q>*6M[#5XM(,]JVGAV6XL)(F257\P<.D6TH1P6S
MD]*?IG[.ESH/C22^TKQ3%9^&9=1DU1]';0[66X$LDAEDC2[<%EB9RQV["P#$
M!QQCU+0_%FF^(M1UJRLI6DN-'NA9W:M&RA)#&D@ )'S?+(IR..:3PEXNTSQM
MHR:II,S36;330!WC9#OBE:)QA@#PR,/?K5W;?-\_OM_P";:<O3;[M/\ ,\NN
M/V=+O5_BIIWBS6O%4>J6NEZ@=1L(?[%MX=0B;#!8GODPSP@-C9M!(50S'!SU
MGC+PW=1?$;P=XJLK9[I;1;G2;Z.)=S"WN-A$F.X26&//^RS'M7>[AG&>:X23
MXV>%UMO#\L4UY=OKMU+:6,%K8332NT4GERNR*I*(C?>=L* 0<X-2M+17]=/Q
M6@WK=O\ K^MSD? W[.EUX#\2VKV/BJ/_ (12RN'N+71_[$M?M2;F9A$]X06:
M,%N,*KX &_CG)^.>A>+-%MO#_B#3Y]:U3Q)IU[>K!JWAW1(;O[-:SD8@FLFF
M5IDVJ@WHP(:,,0 2*]IUCQ5IVA:IHVGW<CI=:M-);VB+&S;W2)I6!(''RHQY
M^E82_%O09-:\/:1Y>I_VGK<)N8+0Z7<"2"(''F7 V?N%SQF3;SQ1J[)!M=LX
MC]GWP%XO\->![-]4U2:RO+S7K[6;^#4K.-KJY@G9RD<GEOLADR4<[=P7&WU-
M>E>"+;74\,1Q>)YHKS5#+.'>.%8E:(ROY0*!F /E[,\GG-= K!NE*3@4WJK?
MUV$E;\_S_P SXY\$_#WQIJWQ!\'>'&M?%%AX-\):L]XNGZYI=O%;6\ AGC$:
MWJ2L;OF4*FU5VJ3O)(KUOX>?LZWOP^U6SBA\6I<^&-.C:*PTL:':QW*)M*HD
MUW@O($!XVA&.T;F/.?:MR@9]>,TDDBQ(68X &:3?NV?S'UN>6:3\!H-.\.?#
M72)=7-U#X-+Y9K8#[<K6TMN5(W?)Q*3_ !=,=\UG?#3]GR^^'.N6.SQ8E[X;
MTQ#'I^F#0[6*Y5,%46:[ +R!0>"JHQP-Q;G/I_A+Q7IWC?PY8:YI,K3:??1>
M;!(\;(67)&2K $=.]:V\  YX--W3;>[W%HTET/#/#W[+D-A8Z7IFL>(FUK2-
M/L-8TF.V%B('>SOVC/ELX<Y:,(1OQ\V[H,<]3\,OA7XB\%ZDEQKOCZ_\56UG
M9_V?I]FUJEI%%%E?GF",?/FPBCS#M &<*-QKTLL 0">M9OB3Q#9>$] U'6=1
MD:*PT^WDNIW5"Y6-%+,0HY/ / I<W+K_ %U_S?WCM?3^OZT1YGXN^ MUJ_C3
M4=>T+Q+'H*ZN8WU.";1K>^9W1!&)('E_U3%%4'(=?E!VYSG4U+X+1ZAIOQ&L
M_P"UGC7QA;1VQ8VX)M MJ+?( (#YQNQ\OI7:W?B6UM=(L]2$=U<VUTT*Q_9;
M:25_WI 5BJ@D*-P))X49)P!6IO&<9H:T<7Z GJI+U/DSXR>!?& U?Q/X6\*0
M>)K>T\36D45RUMIEO/87DH@2$R_:3(#: A L@96+!<KR<UZZOP(5O%$>MMK1
M5QJVGZL8%MLC-M9M;>7NW=&W;LXXQC!ZUZMN4@']: X.,'K3N_G_ );$\JV^
M7W[GDOBG]GV'Q'<Z]>IK;6FIWNLPZY8W!LHYDLYDMEMRK1N2)49 V0=OWN""
M :KWG[/MSJOA&VLM0\3QS^(K/4!J5IJL.BVT5O!*(VCV?90,-&49@0[LV6R&
M&!CV/<,=?:D#@G&>:2T5EY?A;_)%7N[_ -?UJ>4Z?\#KP6OALZIXE6_OM)UQ
M-:>6WTJ&TBDVQ/&(4CC(V+\^<LSMG/.#@6H_@FD?CL>)/[88D:^^N_9OLXQE
MK$6GE;MWMOW8]L=Z]-W#.,\TFX9QGFCK_7E_DA6_K[_\V?/OQ0^&VH^#+>X\
M1:"=:OM;D\17&L07FBZ=%=R6 GMUA>-[9Y%-Q&P0 [2K E3QMKJ?V<?"NO:%
MX/UVY\1M>?VCKFLW.IYOHDAN=CJBJ9(T)6-CLR$!.T;03D&O6L@G;U/I2!@3
M@&DK)->5OEI_DAR]ZS\[_/7_ #9\^>%/V3YO#'B3PUJ \6Q367A_4&O;6VCT
M."&:X!21"+FX5M\TF)"=_'.25).1VND? ^+2_"_P_P!%;5VG3PG>&[\PVP'V
ML&*:,H1N^3B8\Y/W?>O0-$UJ'7=*@OX8KFWBFSMCO+=X)1@D?,C@,O3N.F#W
MK.U;QWI&@/J7]IRS6%O8"W,MW<6\BP,9GV1JDF-KMNP"%)(++G&15;JP=6_E
M_7WGG&A_L^:GH^L^%C)XWN;SP[X7OC=:3I$MA&&CC\J2,123!LR;1)A6P,!<
M$,3D=1\1/AA?>*=<TCQ#X>\1-X7\2:=#+:+>FS6[BFMY2I>*2)F7/S(K*0PP
M1W!Q7?[@1G/%+2#K<\Y\+_!]O#GB)-7F\17VL7']@C19)=0'F32MY[S-,SY[
MF0@(     <#%<>?V9;C3+#P]_8/BF'3]4T[28-&NKJ]T6&]BNX(BS(PB=OW<
M@+OA@Q&&P0<#'N@<'//3K5/6-8M="TB_U.[<I:64#W,S*I8JB*68X')X!X%#
M=M7_ %O_ )L=FW_7E_DCAK?X.+!?ZI=-K,L[WWAR/P^QDMHU8;3*3.=FU<DR
MGY551Q[U1U?X%1ZKI%A8G6FB%IX3N?"V\6P.X3)$OGXW<$>3G;WW=>*]&T'6
M[3Q)HMAJMBYDLKZWCNH792I,;J&4D'D<$<&KH=3G!Z=:&MXO^M_\V2M=5_6W
M^2/'9_@%JEKJEQ)H7CJ_\/Z;J<=JNL6MK:(9;EX8DB$D$Q;-NSHBJV W3C!Y
MKG?$W[)DNOZ]JUU#XNCL[&_U:/6#&VB037GFK,DOEO=LV]HLH %&T@ #<0,'
MZ%# YP>E 8-G!Z57,^;FZ_U_D%E;EZ'*>%/ :^%]'UVP%Z;D:IJ-]J!D,6WR
M_M$C/LQDYV[L9XSCM6)X6^#B>&4^'2C5FN?^$/TZ;3US;A?M?F1QIO/S'9CR
M\XYZ]:]&#!AD&L6V\8:9=>+[OPU',YU:ULHK^6+RV"B&1W1#NQ@DM&W'48]Z
ME.VB_JR?Z7&^_P#6K_S/-8_@!J&AV6CS^&?&#Z)X@T];RW;4'TY+B&XM[BY:
MX,4D+..58C:P88YR"#BGP?L_7'A^WT.?POXMN]'UZQ2XBO-4N;2.[.H)<3^?
M/YD9*A6,N65EX7.,$<5[!O&<9YHW#.,\T+0;=]SQ'3_V9$L/#-KI!\337!AT
M/5]&-S):#?)]OF$IE(#XRF,8Z-G/R]*U?$G[/=IXFFNI+C6KB!I-$L-*A>WA
M426\UI<-/#<J22,ARORD8^7J<UZ3X@\1Z;X6T2]UC5;N.RTVRC,UQ<2?=C0=
M2:OK*K*K \,,BCT_K?\ S8O7K_P/\D>+:_\ L^Z[XO\ #DT'B#Q[+J^MF_M[
MZ&>XTJ,Z;'Y*L%0V)<JRG>6;+Y+!3D;0*SM,_9<N]*TS4%B\8C^UKC7++7X;
MM='BCAMY[>,1[! C*IC*C &01W+'D^V6>N0WNK:CIZPW4<MCY>^26V=(GWKN
M'ER$;9,=]I.#P<&M!6##(.133:=U_6W^2#^OZ^\\>G^ -Y:;;_0O%DFC^(X=
M4U'4+?4#8)/$([QP\MO)"SC>N50@AE.5!]15_P &_ J+PEXDT37&URXU+4;3
M^T9KZ:>!5:^N;QH6DE^4@1A?)4! ",8YXR?4=XR1GD5F^'O$VF>*M'AU72KN
M.]T^8NL<\>=K%6*-CZ,I'X4+W=O3]/Z^_<'[V_J>8WOPIN-/\.Z+X.@DDU&Q
MN_$<FMW]XT.Q(H5NFO/+/)Y,GEH/4;CQBNL\??#J7QCK?A35;751IESH=X\Y
M62V$\=S#)&8YH2"R[2RD@."=OH:VK[QEI>G>*]*\.SS.NJZE;7%W;1B-BK1P
MF,2$MC P94X/7/'2F^)?&FG^$PSWZ7@@2SN;Z2XAM))8HXX%#/O=5*JV#\JD
MY;!P#@U.G+9[?Y:?H/6^F_\ G_PYYWX9_9_N]%U+0;>^\876K>$O#EP+K1M#
M>RCC:!U#+$)9P<RK&'(4;5Z#);%=+\1OA4GQ!U33KQM3:P^QZ?J-@$$'F;OM
M<(B+9W#&S&<=_:M!/BCH'V%[Z>>XL[$"RV7=U:2Q12FZVB!8W9<.2752%SM)
M .#76;AC.>*II[/S_P"#\R4U=27]=CA="^%JZ)J_A6^&I-,="T%]#$9AQYP;
MR?WN=WR_ZG[O/WNO%>5V?P4\6>'_ (@:+I_ASQ'<Z-!IGA)=/_MYM,2>&=_M
MC.T9C9L!]IW##<=2&'%>]Z;XCL=6O]5L[:1I)=,G6VN3L(59#&LFT'H3M=2<
M=,UI%@!N[>M%VW=_U>_^;&M$U_6EO\D>:>$/@7IO@[7;&\M[Z:ZLK;P\V@M:
MW*!FFW3F:29W!'S,S-D!<?,?I69X4^ E]H>J>'X]3\8W6M^&O#4GFZ)H\EE'
M$T#!&CC\Z93F;RT<A?E7L3N(KTG4O%>F:5JL&F3W/_$QN+::[AM(T9Y)(HMO
MF,J@'."Z#'JP%6](U2+6=*M-0ACGABN84F6.ZA:&50R@@/&P#*W/*D @\&A/
MJOZU;_.]NW0371]?\DORMZGF=E^SOHJ77Q _M"]N-1L?%B/ MHRA1IT#[GDB
MA.3PTSO+G'WB..*N_#/X3ZOX(U22[U7Q1#KL:0^1;0P:);6)"\?/*Z M(^!C
M(*+R?EZ8Z>;X@:-9W1@O99]/=M332(3>6TD0N;AD#JL190)%()^9<KE6&<J:
MZ/<, YX/2A72T]/Z^_\ $;UW]?Z^[\#R;Q?\%M<UKQIKGB#0O',_ALZS96VG
MW=O'IT<^88O-RR,S#;(?-.&P0O.5;/%>_P#V;]/D:?\ LW6;G2O*L=*MM+DB
MB5Y+"6P:1H9<L2),^80RD#(SSSQ[%12&W?5_U_5D>/VGP$O+DW&H:]XKDUGQ
M)=:AIMW/J"V"P1"&RF\V*".$.=@)+Y8LQRQ/8"HV_9\N3J']G_\ "77/_"!_
MVI_:_P#PC0LHPXF\_P"T>7]ISN\GS?GV;<]MV.*]DHH6CNOZV_R0GKO_ %_5
MSY*NO _C'4?B!8>%M,M?$FG>%K'Q3%K9L[[3;?[#&B71N)&2^60EXV.62$)O
M5F )PIKT\_L^WNF6VE77A[Q:^C>(].N=1DBU)]/6>*2"\N#-)!)"7&X*VW:P
M8$%<]R*]EP,YQS2T+1)=O^ OT!ZMO^NO^;_X<QO!_AZ7PKX;L=+GU6]UNX@0
MB74-0??-.Y)9F;' Y)P!P!@#I6S111N 4444 %%%% !1110 4444 >*^/-1G
M^&GQC3QG>Z3?:GH-[HZZ:]SI\!G>SE64O\RCG:P(Y'<5YU\01>>)_!'Q7\:M
MI5WI&DZK;6%K917L?E37 BD&Z8IU&=P SZ5]7$9K'\7^$M.\<>';O1-5C>6P
MN@HE6.0HQ 8,.1R.0*VA4Y;76WY7N?*X[)IXB%:,*FDN9J-OMR@X_%O;6]K7
MOUMH?.R^&K'7]5\30^$]#O8=%?PI+#J=O<6TD:3:A]Z$;7'SS#&2PSVY-/\
M#-A;-#\-SI=A)#!%X5U2*X5;5X]MSY48EW @?,7#<]STS7TW#"MO"D29V(H4
M9.> ,4_%4ZMTU_6TE_[=^"1-/(8QDJG.KW3TC9:2A*RUT7N:]VV]-CY1\#?#
M;39+KX/1W.C.T>I:3>#5ED5P)]L:LBS>H!Z*W'MQ5WP):W5OIGPE^UVUT\%C
MJFL*ZR1NQBA$<P4'(R!MP /P%?4.*,4Y5W*^F_\ FW^MC.CPY2H.+A.UN796
MV5+SZNG?UD_G\E_#&?PQ<^*O$GB>T\/M8ZN;2XMM#\-6%E-;,8EC8LSR! HE
MD (&&X!P.<4?#+24U3QJZ0Z1!::9JOA>Y@GLK73[B&"2<,,QR--S-(N>7/7W
MKZT QZ_G1C%)U;WTZ6W\G_G?U)I<.\GL^:HO=DY:0M=MIOJ[:+E[6LK::_+?
MPPTQ(;+X,Q6.GR6EW:7&I)J :U>,I=?92"7R!S]T9Z'%0>$M)F67PA;6NF:G
M!\4+?6A+KM_+!*"UMYC^<TDI&QXF3:%7)[8%?5>*,53KMRYK?U>_W=UZ#I\.
MQITXTU4VLOA_NPC=:Z2]RZETN]-3Y+E\')!X3U/7H=.G37H?'S^1=*CB6.$W
M*@[?12"<XX/>OK0=*,4M8RFY14>W^27Z?B>Q@,MA@)2E!_$DGI;5.3OZOFM\
MD%%%%9GLA1110 4444 %%%% !1110 4444 %%%% '+_$(XT2+_KX3^1H\+'_
M $=*;\1CMT*(_P#3RG]:3PJV;=* .J'2EI%Z4M '(?%[75\,_#'Q-J;IJ#K;
M6$KD:6_EW/3&4?!V$9SNP=H!/:OC73;RR\0CXF^'M,OK:\T*Y\#W&H&ST;Q'
M>ZM"UY'+E7\^7&7 P&6,[2.&'.*^^" P((R#U!JO!IMI;*JQ6T,2J"JA(U
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M_3;V0-;*3/';6P\N:8R[MZ,K'*A=H!&>@^,^I:9=67Q%'COQ)?V'BN#1(_\
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ME 2=IRN3[=O2E^QP>6$\F/8'\P+L&-V<[OKGG-*/NV?:W_MOY\OXA+WK^?\
M]M_\E^!\AV.NVQU.RO5\0ZFWQL?Q0+6ZT3^T)B!:_;"KQ&TSY8MA;?,)-O4
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M5& [(K,6+'Y0 0!BMS0M#M/#FEQ:?8QF*VB+%5)R<LQ9B3ZDL3^-3+WH<O\
M7;\K?.X1?+*]OZ_X?\#X2^%NLZP;77+JT\:Z'>27'A74KC6K'3M9U2^OGF%K
ME)+A)P4M94D[#R^K  X&.SM_#@^'VB^$I;+5M7O9?%7P^U.76?[2U.>Z2[FB
MLH'279(Q5&&]A\@ P<>]?8*:?:QM.5MXE,_^M(0#S/\ >XY_&E:RMW"!H(R$
M0HH*#Y5(P0/08[54O>37=6_]*_S_  )C>+3[._Y?Y?B?)'A>QB^$@\ :CIU_
MXANDUWP%?WFJVZZC+<R7#VUK;/$T$;DHDBAV5=B@8(&#7F'A;QS%'XCUB/P[
MK5LEIJG@76KN]BT_Q5>:RS7,<*/&\TDH$<<ZYD^6+!'S9 &VOT(%I"K1,(D#
M1*5C(490<<#T' Z>E01Z18Q)L2SMU3+':L2@?,,-V[CKZTY/F;?=-??S?Y_@
M$?=27:WX6_R_$^3;/1=7^&$?AN?P=J6LZCXA\1?#_4;N:/4-1FO%O+^&WMWM
MY0DC,JN&<KA  0<8K#A\1Z5IOPX\1WGPG\9>(-=\5R^&%N=8@>\GOH[>X\V(
M37$Q;<UO=!&F_=( <*2$RHK[5%K"'C81(&C4JA"C*CT'H.!206<%JTK0PQQ&
M5B[E$"[F]3CJ?>B3YFW_ %N]/37\%\E%.*5_+]/\OQ9\*>$-8UO3?"GC0^'_
M !II-_X?^R6<FH1^$-7U+59;)&O$%S<+-<AS'+]G,N45MPVAMH(S7JW[/9\'
M#X[^,(_ FMS:YX<3PWIPAF?4)+Z*-OM%R66*>1F9ER<D;F 8D<=!]*6UE;V2
M,EO!' C,698T"@D]2<=Z2WL+:T $$$4("[!Y:!<+DG' Z9)/XT)V:_KH_P %
MT';1KO\ YK_(^*?&^KZ+'XF^+4S>*]9M_B18^) /">E6^ISIOE-M:[4AMP=D
MRNQ*R A@JY/R]3O:S8:@;3XW^*[;4=;&KZ9XB&G)+9WL[_V=8/'9->-! "5W
MB-I&#;2PQE<=_IGPM\/M-\*:KK^H6[2SW&LZD^J2M<!6\J1H8XB(R "%VQ+Z
MGD\UT<=O'"9#'&J&1MSE5 W'&,GU/%2M$O1+_P!)O^33[W*;NWZW_/\ SNNQ
M\,>/;/POK?@KXHZ3X!UJ_P#$GP[@\++J-U(FK7-[;VVJ)/E=D[.6W&(,TD>X
MJ-JY [YWQ1U>Y?QK=V^G^,]"T/0[#3+%O!MSJOB#4XG> VP(GM! 2MXYDW [
M_,8[0",$9^](+"VMK=H(K>**%L[HT0!3GKD 8YIITRS(MQ]EAQ;\PCRU_=_[
MO'R_A3Z_UY_ELNR%_7Y?Y7?F?(/CR;6=<\3ZUI5]KM_;3W/B3P=;7$VG7,ML
M5\R+]^(AD&,.<\8!YY&17L/P-TJ/P;\0/B9X0T^ZOI=!TJZL)[&WOKV6[:W\
M^VW2(LDK,^TLN[!)P6->P/96[R&1H(V<LKEB@))7[ISZCMZ4]((XY))%15DD
MQO8* 6QTR>].^_G_ ,#_ "_$35[>2_S_ ,SXNT#5;:P_:*ELY_$"^,+O6-;N
MM/G73?$-Y;ZG:P.)!Y=UIK_N_L\0PHEBV$!4<,2>>4T'5?!OA[X->"/#4ETL
M=O+>ZL;_ /M3Q;=:780W44X7R9I8RTIGVE"D"E?XF()//WRMC;I=O=+!&+EU
MVM,$&\CT+=<5&^DV4B%&M(&4R><5,2D%_P"]TZ^_6H6D5'^OZZ^I3UDY?U_7
M3T/@WP;XBT#Q/I/P@G^(OB>XMM#%GXEL[B_.IW%LK1QWD"Q12W)*RJ@4*,NR
ML=J!CDX/5MKFIWGAG0TEU34;W29/#OC(:=/?S/YMY8)L%I+*&P7/EXVLPR5P
M>YK[(DTNSE5E>U@=6W;@T2D'<06SQW(!/KBI)+."4J7AC<JI0;D!PIZCZ'TI
MO56\G^-]?77\Q+1I]FG]SV]/^ ?#7CNRL-=\%^*AK]U<#1M*;P5<LQOI88K6
M)HXUFD)1P$78S$G@#ANH!'J0GN=/\?V'PS@O;LZ$-4'B^*_^T.Z_V.B>;Y7F
MDY*B["K@DY1AVKZ0;3K5XY8VMXBDJA74QC# # !&.0!7,^'?AK9:#XMU[Q'+
M?WVK:CJBK OVYD,=G;*25MH555"Q[F9OFW,2>20 !;E><I=VW^5OQ2^5UU(4
M;12[*WYW_!OYV/G#XD:[IMA\/?!S>(";:/Q??WVM3RZAXAET73?WF'B2XN(1
MO9O+:(1QJ1DH2<[<5QW@7QG#KWP[\"VOCGQ-=VGPX&OZ[8ZA?QZI=6\7[I_]
M MYKIBLRQ;3(5,C*6*1@]<'[GN+"VNX%@FMXI85(*QN@91CI@$8XHDT^UE@E
MA>WB>*4[I$:,%7/J1CGIWJ5I?^NUON1;UM_7?_,^-S9>%V\<?#G74UW6-15O
M#NOVFBZOK=W-;SWCQ2#[.JKN42_NVE*L03(BJYSM!%JSUC7=(\&^#] M+Z_E
MN?BCX9TJRL[HRR2&VNXX42\EWY)0FT8R9[M$3U-?7\MC;S^5YD$<GE',>] =
MG&./3CTI5M(%$($,8$/$>$'R<8X]...*$[:/7]=6_P ;_@)W;NOZVM]UOQ/B
M[XAZ3HVHZW<S>)+N=-&T?XL6MMYT^I30Q6MNVFPC:6#@*I8(,D]6./O'/I7@
MHZM/\4]*^&\]Q>/9^"[JZUF:Y>9R;FTD!73D=\_-CSI@0<\VH)KZ%ET^UFCE
M22WB=)6#NK1@AF&,$C')X'/M7->"/AU:^"M0UW4?[2U#6=4UBX$US?:E(C2!
M%R(H4"*JK'&&(48SR2222:<79)/^G:*_2XY)/5?UJW^3M]QUM%%%2 4444 %
M%%% !1110 4444 %%%% !1110 456NKU;5E#*6W<\5#_ &NG_/-OTIV8KI%^
MBJ']KI_SS;]*/[73_GFWZ4^5BYD7Z*H?VNG_ #S;]*/[73_GFWZ4<K#F1?HJ
MA_:Z?\\V_2C^UT_YYM^E'*PYD7Z*H?VNG_/-OTH_M=/^>;?I1RL.9%^BJ']K
MI_SS;]*/[73_ )YM^E'*PYD7Z*H?VNG_ #S;]*/[73_GFWZ4<K#F1?HJA_:Z
M?\\V_2C^UT_YYM^E'*PYD7Z*H?VNG_/-OTH_M=/^>;?I1RL.9%^BJ']KI_SS
M;]*/[73_ )YM^E'*PYD7Z*H?VNG_ #S;]*/[73_GFWZ4<K#F1?HJA_:Z?\\V
M_2C^UT_YYM^E'*PYD7Z*H?VNG_/-OTH_M=/^>;?I1RL.9%^BJ']KI_SS;]*/
M[73_ )YM^E'*PYD87Q)_Y ,7_7S'_6F^$?\ CW6J?Q)U5#X?B_=M_P ?,?IZ
M-3/".KQBW3]V_P"E'*PYD=XO2EK.75TQ_JV_2G?VNG_/-OTHY6',B_15#^UT
M_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_Y
MYM^E']KI_P \V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">
M;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E
M']KI_P \V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1
M_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI
M_P \V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?
M\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \
MV_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_
M2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2C
ME8<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8
M<R+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R
M+]%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]
M%4/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4
M/[73_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[
M73_GFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4/[73
M_GFWZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_G
MFWZ4?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4/[73_GFW
MZ4?VNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4
M?VNG_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4/[73_GFWZ4?V
MNG_/-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG
M_/-OTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4/[73_GFWZ4?VNG_/
M-OTHY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-O
MTHY6',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTH
MY6',B_15#^UT_P">;?I1_:Z?\\V_2CE8<R+]%4/[73_GFWZ4?VNG_/-OTHY6
M',B_15#^UT_YYM^E']KI_P \V_2CE8<R+]%5+?45N)0@1@3W-%)JPT[E;5_]
M9%]#_2J%7]7_ -9%]#_2J%:QV,I;A17E/B;XC7_ACXO:A9SS22^'['PK)J\E
ME$B;FE24@D,<'.T8P3BK&E?'2TUF>"VA\/ZQ;75]I,FK::MU'&HO41-S*AW\
M$?[6,]1VKH]E/EYDM+7_ #_R9R^WAS.+=G>WY?YI>IZ=17B_@SX]RS?#SPUJ
M6MZ3=7&O:T\JVMG:>4@NE0DM(A9PJ1J,+ER"2/>K\OQ7/B76OAK/H-U)#IFL
MZG=6=];RQ+OS%$<QMG.TJXZJ>?7%4\/43::V_0B.*IRBI)[Z_>>LT5XMX-^-
MLEEX'TF?65N==U_4]0O[>UM;411O(D,[C)+%$4*H49)&?<UT@^..BWFBZ'>:
M797^L7VLS2V]II5K&HN#)%_K@VY@J[,<DG'3'6DZ$T]BHXBG);GHM%>/:]\:
M=3;6?A]'I/A[41:Z[>30W4%U"L5P/+!!B4.P (/S%NA4<'-;FH?&[2=-\.>(
MM8>PO7@T35QH\T:[-\DF]5WI\V-N6'7!]J/8STTW_P [?F'UBG=Z[?Y7_(]%
MHKS[QE\8K7P1J)CO]!UC^RTGAMY=76)%MU>0@+M#,&< D E%(%3>!_$NI:O\
M0?B%IMW<^=9:5>6L5G%L4>4KP!V&0,G+<\YJ52ERN72U_P O\T5[:',H];V_
M!O\ 1G=T445D;A1110 4444 %%%% !1110 4444 %%%% !1110!RGQ*_Y%Z/
M_KZC_DU1>$#FV2I/B9QX<C_Z^H_Y-47A YMEI =@O2EI%Z4M, HJIJ^J0:'I
M-]J5T6%K9P27,I1=S!$4LV!W. >*\VU+]HSP]9W>GVUGHWBC79KW2[?6$71=
M#FN_+MY\^49-F=A.T\'TI76W]=?\F']?E_FCU2BL+P7XTTKQ_H$6L:/,\MH\
MCPLLT312Q2HVUXY$8!D=6!!4CBMW\Z>P!16+KOB[3_#NJZ#IUXTJW.MW;65F
M$C+ R+$\IW'^$;4;GUXK:H **,_7\JJZIJ=MHNF7FH7LHM[.SA>XGF<'"1HI
M9F/T )I72U&E?1%JBJNEZE;ZSIEIJ%I)YUI=PI/#( 1N1U#*<>X(JU3>FC%O
MJ%%%&: "BBL71O%VGZ[K^OZ-:M*;W0Y88;P/&54-+$)4VG^+Y2,^AXH VJ**
M,T %%9FB>)=-\1MJ2Z==+='3KR2PN=H/[N= "Z<CDC<.G%:= !11GZ_E1^!_
M*@ HHZT=>Q_*@ HJC9ZLMYJ>H60M;N)K/R\SS6[)#-O7</*<\/CHV.AX-1:]
MXDT[PS;VL^I7(M8[JZALH2RD[YI6VQH !U)- &G11WQ1^!_*@ HHH_/\J "B
MC/%'X'\J "BBN7\??$32_AU8V$^HPW]W-?W2V=I9:99O=7-Q*59L)&@R<*K,
M3V )H ZBBD5MP!P1D9Y%!( )/0<DT;!N+16;X;\1Z=XNT&QUK2;D7FF7T0FM
M[A5($B$D C(![5I $D#I]:'IN 450T35UUS2XKY+6\LTD+ 0WUNT$RX8K\R-
MR,XR/4$'O5^@ HHHH **/P/Y44 %%%% !111WH ***.E !11^!_*D)P*-@%H
MK&\'>+=/\=>&-.U_2FE;3K^,RPM-&8W*[BO*GIRII+SQ=I]CXOTSPU*THU34
M;2XO8%$9*&.$QB3+=CF5<#OSZ4=; ;5%'X'\J* "BL?Q9XKL/!>AOJVIM*MF
MDT,!,49=MTLJQ)QZ;G7/H.:V6!5BIZ@X- "44?G1^?Y4 %%%% !169K'B33M
M!N-*@O[D6\VJ78L;-""3+,49P@P/[J,>?2M//&>U !17+>./B-I7@&31X+Z&
M_O+W5[K[)9V6F6;W,\K ;G;8O(55^9F/ '-.\>_$32?AW8VDVHI>W=Q>3&"S
MT_2[1[NZNI I9A'$@);"@DGH *5QV9T]%8?@[QEIOCK11J>EM/Y0E>"6&Z@:
M">"5#AXY(V 9'4]0?6MS-,045B^&/%VG>+EU4Z>TK#3-1GTNX\V,IB>$@.!G
MJ.1@]ZVOSH#R"BC-'YT %%%'X'\J "BLW6/$>G:#/I<-_<K;RZG=K8VBL"3+
M,RLP48''RHQR>.*?HNL)K=DUREK>6BK-+#Y=[;M#(2CE-P4\[3C*MT8$$=:
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M:I H7. !DY.!C)]32U39*5@HHHI#+6F_\?B_0T4:;_Q^+]#164MS6&Q+J_\
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M_P!*/[)C_OO^E',@Y695%:O]DQ_WW_2C^R8_[[_I1S(.5F516K_9,?\ ??\
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M_KZC_DU5_!/_ ![I4_Q6_P"1;A_Z^X_Y-4'@C_CW2@#N5Z4ZFKTIU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0!Q?Q7_Y%J'_ *^X_P"35!X(_P!0E3_%?_D6X?\ KZC_ )-4'@G_ (]T^@H
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MX@?LU:CX<?2X;#Q/?Z0MJU@]VLD:2C:"IEP 1\O6GM%OKI^<O\DQ7O)+I_\
ML_\ !+6H_M,^ ]+TZPO)[S4=M\96@@CTFZ><Q1OL><Q",NL.?^6I 4Y!!-7?
M$_[0?@7PI9Z/<W.KM>1ZM;?;K0:7:RWK/;<9G*Q*Q6,9&7.![U@>,O#/C;PK
M\11XP\'Z+I_B5K_1X-'N[&]O_LC6S122.DJ.58,A\U@R]>%(S7(^&?A)X_\
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M)E5S(70@*-V 5X^85:U;X$^(&\$ZSI\;VUW>OKNFC38_,")!I-I?1S119/\
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MVS=NSQBM?XB_%;PY\++:PF\0W4UN+^9K>UCM[62XDFE6-GV*D:DEBJG  Y/
MYKQJZ^$?CV73;KX<+I^E_P#"'7&O-K/_  D[7I-PL#7WVPQ?9]N3-NR@?.W&
M#[5Z;\2O!&I^)_'7PTU.RBCDL]"UB>]O6>0*5C:SFB4J/XCO=>!]:E:Q7?\
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M"@9R:]7\*>#]2TGXN^/-?G2-=,U>VTV.U99 69H4E63*]OOK]?PHMI=[_P#
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M;_A_Z9DZG^TQ\/=&\1W>BWVMO:W=G>MI]U)):3""WG"JP22;;L3=N&W<1N/
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M*W_(MP_]?4?\FJ#P3_Q[)5CXJ_\ (N0_]?4?\FJOX('^C*: .X7I3J:O2G4
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M]7-%&[2_KK_DSZ,#J4WA@5QG=GC%-\^/&?,7'!Z^O3\Z^4?AKX]\;>$_A/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^>:_G5&BCE0<S+W]KR?\\U_.C^UY/^>:_G5&BCE0<S+W]KR?\\U_.C^UY/\
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MGI1UL%CMJ*R],\2Z;K&J:MIUG<K->:5,D%Y& <Q.\8D53[[64\>M:@.3@=:
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M'GT*G\J5U:X6-:BLWP]XCT_Q3H&GZUIEPMSINH0K<6TX&!)&PRK<^HK2I[:
M%%-WJ=W(^7KSTI2P'>@!:*0.""00<'%)YB@ [A@G'7O0 ZBD9PI ) )Z4;AN
MVY&?2@!:*H:IJZ:7)8(UM=7!N[E;93;0F01%@3OD(^Z@QRQX&1ZU=#JQP",X
MSB@!U%(S!!DD >IK,U+Q/INDZQI.EW5TL5_JIE%G"029?+3>^/3"\\TF[ :E
M%8G@OQAIWCWPOIFOZ4\CZ?J$/GP&9-C[<D<J>1T-;08$D C(ZBF]-& M%(K!
MLX(.*3>N3R..O/2@!U%)D5E^(O%&F>%-(?4]4NEM;)9(X3*02-\DBQHO'<LR
MC\: -6BD+ -M)&?3-&X9 R,GM0 M%('4J3D8'?- (8 CD'O0 M%%% !1110
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MZU%=Q3A9[:Z8\M&VW@=L$&FYT+Z1T_X/^0E3Q-M9:_\  _S/#]8OM7W?$O\
MM&41WZ>+-$C<6LSF(9=0=F>0I&#CWP:[C5_VA=5A\::I:V&CB\TO3=4_LV6W
MBM;B2YF (#RK(JF-0N<[&.2!VS780_ ;P[%:ZO USJ<_]JW]KJ5S+/<AY&F@
M;<AW%>A/4?EBM&?X2:1)XEN=8AO=6L?M=TM[=6%G>M%;7$XQ\[J.<G R 0#C
MD&J]K1=E)7M_E!?HR/85XW<'9O\ SF_U7];YG[0&N7^B^!H(M/O7TU]2U.UT
MV6_CX:WBE?#N#V.!@'MFH?#OPOT;X4ZY<:KINO:J+9;&:2XTJ[N_M N=HR90
M&Y!&.WK7>>)O#6F^,-$N](U>V6\L+I=LD3''?(((Z$'D$5R/@SX'^'/!>KOJ
MD4FHZM?F%K:.;5KMK@PQ-PR(#T!'%<\*B5-QO9Z_/3]/U.N=-RJJ=KK3KMKJ
M_G^G8YKP[\8O$5P/!FL:OIVGQ^'O%MVMI9Q6DCFZM2X)B:0GY6!V\[<8SWK$
MT?XW>-M2L?#=_P#V;HAM=;UF?0X4+RJZRJS!96/("_+RO)..V:]#T#X*>'O#
MNJZ?=P27\\&F2--IVG75SYEK9.V<M$F,@\G&2<9XQ3]/^#6@Z9IN@6,,EX8=
M%U5]8MMTJDF=BQ(;Y>5^8\<?6MN>A?X?^&_S\S#V>)MK+_A_NV\CA)_C=XHA
MT&W5-/TR774\5_\ "-S?,ZV\G&?,7^)>W7/>LOXE>/-;U'P?XT\.ZU';0:QH
M>H:6WVK3'=8IH9IT*D9.Y2,$$$UT_P 0?@A_:%G86VAB65+GQ5'KNI&6Y$;(
MI!$AC/!&., 9-=$?@AX?DT35].GGU&[?5KJ&[O+^XN ]S,\3!HP6VX"C:!@#
MIFJC.C'EG;6Z_#E_X)$Z=>3E"^EG^/-^/P_UOQ/B3]H/5=/\::U9:;I O=/T
MB_6QFMTM;B2XN?N^8Z.BF--N[[K<G';-:7B?XL>*-&^*$/@BUL--GNM4EAGT
MV\D9@B6F&,WG+NSYB[> ,9S77WWPDTB\\2W6LQ7NK:>]Y.ES>6=A>M#;W4B8
M"LZKSG@9P1G'.:J:M\$/#VM:EJ&J74M\VL7=[#>KJ2S 3VS1?<2([<*@&1MP
M<Y.:B,Z"Y;KIKZZ?K=^FGI<J>(]ZTNNGIK^EEZZ]-?,/BGXJU:WL/B6FBF#2
MI[37=,MI;J-Y?,G214Z_,0O) .T %<]^:ZWQ%\8-:\%#Q?IVK6]C/K5A:6D^
MDK;*ZQWK3D1@8)SQ+D<=JZO5_@_H6N6WB>&Z>[/_  D,\%U=NDH5DEB"A&C^
M7Y<;0><\USVN?"^^\3?%/PCJ%Y:AM'\,Q%EU*YNEDN-0? **Z #&UQN)/4]*
M<)TI)1EMU^48[?--?,4X5H-SCN]OG*6_R:?R/4=/^U?8+;[;Y?VSRE\_RL[/
M,P-VW/;.<58H%%<+U=STDK*P4444AA1110!S/Q"_Y ,?_7S'_)JC\*C_ $=:
ME\?C.AQ_]?,?\FIGA@?Z.M '3KTI:1>E+0!SGQ%\6_\ ""^!]:UU8FGGL[<M
M;P(,M+.2%B0#OND9!^-> _#71/'7P>\9>!;KQ5HFDZ?I5W;_ /".:E?:=J;7
M4EQ=32M/#/*AC4)^_:5<Y/\ KL5]0,H88(!'H1FAE### ,.O(S2MK?\ KK^C
M?X=AMW5OZ_I'Q?\  HZ!"OPR7PY=ZB?B(=79=6M3-.5&F>;<>;YD;?NUA VE
M& &6Q@DYK*:6]_X5K=3^9<_:1X)N0)=[>9G_ (2 X^;KT_2ON18U0Y554XQP
M ./2D\F/&/+3&,8VCI36GX_BK?\ !];E.5Y.7I^=_P#@'RW'X-TS3?B'\9[S
M0XS:^,],U2P\1VD(N)=UQ D$<D@VEL%)&,Z=.K8Z  >N? R8^+/#VJ^,;@3>
M5XMU"2^MXIB08[$ 0VRX_AS$F_C',AKK?&W@^W\<^'KK1[B^OM-AN=JRW&F2
MB&=D!^:/>5.%89![X)P0>:UM.T^VTG3[6QLX5M[2UB2"&%/NHBJ%51[  "E%
M65OE_G^2_'N0];/^OZU?X'QCX5TSPIX;\&:5I.IO/IO@J#Q;K$/BN.&YN%$4
MH,GV%+E@VY(BNT\$ G82><GWO]G*9I?#?B,:=+=7'A--:F7PW+?.[LUEY<>-
MK/\ ,T0E\T(3_#T)&*]9\I,,-BX;[PVCYOKZ_C3@   !@#@"A*RMY6_+_+3L
MF.3YG?SO^?\ F?$/P:_MZ?XI:#<:GXGTNU\9G4I/[;TXIJ,FHRQ!I/,BF0L8
M%BQC:X55&%P>>>ETZX-M-XL>>?4/^$0DT;6CX#>XD.P_NW-USG<3U\G=_P L
M@Q%?7&Q=Q;:-Q&"V.2/0FJ&NZ%:^(M"O])NE*VM[;2VLACP&5'0HVWC@X8XJ
M)1?(TNS_ !7]?B6I+GYGW7X'QWX8GT0>&[&7P-?ZI>:FW@?4'\7?:+FXD"N-
M/4P&8.<)-YOW N#MSVYIOQ!\+-X<\#_"^(7MII?A75=*^WZS>^(;F^>VN-2:
M&#89WA<.I*[]H)"9!XSBOL?0M$MO#VAV&E6H9K6RMHK2,R8+,D:!%W'')P!5
MTQJR;"JE.FT@$?E6L[.3:_K5_P"?WI&<6U&*?3_@?Y?<SXJ\869/PR^'\WB+
MQKIE[;PM?FVAU@:C9:=>Q&4>5BX&)!+&HVQM)N#*2PW8S57XE:O!>6/@WQ#J
M-T]K>CP[";7PMK^HWUM=;U>3#V=W$ )9WPN=Z%N(\@;J^WV19%VNJNOHP!'Y
M&E9%<@LH8J<@L,D'U'I4V_._Y_YE)GD_QPU'5[CX$RWMA%J6GR3+8R:A';D_
M;;>S:6(W04KSYBQEP2.?O$5XAXVN=&C\ :K%\+-5OCX&;7+$:K<7DEU-I=O
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M-TI1&+VLDP#B,$D;3G:P8 FO9RBG=\H^;AN.OU]:%4* % 4#H , 41TOY_\
M _R"3O;R%HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %K3?^
M/Q?H:*--_P"/Q?H:*REN:PV)=7_UD7T/]*H5?U?_ %D7T/\ 2J%7'8B6X444
M51(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!SGCP9T2/_ *^$_DU-\,C$"U)XY&=&C_Z^$_DU-\-C_1TH Z(=*6D'
M2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH P?&(SI<?\ UV7^M+H(Q M.\6_\@U/^NR_UI=#7$*T ;(Z4M(.E!XH
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M'3O"/C>3X?6&H:GX4NM2BT[QI8:M!;R:7;VVJW-JH"S23PQG87#'KP65<D#
MKZ]P/2C QTIQ?*[KR?W-/] E[V_I^%CYO\-?#)]*^ OBU=3M(O#NM#6M2UJW
MO+E%C=94O9+BVE9O0[4_X":]!_9WL[VX\ _\)1JML;76/%ER^NW,#')A64 0
MQ9_V(5B7\#7<^*?".C>-M'?2M=TVWU73G=)'MKI-R,R,&4D=\$ UJHBQ(J(H
M5%& JC  H3LK>B^[_.R^X35_O;^__*[^\=1112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!E^(1FR3_KHO]:=I@Q$*77!FS0?]-!_
M6ETY<1B@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6079;_M2?_9_*C^U)_\ 9_*JE%%D%V6_[4G_ -G\J/[4G_V?RJI119!=EO\
MM2?_ &?RH_M2?_9_*JE%%D%V6_[4G_V?RH_M2?\ V?RJI119!=EO^U)_]G\J
M/[4G_P!G\JJ446079;_M2?\ V?RH_M2?_9_*JE%%D%V6_P"U)_\ 9_*C^U)_
M]G\JJ446079;_M2?_9_*C^U)_P#9_*JE%%D%V6_[4G_V?RH_M2?_ &?RJI11
M9!=EO^U)_P#9_*C^U)_]G\JJ446079;_ +4G_P!G\J/[4G_V?RJI119!=EO^
MU)_]G\J/[4G_ -G\JJ446079;_M2?_9_*C^U)_\ 9_*JE%%D%V6_[4G_ -G\
MJ/[4G_V?RJI119!=EO\ M2?_ &?RH_M2?_9_*JE%%D%V6_[4G_V?RH_M2?\
MV?RJI119!=EO^U)_]G\J/[4G_P!G\JJ446079;_M2?\ V?RH_M2?_9_*JE%%
MD%V6_P"U)_\ 9_*C^U)_]G\JJ446079;_M2?_9_*C^U)_P#9_*JE%%D%V6_[
M4G_V?RH_M2?_ &?RJI119!=EO^U)_P#9_*C^U)_]G\JJ446079;_ +4G_P!G
M\J/[4G_V?RJI119!=EO^U)_]G\J/[4G_ -G\JJ446079;_M2?_9_*C^U)_\
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M6079;_M2?_9_*C^U)_\ 9_*JE%%D%V6_[4G_ -G\J/[4G_V?RJI119!=EO\
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M3-9ZW%KNK-I<L]K=*PMB+>28,=N<D^7C''7-<OKGQ[U6TUJXTG2/"ZZKJ/\
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M,O!<7C&\\-W$MT]L=%U>/5D5%#>:R(ZA#D\ ^8>?:NCHH6B2[?I_PPGK>_\
M5]SR[7/@5;ZI>ZUJ5KKMYI6M7>MKKMEJ%O$C-8SBV6W*A6XD1D4[@<9S[5%8
M? .WACT^XOM?O-3UN/Q#;^(K[4YX45KR:&,Q)'L!Q&@0@ #.,=\UZM122MMY
M?A:WY+[@>JL_/\;_ .;/$OB-^S4WCO6+^_M_%MUI*WNL1:Q-:?8DN+>5X[=(
M8TD1F =5*!P#QD].*U+KX+^(+R/3=0E^(5XOB[3O.A@UV+3(4#6LNPM;O!NV
MLH9 P.00:]9HH22V_KI^6@VVSSCP=\$M.\%Z[X=U6VU&[NKC2H-029[D!GO9
MKR2.2:>1AC#;H^ !C!QVK-M_@##8CPR;3Q!=VTNC:AJ5VSK I-Q#?.S30'GY
M/O !QR,=*]9HH:3T%YGA'@[]EF/PGKWAK4/^$LN+NV\/-,MC9+IEO IBDA:(
MB5T^:1P&!WGT/'.:](T7X>_V%\+K#P9::Q>6OV+3TL(M4MU59UVC D .5SQT
M.1U%=?13Z-!UN>(V/[+]E]CUR;4_$-Q>>(-2>TE35[*QALC;26TAE@D6),JS
MAF.6;)8<<"I=:_9TO/$.GVLVI>.+_4/$EO?_ &]-3O+&&:W4^28=BVC'RU7:
M2<@YW$G->TT4K*UAW>YY!X,_9UL_"+V)EUVZU<6^N7>N/]IMXT\Y[BU-O)&0
MF %P2PP/08[U;\!? R7P+J=HL?BJ\OO#M@ACL=%ELH%$:%2H228#?*J@X XZ
M#)->J44]OZ^0OZ_&_P"9YOXJ^!FAZEI%E!X82V\#:C8:@FIVM]HUA"H6=4:/
M+QX"N"CLO/KUK@=?^ .L:5J?AQ='U_4[BZNO%ESKU]K?DQF2S=[!HMY7[K*7
M51CCAL=LU]#44K?U]W^2'?\ K[_\V<K\.O :^ =.O1)J5QK6K:C=F_U#4[I%
M1[F<JJ@[5X50J*H4= .IKC+/X0/>>&-1\+23W6CC2M=DUC0-9M0I>$R.TR$
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MC+M^+EC^-=%10M-/ZZ_Y@]?Z]%^@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 6M-_P"/Q?H:*--_X_%^AHK*6YK#8EU?_61?0_TJA5_6/]9%]#_2
MJ&:N.Q$MPHHS1FJ)"BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "B
MC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: (YQE!]:6,<428*_C2IC%
M #J*,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **
M,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,
MT9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T
M9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H *
M*,T9H M:;_Q^+]#12:;_ ,?B_0T5E+<UAL:[PI*1O4-CU%-^RP_\\U_*BBIN
M58/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPLAK6D)'^J7\J4
M6D('^J7\J**+L+(7[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
M ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH
M^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L+(/LL/\ SS7\J/LL/_/-
M?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_ ,\U_*C[+#_SS7\J**+L
M+(/LL/\ SS7\J/LL/_/-?RHHHNPL@^RP_P#/-?RH^RP_\\U_*BBB["R#[+#_
? ,\U_*C[+#_SS7\J**+L+(5((XVRJ*I]0****0S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20220331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/16/2022 11:05:05 AM-->
<!--Modified on: 5/16/2022 11:05:05 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20220331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20220331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20220331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/16/2022 11:05:05 AM-->
<!--Modified on: 5/16/2022 11:05:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637882959043526594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637882959043526594" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637882959043526594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637882959043526594" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637882959043526594" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637882959043526594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637882959043526594" xlink:to="plx_ShortTermBankDeposits_637882959043526594" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637882959043538429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637882959043526594" xlink:to="us-gaap_AccountsReceivableNetCurrent_637882959043538429" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637882959043538429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637882959043526594" xlink:to="us-gaap_OtherAssetsCurrent_637882959043538429" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637882959043538429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637882959043526594" xlink:to="us-gaap_InventoryNet_637882959043538429" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637882959043538429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637882959043538429" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637882959043538429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637882959043538429" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637882959043546382" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637882959043546382" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637882959043546382" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637882959043546382" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637882959043546382" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637882959043546382" xlink:to="us-gaap_LiabilitiesNoncurrent_637882959043546382" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637882959043546382" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637882959043546382" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637882959043546382" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637882959043546382" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637882959043546382" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637882959043546382" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637882959043556805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637882959043546382" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637882959043556805" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637882959043556805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637882959043546382" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637882959043556805" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637882959043556805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637882959043546382" xlink:to="us-gaap_LiabilitiesCurrent_637882959043556805" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637882959043556805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637882959043556805" xlink:to="us-gaap_AccountsPayableTradeCurrent_637882959043556805" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637882959043556805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637882959043556805" xlink:to="us-gaap_AccountsPayableOtherCurrent_637882959043556805" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637882959043556805" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637882959043566262" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637882959043556805" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637882959043566262" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637882959043566262" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637882959043566262" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637882959043566262" xlink:to="us-gaap_CostOfRevenue_637882959043566262" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637882959043566262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637882959043566262" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637882959043566262" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637882959043566262" xlink:to="us-gaap_Revenues_637882959043576616" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637882959043566262" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637882959043576616" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637882959043576616" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637882959043576616" xlink:to="us-gaap_OtherNonoperatingExpense_637882959043576616" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637882959043576616" xlink:to="us-gaap_OtherNonoperatingIncome_637882959043576616" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_637882959043576616" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_NetIncomeLoss_637882959043586272" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_ShareBasedCompensation_637882959043586272" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_Depreciation_637882959043586272" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637882959043586272" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637882959043586272" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637882959043586272" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637882959043586272" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637882959043586272" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637882959043586272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637882959043586272" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637882959043596859" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637882959043596859" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_IncreaseDecreaseInInventories_637882959043596859" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637882959043596859" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959043576616" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637882959043596859" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="plx_IncreaseDecreaseInBankDeposits_637882959043606829" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637882959043606829" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637882959043606829" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637882959043606829" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637882959043606829" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637882959043606829" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959043596859" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637882959043606829" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959043616287" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959043616287" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637882959043616287" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959043616287" xlink:to="us-gaap_RepaymentsOfNotesPayable_637882959043616287" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959043616287" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959043616287" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959043616287" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637882959043616287" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959043616287" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637882959043616287" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637882959043616287" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637882959043616287" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637882959043626804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637882959043626804" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637882959043626804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637882959043626804" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637882959043626804" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637882959043626804" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20220331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/16/2022 11:05:05 AM-->
<!--Modified on: 5/16/2022 11:05:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20220331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20220331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/16/2022 11:05:05 AM-->
<!--Modified on: 5/16/2022 11:05:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES - NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum entitlement of development costs to cover per year</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Performance obligation number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted stock granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Value of restricted stock granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds from sales</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20220331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/16/2022 11:05:05 AM-->
<!--Modified on: 5/16/2022 11:05:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20220331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637882959044026599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637882959044026599" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637882959044026599" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637882959044026599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637882959044026599" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637882959044026599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637882959044026599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637882959044026599" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637882959044036610" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637882959044036610" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637882959044036610" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637882959044036610" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637882959044036610" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637882959044036610" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637882959044036610" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637882959044036610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637882959044036610" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637882959044046588" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637882959044046588" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637882959044046588" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637882959044046588" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637882959044046588" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637882959044046588" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637882959044046588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637882959044046588" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637882959044056636" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637882959044056636" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637882959044056636" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637882959044056636" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637882959044056636" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637882959044056636" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637882959044056636" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637882959044056636" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637882959044056636" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637882959044066642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637882959044066642" xlink:to="us-gaap_AssetsCurrentAbstract_637882959044066642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637882959044066642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="plx_ShortTermBankDeposits_637882959044066642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="us-gaap_AccountsReceivableNetCurrent_637882959044066642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="us-gaap_OtherAssetsCurrent_637882959044066642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637882959044066642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="us-gaap_InventoryNet_637882959044066642" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637882959044066642" xlink:to="us-gaap_AssetsCurrent_637882959044076964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637882959044066642" xlink:to="us-gaap_AssetsNoncurrentAbstract_637882959044076964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637882959044076964" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637882959044076964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637882959044076964" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637882959044076964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637882959044076964" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637882959044076964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637882959044066642" xlink:to="us-gaap_Assets_637882959044076964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637882959044076964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637882959044076964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637882959044076964" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637882959044086654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637882959044086654" xlink:to="us-gaap_AccountsPayableTradeCurrent_637882959044086654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637882959044086654" xlink:to="us-gaap_AccountsPayableOtherCurrent_637882959044086654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637882959044086654" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637882959044086654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637882959044076964" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637882959044086654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637882959044076964" xlink:to="us-gaap_LiabilitiesCurrent_637882959044086654" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637882959044086654" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637882959044086654" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637882959044096602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637882959044096602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637882959044086654" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637882959044096602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_LiabilitiesNoncurrent_637882959044096602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_Liabilities_637882959044096602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_CommitmentsAndContingencies_637882959044096602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637882959044096602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_StockholdersEquity_637882959044096602" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637882959044076964" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637882959044106942" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637882959044106942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044106942" xlink:to="srt_ProductOrServiceAxis_637882959044106942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637882959044106942" xlink:to="srt_ProductsAndServicesDomain_637882959044106942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637882959044106942" xlink:to="us-gaap_ProductMember_637882959044106942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637882959044106942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637882959044106942" xlink:to="us-gaap_LicenseAndServiceMember_637882959044106942" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044106942" xlink:to="us-gaap_StatementLineItems_637882959044116715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_Revenues_637882959044116715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_CostOfRevenue_637882959044116715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637882959044116715" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637882959044116715" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_OperatingIncomeLoss_637882959044116715" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_OtherNonoperatingExpense_637882959044116715" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_OtherNonoperatingIncome_637882959044116715" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_NonoperatingIncomeExpense_637882959044116715" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637882959044116715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_OtherIncome_637882959044116715" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_NetIncomeLoss_637882959044126595" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_EarningsPerShareBasic_637882959044126595" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_EarningsPerShareDiluted_637882959044126595" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637882959044126595" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044116715" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637882959044126595" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637882959044126595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637882959044126595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044126595" xlink:to="us-gaap_IncomeStatementLocationAxis_637882959044136558" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637882959044136558" xlink:to="us-gaap_IncomeStatementLocationDomain_637882959044136558" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637882959044136558" xlink:to="us-gaap_CostOfSalesMember_637882959044136558" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637882959044136558" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637882959044136558" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637882959044136558" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637882959044136558" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044126595" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637882959044136558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637882959044136558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637882959044136558" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637882959044136558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637882959044146806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044146806" xlink:to="us-gaap_StatementEquityComponentsAxis_637882959044146806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637882959044146806" xlink:to="us-gaap_CommonStockMember_637882959044146806" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637882959044146806" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637882959044146806" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637882959044146806" xlink:to="us-gaap_RetainedEarningsMember_637882959044146806" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637882959044146806" xlink:to="us-gaap_EquityComponentDomain_637882959044146806" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044146806" xlink:to="us-gaap_StatementLineItems_637882959044146806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_StockholdersEquity_637882959044146806" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_SharesOutstanding_637882959044146806" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637882959044146806" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637882959044146806" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637882959044146806" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044156547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044156547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044156547" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637882959044156547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637882959044156547" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637882959044156547" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637882959044156547" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637882959044156547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_NetIncomeLoss_637882959044156547" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637882959044156547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_StockholdersEquity_637882959044156547" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637882959044166785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044146806" xlink:to="us-gaap_SharesOutstanding_637882959044166785" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637882959044166785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637882959044166785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637882959044166785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637882959044166785" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637882959044166785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637882959044166785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637882959044166785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637882959044166785" xlink:to="us-gaap_NetIncomeLoss_637882959044166785" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637882959044166785" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_ShareBasedCompensation_637882959044176674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_Depreciation_637882959044176674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637882959044176674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637882959044176674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637882959044176674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637882959044176674" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637882959044176674" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637882959044176674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637882959044176674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637882959044176674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637882959044186583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInInventories_637882959044186583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637882959044186583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637882959044176674" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637882959044186583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637882959044166785" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637882959044186583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637882959044186583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="plx_IncreaseDecreaseInBankDeposits_637882959044186583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637882959044196731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637882959044196731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637882959044196731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637882959044196731" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637882959044196731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637882959044196731" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637882959044196731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637882959044196731" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637882959044206812" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637882959044186583" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637882959044206812" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" xlink:to="us-gaap_RepaymentsOfNotesPayable_637882959044206812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637882959044206812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044206812" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959044206812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637882959044206812" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637882959044206812" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637882959044316550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637882959044316550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637882959044316550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637882959044316550" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637882959044316550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637882959044316550" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378829590443165501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378829590443165501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637882959044316550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637882959044316550" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637882959044316550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637882959044316550" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637882959044316550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637882959044326852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637882959044316550" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637882959044326852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637882959044326852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637882959044326852" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637882959044326852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637882959044326852" xlink:to="us-gaap_InterestPaidNet_637882959044326852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637882959044326852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637882959044326852" xlink:to="plx_InterestReceivedNet_637882959044326852" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637882959044336669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637882959044336669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637882959044336669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637882959044336669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637882959044336669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637882959044336669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637882959044346334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637882959044346334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637882959044346334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637882959044346334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637882959044346334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637882959044346334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637882959044346334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637882959044346334" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637882959044356661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637882959044356661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044356661" xlink:to="us-gaap_DebtInstrumentAxis_637882959044356661" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637882959044356661" xlink:to="us-gaap_DebtInstrumentNameDomain_637882959044356661" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637882959044356661" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637882959044356661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044356661" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044356661" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044356661" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044356661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637882959044356661" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044356661" xlink:to="us-gaap_FairValueInputsLevel3Member_637882959044356661" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044356661" xlink:to="us-gaap_StatementLineItems_637882959044366675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044366675" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637882959044366675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637882959044366675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="plx_SignificantAccountingPoliciesTable_637882959044366675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637882959044366675" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637882959044366675" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637882959044366675" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637882959044366675" xlink:to="plx_AtMarketEquityOfferingMember_637882959044366675" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637882959044366675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="us-gaap_TypeOfArrangementAxis_637882959044366675" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637882959044366675" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044376553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044376553" xlink:to="plx_AmendedPfizerAgreementMember_637882959044376553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044376553" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637882959044376553" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637882959044376553" xlink:to="plx_ChiesiAgreementsMember_637882959044376553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637882959044376553" xlink:to="plx_ChiesiUSAgreementMember_637882959044376553" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637882959044376553" xlink:to="plx_ChiesiExUSAgreementMember_637882959044376553" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="dei_LegalEntityAxis_637882959044376553" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637882959044376553" xlink:to="dei_EntityDomain_637882959044376553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637882959044376553" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637882959044376553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637882959044376553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="srt_StatementGeographicalAxis_637882959044376553" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637882959044376553" xlink:to="srt_SegmentGeographicalDomain_637882959044386575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637882959044386575" xlink:to="country_BR_637882959044386575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="srt_RangeAxis_637882959044386575" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637882959044386575" xlink:to="srt_RangeMember_637882959044386575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637882959044386575" xlink:to="srt_MinimumMember_637882959044386575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637882959044386575" xlink:to="srt_MaximumMember_637882959044386575" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="us-gaap_DebtInstrumentAxis_637882959044386575" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637882959044386575" xlink:to="us-gaap_DebtInstrumentNameDomain_637882959044386575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637882959044386575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637882959044386575" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637882959044386575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637882959044386575" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637882959044396791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637882959044386575" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044396791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637882959044366675" xlink:to="plx_SignificantAccountingPoliciesLineItems_637882959044396791" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637882959044396791" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637882959044396791" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044396791" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044396791" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637882959044396791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_637882959044396791" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637882959044406630" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637882959044406630" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637882959044406630" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_PaymentOnNetSalesPercentage_637882959044406630" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637882959044406630" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_AgreementAmendmentPaymentReceivable_637882959044406630" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637882959044406630" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637882959044406630" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637882959044416656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637882959044416656" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637882959044416656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_MaintainOfMinimumCashBalance_637882959044416656" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637882959044416656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637882959044416656" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637882959044416656" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637882959044396791" xlink:to="plx_RevenuePerformanceObligationNumber_637882959044416656" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637882959044426616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637882959044426616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637882959044426616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637882959044426616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" xlink:to="us-gaap_DebtInstrumentAxis_637882959044426616" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637882959044426616" xlink:to="us-gaap_DebtInstrumentNameDomain_637882959044426616" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637882959044426616" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637882959044426616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_637882959044426616" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044426616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044426616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044426616" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044426616" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044436924" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044436924" xlink:to="us-gaap_FairValueInputsLevel3Member_637882959044436924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" xlink:to="us-gaap_MeasurementInputTypeAxis_637882959044436924" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637882959044436924" xlink:to="us-gaap_MeasurementInputTypeDomain_637882959044436924" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637882959044436924" xlink:to="us-gaap_MeasurementInputSharePriceMember_637882959044436924" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637882959044436924" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637882959044436924" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637882959044436924" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637882959044436924" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637882959044436924" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637882959044436924" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637882959044436924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637882959044436924" xlink:to="plx_MeasurementInputYieldMember_637882959044436924" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044426616" xlink:to="us-gaap_StatementLineItems_637882959044446301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044446301" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637882959044446301" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044446301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044446301" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044446301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637882959044446301" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044446301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637882959044446301" xlink:to="us-gaap_FairValueInputsLevel3Member_637882959044446301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044446301" xlink:to="us-gaap_DebtInstrumentAxis_637882959044446301" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637882959044446301" xlink:to="us-gaap_DebtInstrumentNameDomain_637882959044446301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637882959044446301" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637882959044446301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637882959044446301" xlink:to="us-gaap_StatementLineItems_637882959044446301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637882959044446301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044446301" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637882959044446301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044446301" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637882959044456550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637882959044456550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044456550" xlink:to="srt_ProductOrServiceAxis_637882959044456550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637882959044456550" xlink:to="srt_ProductsAndServicesDomain_637882959044456550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637882959044456550" xlink:to="us-gaap_ProductMember_637882959044456550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637882959044456550" xlink:to="us-gaap_LicenseAndServiceMember_637882959044456550" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044456550" xlink:to="srt_StatementGeographicalAxis_637882959044456550" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637882959044456550" xlink:to="srt_SegmentGeographicalDomain_637882959044456550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637882959044456550" xlink:to="plx_PfizerMember_637882959044456550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637882959044456550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637882959044456550" xlink:to="country_BR_637882959044456550" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637882959044456550" xlink:to="plx_ChiesiMember_637882959044466555" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637882959044456550" xlink:to="us-gaap_StatementLineItems_637882959044466555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637882959044466555" xlink:to="us-gaap_Revenues_637882959044466555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637882959044466555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637882959044466555" xlink:to="us-gaap_PlanNameAxis_637882959044466555" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637882959044466555" xlink:to="us-gaap_PlanNameDomain_637882959044466555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637882959044466555" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637882959044466555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637882959044466555" xlink:to="srt_TitleOfIndividualAxis_637882959044466555" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637882959044466555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637882959044466555" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637882959044466555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637882959044466555" xlink:to="srt_ChiefExecutiveOfficerMember_637882959044476631" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637882959044466555" xlink:to="srt_ChiefFinancialOfficerMember_637882959044476631" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637882959044466555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637882959044476631" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637882959044476631" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637882959044476631" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637882959044476631" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637882959044476631" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637882959044476631" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637882959044476631" xlink:to="us-gaap_SubsequentEventTypeAxis_637882959044476631" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637882959044476631" xlink:to="us-gaap_SubsequentEventTypeDomain_637882959044476631" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637882959044476631" xlink:to="us-gaap_SubsequentEventMember_637882959044476631" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637882959044476631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637882959044476631" xlink:to="us-gaap_TypeOfArrangementAxis_637882959044476631" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637882959044476631" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044486644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044486644" xlink:to="plx_ChiesiAgreementsMember_637882959044486644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637882959044486644" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637882959044486644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637882959044476631" xlink:to="srt_ProductOrServiceAxis_637882959044486644" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637882959044486644" xlink:to="srt_ProductsAndServicesDomain_637882959044486644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637882959044486644" xlink:to="plx_AlfataligliceraseMember_637882959044486644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637882959044476631" xlink:to="us-gaap_SubsequentEventLineItems_637882959044486644" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637882959044486644" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044486644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637882959044486644" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637882959044486644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_637882959044486644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637882959044486644" xlink:to="plx_ProceedsFromExpenseReimbursements_637882959044486644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20220331.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_637882959044496619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637882959044486644" xlink:to="plx_ProceedsFromSaleOfProducts_637882959044496619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044496619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637882959044486644" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637882959044496619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044496619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637882959044486644" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637882959044496619" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646974329480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,063,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646974682376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,888<span></span>
</td>
<td class="nump">$ 38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">16,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">5,908<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">16,594<span></span>
</td>
<td class="nump">17,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">56,542<span></span>
</td>
<td class="nump">61,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,894<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,903<span></span>
</td>
<td class="nump">4,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">68,391<span></span>
</td>
<td class="nump">73,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">7,873<span></span>
</td>
<td class="nump">6,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">14,414<span></span>
</td>
<td class="nump">16,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">11,801<span></span>
</td>
<td class="nump">8,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,331<span></span>
</td>
<td class="nump">33,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">27,962<span></span>
</td>
<td class="nump">27,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">5,895<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,496<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">40,546<span></span>
</td>
<td class="nump">46,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,877<span></span>
</td>
<td class="nump">79,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(7,486)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 68,391<span></span>
</td>
<td class="nump">$ 73,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646967743544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,085<span></span>
</td>
<td class="nump">$ 11,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6,034)<span></span>
</td>
<td class="num">(4,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(8,767)<span></span>
</td>
<td class="num">(7,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(3,154)<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(618)<span></span>
</td>
<td class="num">(2,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">202<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,286)<span></span>
</td>
<td class="num">$ (5,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,843,563<span></span>
</td>
<td class="nump">39,933,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,843,563<span></span>
</td>
<td class="nump">39,933,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,028<span></span>
</td>
<td class="nump">$ 4,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,057<span></span>
</td>
<td class="nump">$ 6,809<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973786568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646974348792">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 320,280<span></span>
</td>
<td class="num">$ (347,352)<span></span>
</td>
<td class="num">$ (27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,285<span></span>
</td>
<td class="num">(352,827)<span></span>
</td>
<td class="nump">14,504<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,382,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,852<span></span>
</td>
<td class="num">(374,934)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
<td class="num">(2,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 369,688<span></span>
</td>
<td class="num">$ (377,220)<span></span>
</td>
<td class="num">$ (7,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,316,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of March&#160;31, 2022 and 2021 - 120,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973775352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646967472296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,286)<span></span>
</td>
<td class="num">$ (5,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability (including non-current portion)</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="num">(3,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(2,314)<span></span>
</td>
<td class="num">(2,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(1,011)<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,829)<span></span>
</td>
<td class="num">(9,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(37,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(16,257)<span></span>
</td>
<td class="num">(30,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(22,097)<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">38,985<span></span>
</td>
<td class="nump">18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">16,888<span></span>
</td>
<td class="nump">19,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646974017096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and y Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">diluted LPS does not include 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022, and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three months ended March&#160;31, 2021, because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973655384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973655384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of March&#160;31, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of March&#160;31, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $33.8&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973718024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,809</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973659400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On February&#160;25, 2022, the Company granted, with the approval of the Company&#8217;s compensation committee, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span>637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.</div><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</span></span>121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973660520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">During April and May 2022, the Company sold, in the aggregate, 746,171 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $886,000 in connection with such sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On April&#160;13, 2022, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On May&#160;10, 2022, the Company collected approximately $3.6&#160;million from sales of alfataliglicerase to Fiocruz.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973783672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;7, 2022, a Marketing Authorization Application (&#8220;MAA&#8221;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#8220;EMA&#8221;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#8217;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with Chiesi, announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, <span style="font-family:'28mugxoulnobhnx';">under the terms of the Company&#8217;s </span>outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, the Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and y Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">diluted LPS does not include 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022, and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#8217;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) and the exercise of outstanding warrants for the three months ended March&#160;31, 2021, because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973661640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2022 and December&#160;31, 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973722168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Notes 2021 and 2024 | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973718024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,809</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646971590520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,004,217<span></span>
</td>
<td class="nump">26,769,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Performance obligation number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973900024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,066<span></span>
</td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">10,158<span></span>
</td>
<td class="nump">11,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,594<span></span>
</td>
<td class="nump">$ 17,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646973829832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">2.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">2.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">80.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">10.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646972993656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 33,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646967567608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 16,085<span></span>
</td>
<td class="nump">$ 11,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">9,028<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">5,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,057<span></span>
</td>
<td class="nump">$ 6,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646974592200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - 2006 Employee Stock Incentive Plan<br></strong></div></th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares) | shares</a></td>
<td class="nump">637,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="nump">$ 523,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock granted (in shares) | shares</a></td>
<td class="nump">121,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of restricted stock granted | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140646967750024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Brazil Agreement with Fiocruz | Alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds from sales</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>plx-20220331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20220331.xsd" xlink:type="simple"/>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-25</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ipOEoOOBwEqJNxqVYD1F_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tWPPUkvGKEK_RWlQ1tQ97w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HBV2SgD3KU-05oHsFRVGVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B5yak48wUUafPhw4EIHy6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AqmwNqv8vkWAh_7muHfOwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gvkx-vnKf0Wu9yKA-z9U8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1yHZ2g1o_EW2u2UToeG0rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8IQ8YzoFvU2yjxQe73qorw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_86wb_A24g0O9P6vNpbYVDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_uft0WkxfTECQKQCU4pZbsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_S21-ZapyUEi0AfHd0ZmzGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Cs1RmaB2dk2-zzlPaX739Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yDiuB0IrXUGmEWzXQrmjvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v7ZxPQ9J60mXrkEKrBuF-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_v1cxXGJXc0O9MyYD4oL8bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_elDf2ZxouEeDMOgwfencjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_3xzulSOt60KM80hUQQxNuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8zRl47LpDUWLgsLuXBCfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BOmkiauMyU-HVMlM8M_LMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_j2CUvjm09keHknkDWIvMIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e09An94TDkebg9LA56J2sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kSc5Ga3WDkWOtVnhp3oTgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2-Rf8ep840CPArFgmLRo6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_25Q10gL8H0ejcvFB3qy2aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_qujldeuPW0iQr0wx-0hqGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_oryUP8iiq0yLMk4y318KNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_yI08emDAWU6kcLogTQGSFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Xd_TT8X3jEGIRtcxZqdgfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6kbZygJL5UGCoK2CMw5wLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_5_10_2022_To_5_10_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_letqXd_CLESNLLjD9nX3rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="Duration_4_13_2022_To_4_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_QQ3bC0ekv0uTXXOWJ2xaAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8P6P2mP_x0aZdoJRwGajdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_yGfuKJ8Y0U6-4sMMOBEt2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MVMnGHuu4U2rlaci2l_31w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3TlFp6KPJ0O_taG6Nu2ZJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_JFg0AHq1C0mWxuNhSH7UZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d3VeMhBTD0ySWJQLs_isIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_5E9e4OgdikqRj2Wn6sSnbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2022_wuiTkkd39E-ICmFp5ELdlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_4CakW3DMrUShwcChN38RSg">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_Y3YGIoGOL0-P28Oze-2O3w">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      id="Hidden_DC-WlNaYwUe4_Y9IUplLqQ"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      id="Hidden_FSf8QzRRF0y1vbPqC_PdxQ"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="2"
      id="Hidden_-kAnU6UZEUeayl0wjoSMrQ"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="2"
      id="Hidden_wTNccG_X4E22ngVLWu0dAw"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="0"
      id="Hidden_S9q7KewJekShrqi_MJYrWg"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">45843563</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="0"
      id="Hidden_Sf_oIWLKaEqHrgCEmqHDqA"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">39933972</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_tDJCeFDWwkKr7NBGTLPObA_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_9Cl0h81Hg0uqJ349_PUA-Q_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_LKk6Ia9au0-LBHhy8K4B8g_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_13ZRTmHelkGUQFaH0_h_Qw_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_u-P20IIakEiFlCeVv4jykA_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_nx5iqfTKa0ufVGr4Fm3iFQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_B3Q1rsEP10KSxVnkNgbGcg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_qXEJ0BOYE0y7gb7zXhg52Q">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_9rToRBWTX0mqf4ddbBqRfQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_tF95KsqQckWRak6IXH8CdQ">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_dHbJmZNI-EKngZMhHhKyJA">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_tvEPeMu46kSog3EiQugjpw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_qZB0ReNfHUesO3tYRhwZ2Q">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_V9W3wgdOW0Sp7PBS8IAmXQ">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_GfMgzkr_CEeuOuoLmO_2zA">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_39zIztcwwkWyzJtkMP8AfA">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_paVxdPBZ2EG7KpV55aSetw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_0AsuQehQNUOwZnsG7Wq12Q_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_B_tl_xAtQ0ehL-mkVmevIg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_vvUfXiXYVkeiLyjXdHYyIw">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_CvlmUqZop0uLAzCYKLYw2A_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_OjzWYsK6NE2SdxYnX3jEwA_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_liVvyo4r4ESJJvT2psmvsQ_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_2JCBt4ta8k-bavCNVY-_cg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_vLeNdtWdu0mNCGBR-AG-Vw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_JCl2Hs-3oESCzrnfw4bSSg_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_qpKGmVjyLUW1uOAW4alpZw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tc_Q9TwR4LKWEa9B15Cpr1Bbw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Narr_z3ib1EGXJ06vYDorvonhgg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_10_2022_wuiTkkd39E-ICmFp5ELdlA"
      decimals="INF"
      id="Narr_86DK45m0YEmWF_NFvJnhFQ"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">47063300</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_VKFYOm_P_UuwyJkSLnIyEQ_6_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16888000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_NF47gr059EqqCNJkSIsgSQ_6_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">38985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_GVgaIiEskkWjWpYTDOWu8w_7_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16029000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_aAx3yszuUUisNL37QmS_Cw_8_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">5908000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_f3lTkQeJe0WaWZYO_yfsoA_8_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3442000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_tHqaFQAEyk-BY012JK95Qg_9_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1123000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_9F0Tdt2l0U6C46tHmgon3Q_9_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1285000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_SsrsY7u5PU6SopXnLHv3mQ_10_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16594000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_zZ-6jPKdyUuKASNjAUfR6w_10_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">17954000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_-mSrXLERnkWv5OlfPM9T4A_11_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">56542000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_MwE9y2f3k0CldsLpDKHFvg_11_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">61666000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_jy9BhTZj-U2IlFOGAUhWTw_14_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2052000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_6p9O9eXca0a8UnmCoR2jBg_14_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2077000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_TJC-O6R52UiO1u9lFxdh5w_15_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4894000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_ZQrBUI_u0UuBRY6TcNqN1g_15_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_TiUwMTpQzkidme_lr7CXBA_16_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4903000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_4LtpSum7hkuVtg0TMQQZiw_16_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4960000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_ALZ0LD90x0qASe3E2xEtpg_17_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">68391000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_OC9O_Un0IE2ykhF4tWf09g_17_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">73665000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_1vkaf5WeY0GoTgs2JW0f1g_23_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7873000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc__2MTER9ACkC8MgIyH7pxvw_23_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">6986000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_tPduboA9FUOc27Gy_jOr7Q_24_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">14414000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_KLJHxrEfzkShlgXh-j9_yQ_24_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16433000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_xvd90WZeykedYr0VJGkPsQ_25_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1243000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_eVPdGcBVsEyl9O3dj2EIoA_25_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1207000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_YvhbgjY4QUaEw_-6RZy4HA_26_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">11801000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_j81XOv0kMkWouWRf6rslpg_26_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">8550000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_RjTnqG6-mEWgTn2IX5a9Vg_27_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">35331000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_v_PQ8tzfwk-QLyfEPQ_hYQ_27_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">33176000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_58FdIZhak0aa_a_i--WV1g_30_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">27962000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_skYM21bubU6hrY6dUjUnQg_30_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">27887000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_opIPyn6QJUOeQfHJYw5obQ_31_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">5895000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_Ij2Oo7wg0U-btxW8mBjM_A_31_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">11790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_N3Ow_cVAhkCnG8nYBOei0g_32_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2496000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_JkjtcZyJXEi0FbDD_u8JoQ_32_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2472000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_qWW0bwg_gUGWEx0xOcXBmw_33_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4193000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_Tx_JQTRrLUGO9yQeF0ZFbQ_33_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_kIBzFB6TBEuP4FKt-q4faA_34_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">40546000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_8elEjhWtcEyAMWIujCnRqQ_34_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">46525000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_-BvVk5sxDk-t1bUl7G3fYQ_35_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">75877000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_jIq8d2viwkqgKPZdMvdh8A_35_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">79701000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_tq_Qbk2DwkSEo0yxg3GVRQ_39_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-7486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_BnbkK1U8nUO5WJ_FGsaHKA_39_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_veq-7kmWN0G-DYf8tf_mWQ_40_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">68391000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_S82lX0M0206mBPssfEvTfw_40_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">73665000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw"
      decimals="-3"
      id="Tc_6tJAUrb9HEe0Nrz43VtVuA_3_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">9028000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w"
      decimals="-3"
      id="Tc_kTiWFWJDJ0ufD8UEaJqf-A_3_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow"
      decimals="-3"
      id="Tc_m5yDuzEcyEqblXW6cUHbIQ_4_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ"
      decimals="-3"
      id="Tc_qktQWDHMCEe1SEnCnz6Emw_4_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">6809000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_CWftXDvMyU-UeUvokrL1FA_5_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16085000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_Mwl02EU-Lk2akS26sDuJHg_5_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">11320000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_RJQOws5VPUGxUtZyrh2dSA_6_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">6034000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_qb3IYo9alEyPI7QEX2vE5w_6_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4765000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">8767000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_E5bj0evlnUiJARjI729_tw_7_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_o1dU5w4--U2sE9K77mUxhA_8_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3154000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_L8KcmSasV0-YdlJBL53QJQ_9_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-1870000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_VXDh26oMXEqKSAXPi5ALZw_9_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-3705000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_S-fEy3nczkaC5tv-qhpSHw_10_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">618000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_NNqDqLX9ckSMS6kP_WTbkQ_10_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2156000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_CGHOPlHJX0ue2ZhGa3m4qA_11_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">202000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_Xe_9yGBOU0qmiTsMPw9B2g_11_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">335000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_JzCaVR78AkCGvujh_n-_7g_12_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-416000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_UdV55qgPxEm0Mip1M05TPA_12_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-1821000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_r91IiyhdfEygSLk9RYIELQ_13_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_HEiKBiV-m0CkyviHf0k_4w_14_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_N1_iDizrO0yNnuDHpjv1PQ_14_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="2"
      id="Tc_mIco-pHDnU6IpN6VTFDSJg_15_3"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="2"
      id="Tc_eZBqTZ-qRECE3wuCMPiD0A_15_6"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="0"
      id="Tc_9sIrSPv0mEaFpMVkRRnthQ_17_3"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">45843563</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="0"
      id="Tc_hdeS6r91gkucpxzu1Pjz2A_17_6"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">39933972</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg"
      decimals="-3"
      id="Tc_XnHOJIVKdku-bvE15B5dbA_18_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_qujldeuPW0iQr0wx-0hqGA"
      decimals="-3"
      id="Tc_0JCIYCF4pEaKc6tF06pQ9g_18_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kSc5Ga3WDkWOtVnhp3oTgQ"
      decimals="-3"
      id="Tc_LEn45Ss40Ea_nhsGJwyrpA_19_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">76000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_25Q10gL8H0ejcvFB3qy2aA"
      decimals="-3"
      id="Tc_EsE74qczDUGHKEOZJ6pIVQ_19_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">210000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e09An94TDkebg9LA56J2sA"
      decimals="-3"
      id="Tc_Qod_BACx0EaZrNFkbcBrLQ_20_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2-Rf8ep840CPArFgmLRo6Q"
      decimals="-3"
      id="Tc_Ro6TEY7un0iyGGZu26D9Kg_20_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">497000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q"
      decimals="INF"
      id="Tc_MuvEekivCEKppyszPy-1jQ_6_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q"
      decimals="-3"
      id="Tc_TkZGETImrEmQD7XWNKa90g_6_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8IQ8YzoFvU2yjxQe73qorw"
      decimals="-3"
      id="Tc_R-dXJiWDNE2C8Ng-BtuUhQ_6_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1yHZ2g1o_EW2u2UToeG0rQ"
      decimals="-3"
      id="Tc_ekutbg20zEyOYTQTu8kLSA_6_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA"
      decimals="-3"
      id="Tc_i8CxtXPR-0uhkzHngYAabA_6_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA"
      decimals="INF"
      id="Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA"
      decimals="-3"
      id="Tc_qrq73xVa90S2RIUQ_noXeA_8_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw"
      decimals="-3"
      id="Tc_LgYur5HB0kKJtbQJVokatA_8_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_-Jl06tjAe0KVd98q3mZaqw_8_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA"
      decimals="INF"
      id="Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DFGXVX7hmUWCEDMEL3ZUAA"
      decimals="-3"
      id="Tc__yhwq8Ghf0eVQkoePgRHUQ_9_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw"
      decimals="-3"
      id="Tc_l-6_C-sz5kS43bvrDrba6g_9_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_coZZHuD2KkmQRPXHen9tiA_9_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw"
      decimals="-3"
      id="Tc_nRUwAAqTG0GfspP9trq7XQ_10_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_CglUhRUHjU2Twr5uyvIA1A_10_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NdBOTYKTUE6y91sugNJJJw"
      decimals="-3"
      id="Tc_O4BMRTvXQEqqDtSfLwGMdA_11_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">306000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_VUmYKBdyJ0Wmf-KVNhXY-g_11_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">306000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v7ZxPQ9J60mXrkEKrBuF-A"
      decimals="-3"
      id="Tc_Q7LWMxP_ok-cGOdkUhRYrQ_12_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_b8xhQt99X0GxLFcgY7rbAQ_12_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q"
      decimals="INF"
      id="Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">45382831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSnO8Wv280W5OHE19cNu8Q"
      decimals="-3"
      id="Tc_qRgywLMj4UC8US0AeA9kcA_13_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gvkx-vnKf0Wu9yKA-z9U8g"
      decimals="-3"
      id="Tc_zgCNu-89fUW_NNZESrmO3g_13_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">367285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AqmwNqv8vkWAh_7muHfOwg"
      decimals="-3"
      id="Tc_HiU7xk6CvkemCn0kn8hmUQ_13_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-352827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww"
      decimals="-3"
      id="Tc_CrKi08qWZEmV10KV0SjL0Q_13_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">14504000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q"
      decimals="INF"
      id="Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NUF9i5FNrEeKEOnhttre7Q"
      decimals="-3"
      id="Tc_0gItQ4XhT06POAvCfEebZw_14_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B5yak48wUUafPhw4EIHy6Q"
      decimals="-3"
      id="Tc_JM-1cuZ6fEqkQ46Wn3eAow_14_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HBV2SgD3KU-05oHsFRVGVQ"
      decimals="-3"
      id="Tc_TWI7lXq62kqcyJmnBD9-gw_14_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_sBPJzE1_V0OE8fi_Qa-D-g_14_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-6036000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA"
      decimals="-3"
      id="Tc_ENbCBaRIikKWnpIr1drYfg_16_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_5zDDlygavkGkDBr-IF3B2Q_16_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">149000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Xd_TT8X3jEGIRtcxZqdgfw"
      decimals="INF"
      id="Tc_gFsSd6wNLE2dyPmazIX7-A_17_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_j_gb86vJwESEDBpjzOf4EA"
      decimals="-3"
      id="Tc_FUS-akZTnU28m7bMw4u5wg_17_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">687000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_pW1kBdk_60Of_uj_erIugg_17_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">687000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yDiuB0IrXUGmEWzXQrmjvA"
      decimals="-3"
      id="Tc_hy8t91ApqEGU7EuPwutrcg_18_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_DEI179JujkijLTJ-r-iQGw_18_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw"
      decimals="INF"
      id="Tc_kxeunX7HskqujxoxGB5SUg_19_2"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">46316129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rVTMYf4pKkCW75UKC0-ZHw"
      decimals="-3"
      id="Tc_qdOEKEcM80e5Ex63DqRgeA_19_5"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tWPPUkvGKEK_RWlQ1tQ97w"
      decimals="-3"
      id="Tc_G33HJiaWoE67oefSIGEjTA_19_8"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">369688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ipOEoOOBwEqJNxqVYD1F_A"
      decimals="-3"
      id="Tc_m2BSVNhmIkS9YyTqB1519w_19_11"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-377220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_5x8_EBzaTE6nr5nSjaVaVg_19_14"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-7486000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww"
      decimals="INF"
      id="Narr_jA1NqXXhhEWVuJN-DQWa2A"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="INF"
      id="Narr_2o_iiWMr8EixYw23S0pqNg"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww"
      decimals="INF"
      id="Narr_iwuBfgsfAUSRkRoRaTeHag"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="INF"
      id="Narr_WCqigvJ1mkG0i3-B5VflFw"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_er09fJFvhUO4LMZqYhNj5Q_4_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-2286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_9iJroCv9tkSU5X2ZmmlYtQ_4_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-5475000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_Mc7_FvC2R0afhlTCLdiexg_6_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">836000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_uuFIOIOadU2uUfPJScSj-g_6_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">816000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_DDUj_xtxg0q04QSzYBBPzQ_7_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">270000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_OVZkn3c35ky-cgHNR8gcMA_7_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">286000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_7XJ65M5MjkO8_WCwOarNMg_8_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">198000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_sxdzHp4ZckWxG3qlS5dMog_8_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">168000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_qwikmqh6M02CFGhkIzTjXw_9_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">75000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_rUuVzXWs7EKIhZ2mo16JJw_9_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">42000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_-2NH-QdsTUmjEW3tYBqbbg_10_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-10000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_SCq3fOj7bUeo0eDm1JmGaw_10_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">14000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_b-G3AUFqhEeRUzz942Qajw_11_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_kpEkwf2ySEiM4yMgv75V2A_12_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">75000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_JUMna6Lk7UuFwtxLW-l04Q_12_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">945000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_xOs_PQ2ca0u28IJhCUl4CA_14_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-2644000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_UuQkgu_G50yaav1cWZrLvQ_14_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-3692000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_aXYszJ08zEODGwtUCt_Uqg_15_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2314000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc__wt6lkSpNU2w6Xm44HzJJA_15_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2282000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_lq0gAsKVdU6gq_b4eb_FrQ_16_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">2000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_gQugblfKnUW_7UWZUC9UfQ_16_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-42000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_SS2Hvn52VEKgAtWDzo2Mdg_17_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-1360000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_1POLpt8bMkqvPLfyNeCv_Q_17_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">833000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_LXRVGK4PLkyvRaqxlXBnmg_18_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-1011000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_ZIU_8hX32kWTaE8CKWLw_A_18_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">575000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_GDvnlBnRZku4LAVkfX2b6g_19_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-25000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_QN3vdPXlSEyGaBzPd_1Seg_20_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-5829000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_qFVp7YZCkEWzcCAuw2zVjQ_20_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-9834000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_NIJBi75CkUmVy0IiLwkw-w_23_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_N_mh67PBLUm7FL7nasHNaA_23_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_iQ38IDZu_0GJgK3fZYqyGQ_24_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7500000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_VXK1_OV_rUmMM3XK8SjjYQ_25_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">229000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_Uoncq-b5VUq3TV_KH7MuTw_25_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">386000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_yrgCchJ4V0KqvWfLkCR28w_26_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_hCLYdDphDEmbY3xn8eiVEw_27_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-12000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_A24KZrobUE-3FSkyS5xBvA_28_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">28000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_TBMxeej_uUml9P_ZOjAlCw_28_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">28000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_Kqlz-R1WOE6ZFxKktePOug_29_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-16257000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_5RmnZIb1WUCWb3pom7NxQQ_29_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-30684000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_FAW0457PPEadSd39tVfBCQ_32_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_no0v9dNGUkKMgAk9S4vX5Q_33_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_fWiSrZxEmUWjXZVHn9NfCA_34_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_-oDxNKIGH0eCvPGi7YcNIA_35_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">42114000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_NGWVI8NZw02Cz9EvcbRAXg_36_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-11000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_9NzQNhblG0mfnZ-jqvwEFw_36_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-31000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_deAJkhfdz0S_VkdQyQSSmg_37_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">-22097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_3Es-Urbu6UKUzaH9ZYz3XQ_37_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1565000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_QOXPiMoOyEGb2Lsx70IoDQ_38_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_JSBFAVHkSEGfWG1FadOlJA"
      decimals="-3"
      id="Tc_dtfCj0RpZ0aF4b34QMaPWA_38_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">18265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_UGFrVkfb80KHHtaFCc0-bA_39_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2021_abbV6NtfZUKWvwWfuYF4Ww"
      decimals="-3"
      id="Tc_HQqne0AofkO-F2fGLmXe1g_39_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">19830000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_5oj6RzF1j0S0r30L2PMoGA_4_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">67000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_TX0SVaTfCUG45YchNwnoUA_4_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">202000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_ZP6LbJMreUuYC2Hk7r2ZQg_5_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">99000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_DBitXD3BKkuA0_mrOUlSlQ_5_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">122000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_nefZAgYIDkCepQkDnv2jew_8_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1120000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="-3"
      id="Tc_6cOCTAXa6kaF42LYEjqLuw_9_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">36000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="-3"
      id="Tc_QYI9JAhOY0uUOOAHQk_9sA_9_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">136000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_hEcggLMKO0y3LvdytY20zA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with Chiesi, announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and y Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;diluted LPS does not include 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022, and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three months ended March&#160;31, 2021, because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_5GY229hNgk6rVVnTm7vytg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the last patient from the BALANCE study received the final dose of the study in October 2021. In addition, the phase&#160;III clinical program includes two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and our phase&#160;III clinical trials may enroll and continue to be treated with PRX-102. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;7, 2022, a Marketing Authorization Application (&#x201c;MAA&#x201d;) for PRX-102 was submitted to, and subsequently validated by, the European Medicines Agency (&#x201c;EMA&#x201d;). The submission was made after the October&#160;8, 2021 meeting the Company held, together with the Company&#x2019;s development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, Chiesi and the Company discussed the scope of the then anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with Chiesi, announced that the receipt of a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 BLA was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the U.S.&#160;Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (agalsidase beta), a therapy used to treat Fabry patients (marketed by Sanofi after the acquisition of Genzyme), was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. In accordance with the term &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;sheet, Chiesi made a $10.0&#160;million payment to the Company in the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. The Company continues to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2022 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. In addition, &lt;span style="font-family:'28mugxoulnobhnx';"&gt;under the terms of the Company&#x2019;s &lt;/span&gt;outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, the Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million.&lt;/span&gt;&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_j2CUvjm09keHknkDWIvMIQ"
      decimals="INF"
      id="Narr_lbQwoXNs90CYcdU7gTufuw"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA"
      decimals="-5"
      id="Narr_lrwJhCuCXUascmBgLL81fQ"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA"
      decimals="INF"
      id="Narr_s3ZZqU9fV0eh823IophcWg"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xIyFEuR8I0akgjrMsxWtZA"
      decimals="-5"
      id="Narr_c6y-Uko4y0OX5ic5QH08OA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_yI08emDAWU6kcLogTQGSFw"
      decimals="-5"
      id="Narr_yWPWxEiJ5USqUdhnKIhqBA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_oryUP8iiq0yLMk4y318KNA"
      decimals="-5"
      id="Narr_qmcROuzHeUGz9fS3njuefw"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg"
      decimals="-5"
      id="Narr_UBWNDWXmB0y5Q-gobYSmOg"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg"
      decimals="-5"
      id="Narr_-EGsAXXohEKuQa9I9p0eIw"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3_b1Yx_y-EyyelPoFwO_mg"
      decimals="-5"
      id="Narr_0l4Oa6OyLUifRhSbkuCI8A"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA"
      decimals="-5"
      id="Narr_pWwrgqp2aE-ytBPsQ_pgKA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA"
      decimals="-5"
      id="Narr_fM2Dtvd7yEyy8aQnHWEflg"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_Uo2ewv-g-UOpWhMEa0A3rA"
      decimals="-5"
      id="Narr_BaUNMIH4yU6ZDnrQVMWFzw"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_MVMnGHuu4U2rlaci2l_31w"
      decimals="INF"
      id="Narr_l9Fj1VYtm0aLZJMQbdXHcQ"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3TlFp6KPJ0O_taG6Nu2ZJQ"
      decimals="INF"
      id="Narr_lvYq8_c_e0WQt9H7brIfXA"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_8P6P2mP_x0aZdoJRwGajdg"
      decimals="INF"
      id="Narr_2pkG2f53akeOf0pblZHcnQ"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_yGfuKJ8Y0U6-4sMMOBEt2Q"
      decimals="INF"
      id="Narr_btQoQ-s3m0K7kKoh2VISlw"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_5E9e4OgdikqRj2Wn6sSnbA"
      decimals="-5"
      id="Narr_lrJH2KCyI0yy-LhGbvLOPA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_d3VeMhBTD0ySWJQLs_isIw"
      decimals="-5"
      id="Narr_3I7zw1Vpt0S40nSJi5VZAg"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_JFg0AHq1C0mWxuNhSH7UZQ"
      decimals="2"
      id="Narr_HZc0_5_Jq0SUq1MrBFgmzA"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ"
      decimals="4"
      id="Narr_1teeMAb7jUKdKERzEeKKTg"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gI_FfaDVzEOCRz_bkQbxRQ"
      decimals="-5"
      id="Narr_5BfrsCR3zEKmBDJzhHi37w"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_aw785iRfQUmWDw4Pa4lObQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed by the Company with the U.S.&#160;Securities and y Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2021.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_tzB1vxOA-kmA5Ks4J1rlng">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;diluted LPS does not include 33,004,217 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the outstanding 2024 Notes and the exercise of outstanding warrants for the three months ended March&#160;31, 2022, and 26,769,693 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of the Company&#x2019;s then outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) and the exercise of outstanding warrants for the three months ended March&#160;31, 2021, because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      decimals="INF"
      id="Narr_6jlsSsW6gketmz0cA7LHjg"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">33004217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA"
      decimals="INF"
      id="Narr_w8phlz5rI0Wi8LDT1gznog"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">26769693</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_BOmkiauMyU-HVMlM8M_LMw"
      decimals="4"
      id="Narr_KUqR1dwcgEW_GXwUrg2dEg"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_r3OV8P154060a-hrIdJ1Qg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_6kbZygJL5UGCoK2CMw5wLQ"
      decimals="INF"
      id="Narr_vsdivaSWGE2LBtlVgj7VMg"
      unitRef="Unit_Standard_agreement_4CakW3DMrUShwcChN38RSg">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_Y3ZxNhYUrEuEOimR4jGGeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2022 and December&#160;31, 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_JgqhkkzNIEiIPBK9_bVwJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2022 and December&#160;31, 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_IN8gLXCIbUmlQgNq-24HMQ_3_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3066000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_C8e57PaI-kadXCL97GCSLg_3_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3166000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_w5llgLQ0RESglK66Svpviw_4_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3370000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_dWP4p0efBUWor8dOUxITlA_4_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3262000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_InsYJ_pIFk68wij5QfCZFg_5_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">10158000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_eDANZeCpqEO9_QWvjbkReQ_5_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">11526000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A"
      decimals="-3"
      id="Tc_oJQJWgXTp0epzSeDnbHm4g_6_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">16594000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_Pdnt3OzrJkuzrwrZmQ47UQ"
      decimals="-3"
      id="Tc_LYAuPgjfMUus4TNFq2UzMw_6_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">17954000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_WbMguMynD0eRFUIAFbzKyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of March&#160;31, 2022, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of March&#160;31, 2022, the fair value of the $28.75&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $33.8&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w"
      decimals="-4"
      id="Narr_aF0Wk0sgCkCg0sNCmX2SwA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w"
      decimals="-5"
      id="Narr_1gW6yLh-xUyRxcB09KpK7A"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">33800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA"
      id="Tb_ANmzZNTd0k66qmaTPy9Adg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A"
      decimals="2"
      id="Tc_TFE4vlbPi0yeS40NhO5UgA_2_5"
      unitRef="Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg">1.06</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_3xzulSOt60KM80hUQQxNuA"
      decimals="2"
      id="Tc_6k7QL3chX0y6BAgkHI3AlA_3_5"
      unitRef="Unit_Standard_Y_Y3YGIoGOL0-P28Oze-2O3w">2.42</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_v1cxXGJXc0O9MyYD4oL8bQ"
      decimals="2"
      id="Tc_gVCp-qaHWEyqRwHdk1bOBg_4_5"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">2.42</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_elDf2ZxouEeDMOgwfencjw"
      decimals="2"
      id="Tc_slmCPFLqJUu_baK0Gc7uKA_5_5"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">80.67</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8zRl47LpDUWLgsLuXBCfPA"
      decimals="2"
      id="Tc_acaOXC3_KEyWwMF-anPgjg_6_5"
      unitRef="Unit_Standard_pure_ZPdnS5RcgUua4gHL5BgzSw">10.39</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_SUDBqRW5-EaIPNLElIXQMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_TeK6djP6iE6GsgJbqZPbpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_86wb_A24g0O9P6vNpbYVDA"
      decimals="-3"
      id="Tc_Sph0jgYwhUaDZ8TSk4vO_Q_3_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3356000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Cs1RmaB2dk2-zzlPaX739Q"
      decimals="-3"
      id="Tc_MtTHcP8PFUKHiW54Rq_tzA_3_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_S21-ZapyUEi0AfHd0ZmzGA"
      decimals="-3"
      id="Tc_UpQuJm8HXk2pU5FXZyUL4Q_4_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">5454000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_uft0WkxfTECQKQCU4pZbsg"
      decimals="-3"
      id="Tc__uowG6K4skyNkAPwfdHguA_5_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_JtRrWB_Tp0S2YgAfn4qxIw"
      decimals="-3"
      id="Tc_XeVk5pPYw0GYiWFUVpkB7g_6_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">9028000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_x9DSk4jH-0O_5iYghH-j6w"
      decimals="-3"
      id="Tc_ghbY-hqOj0e-YsHfdxOdzw_6_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">4511000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gELJ3cn0nEiL48-LYjygow"
      decimals="-3"
      id="Tc_tfqt1-V71kudSA40_Vo07g_7_3"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">7057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_3_31_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_RKxEUwV3mkKKbkVxHGzmYQ"
      decimals="-3"
      id="Tc_vFeR9-g5q06wpQ-rokci_w_7_6"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">6809000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_EQpnTLuB5kmHDu9je4tCqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On February&#160;25, 2022, the Company granted, with the approval of the Company&#x2019;s compensation committee, the following:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;1.&lt;/span&gt;637,531 shares of restricted Common Stock to its President, Chief Executive Officer under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Company estimated the fair value of the restricted stock on the date of grant to be approximately $523,000.&lt;/div&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2.&lt;/span&gt;&lt;/span&gt;121,951 shares of restricted Common Stock to its Sr. Vice President, Chief Financial Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $100,000.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg"
      decimals="INF"
      id="Narr_N0WLZMBvvEKsDk2yyQIaMQ"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">637531</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg"
      decimals="0"
      id="Narr_Y7zqgkDc0UiQjkmr9C8_7A"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">523000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg"
      decimals="INF"
      id="Narr_cXJ2pwmPOUqmnEbCQqQnsg"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">121951</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_4REohDj2-UGAk-BOabS3Bg"
      decimals="0"
      id="Narr_ca8ydwL9nUC_5za3Jv6FrA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA"
      id="Tb_8FMp8zF-QEKmxiMoEw0y-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;During April and May 2022, the Company sold, in the aggregate, 746,171 shares of Common Stock under the Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $886,000 in connection with such sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On April&#160;13, 2022, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On May&#160;10, 2022, the Company collected approximately $3.6&#160;million from sales of alfataliglicerase to Fiocruz.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ"
      decimals="INF"
      id="Narr_anB22yu0bU6SUuY7yjDF-g"
      unitRef="Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw">746171</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ"
      decimals="0"
      id="Narr_M9H00TPIM0-mc1JGNxyhSQ"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">886000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_4_13_2022_To_4_13_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_QQ3bC0ekv0uTXXOWJ2xaAQ"
      decimals="-5"
      id="Narr_QMArHEPafUy15SjkjKEwQA"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">1200000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_5_10_2022_To_5_10_2022_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_letqXd_CLESNLLjD9nX3rA"
      decimals="-5"
      id="Narr_TwSZEDy5f0SwwPxQFyxmew"
      unitRef="Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g">3600000</plx:ProceedsFromSaleOfProducts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_gFsSd6wNLE2dyPmazIX7-A_17_2"
          xlink:label="Tc_gFsSd6wNLE2dyPmazIX7-A_17_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of March&#160;31, 2022 and 2021 - 120,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gFsSd6wNLE2dyPmazIX7-A_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2"
          xlink:label="Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5tUoCd2SG0yFXgxAvcKYqA_9_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MuvEekivCEKppyszPy-1jQ_6_2"
          xlink:label="Tc_MuvEekivCEKppyszPy-1jQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MuvEekivCEKppyszPy-1jQ_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2"
          xlink:label="Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Mzz1QjHXBUWetmhGYKIOrw_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2"
          xlink:label="Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zKNZA9dxTUy_M-P4sDOuSA_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kxeunX7HskqujxoxGB5SUg_19_2"
          xlink:label="Tc_kxeunX7HskqujxoxGB5SUg_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kxeunX7HskqujxoxGB5SUg_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2"
          xlink:label="Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_wLLzT9Hl6kui0Dt-EYF7Tw_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qb3IYo9alEyPI7QEX2vE5w_6_6"
          xlink:label="Tc_qb3IYo9alEyPI7QEX2vE5w_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qb3IYo9alEyPI7QEX2vE5w_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_RJQOws5VPUGxUtZyrh2dSA_6_3"
          xlink:label="Tc_RJQOws5VPUGxUtZyrh2dSA_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_RJQOws5VPUGxUtZyrh2dSA_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_E5bj0evlnUiJARjI729_tw_7_6"
          xlink:label="Tc_E5bj0evlnUiJARjI729_tw_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_E5bj0evlnUiJARjI729_tw_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3"
          xlink:label="Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_I6G00Q4_SU-1LiSCZvEUHw_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6"
          xlink:label="Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AZ-t51jwPkeE_ZcB6EiqFQ_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_o1dU5w4--U2sE9K77mUxhA_8_3"
          xlink:label="Tc_o1dU5w4--U2sE9K77mUxhA_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_o1dU5w4--U2sE9K77mUxhA_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'09/P>!%]G6E5"/'=9$>IU_C](TX%WQ+&,!E2?3%\=7B0.1< =,8H;8W&-3
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MWU(+ A$+ G_#/;S@=84_(S=>;O<KJ%^V#E/ZE9V35VB91#NH=,B.WZ)ZUC)
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M&1#: +\O.5>[B790W(\Z_P%02P,$%     @ +#FP5/=K"S^ !0  3!8  !@
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M@0\XD79J9] L 6J]3'3+5%! ]<A3U$X<"[%E0LH8$&PZVU0[D@34EW9LM>%
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MEDA5DE]=Y@-.=]E5VQWEG$;9XY9@\3,H%1#OUY3RQT&Z0'F!//H/4$L#!!0
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MSKAC9X+N629W OE91*/3^0/0HE0%OZMR@XT+W@?\"R+6[P@/,=;@\3X_W3+
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M;YNA;(M&[/1.D5<(C>_4NJWQ> 4=03HAJY6<"&/%AX__/IH=SZ&IL;6( EK
M$XV"IBS/U@#&&U805/%:+K&,4CN%06D,"X5/Q!K^1*-4>V><V9*\VAE;*CN!
M\76Q(9%H,!C_-UB3AI("1H)DY^?GHH#8;"B(L;9R.V6-!%'ON \:*:JV5#2X
M51A>[:0EX5W3EF1N/SDY!7!<60O--D9(+\S+Q<7BW>F9>/GQ_-4;_O'FYT^#
M3^]K\5HM;4O6>^KAA98-O/F"%==KL6B;C;'16Q:[704!^??[P5'?+A8I(E:=
M!<2UY%#:ZJ9AL2;L@10>ZO<6^D;(7<$/R1BE6 ;G/VOA3DK6XJTJ=0%C.[&
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MPU)3S&R2M&[:2S4%E49D,^D,T3B2G IQ/P_,![7' HV"G#@2L(5U4HO_:?'
M?*00@U. MG'*8H50;4K3^C:#>+]:*6:""\)_7E9.#BYEQ6V <"W1!%;TS]-3
MD"NLZ]I2[UG\2VYWSS#O="(N+DXGL1<RU*7C,8'7@[FHV9#-P$!#I%9NR39E
MJH5\JV0J/K36M=PX"Y1.V6W"X('@?95L,8PC^//EI XQPS\WUK1KG[=9(.&
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M*,)'L=UJT\C6\(QG^BCY!E;&.GNWP/:OA2EH87[::;9@;PX+CF+0,.GB8<F
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MY,-OJJ258N8SX(22)3B*-8)^NB 0C"75>:=-8+Z5UL;MAQ9X\9")I%NIF@8
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MD-P.(CW'BCVI"+R9JK9U0YM(V25%%$:;\3J(6+H0A3$563HC$\=W24Y 7I4
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MOP*>#/V5 ;TA+MQ>?W3M?QB*7CE!$G+TOW$%W"#A$I[7T >WOWBXQ/\K57:
MW:MVL)U3/],U[;L+TV1Y.[HM])H,S]C<U_T6979I'_(#4+E"#O2^)U*7H,.P
MN'(:\3=H9QQW&[>1I#.>UZ0DO2;L)!NA?H,NFNG6I/R]AP/^_96,Z:3-C5HZ
M_Z=GOKX_WZ+]0ZC\+*+RLX-P^M%E?=P3@'7<A\F'!X%OC8S3+]0XS;B%^52S
M5W!8=*J[IOQ#4+O<&?=%N/Z,"8CP%ASIV?&S29R.]_8,<99XJV\8.>.WE\![
M([ NKL_HL>1XE6.I_YJ::W(_A(=S_P84U5_NE&5J3KV,X$8_>69BV)[C49Q_
MF@W&=X'2VRUL\*Y-INI:@SVKI4>5"<=Z#"S+TK_48?MAG)I+%74W*! 1/MGB
MOL<8]'W-HM\8360;X$<<E;"16BVEN7'DWF=,+DDG_ VJZC'N3IQ^:V,J5B%=
MABA]TQ>&%+EOXZ$#\&#(WR#$9*A,F]8&J5VW8;G<FT.9Z_-9NG[90*4["&+&
MS(>38=BDGIP>E/"MA-VA9#,LD-XC/DT9GDU5&8S"FU#T#>M?-:&@W5&!KBY^
MCX2]V@N'EZ"Z>P6^9Q,SKB/$*IF;LC&ZW!=YEDC-/D;-%H[><!'>]IS;._V?
MS"C&GG+:H^YNX*+RM6)*@<BEHA1\Y,?NY2O]R@X5FW>^S8M!N@C',3OX]'PZ
M0(6](GTJ,AF7]RCJNVIN];U:HZYR?P;0C24(R<I2W_KF/4[ODDHL$1'.+#AY
M3 [JHOUP)]?\4;1YZ(FNCTN1N/:JY4.V7F%[D'@&ETR:08-L^^_I?%W2CGRX
MOK%0_*.>XE+>)['ETKK7G&^-6H(1K^!R,20'L4@:Y/#?)I!;[3=HF$(XD)%>
MD('?N&:/(F+R7LN8KU5Y>D<OU;F9QC1.MIGLFNX?^8;^L'2L_7>'8$O6IX(#
M4 ROJA'O]$;*,,=Z<X<H!ZPU1=$I$MQ4[#@1DN#F:$3F2'Z9$R<Z\NE(*$]$
M^_E+5N\4NA\E;AW6XP._++D"*;KS/+:#1!J4>CA9%?U+#WWSQ+T"&*FJ)>B&
M<]]]"G @1/3"2O"$[FA]&PXX\PW5)4*Z$C:@38^U["1YZ3 QGSB(SEW7L,O%
MO>$1JM'1.#TD,J8.N#BNB3X2T%NB%>>8]^BMM8$M\!NFI?I"-E<!(C1(W:)R
MG"VVJGOCVM^_$-DX"A0=71J-TZ+'F2EB&.MZR/.VXA+537=2XD(L&23K9NK>
M:_*M&SR?2^@2Y!]?:Y^ZM%2O3\7XO2W6X2RUSVF<\*Y[%#+>)SMWAGHYPL%B
M&E0#^"4%H6^ ,%>(96O;!9_W;\NZ>R;]M7._7-C3U#6_;3ZN%W7;R &9XG1G
M)]1H<M3H(_H9#>537[/%N&:#0?3BD_2M*S%S=@@(];4<]-DU? TNR) $[G$8
M'%"!I+GGZRK@<WQ?*$_Z(?ZZ4DX&4GSD[MK7W4R]J_^/^^-#\7_!& ]EI*<Q
M(ST]F$Q>:FN[+MRQ9/3P\_DTZP_!]4)76R]4V9*-E?T;0O)S>77=_7D"E[5M
M6W]H4J@;Q?R+FESX>5_TN.4_P$&\@FK@8.!URUDZ04)L/!ZKU*8]Q>#&C5'+
MMNG>_NNZE#>Z+(CRIJ_'K;3OW70E*U\I$65LP*?^,+]:+*L[C BUP9.3R?'Q
MDPE$2<3LB<0%YW(W?#%/^S,)5UL??9+JU[P0=EZ@,*%DTL><#C<_GC^A@T?/
MB-G [BCEL^Y@(;GU5AA"MZXXXM[K]V5V5R3IE_/=B>'\V>3TV8^39S^>_/>7
M.MQT.E_IS7$Z?7K\S^Q:UA35N%0FZ54_&J?A@WNG&WHAD<M;:<6,O^#KO;^J
M\1_5(?Y?2CZ7\?4*=UK9,2&*-T=L:@C;HP#P./DS,<">-?\Q'.O>WG!_,29^
M&__>SL+]F9GN=O?'>B#:FAH62KG"H\?3TZ</7/$C?&CTEO_HS%(W #K^=2,%
M=I=NP/65AKK\!YH@_A6BE_\'4$L#!!0    ( "PYL%1RJV7JE@(  !0&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*55VV[;, S]%<$;AA8PXEN2
MIET2H.D%RT.[(NGE6;%I6Z@L>9+2M'\_2DX<%VVSA[U8(L5S>&B9]'@CU;,N
M 0QYK;C0$Z\TICX+ IV64%'=DS4(/,FEJJA!4Q6!KA70S($J'L1A. PJRH0W
M'3O?G9J.Y=IP)N!.$;VN*JK>9L#E9N)%WLZQ8$5IK".8CFM:P!+,0WVGT I:
MEHQ5(#23@BC()]YY=#;KVW@7\,A@HSM[8BM92?ELC7DV\4(K"#BDQC)07%[@
M CBW1"CCSY;3:U-:8'>_8[]VM6,M*ZKA0O(GEIERXHT\DD%.U]PLY.87;.L9
M6+Y4<NV>9-/$QK%'TK4VLMJ"44'%1+/2U^U[Z !&X1> > N(G>XFD5-Y20V=
MCI7<$&6CD<UN7*D.C>*8L)>R- I/&>+,='[[>'5[_WLQOUJ2HWNZXJ"/QX%!
M9GL>I%N66<,2?\&2D!LI3*G)E<@@>X\/4%$K*][)FL4'"6^HZI$D\DD<QO$!
MOJ0M,W%\R;_+/,#6;]GZCJW_!=L26R-;<R R)W/Q L)(]?;96SM,LX,RT(0:
M@C6G95LTH2(CEY!"M0*U\T8DE=@/VD!F<YL22"XY-A83Q1GY\6T4A\G/_U[W
M0M[EWQT?D8?>LD<R3$R5)DR@#KG6J%<?MT&NA(X1M<:";O #-J 8Y;KU?B>)
M'PZ'[^RH8S]A;]M4M9*% KT')GYR$GXH(?'CX3[_-1,,6R0CA939'AJ%?C08
M?<!&D3^(]YGOI:$<4V^ON:,P&OJ#TW[7<>*?#EK'9Q]:T.G4"E3AYI'&6UT+
MTS1MZVU'WGG3Z?OP9E[B+15,:,(A1VC8.QEX1#4SJ#&,K%W?KZ3!*>*V)8YM
M4#8 SW,IS<ZP"=H?P?0O4$L#!!0    ( "PYL%3KD^4C9 (  +(%   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U446_:,!#^*Z=,G5II2D)"6]8!
M$K14JU2J"@K3'DUR(1:.G=E.::7]^-E.R)C4\+27V'>^[[OO[-P-]T+N5(ZH
MX:U@7(V\7.OR)@A4DF-!E"]*Y.8D$[(@VIAR&ZA2(DD=J&!!%(9704$H]\9#
MYWN6XZ&H-*,<GR6HJBB(?)\B$_N1U_,.C@7=YMHZ@O&P)%M<HEZ5S])80<N2
MT@*YHH*#Q&SD37HWT[Z-=P%KBGMUM =;R4:(G34>TI$76D'(,-&6@9CE%6^1
M,4MD9/QJ.+TVI04>[P_L]ZYV4\N&*+P5[ =-=3[R!AZDF)&*Z878?\>FGDO+
MEPBFW!?V=6Q\Z4%2*2V*!FP4%)37*WEK[N$(, @[ %$#B)SN.I%3>4<T&0^E
MV(.TT8;-;ERI#FW$46X?9:FE.:4&I\?WDX<%K">/JQG,9Y/E:C&;SYY>X/R%
M;!BJBV&@31(;&B0-X;0FC#H(8Y@+KG,%,YYB^B\^,.):A=%!X30Z23@GTH>X
M]P6B,(I.\,5MQ;'CZW?P/0F-RI+U@/#4;OKP&Q[Q%1G$)_C[+7__)/_2]$U:
M,021P3VA$M:$50@39?[[TOZ)ZJ-+/<WY^=,@"N-O\+]75WQ](0?74HMD!Z6D
M"<+Y:GEWT0GN^>%5:\S>2M-GF()&673G\_M1:RRHVD$F$4$2C:<Q9[ 6C&C*
MJ'[OC!R$_M6U"?U)D:7=LD,__@IG'[UT<-1'!<JMFQ8*$E%Q7;=4ZVT'TJ3N
MP[_A]30S?^V6<@4,,P,-_6O3_[*>$+6A1>FZ<B.TZ7&WS<U016D#S'DFS+,T
MADW0CNGQ'U!+ P04    "  L.;!4C OE2Y$"  #9!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6RE5&U/VS 0_BNG;&(@5<UKH4!;B1:F[0-3U0+[
M[":7Q,*Q,]NAP*^?[;19T*#[L"_QO3V/[\ZYFVR%?%0EHH;GBG$U]4JMZPO?
M5VF)%5%#42,WGES(BFBCRL)7M422.5#%_"@(3OV*4.[-)LZVE+.):#2C')<2
M5%-51+[,D8GMU N]O6%%BU);@S^;U*3 ->K[>BF-YG<L&:V0*RHX2,RGWE5X
M,4]LO MXH+A5/1EL)1LA'JWR/9MZ@4T(&:;:,A!S/.$"&;-$)HU?.TZON]("
M^_*>_:NKW=2R(0H7@OVDF2ZGWMB##'/2,+T2VV^XJV=D^5+!E/O"MHU-SCU(
M&Z5%M0.;#"K*VY,\[_K0 XR##P#1#A"YO-N+7);71)/91(HM2!MMV*S@2G5H
MDQSE]E'66AHO-3@]6]T\W/RXOUG#\1W9,%0G$U\;6NOTTQW%O*6(/J"(X59P
M72JXX1EF;_&^2:?+*=KG-(\.$MX2.80X'$ 41-$!OKBK,79\\3]J/$"5=%2)
MHTH^H%J;H<@:AB!R6(BJ)OSEBX)KJDA12"R(^].,;X5/R!M4[W7S\ U'G\91
M$%_"_YYWI41\\S)@^IJ6KK''<#]<#R$3C!&I@'+0I6@4X9DZ<5VWGQ"6.7U%
MV5%^AG@0CTY[>C(8A2',)7FEK&<>#9)1TM.M%$:7L"@I*MIS1.'XG; [H0DS
M$]^V$'(I*C!S;#I50"%$IGJ8\T$0C?_*:/4&RVAJM@B"*0]61Z2J+Z\-GWPR
MYC[5V2 8G?7TT\$X.'_OG_%[XU:A+-Q249"*ANMV\CIKM[>NVG']$]XN/?,D
M!>4*&.8&&@S/1A[(=I&TBA:U&]Z-T&85.+$TNQ>E#3#^7 B]5^P%W3:?_090
M2P,$%     @ +#FP5)>3&_[U!@  WB   !D   !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&ULO9I?;]LV$,"_"F%L0 )TL41*ME,D 6S'33PTJ5$GW4/1!T:F
M;:*2Z%%4_A3[\#M*BB@G$N6UF5]BB=(=C\?C[XY43AZ$_)ZL&5/H,0KCY+2S
M5FKSOMM-@C6+:'(D-BR&)TLA(ZK@5JZZR48RNLB$HK"+':?7C2B/.V<G6=M,
MGIV(5(4\9C.)DC2*J'P:L5 \G';<SG/#9[Y:*]W0/3O9T!6;,W6[F4FXZY9:
M%CQB<<)%C"1;GG:&[OM+/Q/(WOC"V4-2N49Z*'="?-<WT\5IQ]$6L9 %2JN@
M\'//QBP,M2:PX^]"::?L4PM6KY^U?\@&#X.YHPD;B_ OOE#KT\Z@@Q9L2=-0
M?18/EZP8D*_U!2),LK_HH7C7Z: @392("F&P(.)Q_DL?"T=4!$B_00 7 OB%
M &[J@10"Y*6 VR#@%0+>K@)^(>"_$'"]!H%>(=![(>#U&@3ZA4!_5R\-"H%!
M-KOY=&1S>4X5/3N1X@%)_39HTQ=90&32,(4\UK$[5Q*><I!39_/IQ?7TPW0\
MO+Y!P_'XT^WUS?3Z LT^?9R.IY,Y.A@N%EQ'&0W1-,[7"MP=HH-SIB@/DT/T
M&^JB9$TE2Q"/T6W,5?(.&N'Z9BW2A,:+Y*2KP%;=8S<H[!KE=N$&N_Y,PR/D
MX'<(.]B]G9^C@]\.34?YWQJM8[O6*_J$7+*EM$;)^0ZFX4R+.VC6,K%K^12H
M(^0>9UKZS5H^[*"%N)D6OT;\HLT?\ED<X\((NI*, 9W4#NZ^W%W];I/8A? M
M8QB7,8RS;DA3#/-5S)<\H+%"PR 0::QXO$(S$?* 0U1^_0@":*I8E'RS=$?*
M[DC6G=?0W5A$$5!WKD3P_1V:48F$A#NJV )]H6'*T(Q!@QX=.H!5L!!A2&6"
M-M":C?D0_5-9-'6SEALPR S0V>?^S#ER'/>D>U]U?MM;6Z/SRM%YUM%=2)&
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M>GZCQ";[-'LGE!)1=KEF=,&D?@&>+X50SS?Z:V_Y+PUG_P)02P,$%     @
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M]Q]H_=I)O]')DC.B**/JJ0%K4(L-O@!K\ ZK[[O=WG&NP'\M,'ZCF7N*+&Z
M"@Y*5? %6)7HF__,=UN#?[B\@QIJ[B-=BC8TE\ PT7F^V],?M-B7^'V@>&'+
MZHHK7:1M,]77(@HS08\G7%?#*C"5NKYHH[]02P,$%     @ +#FP5'5Y#[L6
M @  +@0  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULE51=;^(P$/PK
MJZ@/(-V1D)0652%2^-(AE0I!X9X-68A5Q^9LA[3__FPGC;@[^G O\:Z],YZQ
MUXDK(=]4CJCAO6!<C;Q<Z_.3[ZM#C@51/7%&;E:.0A9$FU2>?'662#('*I@?
M!L&#7Q#*O21V<RN9Q*+4C')<25!E41#Y,48FJI'7]SXGUO24:SOA)_&9G'"#
M>GM>29/Y+4M&"^2*"@X2CR,O[3^-(UOO"G84*W45@W6R%^+-)HMLY 56$#(\
M:,M S'#!"3)FB8R,7PVGUVYI@=?Q)_O<>3=>]D3A1+"?--/YR!MZD.&1E$RO
M1?4#&S\#RW<03+DO5$UMX,&A5%H4#=@H*"BO1_+>G,,5(.Q_ 0@;0.ATUQLY
ME5.B21)+48&TU8;-!LZJ0QMQE-M+V6AI5JG!Z62>+M:P2Y^W,UC.TLUV/5O.
M7EZADV89M<=&&"QX??<FZT)GBII0IKKP'9[Q@@PB$X5!> \O0J.".Z <7G-1
M*L(S%?O:B+1;^8=&T+@6%'XA:$ED#Z+^-\L9;C=3Z-QU_V3QC<769]CZ#!WM
M_1>T4]QKXT1I69J6TC A4GY0?H*T$"77MW36A ^.T/;V)0F'CX,@]B\W=$2M
MCNB_=,P)E; CK,1;$J)_)$31,/A;@G]U_?8EF2,\4:Z X='@@M[CP -9=V>=
M:'%V';$7VO27"W/SH%': K-^%.8JF\0V6?N+2'X#4$L#!!0    ( "PYL%24
MDCF"TP(  !\)   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)U6:V_:
M,!3]*U943:VT-7$>/#I *M ]I'5"L'8?IGTPY$*L)C:S#735?OQL)X24ERA?
MB.W<<^XY-^3>M%9</,D$0*'G+&6R[21*S6]<5TX2R(B\YG-@^LZ4BXPHO14S
M5\X%D-B"LM3U/:_F9H0RI].R9P/1:?&%2BF#@4!RD65$_.U"RE=M!SOK@R&=
M)<H<N)W6G,Q@!.IA/A!ZYY8L,<V 2<H9$C!M.[?XIH<# [ 1CQ16LK)&QLJ8
M\R>S^1JW'<\H@A0FRE 0?5E"#]+4,&D=?PI2I\QI@-7UFOV3-:_-C(F$'D]_
MTE@E;:?AH!BF9)&J(5]]@<)09/@F/)7V%ZWRV#!TT&0A%<\*L%:0499?R7-1
MB I \^P'^ 7 WP8<RA 4 %LY-U=F;?6)(IV6X"LD3+1F,PM;&XO6;B@SCW&D
MA+Y+-4YUAG>/=]\?[D;HL@^*T%1>H0_H8=1'EQ=7Z )1AGXD?"$)BV7+53JA
M@;F3@KR;D_L'R -TSYE*)+IC,<2O\:X66JKUUVJ[_E'">R*N48#?(]_S_3UZ
M>J?#\1$Y05F\P/*%AXH'2V +V%N9'%FS2/,N+3NXYC6BEKNLZMT3A0/?*Z->
MR0I+6>%169\YCR7Z=0_9&,3O(SZCDC ZVV>.C"H.FI[?V+*Y&Q1&&.]W62M%
MU=[@$OU#@RE] 7&*[WJ9HGZV[_J.I2"(:EN^=X,.^VZ4HAIO\]T5Y(6FI_AN
MEBF:9_MN[EB*PBC<;PE[FR[DO<U4+Z$@Z2FF<*75X;-M%="J+Q\W#MCR-QG]
MHQF_T8F>>(!T^T3#=R2;?^RC$8BE/C[I!<6;3H3/;T5XM\O4O:B^]5_=$U5K
M>,VM$KB549.!F-D)+-&$+YC*^WAY6D[Y6SO;MLZ[9OK;$;:AR3\==)>>4291
M"E--Z5W7]4,1^33.-XK/[4 ;<Z7'HUTF^@L&A G0]Z><J_7&)"B_B3K_ 5!+
M P04    "  L.;!4#,DR,*<"  !!!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6S-5=]/VS 0_E=.$0\@#9*FI#]06ZD4T*IM4%%@#],>W/326/A'
M9SL-E?CC9SLEZD1;\;)I+XG/OOON._OSN5=*]:QS1 ,OG G=#W)CEA=AJ-,<
M.=%G<HG"KF12<6*LJ1:A7BHD<Q_$61A'42ODA(I@T/-S$S7HR<(P*G"B0!><
M$[6^1";+?M (WB;NZ2(W;B(<])9D@5,TC\N)LE98H\PI1Z&I%* PZP?#QL5E
MU_E[AR>*I=X:@ZMD)N6S,\;S?A Y0L@P-0Z!V-\*1\B8 [(T?FTP@SJE"]P>
MOZ'?^-IM+3.B<239=SHW>3_H!##'C!3,W,OR,V[J21Q>*IGV7R@KWW8W@+30
M1O)-L&7 J:C^Y&6S#UL!<7M/0+P)B#WO*I%G>44,&?24+$$Y;XOF!KY4'VW)
M4>$.96J47:4VS@RF#W>C+_!P/[R=#D</X[O;*1Q?H2&4Z1,X!7>V<,V73*X1
M86ID^@QCD:)P>PD31D0O-):& PO33<K+*F6\)^4-SLX@3CY9\#A^G%[!\=&)
MSHE"_2=6:$NIZXGK>F(/?KX'?)13S.#Z!=/"4[S+,IJB.H#<K)&;'KFY;Z<<
MQ5.G@#F,)+>W0A,OK*%21"S0*M7 ; W;?A.R]M/#DJ@Y_/AJ(6%LD.N?!PB=
MUX3.#Y9Z6_ 9*I"9O1S:*)H:FU'[(UI81LXZI@*JK3V!5]BUR=6!58D2G\A=
MX]6@U6PGS48O7.T@F-0$DX,$GP@K\""_5SC:1:>";6W12>)F%$6[Z;1J.JT/
M2..&"B)22M@'I-&ND=O_AS0Z-:'.OY)&YYTT&G&CF^R11K<FV/T[TNB^DT8C
MBMY+(]SJB.YQ^4;4@@H-##,;&)VU;4&J:MB58>32-\F9-+;E^F%NWSA4SL&N
M9U*:-\/UW?K5'/P&4$L#!!0    ( "PYL%1E.J\K& ,  &H*   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;+5644_;,!#^*U:T!Y 8B9,T+:BM!+1L
M2-O$Z& /TQ[<]-I8.'&Q'0IH/W[G-*0%D@RD\9+$L;_O[C[;=]=?276M$P!#
M[E*1Z8&3&+,\=%T=)Y RO2^7D.',7*J4&1RJA:N7"MBL *7"]3TO<E/&,V?8
M+_Z=JV%?YD;P#,X5T7F:,G5_#$*N!@YU'G]<\$5B[ ]WV%^R!4S 7"[/%8[<
MBF7&4\@TEQE1,!\X1_1P3$,+*%9<<5CIK6]B0YE*>6T'9[.!XUF/0$!L+ 7#
MURV<@!"6"?VX*4F=RJ8%;G\_LI\6P6,P4Z;A1(J??&:2@=-SR SF+!?F0JX^
M0QE0Q_+%4NCB25;KM=&!0^)<&YF68/0@Y=GZS>Y*(;8 -&@ ^"7 ?PX(&P!!
M"0A>:R$L >%K+71*0!&ZNXZ]$&[$#!OVE5P195<CF_THU"_0J!?/[$&9&(6S
M''%F.+D\GHR_7XZ__2#C*WQ.R,X(#.-"[Y*/Y'(R(CL?=ONN05,6X,8E[?&:
MUF^@_<KN"?7VB._Y?@WZI!U]M%3[A :-\-$KC$>-Z/&_T&@\H 6</H6[*&ZE
ML%\I[!=\09/"^53#30Z9(>-;^_SU!5>0,P.I_MW"'U3\0<$?-O"?:9VS+ 8B
MYR26:8JW#T]-?$WR; :*F 3(A G0Y&BA /".FSI-UC:BPH9-+K?#7J?;\3RO
M[][6.!=6SH6MSGU24FNR5#(&F.DZP^';#'<JPYU6P\]5;Q$ZJBBC=]G(;L7?
M??^-''5?ZMF+&N7L5;[U_K-O>R3#,K?#<6'"%.BZ)#):&^UL.=L-(]JE]<X>
M5,X>O&GOR1]RDG#0?..=;MDOZFURI_<N)X)N96?:&LIY>7/(7,F4P!WV!QJP
M0/-TFBM=%TJ97^F+8T"Q=V@\!W23S:C_5G&/%7O@8B,NEC"3D%,N8Y4_X/R1
MF&-I$GPA> P*JWJ;-)NT1X/W$7^3NVA[\GHJOK;GN[82ODQA052GM;M5IFT7
MAI5FP3--!,P1Z>UW\2*H=6.S'ABY+"KW5!KL XK/!)M!4'8!SL^E-(\#VPQ4
M[>7P+U!+ P04    "  L.;!4PNQ-7@\#   P$0  #0   'AL+W-T>6QE<RYX
M;6S=6&UOFS 0_BN(3E,K326$E84U1-J0*DW:IDKMAWVKG&"()6,S8[JDOWX^
M3,A+?577#ULZHA3['M]SC^^.&F7:Z#6G-TM*M;>JN&A2?ZEU_3$(FL625J0Y
MES45!BFDJH@V4U4&3:THR1MPJG@P'HWBH"),^+.I:*NK2C?>0K9"IWXTF#Q[
M^Y*G?AB_]SU+E\F<IO[=Z=N?K=27;SQ[/WEW<C*Z.[L\M)]VP)D?.$DOGD%Z
M/L)Y#891Q\^C?I+;D@=]@F;30HK]/('!1"<5]>X)3_V,<#97#+P*4C&^MN8Q
M&!:22^5I4R C)P1+\V#AT,Z@=CU/Q81476P;P?Z=]\L/@,T,!#+.!X%CWQIF
MTYIH396X,I-N<6=\!'G]^'9=&X6E(NMP?.%O';J;"3*7*J=J"!/Z&]-LRFD!
M<A0KEW#7L@X U%I69I S4DI!.@T;CWY@:!>4\QMH[!_%'O>JV*GK"*HJAJ$1
MU \MC9T _RZ;Y=ZE';V(UZO9O=2?6[,=T<VA6^BUH@5;=?-5,0C V$.<G=0U
M7W_BK!05M9M_=L#9E&S\O*54[,%$@U99& -5OG=/E6:+7<LO1>I;NM*;=EH5
MN.;Q*]3\=_-<4D$5X;NB3>\?<Y9?K#CZ\*\D=_]5#@4[-?:GU;&+O'@-(N/C
M%QDE1ZDQZ$^=G:-M[V ;K!Z\0*3^=WA=X=N@WKQE7#/1SY8LSZEX=+X9>DWF
MYG5PC]^LSVE!6JYO!S#UM^-O-&=ME0RKKB$1_:KM^"ML+XR'MQ<3BXF<KFB>
M]5-5SKNA9P8F:G^!PR%RU5UN!/.QF!L!#(N#*<!\K!<6YW_:SP3=C\4P;1,G
M,D%])JB/]7(A6??!XKA]$G.Y=YHD413'6$:SS*D@P_(6Q_!ULV':P .+ Y'^
M+-=XM?$.>;H/L)H^U2'83O%.Q':*YQH0=][ (TG<U<;B@ =6!:QW(+X[#O24
MVR>*H*J8-NP)QI$DP1#H17>/QC&2G1@^[OI@3TD4)8D; <RM((HP!)Y&',$4
M@ 8,B:+N'#PXCX+-.15L?R.9_0902P,$%     @ +#FP5)>*NQS     $P(
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MJ_A/LKX[M_SK+]5V+8Q4]N#/NM\!LT]02P$"% ,4    "  L.;!4!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( "PYL%24Q-04[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "PYL%297)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M+#FP5!2V%1I2!0  +!8  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "PYL%2[_BBT2@4  +$4   8
M          " @94-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    "  L.;!4%=?E>?X$  #B$@  &               @($5$P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ +#FP5/X";5/^ @  *PD
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M965T."YX;6Q02P$"% ,4    "  L.;!4T]?;.(\"   >!@  &
M    @(%I1   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M+#FP5&S7'4]G!0  (PT  !D              ("!+D<  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    "  L.;!4JV&FGJ0"   7!@  &0
M            @(',3   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( "PYL%0\M^X!+0(  -D$   9              " @:=/  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ +#FP5!P&*V_. @
M0P8  !D              ("!"U(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    "  L.;!4ZO4^FWL8  "12   &0              @($0
M50  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "PYL%1R
MJV7JE@(  !0&   9              " @<)M  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ +#FP5.N3Y2-D @  L@4  !D
M     ("!CW   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "PYL%1U>0^[%@(  "X$   9              "
M@8B"  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ +#FP
M5)22.8+3 @  'PD  !D              ("!U80  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    "  L.;!4#,DR,*<"  !!!P  &0
M        @('?AP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( "PYL%1E.J\K& ,  &H*   9              " @;V*  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ +#FP5,+L35X/ P  ,!$
M  T              ( !#(X  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  L
M.;!4EXJ[',     3 @  "P              @ %&D0  7W)E;',O+G)E;'-0
M2P$"% ,4    "  L.;!4]69,.;@"  "Q$   #P              @ $OD@
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +#FP5*_LDZ4X 0  'P\  !H
M             ( !%)4  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ +#FP5/[?4.AO 0  %A   !,              ( !A)8  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     "  ( "7"   ))@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>147</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20220331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20220331x10q.htm">plx-20220331x10q.htm</File>
    <File>plx-20220331.xsd</File>
    <File>plx-20220331_cal.xml</File>
    <File>plx-20220331_def.xml</File>
    <File>plx-20220331_lab.xml</File>
    <File>plx-20220331_pre.xml</File>
    <File>plx-20220331xex31d1.htm</File>
    <File>plx-20220331xex31d2.htm</File>
    <File>plx-20220331xex32d1.htm</File>
    <File>plx-20220331xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20220331x10q005.jpg</File>
    <File>plx-20220331x10q006.jpg</File>
    <File>plx-20220331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="209">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20220331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 67,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20220331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 245,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 11
   },
   "keyCustom": 28,
   "keyStandard": 119,
   "memberCustom": 16,
   "memberStandard": 19,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_w-AiU3m0ekC8zKByhpjVfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_tq4eORklZUiqk3IJVqdf8A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_qlkFIEWk_Eizmcf-y0eN0w",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "shortName": "REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_86wb_A24g0O9P6vNpbYVDA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_2_25_2022_To_2_25_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_KZFMPdNjFkKDf-xGOqXOXg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2021_To_3_31_2021_vO4apQCLgkuxkIh2az8_wA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_4_1_2022_To_5_16_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGc0TEDDBkSJ3lw89HssaQ",
      "decimals": "0",
      "lang": null,
      "name": "plx:StockIssuedDuringPeriodValueSalesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_asCyG8rAxUujHStZ-c_wvg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s5m0PChKQkarlV9DM_nv4Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_QHMnf7k2NU2SmWIlHerKCg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "As_Of_3_31_2022_2dCNWaLRPkix7fXpFVIR3A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_oEE0k6HXck6A7DEOye9GBw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ZlUXKu8MdU6mVGDihMLG_g",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220331x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_uHkHZqnyC0eoWnp4Sk7KlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 35,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the product, alfataliglicerase.",
        "label": "Alfataliglicerase"
       }
      }
     },
     "localname": "AlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi [Member]"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockIncentivePlan2006Member",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year",
        "terseLabel": "Maximum entitlement of development costs to cover per year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "localname": "ProceedsFromExpenseReimbursements",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number",
        "terseLabel": "Performance obligation number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Issuance of common stock under the Sales Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20220331",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r148",
      "r168",
      "r201",
      "r202",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r286",
      "r289",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r148",
      "r168",
      "r201",
      "r202",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r286",
      "r289",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r117",
      "r185",
      "r187",
      "r265",
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r117",
      "r185",
      "r187",
      "r265",
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r148",
      "r168",
      "r192",
      "r201",
      "r202",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r286",
      "r289",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r148",
      "r168",
      "r192",
      "r201",
      "r202",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r286",
      "r289",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r185",
      "r188",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r185",
      "r188",
      "r288",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r121",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r208",
      "r209",
      "r210",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r203",
      "r204",
      "r212",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r204",
      "r206",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r67",
      "r161",
      "r165",
      "r166",
      "r240"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r76",
      "r106",
      "r109",
      "r115",
      "r125",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r218",
      "r220",
      "r229",
      "r247",
      "r249",
      "r267",
      "r278"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r42",
      "r76",
      "r125",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r218",
      "r220",
      "r229",
      "r247",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r32",
      "r69"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r69",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r232"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r133",
      "r271",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r52",
      "r76",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r229"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r75",
      "r77",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r241",
      "r268",
      "r269",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r162",
      "r269",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r75",
      "r77",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r14",
      "r189",
      "r190",
      "r191",
      "r200",
      "r266",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r67",
      "r129"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r50",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r92",
      "r94",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r223",
      "r224",
      "r273",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r50",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r94",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r223",
      "r224",
      "r273",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r103",
      "r126",
      "r180",
      "r181",
      "r208",
      "r209",
      "r210",
      "r215",
      "r216",
      "r222",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r290",
      "r291",
      "r292",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r154",
      "r163",
      "r164",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r225",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r154",
      "r163",
      "r164",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r225",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r154",
      "r163",
      "r164",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r68",
      "r230",
      "r231"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r66",
      "r263"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r62",
      "r64",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r127"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r40",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r127"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r127"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r76",
      "r110",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r219",
      "r220",
      "r221",
      "r229",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r76",
      "r125",
      "r229",
      "r249",
      "r270",
      "r279"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities net of capital deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES NET OF CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r76",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r219",
      "r220",
      "r221",
      "r229",
      "r247",
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r17",
      "r18",
      "r76",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r219",
      "r220",
      "r221",
      "r229",
      "r247",
      "r248"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price."
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r47",
      "r49",
      "r68",
      "r76",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r95",
      "r106",
      "r108",
      "r111",
      "r114",
      "r116",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r224",
      "r229",
      "r272",
      "r282"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r106",
      "r108",
      "r111",
      "r114",
      "r116"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r41",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r189",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r130",
      "r249",
      "r275",
      "r280"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r214",
      "r264",
      "r305"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r126",
      "r208",
      "r209",
      "r210",
      "r215",
      "r216",
      "r222",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r48",
      "r76",
      "r104",
      "r105",
      "r107",
      "r112",
      "r113",
      "r117",
      "r118",
      "r120",
      "r125",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r229",
      "r274"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r45",
      "r46",
      "r47",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r103",
      "r126",
      "r180",
      "r181",
      "r208",
      "r209",
      "r210",
      "r215",
      "r216",
      "r222",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r290",
      "r291",
      "r292",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r103",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "Number of restricted stock granted (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r20",
      "r21",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Value of restricted stock granted"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r76",
      "r124",
      "r125",
      "r229",
      "r249"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "CAPITAL DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r306": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r307": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r308": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r309": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r311": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001558370-22-008847-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-008847-xbrl.zip
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M,!6?L!>0/L'ZN\9F@J<>V<E,<BCSD+\$Y"^WTY&.U1VA3U;OL8WZ;6O\.#*
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M,P>%W-87IC-<)6N5@^J17- :)6J.,VR%#BYRCB?V0))_"'&>_L-2]R+I^1Y
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MEJKE<E.O5^OU<K68/<!D+.I9Y%Z*WC7?)(S*9D]\#4^,'4)EE:8TM'&Q["4
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M(P=,P<((1?'1WV[ YQ,/KC<.K3#\;H7!XO/)QGDYI6H]?Q-Q]Y>93\R#VM\
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MH(WC,877L/#*S["Y6LH3ZM"!R>HKS[UV>ZRRNZBJ]TEK)314V@A5X10CSPN
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MY%5ZPDI0F1:AEG9,K*)$M$M8X@ )<W4:,I.BNK1(:NK22HH$HC#:%SQZX%M
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M)N$W<?+$T+_][FT!^)6 _.%S&M2@/WU7P+Y[^X^[V^7ZF6Z]BR!*,R]:'["
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M=$?7&00)Z787QJ^4DB1X>F8=L=_%\'L6)/P4'-%R[Q,(-F:O(&(VCGR(?^^
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M 53)/"(Y72((DRE/6.%],=^0@C@1U F0)PNMX9_;.3E;C_#.>//D0=SK1/U
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M:D+GR[B5?Z_ &L(&5RN,?I<KH0QDJZOA2U*CU3,]E*K*W>$X(?$^XQ_5;U;
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M,/A;Y_!V<8&$:Z3=!"A[O\8U^URVP!;H7]F7Q5?L?Y#<\.__#U!+ P04
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M\;JAQ2%%<@2KAH< G:*X [@56SGNCGI*M"]5-VSR.Y] 4I?@ADBNV4:WK/O
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MYC)AGD)8H$K1BV8/4&#+"2\I#]^W:-XACFA*G>;0@%_,LL=3ZM!B!BP+);\
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M^>IT+.,/*.4.ZRI.*CM=65/P/NIU3GGP)EM(R4&:KUZ<$S17+$%CT9*X$G\
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MZ[81W3G<.':H+0)_<NLUC3K%!"8FP#M'M-%/EQ%R\#_HGNC?_Q]02P,$%
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M<V;1Q5)G9@SXLX/4[W/I/ #WYL$\)Q@/CW]-,LXC\^2GXKAE^E;. [#/ 'C
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M+8\B@*O\("R7^!M"X7#&KU;K:2F@8J<>#PG@+@$2 3Q:B.5AUQ)*X,Z[8^E
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M_"0KTVG,T%<6IKVE"$/K1G O3MN% ^WCK->-YW\?P<0 ^N;XRQ,7X^FWMNF
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M=,RU3"KPA2IO5*#JCS0/^*HK283%%7JZQ8FIK%1? 2&?7EP\NO')"2>&&QA
MAX^P+S!T$A1.BG@L\:*OU@>H@BZQ%O%%:+8MRZ %"2]F)KDI*U4,).*;;OQ_
M+HJUW('=YBB_4$;IA7(TPGH81&H;ZN\=!/!<MLRP$^)&FG1S:BTW+SDC=)TD
MD[HD./J21G67'M/A7VP]XZT".'"X6G\QM_$26P /8.[#>*Y^EC0>NHY[][KJ
M[57FCS.G#MU=OIO^]!M7FQ^!%H;I3VUM]9$[NW?3>-[*0>*W1KU3/_C__->;
M"I_K-M \E!$_VD;7J8AA0X"OZQMK@P!XUYJ]T%;^QL?@^2N*N2^ ?L\->IUX
MQO/_@SV\C/RM:%0[HT$!_)V#J(\"].M?/0[1;SY[I<CRAFQ(9NB'H/[VJ.OG
MIR7&Q'QZE^CLD'-',I[RZQ CMC>K"PRC]UE--09]4F6,?E_M&SQ0*0HP'"!8
M71ML#T9__0WFZ,YC[.$*X?OMOG8]$YLQML5T14*7D67JM;94:Q_[!OC3I]4>
M:ZOO]*?;'Q4Y35UQ?.Q*QJ/J7)'#BZROZ^@5_#7X@[C$X5=_GD3G'?L(\)N+
M]S]B!\]=,0D[8L,.]NK%6.T9<.,#=RV\2S_$95T_'L3.;T:O2.G)')[]!?^U
MPR)O-P@:T#;_^.G*EZ3V_JK/U!4IG(SE;RXY_C#HSQ',EZRTB"ST^M^UM3OR
M4$SCOQMBJUW,%6MB+5,4*\4:,BE%=.FL2G,TEV+VF!F]AMZD-]'L0V6A48=8
M,<JX(\F_L/NNL9V^U^S7WK>7^P(63L;X$[A+1Y7X4VFU>_$H!F!"YK8[#5$!
MY>C<ABIP LD>/HCTG(!L/KKX%W6ZB?!=W9/F3=+PZ.3[5ZC[TQ+FOC_LH<./
M$6AD!@"'/]31 Y%UDH#H_(V=^$@_].6S4DV6LO"%7*\4LV);RJ;%"E3UDER0
MI+:L,@(CL!^#0<9%5\VC/4[X*C(SHH2GM&9KJ RC/ (@\+$_%$<+#2CGQI_W
MJXT8!;^KFJ>/U@J&)M=;"%$6>!;H )44??05^>T!1B60B2MDY#;\6T51L7JN
MWI!:T#HZ*F0>EA&$B_H4K/=L#X,GMSF*V88C!EC5C0YF25&.PG.(^A'XH1/\
MG -^,@6QEI?D$^(G$^53^"CGXOFS<:\^*MKY'4%G"7C^9F,60R<9@Q7VQV]T
MF]&F9@ MQRP8F+H)''WU9\Q1_K"G=_W?@^B_F &?28!_%L 7Y4*N4C\E\#5_
MA.5L=_&.A1,DD#H *3:!5 P@5:NW)5(NYFO%7#$CUMIB)E-7:NUB+=^  ,L4
M)5E-"31S^$3*JY"JN0$<9.!BSV#K1T8Y4N<C^(]B7%15<[3AFDE9T]=#WX<.
M!%1AHJ/9*]_TW4'N=Z. U%E' 4]'H8>.[Q/X'AX0+2/;1Z!%Z@%6"'?KA'+4
MI@7\T'[J 'Y[O)%GY+4]$B>ZB9+UH2F/MHTA_^!;>_,.,=]V_=#[7<#19PVX
MTU%HM^,(.SM=8_=]PWF(?3<,D'%G@0!KF;[U[?%$G>L"QD!M&'BN[4-^-CQ7
M!P;BH,IS+$5QOPLDYJR!= +2;'N,T//09P*/))WA\](9BO5V06KMYC*D4@3#
M$Q_,97A(9HCZ31(9SF@/]O%^?04,-3O22E$1.E_E4APM'*YI_'.R&(Y*E:@S
M;*>W[Z_ZA7.%@X@LUYRF!Z[GJP)/TZG4;T-!/&\L'(TDJ!]LTU$"@;A"@%*<
MARL_9,T&OCN0HKVXATK+/SRZ=3(*[7:,13VC$-6Z[]U"U\B34/SHUI;-LI(
M*K: HK-@H*%PHS)U'1DXINL]L%)E"9:B?SMI],RC5R>CT+9C#/6,K;O> 5("
MFKB"AJF:#I"U 0A6#T%&E2*8%$_^\ C5T2F#.L36/>Y&=!-PQ!4<;!U5Q2DZ
MZW(=J. ,EQ(HXH-[TP_ 8,\:&,>E2M09MM-; H>XPH&3EB.S;P:^RE,"R_YV
M[(H[:Q@<AQK;3GZLU.NNC6;^SP5U\2H"!.:*^/22OO=,1TE+8EMI2;+*II@4
M(7R,XS*<DQ;\B(6?)K^\E.,[3O/'))'O<TN3),61XE$<Z>G^(G%@@W%=6N<#
M*J<=59%!R<1N5 YF7_,<IX#1@$JQ.BW0T$LB!BJC:WU5&Q"<2@)6$VB2T@?<
MX]LNWG "_'B5A/8V65_17FAP:T.EN*VZ^.*Y\OL22*^?SSWAI)X($G<O1[M[
MAL_DP1Y-^[R;U*UZ&_*_AZ77^^=B0U+:Q8Q\N:%_+7.U0]]WG #].NFY'R2V
M.TIL,TQL/<XCDOR5X?RA7,E7F($J1GG1*:)@Y(8H^<;_\S,'<7^ X?,>^LSB
MQ]TKW=^XVHCB0+^?XGE5Z-/&NF(;SPYX53,T3:"T%,72_4<*#UTN-*PV'%?*
MX1(G>$.I0BT&$^[@-42C6:83S&^-FL3Y[NK&QX-)VD#7$+%/6U)<+<VYP_E$
M"MNALYA-?= JB"J]?UT2?7O3R9>EN:GDJ_E\!YB*S3!-E=UO*9E211IGZA5E
ME@(KL6TM'%=>J-Q^R]YP4F_8TSM"HE2Q-V>5A=MTFK#EWHSH09\QAB8H2RNB
M6ZX7E!X^J:$^]V94<-K+>8=G=44>X^V.G[<9-C544_M/[V>&MX$T[,B$G!&4
M5)WN]>_Z397?;\GE9#9-W10GECE(WVFI8*%W%TU5V&\9% <%O.2G>]**'68!
M\,J" 5N2Q'Y3?C"<-.5&U58H"6@W2SKKW\UATP-75>'Y]K F$7K-JN=ZKM_L
M+LI38XB:[A%JD-6K5<Z_LZ3RI%[$1]G4L%=>H*;[O%\MR$H_+*@*Z(_*G=!D
MFO4>', !YM_YA O2HUJ+F#3:S<%H5*RZ'NR5V6^:"J24[ZOD5.F.6FDCL.4<
M'8BHZ=Y8NPUJLBQ90%"X7DM=-I<9OSH=HJ;[7,WI\M@3<V,EPVNX/ZF1]705
MCO6 ^%6%;H.LDE-&64E#SJJ/R P]@ ,X('\:;0US9D>9$ES![E".,O?2-)S6
M 6%ATEV1&!-.RRIW)@6V:W!2_D9$3?>F5>T8@=(9Y0O*A,A9JYM@S,S8J->]
M:<T;$C'MUUQ3P6<^&&5ZAE@:00H<D*R);::FE,@6B7*_M<P8&4L?HFO #HB+
M)BLWO6Y+Y0FPX,! %])S%E* HO:;UC/S+KX$/4>:J2UZI973? &R@#H@ P.%
M$=EQ7ADHG)$K*$H[1U=!U'2/ N/>JMTJ#THK::5YW0I>*]O!1$1-]R@0&/66
MOQR7ETIY?#MGE^2\4YW!7@](EF8[K6:FPM\JH%U0>U7EKC//00H<D(% SPXF
M>9Z9$Y,)?4,4E6)1@"R@#LB ,A$&GM@07&F59]+B0F^R> HV/2 #^5(]Q2XI
MQ91 RF@V9Q)(EP=-U'2/ IEI5VPORM0(4F":=LP:8,?UJ.D>!<QRI5;+X;<+
M8M680@0,Q6E/@,0Z( .AN:18NS7FI) E."-T\TN0&ZKT >U282A![([*>2(S
MZLR#HF7;XCQJNC?62</JU>I!3B8XB(#,*BCI>KJ)FNZ-=48.54-:R2NIVZ*M
MCGECCV?* M5/WQN 87&ML6?E:A*EN3U/+K:8# %7E@-"Z)&5%6CK@YJR(H#;
MX!9>,1C#L1X0PJ)0OB7N&K=E*R\.Z^6"XQ3K,SB  ^(R:O?"5"8]RDJKC"&5
M7<*GK5;4=(\"8BW;M :MG$)0K'\;3L)53NX,4=,]"A!U/-MFJG=MA;-*1B%3
M,QO# FQZ0 BG;+OI\=/>C"A/)]E1MB4*?"5JNC\ 6BTK0"D;%C HN5MR*K<Y
MHHF:[@U@150*K>DRI4DSMI0=9X-.N2W"I@?DE9Z/:W*1KPT)L[T8XMUND TA
M"N@#DI4FEG:_7DCI!%PU+.<V1;LMB%CF@&39MX0_FUKFC9095RJ^NIKC(!TU
MW9M6WLE.')*Z(:UZME9L+XR^U*T.4=/MM.)X(^&'*YD^"C-SJ2OVQ0MQ3ERM
M<6.;1@_>*]SX"8$(XHI@'T(1GU@Q\[5P)W5%OGC%4,*7K^$+>46_>(=2PI<O
MX@MYQ26*+(:,2119//F2*+*8\B519/%D3*+(3LJ7UU.%WN>X?!D1WK/M?%*!
M//(-8@<(\%(M\MV;W![?CM=_//G7,V1>59GT_[RGB/HIR/3JB=JW$^YQ7:O-
M01>"HO8(ETA-(C7WA-LKP'LO..2Y",[O*-P]BASWI'6R])R1+'P*!5YSGSZI
M4$.\:/*:Z_(3B9) )8%* I6?!95X&A1'M#9%699VKIO\5FS_1CHQ9G/^')T7
MKTDGPOU#YIP(]UG-.9Y+=,+>KYYSHKM^R*03X?XA<TZ$^ZSF?(8+\TN><D9I
MM:1:&UM[S->)RYPHKT1Y)<*="'<BW.<VYX^MS+OWINDZ ,_>FW;JV4?GG]%E
MCOXH*GRJHQ?H=LBY9M_7!S@&<V,SXZ]59C$CP_\]GL;Z@IGM[-U$!\%VITH_
MG2KVM[F$ W=RGJ9'=U6%CAFT4(T5!;Y0Y0"*O^89JB)GU5M;Z95#OFHHW*23
MSYJC:B6O#B^PZ,C:<OTKT5?K Y5&!RA1(II*&9E:5ZNT&I:Y3 UZTURGV*+%
M"\P NCG1;/^?"YR^P-85[_ZY,)?!M1-.##?8?'^!.=H$$B3T\:&F3:\1(D7'
M0/](#W 4@XSF>2M(R8YFA^ "\R&?X*]@SYMS>YUR[J8^41NJ$BY6)4NN.,65
MA,[ETQ?_DMPES_-__WI,B.,I\)@)=X+Q!./'P#A);4!.J@W#">CZG5>RPCMO
MX=U.FDQ*:7XZR&LY)C7T"%:09K-,#:*\Z ]E!'+NXE^:OQ1X-@'Y=PJI;*PT
M>>1Z 1X ;X+U-<>"4A<=>CB>D7:6C$S<R_BYES'0VD>WS*;V\CI"8!L", WQ
ME]W [X""SG>&6M&4?,OJCKO3FW:VW@WYA9K:6&$$*HQZ*@7]PP0Z ?%7@#@&
M5#AC:?\>02-1U^%@ A_S@ Z@\8K*P6S+9;8]S0")S?FM'<LWW^29>)=?$4':
MPK-UC\X:"#*AYT$?\X#)HHE+>N7?A8IB^K4*G6I.9#6S4'EDLK"7 I'$C1)X
M)_".4?#HG?@>T';;:H(2(+I:]_:FKJX&OBM"?*.8T27#4 F^OV'(:'W3CN;[
M( D3G:V'>6Q-_ /4[LFLJ@A08H2GYW5M4)AIN:8HK2P\?4.05*DLL,VA*D3A
MGTN2HI/H3X+-'XO-TYE$;P*GD"/:1D#9A,)E&"XH3(:N0Z.*\!P")W7*O;.S
M!.?W"%85G3D4!]>++J9-[-H3^ZU?6$(H#G[M5T\_!DK^9 ;8%L@KZ.T>T.ZR
M[_DWJ9!M*)SL3GM.I3"G)]$M'NNM-U9@$D<W40B)0O@^5M\K&N'N%N?&C;*Q
M4L*R*-?&HC)H<0ND$9#!E[H4V$0C?*_0%Q\]H^T&FHWI:S\@"8$=0:W'6(<?
M,\DUT=6GVY-\Q3?')[+7JT@MQ^K.V;H]:%2%-B.B*]#0+B2TWDZY39%@.L'T
M]\7T"3<B7P%U=2$)*VI 6T3&-OS*-%LNY.;1%8C0 ./(2X[C$E!_JY ;OS_]
M=<N'&[P^,44P-G2)G5?^P\@0RSR4&! F@4D"DP0F/PPFYQ31V3SBI9)"M7H-
M3\H*?9^\BF][JB9>DTZ$^X?,.1'NLYKSN4< UDDW.3@2'S,=S /^%.@!Y@XP
M,)G:[@H +#+Q?"R<NNC[P/3 !#A!8J=]:W<F*482UZV9+!B8#C#2P($O@H:M
M.>NX;L[UT)O-YW[-=?1G([WCE9 >M6_'N$(5[5P]+RJC;GNAD@S:OJ$N"38Y
M9)+@/<%[/+9MC@%X;BK4!=#3-4+C%6>2<5O4.#U$@.<BP*=2">"_4R!F8]<U
M/'<*A[B*2D:B:I%39+I=8@XXGOUVEKP\8Y\T.<@2'UMLBR^DAP/1,:0MQ YG
M.+9+&;S.M5A*,>MD*-BYI3%BH=G%(K.+N>1/F?*<P#2!:<QA>CH3ZITXO6UZ
M::6HAH02IELW7%NOS6KD$.&40S@5N"2Y[3M&P>I01K0 /A.S@>9O E\H%!;"
M-T?.2X[-W&/G!7]U"F!R N6KUX'3U038 KR"\-U"TZL/%!]$_O0A>\U4%M7V
MM'EGF<8$J+:7RO32HDIR:WM-($Y8'R!1$(F"B.7T8Z @3EB8X)T:@JD$4SF<
MI$96V F&1+O:;-Z:"Z0A-I8BD6B(;Q57VSVREAQ5._*Q%AHJ,\,-47W2."CS
MDYUK^8)YQD!KG_BPV@'M+%9NB4I6();$3)0!+5%+*9A"/SXJ[\WQE[1 )HY\
M N<$SO$RPI[%<STCU%7%(8H2M;)&.2;H#@@APC.TME+T)<<E-:&^56#NJ[39
M]S*POU>FRD\Z:!,O.B2H2%"1H.)[H^*<@C&;1[QTVJQ2%-/%2K%=E&2L)K6Q
M>@[+B(UB6ZQ@62E7S!2E6N8F.7^6Y%G$(L\B!@Q-A#@1XB,+\7IR1YOB&4MH
MXHTG%E;B=R1^1X**!!4)*A)4_#1O?%OW9<<K3XJ_)'Y+3/V6Q/E.A/CLA3AQ
MOK^)\_WT+N^IMHHN\D8G>S5=]T+-]J\3 ^I;NQ7?_*;?&+ ]D?Y$^N,B_2=9
MNF/&TQ_A&6\/#7B: 7ZV#7;&7L(1LX=_0'+PZ7+]-_9O8VW^1IAZ_D8+<FYI
M [8+;HB\VQ[Z5*E+#,BA2M'H $#JDD\E%SPG /V1 #UA]OZ[$*I2U;;4$L2,
ME>&KP^*JD)HNYPN$4'3GS*7 )U?.?*\PQMH6BBX 3XS:Q%\[7W_MFUE2$2*?
MU]-!PPC[KBCDE+I.I?(K=5SW4DV5BBK&DLPE0R:7LR;X3O =7T/L%8"7*Z7"
MTI,&=Y8\LH>]$3X6U%4$<"ZZCYVADV(WWRLJ=;CHF6UJT6Q-D%2V.%=7^#OM
M:)^[F?6XHE!E@Z[5\XIX.3<$HGL+5A8P;CRB4\I;#1\JXJA(+'E),4G,*@'J
MSP7J9]7^>@-20:=AY/5TQY=6ME"GC3$E%5T1(96+D$J<L*C^62+UW&-7:XLI
M ]LB?OKWMM(J,81/[NE^==G#+_:$OWKZ,=#\)S/1MH#NFL$H$_J0P,![@_J_
MF8_ZP_$-TU0T::'B7.MVQ12@^H^JPY+D)4^<L+I8HB@211'+Z<= 49S.1/R@
MIACS9*\^)ZRJU77#;FO >;X]'2)- 0U%_I)EDRJQWRNTMELE=G,I5Q)8.TF-
MR7CI]Y.5F/R1>OQD!E_E 8K/*^W6N.W,\AP^D;K#MD,5>ZPF=*#2CHK'TNPE
M32?%8Q-@)\".E8'V)F3/U4:3#^X&"PMO5E8#J=%41S=-A&QHCM'T)9E*DLZ^
M5>#NJ_3:][+ OU?V2E*B(T%%@HH8D"%!Q3=$Q3E%:S:/>+&,;+V6Q]I2JYJ4
MKDE2+^*7>A$#AB9"G CQ.9Q_/TL)/7/W^R%O)AHUJEKCN,$1MT%B,]/$ESA1
MS/1''@TY9<++%HE9T ]JKJ,_&RQE^9Q1O!UI%J%IJJ::.-[MD$.5)M V")6Z
M%#@JV;Q.@)T .Q;['^]!MF_=5"FR'_85;N3=<(8R5IQFA&PN0C;/GS!_.68B
M_2,"'9^0OWR6/$P<P%@X@-_ JGH^.?!%3>Q.BXV5PS5+2ATT!X72S8)U^TTT
M3FACL9>\D%QKFB#VYR+VB_)Y7X1L<4S5W=1B2"AX/UAV^4EZ7%5%-$XN2OY/
M"2?,Z3U+S'Z/(-:]=" AP\!D:KLK + (&CX63J',>R P/3"!<I-8R]_:#TX*
MH,3:'FL QX>C%!TC*GW2</W@ 9KP4_3!&L#H@S1PP, ,&K;F^#M9A"\N C6Z
MOE#UCCBR,DZ>=V[2=6 2T(.FHMC8)2.<,(\P9EA(5$*B$L[ X#N]3BA9XT"_
M795ZDDGD^MFL&O(EMXET A?IA%02+O^.0;6DC-+/.Q1R=&6?G SY[#),+ZKR
M6;=+]!=#=:CDN]*26-;U7GJR4.FH>CAS20I)):8$ZPG6XV?E?03L[:5::K9;
M7D7)UX55$^2(VQR*P4>%R)E+.CD3]LWB>;MG]&T7&FX!\"8GL=MB,^?8N>I?
MK06_+LOEJV<> _W_&<?[7U3Y5C%]ETMS[;04-IA<.<!GS$ 353JJ:<X0ERR3
MQ.\2I9 HA>]A%+Y5*_# EL:C;J!+*[':+8;CC-.:-9%60(8@=\E2)\S&^"Y:
MX:PB>(\LP21N]^U]^:28R[F9<0?4-)Z>=RS67V8M/"#[BIW*TX,;J*:C,NDI
M]I)/)=67$T0GB(ZK#7:H3&9QQAO4W%Q8LV&Y<6M4Y\:(%Q&DH>65$BY3IRRH
M>Y:0_AXQN$?37[?$;3 (HB$DQ3=BX)+_,#+$,O<F!H1)8)+ )(')#X/).85R
M-H]XJ913IEZM%MM5J=:6D_I-9WR.ZLOT7:+<$FG_"7-.I/V\I?W,8P.)\18#
ME9>0(:E.FZ B046"BA^ BN_FZ(N-8ENL8%DI5\P4I5KF)O'WO_$6\-=IP1AO
M&.]1"?OCO') Y,#5K1$$-/!\:19"AEY@/IPJ[.; !G(P4YM]B\HN+%ERB=5R
M2.<[K:9*"U%.R"7#[^?S_IDHA$0A) KA?%)(WJ<1TD[?*I,*[RAUMEM2<WE?
M*Y1%I!&XBW^Y2X).-,+W"AMQTX.YO)@# LP=8+HV-=%7!AB8N@D<_7BE+V-#
M@M@YQX\5(@T5HN&&J I\'):)SSS1\053CT$ZX6<D"(N.<7!AV+OZ$<SPE#7I
MUH@\GKT9\,% G72;*A-5,^?X2UHX88IAHB$2#1&_J<= 0WQ*PO%;583,4W:/
MJ!(4P4W2#=\?2//V8(%4!,I"IB\Y+CG_]38K\E>@04$^_CB?#FRGX7V[>_<+
ME6=ZX\@_;YQ,#,:Y@WL=0$1Z3T;^4FRU/0*8INON!(YIA8I>1??Y8)H'/W8P
M$_8V]*"5/=6\R.H.8'.(>C@A'QCH5>00:P%\,S =S=%-V-@/X >HZII_=1^H
M_5R.O%7 #7/^[]_PS[87W0::AP ^>L)4&CURLP 0Q/^<1&<?XAVU,\[H[__Y
MK]WQ/B@97'=MU[O>+C4[$QFM^4U%6F<(\+X'- O7!O!9UYJ]T%;^9F(\?T4Q
MVZ#']?URA::.L5<\_S_8PTM$@#WJ3;0EOD.CC8Y;'P!8_VK[4;0\;3]S?1.I
MWFL/V%I@S@'J^U&O$2,"=WHZ+CS1G#3QH#<U;.2A]>V_V_7,09E#K^$" )<Q
M^Z]=@&T^@A!#NA.!!]6H1JBX%T'M+6+XF*:'B*5%"YZJ\0S/ RZEZ@9-J QI
M<*K L[J:ZE-]BN-2NCX@+]9//0[5]M3)*\+<:-7;8J78P]+%>KL@M<2&I+2+
M&?ER79*I6,M<1?18SR=3KV6EFBQEX0NY7BEFQ;:4E=OP;Y3R6<_5&["+=O%+
MIW0_2&QWE-C#,+%Z#ML,%#;X/*7_AW(E7T$#U+8USX=Z'&IN-_2A3>=?8F"I
M RC@_FBMY0UL"KS-.ZC*M3\_<Y2.%AK0CC(^\:&'#BE]8.W>H(YBV%2* 'V5
M3 FLRFC]OBHP U8U ,,!CD@-^MH6==K6,'6,D,_/YW<CQ13;XU(.XK:8$U5"
M)9ZV[ 5ZOS%-ATV":[D OTF1/.@/56AB/VWI:H59L^9,;RRS:E#5FNK=VMQ"
MI?9;JK1;,=@J7;0X=JZ.T]U*.Q"&L"7[M&5VX=(=ENB%2H8@Y@PW=!HN/E3I
M_7'6&5-R?+_H*IHES#RYX FVB%KN/;U9RUJ=NY J$#.F,5\LQ.*$&C=AR[VG
MVS>WLJB/K#NI.[RC!\VPIN2IH<KL/]WQ"G7<%SL#B0JG=UHS51\5*@N5W6_9
M)3RJ/Z\W@!(6AT'-4JP*DQ95;K_ES,ZV\I24O2'J>'4@9JI#:W(KJJG]EFU/
MDVZT52N0\AU:%?*AIO7,A<KOM[1D3:AD1F*)P/.66AC6E3MUVE2%_9:"9%ND
MF^4"0N;H;D#0#"?PHDH>$!'Y;AHH[D0@I$FY*_A\FF^69PN5)/>;+F]<W>B+
M5$#,1C:^[),E-8LOD-.VUW1EMA?==F!4K'R:*=>U&2-:T'<B#_ ^Q7-:KS%+
M]95,K5]=9.J^6X?S)P\PZA:BHE=W;WTK/V.S):WJ+.3\$#7=DQ.G.QD!6Y@6
MB3H(9\5VHY:><E&O>X+2N2T/IFUSGI$TM33WZ;2IT%!0R /\+]XM&SIESUK$
M1),K=+M1X>\(V.L! <@O\=M.3>GPTFR>;35S)2850%$A#TA ;>(V=4%1\Y*I
MS@M5O-*SIRW8ZP$1F!73^7I_XDX52LEWQOA@G%U*4=,]"ECC&X6C.DW:DH=&
MJ;6XZY>#NR9JND>!9KG'K 1<L@EN4*C5BKQQ&[JPUP.2-2QF<S?#>3%CX2U-
M'$][(%1'3=1T;P#B"!2F!;Y:);1)2I@[_;MQN1DUW=<4 3,OC/2PKF3HN^'T
M]H[.3I#V.2"O6FK:"?)F6R.@S'*#(A_<M4M#U'1O '=4A\[U2\VF5*[UFD/?
MSDGN*.IU.X#(+[VWAM<!&!TM>E,?7&]?[*X/:%=A8Q$CTTI?FV1;:S\R57'R
M*D7P-,T*3VS8'<=]8\'NVJ/T%4-&)FG@;0>T>1"Y7G8^'%!@^2OAI3VH'<MQ
MYXDN?,K =A?;16S['D<]7Z^]@ 6DV*L&^&9MC!Z\;:KUH>,7!N#HUO@K88S5
M@?^>NDAO#-]L8C4I^J>0]ETAHL<L>9<__1XF/!]?3O@22[XP5R^>GTGX\C5\
M2?18//F2Z+&8\B718['D2Z+'3LJ7=Z:$O>9X?!D-^'?0X'C.P#E-%_J^Z,-_
M+MB+#T*19J\X\DMS8/E78KGO/$;2'GD 8%7XQ<C'),< !G:T<R0Q%IP]2IPP
MA_3G*(PO$P7^-0*\!('U1MO^WST<W*L/ZJ/J@^2N&/H[J8^JYNFC-;EH<K-E
MB7(AST6')((3+\$A$\'YP#+S<HS\<Y/N?HLP+:DCU11)QG*M>A63I4JE6,MC
M^7H]^]YJ5CM2$.>DPR-:);\9CHF7E!PE*3D*9WS^O+XTXS@;HJO!7$<EU<VI
MA+:[<T3!]P*UX;E&J =U3P;>W-2!N#1]=9-1O/VR"B9]X*FEH.5UTVI[2LC4
MS5 <.,QL65Q\.%VY!>; "0\61^:"DJAX?:$@ :+FW3%T)^B$HAK=12A<$A1_
MFJ3D\](/B3I(U,'OJ0-R5QV0[U4'2R$K6\RX@!-UE35OAJ,"/N9.H@ZLMMG-
M=4O9$A$.LKPB::79 $?J(+JMD"5/=(SI^ZJ#N,4LCF@F5HH9E&V*B;4LUOI?
M;3+]*PM-QU8'?OP;5F-,>?ZE)N+7>I\O4>QX]]>N5XG8^-E?OV2\UX*LP \<
M'Z#S:.MO-XO'4*J4:-TA',FL,#Q>N1FOANY)%H\)N\J&=Y*^DF9]N]?E=*70
M+S959ETFA6!/='-.C+5&HB02)1$KN_(Y)=$J+R5ET:$G5KG<MSK+0OYN<O/Q
M\[$O*(F9%32[V4(U(P%2EIR,<\=)DX7*K"NG\(20*(ECFY/Q\BE?WA9%A[*P
MC9V9A!Z_4ZPA_NMH$JC8LSK#@E6XG3FK# '<KC-E9"M5MC]>6N6%=2'3'02]
M[+RZ4G %*'/7\BID3E2C>Q=)[I+@3U0>(0%"HAT2[? Q<W->9[1I,U,96N'2
M*HXH[8Y7%R?1#M6%35"2@E<L2K-DBO.S8:DP5*,K'$GRDJ:(CVB'"906&_P
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M3K_^S4S N:9NM=1B1^Q:U58*F4\^\SC0P/EW?;A-3ZWS*9?^^%[/GD@O0K(
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MVQ!5XB_J[T *74]-N9V^7F=!GP!U M3Y#=-9F"KV_428 N2Y)>3)@J$B*G:
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MU7VC/[CVJXBXT=0"/_U?=DDK#JG%TR&0,!)=(>;K1UBX"XYM^!^XHAU_LJ<
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M*/:(4&R+L)R!I4B*8$*6$\(J*]+V:/*?C*OFXG]1__R-VVR@+RQ&\#FKL+%
MU9C[W][LH&)+3_@+VST]=0^VL/>R]LYS_#>&L&(]4(SI2(#Z@(A/ S5F5_^&
M"Z%-+CI(M39T_"P)P.<:N)(8OQPNA-P":=G*&M,UTB1, #\>(/7;1E_RH83:
MB=A T2UB(.P\<@<(5.(?"S<=@7NT!7.%SI8!FL8N_V,YTV-E.O$$+=T]-1R+
M+!]=#HD1TB$. "6B2,]VIK_\'1%@.85BPT+[MU86-!:(OSRH;7;@@^R)Z!@$
MLC!"N[LG1@*Z9VCQ6];0@9?G0PJ>$]V.K#DB! 0JMM6& O$7Q#$5("L%*L?
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MAB [MP@&\E<(>_]U;)794;M<KCI17#T-O7(B2!#:R%>('^A1G7O")#XA14R
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MVZ398R"\46+GK=XLW:FS\_[D9BQ#-C:%^C@JU1%6KDUG;"[3O61\HW"/YV:
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M2NR<E,!'Q2V#T6'W=#+\ ?Z[KY!]"EL.E92#@#J\#*Q>(5F 4^(PL4%AN!$
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M8#\G2EZ:LI<5^WOI=;WTC5V!OI1]9?>_M*+CT;?AP7D45,\.M[Z7SV\/$%
M%:-&;KVVE"O[R_F_)%1+&J_LY?%&?@1<Y,56\(-S%O G@V*Q/"B7&Y>]867]
MLMKH-R[7&[WB9;4RK/3-8K-8LX9I&(QCOY??JVUN;G?RZ].>O6\>?YYNM[)
M37K?!^W;Z='QWKG=./EZM9-OU,K33%"31K7K1-XDJ!:MZ*;4W/DXN'5&LRP
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M_/[1T1[^K7=$NG>7<5C?^.=_#S[6.MPT3G>[>\96JWUV=-HUNN<'!S"=%;@
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M-^+8MZ]Q\MK-V(?_B!Y-8%H#VXBOR'J-/(J!==\4<)6>"PQ#'!8-QTQ@B+X
MVI9KVYH%N(-B'A0;HMW$GT_,@;7 ;_B.&-:UXNPQRP<10@S.[5LY/C^+O:*A
M>64!US>\GB,7!:^*IAR+\K$>U@[@-Z")&@,/?S8VKRW#-*8@6/ISG!X]C&N4
MCQ/[PB.^<Q-P#+E:,5_X<=_V^]$$'H)9P@+0NM#B8JX!:EF?<Y'B%P$'H,U
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MI <2/TO8J!C$(AR'*1#+=$P()X%JWDL1]T&>@KZ&P E+81T++\Z5/7"M>2
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M"6!TW-]-48+KFX@>*QN^<_:T? 5*L\B-4XA=1E49:UTHM)W0,M8%9F]_#CH
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M$K?U8#K0%&%68[DM(?6#0</%YK@IZ&L"C8>72ZPN1;4R+14=#RP#,0#YPYN
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MEU(6/1%URCKA4HPX'Z,WE[[UC%:6U&Z7Z\J635"-\H^6"*HT-QD'(UIY,5R
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M-:ME'CP3:993[D%76]*[]C@^R"_%*ZWN,O7(HION>@P-2@=;*_Z] !>;N>U
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MJSD#ABK7Q>V:<FD17Z>T6&.298^=%<(/4O:PI,!CGGCJ)I?CFTP6<E;+%F0
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M:7<S7UHW=H&I<&]4*>84."QWNUPID+&'<MWB+$XU11A^8$WL/B&+$C_%=O3
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MY.X.QI85)DS,17UY9NDZA3GA6CIMRS5C%</E_H"A4-%A1/IRY'._$5<D[[M
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MUZX! %]8"1<_ 0$IV<L.'IK5XYWL*ZI8U;%=2D5&V.'<< WZ)1$^0A.@)9P
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M8@8J#Y:EIP!!W4ME@A)U8N.RQXR&:'<2FVG\*BD)E;>4A+>4A)=.2=":HB]
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M$2^[R)5;\-P_><=09IQV=65E<QGD8:VD4M%;U9VQXE[=?&[L7.?]PE/2>VF
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M =0-;)II;VFLI'UD2'L\EEU=S6EDN/SEJY4>BKG<:F6K"PM:KNAV*OVEM/'
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M2L$LY4^5?J2S+F=31V^2.'H@<[1(O1@DT;WXWU5^/?K+_P-02P,$%     @
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M9.3?6X $=QEF]T9U+0B(^JN/5NG51Y5LU8$)RD[MUP*1(#N0/[%U5$SG00*
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MUAA"3'5?'QM;/<H[@CYSLLA?E4Y'FF*PY>&OTL7YD\>M6@EOY86^-2:3C#E
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M)MMR3\*CGHK#.3SFC&J5=JH+<^V+.[=3(XV=W+AVZC8QCY2/+M:H5 O^KNC
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MRPQ'+:J@MF.ZFB#X0XNA#>O3"O[\-L=67#4,R+\L^1CUU;F)&T($;S/FSRV
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M;]@9_[GVX'SQT%L8%O^MD,3(I+]N<&M5G]@ 37;&'H'"L6.KC;C$%Y&%))V
M&HX^A8G=P,10]BPGL ?:H*"K.P+3J^-YMAO&ER@ @C<$3.F/J.C;9(-FEH(B
MU'3A)Q9051QG[@34&Y>=B^3S&I7A&L9>[\'3ZR>(L_IPU#=HELX']V2N9(;
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M&XVDGIR^(/^K/$S^5^;LZZ\H8]NL@<G?]G3,MMRRS_;L%N^['=U5Z"/]D(^
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ME!K"5(; WD=$^$[<+L@A @;;V;C_5")7!5342?B#!;@9J?$Q048'P7''9 A
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M663D;X+GT"5P0HO.3$-Y6F%C!Q0:%75D(DY/,[%9L-@9<FQJ1 ]TJJ3I01;
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M?2,[_:Y-0.1;4G"?4]C0J.'$-.!?&6[K84L15_ZDOH)(,%%\D9H*NV?;'5_
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MSWC3%-#*>=KY>WFH68'DU5O/Q06@KOK)S9%;Y\%)]?'I)-@%:,^>H"+V[9!
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M#(QB,FRE^=:)J2[C?Q=+Q8! -^8<O]KP[\I<S,FY)33GG="/,*2R7($_1?4
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MG@% 7V;N,4)"P4,0 ]]'U\G9JGZ#L.+K8Z1,6\4\$OTN1X.O]/U7LU(T)8N
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M=QW2KW8/^&SP9I^<?\GH[:(P3RE]R[4F:55L$$%G $&L%.,JVA..F[Q@5]^
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MS1EB-K!ZA6E_A'ZR;A%QQU&A7FGN"/]0O"$?Z.%#57X95#]4+[3>D3+"/+@
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M@G('<P\3GJC@AQ2;KD*AV:FKD2+1V]+K(!]<7\6D[I;]PB8OXS6*]YW,@_>
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MHE"@4LU)1K<*9#T/[IH;A%@C4RLWD[5S=IAPAVFX+#QL\6'V4-[9'E+I.;'
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MT[>+&7D^GXO?H1K%W7D@X=6H;L4_F8Q#,S33Z;4WWX&]V;<])-R$@8>>8HA
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M\,[#^W\!34WV/<!Q@DDMR$1I7O>#D&*3UZ[L",;G7,$K1PAIEQ[O+1['?_U
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M?"D<3,^$/7,^H;BJMF5F!"5X.&UR]3)9FIP_"*MX[EF";&7N8U"W+#*H0^<
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MS2)F'LM[&TAF)6.:X8^[;HG1Q>6(*V6%IZV_U?0D>/YU?"$Z>S;D)T9W2"X
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M$*7T4IX3Q& 8T3;#-V J*38D)K/&2&9IHWD6J.VM.,2/@XTU:+\KC=]!B/
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MD$OJ6 >RO_6_J%BA.]!V*$WNLWC.LF&8:DLLMIYO,ZGHO%+3Q02RT&F>7>]
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MF?F57>>+@9? _J.[<:6W-L63,<(/-^4I4%$!?J;C'E+<T,3!4G-5Y[C%H":
M%A(R%7WI.X[4U.MA(Z\X@IA1'6I#YK(3O4,>IOZZ7JEMT+:7VMI7.V)S'T-8
ML.*MN[[&%^"352<2UP\HRX4Q66*?A]MUXL" +%A[Q2RVB@:\O4BE16"ZG6$?
MOGOL #/98Z0@G9.5&(/6)521$] =#UE=<N!^=RU10Z1I3RI<O\42F$?.JKG:
MC"7-SCU1%\^#*\E I>[8D'H_[S:\N+]5>J1\_0529#+HY>=.EEVHT:BVQT79
M$SKQ.0%P/NY\+".GN*$!KA?*N4ORI/-)0TQB A-1B")1SL2A^Z4.[DWIR@A+
M][N*]OV53#XK5(J@#KS2_R=)?F6F>LG\HP]F9R/,^CI.K!RC5?)<^#1UG =(
MW='($Z7KR#/,P-EB[9)N8M(*(QOUI/T]5<2]E"<G=EA]U(V\JEA+HYR;[Y1-
MW5__F0BD[YH>GB3XTOOO>A=5Z7W:=2Y?73Z-MQN^EE/JDG\$7$#@("=?5:='
M!WI/BBE=Y>2=+VY#IJ])(>9/)II%?=BB*^Q0Z/*]C'N+VV#5^E2YO-"G=9ZQ
M%E_9K:O;2Z *5<*'M#> JIU?>\[B_)J&2[MT1F[FB@W)0Z@4&\T!MT[VQ 1O
M3J01^E*IR"$9I/QU.Q7DCTJZ!RUHK =F>,E1$E VM, U_0]7JAYXK_8TML 3
M2_Y=)\^)5Y; 9.M L#(9,2,9ZW:'@3@I7@9.N;/R>B'D$KUW[8]%OM:IXH<G
MB\QM]4^Y4VI?CG6L:P!PU69XPN609S]H)0TU;P#@&T"BX431UEE@^K$![>%'
M5GY<X"7_#>"^7&^<K*(?AHU2\60%^F4S57>^T"G=-J*/3FJ5Z$[&BZZ3;EMC
M?S5\&J8MO)'L.':O<)]E88TQII%9VC^CK%SS8R"/KA6,K7?=?2NJN'PV@!"I
M=BJ?+Y*7P'.\J/)RS9ZUOL1H(*V59U*<C4IS58ZW^W1\D"+4+MT ,0W]-9#T
MY^VH2.VC>1&5U0'LNVY?WH_'^]1;Y@)8 W@U)OTX,\!"M1[MHMF->/ U0:7\
M6_"#!V7)<6K'/&G_2=W(1!UO7=O7COMW'<JV[+0QU?T35Y4E*XHCZF&CW!@7
MB]9B".R0!HU=Z$!-!-E3]EZY?P*VPYYPZ@P^D*2<AY5#+8QQ@N&1ESJ8)@6&
MBMTU>;H02YYT4D&KW8U=008;010[BK?2-TIVZ;CMC!9ZV;;\G\5;9J.5Y\.'
MOZJ?R!L]3H&# TF5OCZ)*$@>S%Y3/KS'?DR(&ZOQ-\.T139Z14*;^0N<6-FG
MA* >W1.\:#&\Q^>B]"QL)8J;YF6+O&)3#BBVK7+J!O HT"+M+%=]XMW76:95
M&Z$ODOD*8G/WB3Y3_XUJG_?X'55)3S7[8,CXET.\X1@2J$*7H"OC8&J< W3-
M;M:&F_Z+SFF]E=Q._Z4>AHWJ\@G.*PI&@0=2Q(I[R\H1S>P5UZ&BC"_[V\]2
M)'I>#!M)T6]K@5CCEB;;D4;7*/FB;Z<9*3E9;Q]ZN8'2UQYT\:3H_70?->)-
ME0_-.%M5PVEU[T!)N@SUNGUH]V>L<[6:<2S#"6G@F2#;6.C:LP35>9''#.U<
MXV*YD;Z7GHTNV:5.TMW#2,?*N5Z8/4:0=9)D&@.SHD$\CWH!Q  [,CRGSO<M
M)?_1J%0&<"O[_W4U[R_%THUWF'.[,MT7;%;\ID:8064"+O?$55YRN:)^<D&9
M4-1X@[\&\P,?KNLA&P42ZMH]MN.9PYL*<3SJ%V"/>OR4OJ @/WSAX#!)\8B&
M:WHQ(U=Q@G_!2W.<RV%?G$E#C4Y!K/#PVX/TGC_4XURD1U4"^#G,D%6O;NT8
M@L75M+KU0B M:1;OIX&LS\H_\N%N=!62.OQ!WW],N_[PFA\M"UN!L$ ,GIR'
MC8054DM_"^IVF7 /&UA;1;%^2FV;JCHCV[KR_;LS:K[;_FLB1^A55)6##&3R
M1OZ1U</X:=$5Q]NO1'_>Y<0>FK1C%Q[KCV3]D6T?:5J?5I$C<U[R-YJ2?<YA
MLB ](E[4CG9=J]=F$.O15FPG2'@S?Z''[>1G*^*SBH2K%2<^@HL+' !_&+S8
M5I.]92'C/=*]1)G#HF X+LYB*$>^SM,&PUY5I SM-H/;/&Q"_$4[$39_SN)\
MHW;D!9;:8@/M=K6TQX]+"\ 5XCP7T)::'CL&IN#83F>BK+B"R>1&S4_()+,1
M_3'Q"H4N.LHE1Z^3QNQ/#0=[SALF^?YN;@- A6S3JDS$S@V =F:S<:(U<_5=
MWBQ>1A.5 LW41,Q]  FN[]W]@:188#76,DTVT^IDH_$NZ+T!/!#G+ZOP]2-C
M[)D=AHU:UH7;Q J /\O&%)V$]@%"]PV@SA&M:?;?>8KLN2_K^+P(%KM"U 13
M#43R<V*,G@/.,ZHM)/P5<2YE*X&S1'I1[:W9]E^-C<'F.QCQ!,<^&REH++KZ
M3.F!@7NR#CX<H]HU-\($6>VLRT"<VP5[IUJ)):MK\,'O;C0ZKID$OU6[*U<P
M+LZOWSS@:WIN'G66IH\OP"F9X.!(V)>MC(RM1KD#$!.P:"Q9RS),^"0\QR#W
M7?^/U^1W)0UVEIB\T8$=%A@Q7#YX=I.Q ZRZLE&+\MY0>4*JJQ9[$;>**&61
M^85$'<]=_O@;EIC%Y_WY9_)*P!KU0AF+2J0=# 8_WT@7O,5V_CHTA/SFP;G&
MB"]1=Q=LR;.[DE\U=4U)),TK6KL<<)$0?]=F>&I,?9K).R5NKX8KB4&6Q8K^
MJ,+T?D>##9NKT[JBK8EF>>(>$'_K&5R_SR2;W4($T/Z7SO3SKZ?WKX,S-^UO
M-H)FI7+OT!>3Y*ARG@:8?9FI2=':.R[US7""]3?\HYL/_EN)BM6HLJI"^EI;
M"FIHUG-_>'XU9A4)4 .^N:OY[@9 TAMW-U3ADC<<*(V:+3IHJT:=F:OL)\NT
M1;- "B9O &L4 3< 4ZX;P"]-/H=*L<H_($E* 7/'1,+ )8%G9^,_"&T8STX[
MKJ7'_P3:@^G%AJS?!)@OSBH<V:8R9"M\(+#CS.FMQY0Y7#_&V97)QQS@&T\>
M'\N].>_'P$G>5BL_&'"^FB*5>^.^I7_DK*&W&2^O\+3X>/&N^IH-19&:!2]$
M7GA2%NQ8T/]U>\0EHA'Z<TIBBU0P5UY98+]V+XO\?H^6(NA$X:&LVY212 =N
M?IMS5_W\5=J#MM0(\AZ@KH(XL)VKR;+V*'_68@K+TJ;5=?X66#3@PA0T/'\8
MI=U^Q-&LNF)PR9C;+:>R(4R52S7$$^X\#NSAL'3GI$J/?4'_?/F /QT[%>%R
M9*9RJ-Z ,YL,+QXIV]8UW=8;O.5M8W17ZOWFR[N$=?2V3;J^,K[7I.8?<J,:
MCBJXO>NJ5MNH-;#QG8SI30'"!FWHB@K;ACA"4IQ,@C%_R*VWM[9ZO,O#<'O(
MAQ&5S0K?\-^@G*JU+4U!.P<D'NE1=YYU_>E?#X7S[H5,ET LSG>O+4<5=JK.
MV%Z,6CR;]G^-RRFQK-HVDEX[T2IT/#%Z!U*%$O?R>7:*PE].PWX#8NRCCBSH
M\'-=?'<3TK39B+>,O" LPW6HI_WK7=K?.=WX65>#TXC&2[^4$?_^=A;%++12
M'Q.<XSAQL)>,:?$S1$/%H\V@Q]%7\H(OBE;@["[0_ ; %^(\=WK9X*Q@<"ZV
M%I;M=#)YOM\UY@WN!&6W]'RQ](6N;E;4/8Z <;?JU.>=97K>HDDM%<FHE8?G
M-]]=Q;QIAMTOT83!*UA+:;/K@B;[HMV=IG]N\%A(I@SND87U/&G-QE%WJ9]G
MO=L9=SH/^P3Y.C I EHP[B>6YU:LI@.JF2;$)Q]@?7]Q;FIN_P?OJNQ8TEV1
M=QEG!0:XZ_S9C^;"DKIYS>-"/.,#G:QOZ_P^&E^? ,[>:,B__,TKU6V/BA6'
M>IF.6^>:I^[),5G$OLTAF;8Q0<W4EKL^Z8HX<T>\#:2[Q9OQKX40:#IP:L5]
M.\HAT21=Z?8@FJ"OZC.B*KI5(EDK:45H-6</K"1^W&2J*..XN\&1!BR(][ T
MR$KYG'QP^J/R='G^!"4OAT/4M;++<ZE<L+J:Y%MI);0);:+Y>L=G,XRXFUC;
MN$J)'WKI*TY\7B9V8X\)M9"$M%$ALY_#+DR.5\K,Q6PQ$%Y$8TV$ "Y&5D5!
MA.Y6=:3D;??01$.$!16^RJAM5':);DF9O+1LFXZ"] 'X%LTSEV=_?KZ"T[,]
M&QE+TXBOB,_G*^.H9G_*Q<S,"F^U"\>T-GQ5=CY=%)5^-;CRY:OB;667-F@3
ME7J!3,+>0K6B<H][SY-&_$Z7M&&)Q[=>E5!=='&:=J-&F9]=E"V<JMJGMHSC
MMSLS93(J#I[=5I4=>GXI%*"JEH'+I<2?=M&U$2 J/ -T6=CT<S##SY'W.$TH
MK7TF&-H]"%+D/)?M.:-^J\;)J@6LRDF^'/?7@GW='/%[G[#M1N+.?5#4_-['
MK\OV@PE#VOO@K=EHT+4%5N$G7=VA? 3O[2#%37>+9Q!SL2G8_IUY<$E$)8Q_
M0>]E6YKA^#(PY:B4ZJF^$'J!C3N9(NE=XE@)$I^, <N9+PZ,&*B&3)2_'1_S
MVX&BL(W=K2J*#$FZ7E)D= #^$97\V6G-.8N=+T>%[ER#C9)&IJM/WO,='TPF
MXRBZO7R]HBKS<:2ICOF.L5\[H5"(<V(_>T,V,'!AK51?^T5OI;O98N;JE3I;
M9&HJZGS.0M%/(9DV+DV\J1S08RQPLBZ[WG-?I(QVJWWHOH5BBY"?P?]#VJ__
M=C?V?TIW_'\U"OR^.)['?;$,@#DRGZ:2CT!$0QOI;)]T?\A+-"KK:WU^J35U
MR?1U4YH-_F=O#0U3%*N V>>W5G ]Z[GK.5>>N,>5V.]\:T?]A&&;$1YN^6U^
M>MX<I.PN'@.'V"?8=*W1SLMA@9>0K#%Y<CS;BTE7&%2RH]$VKLBWO'9!D7SJ
M[9(?\V5#__"\7?.^"CX%1]+#M[) OCC =@\/WW4I:6R<\HB\B[=\0IN$[B-.
MER2O]%Q>E=5O(Y,7\*[J\KT!P(^NWFZM+<J7L2Q-[_:938[4R7W,"M[)01IR
MMU  6_"0%9D+#1FFV+]'OB T9^S>4Y4^IGUV0(@^+NMWCN^$QO\T_RA7\^_F
M4:#<=C.?F7.DWH$4;P^YOG?6[X\0NEUNB;+AT^G;<X/DH5O%%K<-I5M+"[9!
M=IF%H!D0EY?D9-*"W<$']2?*AWT#S?=Z#3FY=#>+KF W .%FSXG>];- \_!\
M2!O9)2^&B4Q]Q/!7N3 4QM?=C?;B2Q3+NT.1])X) % A<\#;=_A*AAQY(RI(
M7M>->6P>&"Y.RD4GHW/6<O62+:3B(T'[T8@A+2".(+/?(\!5/8EI1LQ$+)U'
MC7MDR'FOV\TH- <"[E1@^1M(*-!WNQ.%BVM4D9LZ49E<9;"1_N2 <R>4Y)[<
M ,3@G S\Z\%S8F-;5\YM/S6OV;"!?:=D_.TY;+_V4C<Z@76(>N/U2)L8YH^)
MJ#[I([NU<<%65KQ+]UMC,;#Q*[J#V1Y:\%J47N,KYB.K]Y#>9E&<,(89AP\$
MHX\%R34?&DT6CZ9V++VVS7BT(:TJF;GQ-D'?5B)(U7=+P=[[\N42^;$*^O@S
M4F-J0CAUT;7F\V4-MV6?T!S<[<4J093AV U@J@2C-WIY QBQ:-\YWO]H3HJ3
M#R]VF$7!$1=7HJ\!)G.:#/PN@'9B]X1G<[*GWZ3#VZO"C6:9&36G0H_<B\#J
MXYTNEM,)30&8P@=&4@R Y7.C.U\O?28KQ#0<+5&(3-UQYTJ[R3P';)F(0@HC
M]L.+88.F2Z02ABCBTKI@4WH*?FD66+@3.)LAD!&&G$RWFH3/%PAMIFNT'I_5
M?[C?RQ&^=!XX$;9^%0C*:0C$YOYH+#D)G/67+.D3$)P=0PO8$FI_[U1I IX!
M=_7PR2NY8;*6EB7&.Q_8JB<$Q3#%8_R?3^])Q)"5/"< D-KG'&^<*M <[PIW
M*% *353H7$I#\\<'YRZ_@&AX Q4DN<X-W]3B5#$"(M[)!M^;?@76>)BIS XY
M"SF;#K[G?C5L:\0DD=K7D>3[3K,"^A=0U#F/+[P4:]W>N!AM6VCAK:?1..Y<
MZ BMR&%+I;-.Y0]-N+\M&N_T-Y"8ZD#-AK4<7;-]3]U>'"WG<">_/??]1[3#
M<J4,I;DR1BO&7!Q+FQ:!:'EE@@\U1[4A$#6-8XCT>]WMO)F6CT1H9MT(8A=P
M9E4_A!GQ9=W:3I[7C\=@3":"7%JUVY*SG%L*$,.="W@B5O^45/$+Y!_E^;,6
M,CG^Y?C.*YX>S(@6MC@-"I%567185@K7_%&'&DKN(YJC+5BE"&NEQ)V;5$5<
MREB67\5?RPVA?1QZ\]A#XZ0]3JI8QYOM5TGV:87#_?EY@O/$KZM+N4[?;YD[
MW.;6Y7I<V32?W,^;V]$BNM(6!R-S7UGOJ:K@HMH&^:<]-<WDXF,>NL_YOI2K
M<EG:!E-\&B]Z3&(R-[PT->])]&I\#BBM4UUW_?.9#YOU05K_ 2XV\UF,-=+]
M QO^^7(@\0\8>?**F4@'_U?-E@Y5<D/CR'X5PJR8\ZED?W'\ZFH5#612TFN6
M/,__>:E G+D%V9 ]M"2/L!".'>BP7;;Y9.$4_0I_BM%P99@NVMUM;?NR_6 !
M6#S>F2;QH,M*!?9@?F!I"[#*,"NG++G!"CRNX%]N"_*7RW>2-DC[>.1G)JK-
MMN5&?TLM_&UWI!0+W$W&JN17*R5>M%,:VI*:N#)()C]+$NQ#U1Z^_CE@1D2-
M*VZ&I]FKFY43M]&$3=:=."X;H3#=S#A).#6<],2)MW0GV]"\3G5%W);'=23X
M&;ECQ[L^/*G!>9C3XP3WTDN[)6+IBAR%LFTF>VX=E$;6[+9]/:N71X]Y0:HN
M%=8M94P4_FKS<X;"'S0U1@2?9IS;B>(C&US@RG")@ J[T(< <K3$>H,HY$%\
M+L?;O_#"+VKJQJSB7]?!R5AB4CD3ZGZ^OV^:(YW3BER] 3!^>(I/_C&[6'(5
M6@;2H$NATI!(=UT9S%9<DDV4&ZCI=>U][2(W9'>I@0N/OO19;F/2*IYW9 P,
M/VJ2RF_XWHCTL6]TY#2RHR:Z_50T2*+.;TQK8?R+X2ERVX\WYIH>KX AF=7"
M0 G>3()&/G,UO_Y#]'581?'H.4UJ&W$SFWU)KZWKRAR]\]C=.B#G2THKNT5M
M4FS3=S?^KF8OC/!#[Y*5I2B53%CA#-[U%1)5G=.S/;J(V?R\:O?NJ1MGC\K=
M,0I?,]75M+B'7<DSWJXOT%5'"_0_G"93<QA3CUTI4HM09@+?V'?:[RT>[=K;
M7OVCX>D>E?![4X$M^ %"1>SZ*W_%0S0:)@5?1E25?'0U#9@_#(WK#NYU6FK^
M);;P$ASIX@S]G;1!4?OZ@)T'6)O]\=3"Z>P0TQLE:[%J<0??<3 +%7V#G<QT
MIXUI-)C(1,Y7-#!D#343LF<13BOV@LY%!J]E*VX .TF!FQS1CE>PAW]=GI_X
MVA7)4'_/.LXN5L9QI.OWH+H>C)"5SJ@B(4MSP'@O$KKH[:6!%I,<K11@3U;S
M_L@SXC)=1QX='$-.I#Z:GS"LT:5P7_8AID55JVU2]EGQME$=<2E4KDLF0]RB
ML>7#VZ=/F3A0 K(RQ8Z^*7M?'&W)D+M[(X@A^DX-A*7[7'![M\/H"_J,\! /
M%M!OG?KF,6BE/1HZ.;:[KOL:&YH0._("PJF'%U^&VIM43U1=\A>;.QD"(^_\
MQ.[!#.BUW[M-[S9)50Y$21 D3<I3>0MWR7.C<'=+5@)$+DQ"7=-\Q #UO0LC
M=KW.H5&=OSX0XM\/=ONF11R;B6I.'/L@B5H034ESIZGMP6']4ES6H7$R5BT\
M4729!%/NQ&RW\1^6=,U>"O+,"!MN[1NZD:_(Q(AE^R9VOV>CEB=3QES=+Q?S
M]F R2,55N50@*P2K!"MMY,SJ^I(X_0HH?(\&^$"K;7JQ>"WL[-R*Z\=DE1 @
MMV?Z'@\$'%C;V3(,C)/-_B9#FKP-J<F/*MY3-_QO'0OA_V%G87$4S0 !REA3
M;&F*7R&"N>3,K+2U5J.R7H;2*Z\FMF.^K^+VPVVG%*JG0#50+9D//WF8H@.]
MKO9=D"T9@-@*2YLG5B\+WX84$&JGCJKRJU=S]+7?7GG!11XJSN,P!% E0TB<
M'>0##]Y[/F8H[K=U??P6J[+29S<?M!;W\7Q,.1 JAYX<'6&:5PH54&^OL;&Q
M\>PK/7QQ;[0,0!Q"Q$[Y.G62X5-Y(F>I3(0M(?6.KMTW)^F6U(0$Y"[:L$RL
MC-#.B)A5:53%-SFT&V#RM,?+EF9O&3=9ZZ^T,A=(92*(.%R8N_-VASMEL'WY
M2O] +D[9:<PNZ"D'5B(-NH(:%9ST@SPG(/*VMTT_9:X6L?<$9V4=9DP@QYS_
M_('^P=3%0BLZRG6@A$+2UN(NR6* 3E?*SZ^M]1XS*>TR!1T-:4]<RMB7.TYY
MZI;]H)VB%B_[G-WK9N+FP\SFE+H/_OX])3]G[_&&/A7]H/^*!I0LKGZ$H61K
MMB*GRL6^IB%J^\$N0Q(=Z9=/*W!5-^\\(M!679UA(JCSMJHKC157C/ M7^NM
M-W2&._0QBO0QUL0/WEJ7T$I )):Z,LP6CE+=+!3%T>_%A&F@#8GHVP;5OX)4
MB29CIYW--1P*?%@X7OD\]S0 H*8F(P3SZ\R^=R4*YS\F."H5U7CQH"*+^$ *
M_O0@X.2>R)+>8LXCQ1B.&.8X:<8 '@<"SFM*00%\&++ B3P/.C;GP_55V<ZV
MXXA(P(= O$2P7+2 *Y$KHI?;1)$0_<DN2%16::6,@L:8.^?+_8P%GCBW;^OR
MWM,B.7+MJRT649/T.G12B;3RFP8 X?&QPOP@SO]@LU+VD;^X\P];1IWAYFC-
M#T:$];V7I%^/6%/$:0 _7!\0WOOE0J_P>$V7Q-@P4.I5B#/T4")V^FC$5/\A
MJ"4E=K<HNQO]=,$LE0[;MRQ6I )VV ]Z[[3H<,NA?+I9K4@S@"S+-Q:1IL?P
MRJT\K_9S'Q5 9I>+8%/3X=?M466>OZ\5#M$ $ ;@%MVQ#HBQBXM5"+A4]BN5
M"F#@0@.J,[^BUILG;B\&0.BH90! ?")W%&T#H:4@59BCK)?$6.5:*@]IN9PB
MBS+ .+_L;RCF>5@H0N3 -IA >ED1].Z,TO!_K5+K?UMJ8T,5TZ7TK]9'8+!R
M^0\W&Z0[-W(B9;XN[>DS>I[G5K:V?<O+AV:"/JK="K3>R2_P\<N9KN0S&N4:
M/BR; 0)+)$ >?CJ#HO?T@!9W1*XBD&QP*825O/67V-4CQ$Z$X!\NQXH]0=??
M\%V6U@NFL'>/!"]-7#-;W'-HK[*/P('W3!S.=ZL=Q795MK<'H$^N_;RB^$P3
M<JQHK8BS1+)"]_4KY65,2+*9]-"(*PV-I$4Y97$2FM:[4CRH%V8,@#F)]Q(2
M1@Q$+-^Z;@"LL-B[P]L6U-Y\")/"<9X)L6G,!-6:&9<30T'"-XHGFH7,EN'F
MCKM>?SU.(MN_4W857)X:;_VC=D:CT''?R7DEYQ[-O,PWKJI6Q1"??I9S WT\
M_S*^F1NV\A6!"E5K:/([,1:RB=.OMYNW43,(+2#H>Z(B8T2 B9]UL2!R9&3:
MD>:)+8 P_E39FQPWP'%Y3NY D4!'7H?ZA+WV6(-69('7A;+@?K!8/#4^4'UL
M7U"X^8? ;%L$].C"V%P4KOP)+E+-N3Y=SYFD3#%2<GQVS=[<^%?3:<L>(-YV
MA3MX_P5D=NQ6ZIZ#D(M= [HD1VT]#*6RM]=52X#^G7-LM;0<'KKK_V;V#RA@
MP(QA:&H&_D5A^N/O\ORYP$]LK;O(@>GK7VGF3\9D%7@_^C^>O:[X9J+V5<U6
M*#\5-]?)],=Z8Q>ZAB()AJ\FFK!A6V15B[QW+.HG+N7D<L,%/<"0KQXS]@;-
M:FOOOY#:$OT<.CB8!A ,.R';CJ\\Z&(#+:;TT,MXVY4=J+#&> 'B$\@1U:M;
MI^2V5G@QN,?[W+(AGBBJ846+<$N>V$Q1+&*//>I\O7(]"IS.'6OC8MQ3#HRA
M[B<)SC@,L%A=K%T1E#'ZJT7^"U%P+0)\X<<$U1&R:OQ8_Y+PRT-(J64*?_Q+
M2 U:-L!OI2J\UCN^2YJ]NB7&QM'3R&JMVCH"K894V>@;H6<M+K$-W#D?Q[+N
M+4T=5V' =7CKE6B--BI3GF1J-8P(^5<N[M15$L3M^^WT1]W6FS> 6Y<,7V:<
M#.M.'KH+7K+99H 75/S24Q^\YXA38\D0(R1]LFR4;79IC;. ^T.JS/'1G0>.
M^;VOX+:CUA/*W;6U\T_.HMD5#]\NKP?4J(K/X2]6=;!RPTWW1M_D>0P)L0#O
M-$S;B0"I!R]*Z(?=SW5JKAM-_9H"S4AR./%$R[FTVUX/9^,RWQ^:ODH889;^
MB%-ZJOC1/M:44_K$2H3?3@LNSY+1JX> J+UF3/GIY<5_$C[8%W2'_7<,E)D<
MN2'/CI\KPROIM+2@+X7=Q(%'?;R,KQA_9[H8JG7P$'VB40NY[]JY6!??:Z:J
M'@Y&3#5SS'I%E(,6H(A!334AP\,1J^I;0MWWWC^=(6*IU;+80>?N8&4TW5?"
MX<UJ5[5712695;N!_+LFZ>AD5O^ZE_<>#^80+Z,7[^,#\B\5ZNJC@5&;+9WA
M.1O7)^#!2.!6HXG)Y]7O([31V N,4#4FGAH"(F]92<%N%!4ID=8(&.UX,>=8
M*KP+$29@ 1+--M\ %/$M&"URIU:N *57N4;8>7EN/Z*)8O0GN?S6]FCF.VHV
MNCYG:0S+C%23@U5GA9+():V#ANU&^TX%"D?&>=^6BL+20.;#>8%8MS\$/P$)
MN[S,05*[LXA+A94 R8YS_Q.0_UU^DY(DS*LD)1YSI;3G<I&[YC!WW/ U2?\Q
M(?93$IYG\09P(6WF89&7!:1_!*N;2WY@'3)W>#UDLQW( #-S?37IRM:9O'4N
ME/NM,BOM)&,I^9ULOJTYS2O@:^:L'%^_,=",\(XK'K!0N73<=DE=.]IZ!R^J
M.+&&AGK,A>RVV9:?'@XZWKW<?_9BV#HF*VN7H$+_UPW OHK0V\^T9F)7P'7Q
MO*\>*>E;,=3Q(N:>PRC7^S(&HKU;4>WH5BE\B1(^]B$<QG9G"SY?GB;YT/=#
MLPLW F&:*^_0'':/7$KWC#<XH[;$'S9!8FP&824/X'PUL9IX%+VT2Y.^\21L
MPBY2VX>[O>_'AV;,QZ-Z,)CQ)+!V*M@9A.\N,J5MBEPY6$?S)@JNNJ>!8?8<
M#[2T@XPL7%=8A.;,0TWBB!@_2BAIJ<E.LK^\)^-Y-/SB=X7/FUC<?I?O1.Q'
ME/Q]30;Q%FF_"E:OB3$]KL0OT)JO,3YO@Q,^N+KQ*[S"KV*&F%84X,<5UDJC
MO]'"[#[%31.R:G?"FIY4]S 4S(]1CM(^?3:HAS>X"/QQ PAAN@&8A_M@;@!!
M'TAPDZ4^ 673BX/<F*^-(4MZ]2&+RU4+CH]4[_V1><9 D_,(3["<2_.Z9IL1
M.IY;RUT>35X@R^<6 =!Z3MG1-QC'$,Q1?7D+QW?-X3W^$EV^5E\W!F.C:)G^
M[NB5W\=##(ZCQ[IU?BV<N)93L\89:MV=W4QU1U PJD_YHB6\DL*O9?Q\:'SZ
M9!*6SPF4R]&!%2QA?HL64RI0[_AEMA!_(V\7&)G$>O8*D%LCX*6W5;8V &X\
M^E=N,/PML!26&]Q*/H4LFA ZNOCB7B>>(0-]B;DG%$+*F_NOS5T\YFXM](/P
M]GE59.6C,?^'7M_P=K.76[4[=%/JXP*=^R)ST/Y(K3NHVW+\U->,=!AA5C#>
M7G=4;.=6(-?D9 4$0R^T7P#35=*$TE]-2VVS5/<X6MA%U6UN^VM@'_Z0%YRP
M1XN3B:P.9_%FLR OL8K\/!(R73&4V6Y/NVR,\E1"'D\\#-.F"2"B/0RY'G?S
M)NDP9ZAIRWV#%A\L,Q'ZG=G%N.;[WL?*4">2Q;@IRRW/<RWJ>(3<'X0]C9+E
MM*TTL9BU.QBMM*Q)VGO&OTOT!/#<19$!$#H)1^LUC9(__;3N4-;V:_=QU5.M
M6+^__Q^+W@4SQ2[>/FW@0NL\7I"A.CM7PG,UK\>I*KA5PNF:JQ5[>C(2FMEY
M;A'!:5V\&*LFQ+"FK:;&24QL0UK:/^*O5]L2T8@<,<F/XB/]OY9Y1 '\_XLA
MTNJ_*".U;X_SJ'J;60?R#214Q>S*Q?$=:1.Q8#L[KKFQQ:%R)5&R^M>";7ZE
MW!J]2&-BE:&4>)(I@I@IG5)%P>%<=QHJ'[U^:H'W@; (=K;VB8S'OF7/2NS=
M>YHI_: %>%$@MKAH)4#EP@R13 7*O/OL[$ODA6I6YT!OP%SD[R*?XB+8JEK2
M[A\K'(VDEZ$1Q(=9Q^)AE/;.>BCG@S!<EL_C I;[564X9::F[R V::=&HHB*
M2TWK(E N)1F57X6\R8"I:6X+]=E,\G/B-Y*DRVSJ5&3OQ[8W1DQ9N>29D$DG
M+ I_X%O%AQ_#^^?[#[_/Q89%FC>(']ER2U8=7T%_:6AUGI\=RQHMUX5]<\P1
MG=R7583XT"$#K.T.M!Y_*BQ4A?^^,E_V9G<W#RA9V&DL":LL^27DKP:K<D6G
MGIMP-7I?!C&K</*NS3.Y#.5*@LYKOCEF:*9&0TX@),;.NZ</#_)>1">]?T/T
MWA'UDWLOA^"KPWEEHEW"0E4D<6LL<X;6]$9SR@T  >2^'+O?Z3+7E<LCNJ\O
M3B9L@79!'.'(ZE#NF*[)MXEDC:;B&6!"9\G!B[Q;LLF'=ZN*<,ID"TOG?T]?
MK-SM6?#Y[!(V0"L]KPW7/9R=;[Q5AKE5/KV)^K70C!TN/<GN1PFM0EH7YMYH
M59<Q3D^T=I<(A<@"9:5XB RDORU^$O&!!+..'&4WG;KT#C;18UJ3"HL"=S9$
M>]?J<<II[;^F2$HMG(I"-J36X;"@_HE/KI^"LM\=)FY"X-C%3(R<=3?(,_W=
M#>#^+6S?A-VM!//9+BR3#>>&EXCS4M.=S*H2]7.G*.DZ%@'_$M98C)0]8U9=
M(W9R23UJC"1/J'GR?L A'V?,F?%S%R#7X9##EJ]7Q!]!GO@.+&1RD0\R=R9$
M=RQ$-=4G;QD3= -H7*]+F1LQQ66<NR3!]_'7TB&C2^>SO4.G]S&<M1< [P2'
M0'O4]>+#7*?#GSF6A\W9-P#YW?J%]7=Q69/:X\TZMK"RMI"*XPMC%V'Q^]#9
M/9D4J@\;+#'^P\"+"\G3K:$ C:C'K?_J8]98VJIV?IY5:2)QA+-TA39HI(8F
M-^BVM0;+&^"B-MM/0Z$E!^(/9HO&Q/?H>;F,*BZ%<)0-V)/,DFTZ%*-=\:AL
M) 0F-B[35:D/9-5F(PHAN&RGS-A[IQ.0Q(8,*!G00CC/;.R>U?V6&BEZ2!N?
MBP1>NBQ1N9X.^=#VGB1*V-&[K"E9QS<=?$?-JNHN2;ET39"Q"EIT7#-B3XJ^
MS> +]#6&&->1?DK<:S6#(H@/Z@GW'>:X8F+>9:T1GX.B-)1==R"!YK9R9B,9
M@H5H6::5L@ _Y9:)*AA3?T['28]=RX%ETO*M^V%";IY=TX/D0 %-+>ARRP>2
MXL/*9DW92(SQG\MQ'QB\YN##!TGK00$1,(M?U#GYJ?)W=.6N4&4%1WT]PNKD
M -@4\UKEONF1U+Z18XE]X$[))5MS:F7%5:#%FG];J>*JL6!YQ1Z3OB;50M47
MU*'AU0:U8.<]M:=LS]J\4);O]0^3S6@SO9,U<:FAXK@)V*ZZ16U1%P7M0N[,
MCQ@BF(T=RH-(8. &(*$&6",^W7ZM\Q!"MN/>?2VC6:[V#0PVZ2XM0IUX''2*
M9YBI5WB(5M,*#N2*!BDF=AS^.C1-09;$B).0>9DT6CRHK(+0Q0M&/:Q7IJ+]
M: J-L 27A=/+'8;P;X% =!&L;5-?#D?"/'9?_N[-(6^8$(3U^ZNYRN$FBC-D
M0AU9UYDD4J]^Z3Y#V;L@2U?7IT8BCZ]"P=<SAQ6!*TP2\H$SKP*;#KUVKY8L
M1 /3+Z5ZG4Z?O-8)"&TX9 MK919KY:NI;AB'0;R7FR?7&[P+&R.59*L1K]3O
MK:0E(K^_VR8S4)/G, ^TZP\4*KFS:CQS ["K1K4XTIE22-7T&(K,U=:_>3&W
M:Z$WI@OB:B+8V? )[&!A,PA5P]%>?[G*@Y4>\Z]%;(N^-AJD5DA&LD3H]SQ#
M>!Q7WFWW#O9_&GT;W[RS+G@#6.$4WC@S/DP;.?!RWZ!=B.=<GQG/1AX%\/ M
M+H6O7 <HG5^W*?W6T*0VFO*'%,^"<ZF$@T$'ZQ5CCI4K=O%_JM> 79&W?9H&
M]CD3WO7P9TY.=9NS8&D>UBQX9]QW:9:O^OKF<-XG?]FLHRRD=RW96@KP-G%*
M_#C $'W4).<TH"%SX5 ER-6#MW^Q.<T>$[KY0B'L8>UUDYC"#J[A<&@O%\/?
M\N:YO^#=4HDTVJ7THM;B-%+KQHL[[9Y7IS\Y#TFM!0_V>)D-/R2R1;=5BS_:
MV"E>FWF5+P,4_ABN?V@T:.<S1T D__:%]4Q63M"5_#?:%P0 MSLTL.NVJBW/
MAZX[YS> \#WO3UZ^&YD7LMZ-4$.H[E2WF\DB\O( N-VQR<>]FQG$L6D]TTZ_
MG[%6Y8S,U@UXPG*K67N1*>=0 [Q1GX3C<8S6. EMB'#+E&U9LQ2-<<\XU] 9
MKX#YD43SSWGO[0H]Z!6@?FR3"/RA2Z'MY( !6NLKWXL"&# #B)RH3QM:%"A^
MF0GNX'/N\*17%M<Y)XIW8FY5?-;W2>,9O&#CLGXG;[[$SYR\X9-SW+F5H1 E
M9D'BX LK!^5DVT,+!"02[XG3)0D"94,L4D5$VL_\_,?7$W^MP@)<5?@$'Q[_
M._9A3!/_90C$Y+W'/;1H(#< 2O::*3:+ .[*8PK97O&A9E+Y(<?U@]B@ILNQ
M/ G1)H:-TBVC#X^#O%6NK\2'K(TE3B+.3;?\G#>5H%XFR:>O$@^!M7$O5SDY
M6C\5=HOMNJ8M\[MN$*OI)(9N:2C3P&G^BVSE?PQKTQM ;U<N**IR:39A0WG3
M]\) X*^G4< 1\__7S _'AV+']GM DY'ECJT\?ZU>2:$ YOXN-#_K6:)G]@XO
MX:VY-J37<QH;;:*4DC]G!?U0RSM[13X?..*PYH,B7Y/.P2E=2=7T]U3NWHXA
MO670MO)"L]1D41E#P>B4\RCM0MY,5"MU8_)>:R=I%&VFTZV-?L2MEB;/C1:O
M?](/VZC].9(-XA4;1B]5W5=V78&U=)3;SV8ZW]<J(94$$@:(LW8)*4/(;/"Y
MRUR+[&G*3?$]DMCM1G\JL$8@K 1D+K;YAR&J,+*&IV\EP4UJHP7R]ZNL32'C
M2KT>^S.+6N2;YUS2%+'BFIQ&XQPY4Q<F4/:4/>AZ0A-7XO>YA#=*,0]\NL&M
M5[G.57M%(OAH@Z2Q50U-Z77>.8&#QN?>>[(G9RD3D5(]% 3TM-MG-#8Z;K)1
M.\NDL[OPTK]&FRT&*1AHU(S2D#IFJ& /_X/E#Y^M5@T3Z%;YS<O30M+=2EF+
M2X,+(62F4J5X8WBS":!)$J:T,/F\((CK7YB2AF39(X_8:B]G,R%ZWM$]&241
MPC!-,<<*=^YRN@U:(_*XJ%"7Y1?#BB.@*->9C0!=%L?C*L9MZ>$OWZ:5+ 7G
MZ[1[JZV3?3^]ZHC[S(D;\F-59J"YNS1U/'T8S^!/B\3%U0I]$:IXYS0& L_2
MKP8;WZ+)?S'#6\H?XUF^']5&RJ1[ _@8VD7GM@TJ+H'=^?;#OKCYF19!^_JD
M<8962A;U*1BPRK#18OT7J3BC?:S_'6QO5 5RG]H[LUNX#-GS-4'IP=3;.E0C
MA^S:9^A,DOCOX/KD_LJ_R[-0,1E:L65OD*VG/]%3.1:A_WE:)%> ]$#>O"0'
M\BOX=AI']K_N7X>\YU<43QKPY$+B:AC6)^A5;,QIVZRHMZ-E^*#CZ5VI7-:W
M,=_[%<\FMN1)0&VAQX( I]/[+'O?8'IN[&:CU6X7@.%[JPQ5JGT%'*E+4R5G
MCUJ\KMO*<D17V()\?X>)F[W1P1&O:H\CP>F\Z H7A(QA!@ZLT.07\OHS8-DZ
M;\L(,1(4[RJ. *7%B&O: \>MD^0XW]2CPN@&?5/FAX/$NA4[]GKD=B9%'O<5
M%(56#-]F^TB7"/*6GT'R+<@^=Q6L8>-3K*=@B$G]O<[.C,M8!9_8ID,1GT)[
MIMQ&2GX()IFJ%8+>?/@Y5,\127!OWI[5ZL OZI0Y2N2Q[QY1CK\T_KDK]D"3
M.W]2",99LG7@N.WR2-F1MNA0LEKOM+:7X&ZI]\7RI[8'R+5<;9S!S*]+=#K"
MQ^/"I$XZ0379K7_CY7WFW>=''"U*?[4#75B 3\FVM!(U2^^B4^6%)SU&R!86
M NI6%1&4^<W3/SB6*9YIKW+?^B&WDSNJ8,<]BJQXLG]-=='O[%&&:D!\-Q.:
M?'0()]3@>.P#WI"R>WXBOL= 8Z,[3<&3O"R02C>KM\DJT/P+!N:WJTTZ$Q#<
M4_[)/;CK4'1'D1#;ON8W9>N*75(\^+..%KLP@QC6A?8Q#ET5"OLJ$E)QW2,^
MEA4"5.;^!:FKKCYF)!:F-N:/7AN?4X52T%K,G.RH1TU:X#5@FG9+*E&;CB#3
MR>\<*C4]G8,">0^?RXJZSY;@E;!^^J.(?1(+[V1S]'ZN6MT-0&E4:"6,JL>0
M\)F]8N-+(H)WJXLM\7]%%,Z*.*TH_X-.KZ/R]PGX[_/_R/7\65,G4N_>$87^
M_Z1F__]N4-S,_!]02P,$%     @ +#FP5 :OCR:V:P$ <YL! !<   !P;'@M
M,C R,C S,S%X,3!Q,# V+FIP9]2\9U237[<O&CI2I/>J-!$!Z=)%I M($:2+
M2 DMTD.-%.E%04"ITFM ::&'CDB3+J&')F @H08(X?#?[S[W?KCO&6.?L\?Y
M<%>>]6G-S&?V^9MKC.3Z]_4J@%974T<30$ ( !#<? #7"P!U !$AX3_/S2*^
M>4C(24B(B4DHR,A(R:DHJ*@H*2@IJ6_3TU+?IKM-24G+3$O'P,C$Q$1%P\+*
MS,A*S\C$^ \3 J*;[Q"3W"(AN<5(34G-^+^]KKL =.0$4\2/B CN @CI"(CH
M"*[[ #PW<I(0_,<"_.<B(+R1D92,_!8%Y0U!(RV D("(B)"8Z!^I;TY#;\X!
MQ'0D]'<DU$@9C.S)[GHQ2H9_+"#G>_*]F\EX LTO]=H[XA8%,PLK&[N H- ]
MX?O2,K)RC^05U)]J:&IIZ^B:F+XP,W]I8>GPQM')V07HZN/KYQ\ #@R*C'H?
M'1,;%Y^:]BD](_/SEZS"HN*2TK+RBLJZ^H;&)EAS2VM/;U__P."/H9^34],S
MLW._YQ%KR/6-S:WM/SN[F,.CXY/3,^SYQ3]Z$0"("/[G^K=ZT=WH14A,3$1,
M]H]>!(0!_Q#0$9/<D2"E5S,BL_=BN"L93L[XY&/!]^Y;?%+&:*;7WA,4S/S2
M:P*8?U3[#\W^:XI%_!]I]O\H]O_JA0!0$1'<.(^(#J *N-+J; MV>EQ@H+;W
M MXH@-\-T\ROO,+BH\MGXT18=0TVX2@=2&O^QZ)+8[O]L@W7$D8+AI%A""+U
M&N"GRJ=U6@Q?,OPQHWNO[K:3%7XZ\[+BG%WU7VPJC30^^$BN_(MBXJI"_,SD
M4,8X_D'DEXQKP+](4O[%N_*3T1O.$=B_2*0AKGI7T[@DT\($WBW'_^_;R:1$
MKP'_(N'Y3RE>W"O\(?\%]"\:E_^4HD*#6>W_CJ!9>R\^::J8[BJRO_33T>:Y
M'Z99;IOS1'69\0_-SW_8N_S7Y$L\WIB(,'BH<]S_;P4EYROGV_N_8$'61V.W
ME;W^>XQY$]_0Y6EJ_->=4:[&I<9C]+_AD<C$U?52E_^6K]XQ_&)8B7]>TKF;
MH=(K_8^HD/_SL'GXF(R,K.#?T6O>(E[]H)#C^U_F]8S3F8Q+ZK\9G8DW3+@;
M_KW] 7GO<GS^?5#]E_DGER7K_SL.3QZ^!4O_EV.-PT"J8;U6]]]YIT#G3_'I
MJO%_-_%YD[\F'HW^^P3B78V@^;<N^U^X6%.2?/Q9\O_"J#<O2H'^6XN0[Y)?
M3/QO1&4.H=?L_Z^J8)9LYJ3A(TT* K*OA54[*YA3N+J&GFQDZW3FBTO,%;51
M%:)V)>6/:Y+Q[P$[!J7U03BMDH8'<L&.'"NE^WVZ<;M!X7W?1?4H$[2:HZD&
M!9>2HGU+8OT+?\=NQY8FVQ0;7CJXYM86G.8Z3!4-WD]^K/E.S :61[B:ISAK
MGHP30HY*#7X#3W5G7(15! O$G'J<IE<8O+(HHNG@XN<BY]_@GHE!'L2$*6*N
M >$-9W,;4R5SU8V?9NY.25]F-B8^)K"K3TB7IXE^],&!K&7/!I,D1U[FYA<:
M< T0SQPYVKS_,2>K+91%'SZ^?:@@SHA[W9C0<^'T?:V%=YI^W:IQTI-^5Y@/
MK#2(V)W(K4XFO<T:\,?-K4M%HAUC"UT7L2I_%:_,8ADJ2T3NWNX:VYW/CYMW
MF")"M*_C&?$URPQ)HK[W?*&:ZWU-EB7][5G3L$E6>T];G1)^Z>Q@<;+X8YH8
M;J;I$#DH>&L+_V@]P6RN&-X@S.O]Z_.$&F_H5+H2M\LGH*:DWO@UP!UU#0"%
MW4VLTO7R7C XO0R]!J!6NGHF.Q_8KH16H4R K0'IR%DTSM:Q_3 0DVBOV>/_
MTSO,Z9Q4GNG;"B>.-BL;> !U;[':FK(+K>YYM$^P\'W%:69HE?YML%-S ;JL
M[U7*L8OJ1A@W[S4@Y=/-5E$!G<%_[[TXH8E2X6]&\\0U-*-$\0N0=8+J'CCP
M,?MO@Y1FV.,%M7-#Y<KI>S\7QV'X!3QH7]"DEN.PZF#B&A"TDFHG-263$K_,
M]"ODL:\5ZL6K3G/MS:N1),;;UP OQT_"VO/-74[$6X73>'&PGA:&\@\LJ"+^
M0CX5878I#266A"\EZT1\GDC6)'JH%']$0X^[/2,>XH4,-$CBAA>[G6&6SZ?
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M9B^\4?Q)=ZDK?Q:EO2.E*8)U0TEP4F)1CIV7C%EG.'[']LV5T]I&RFIG3]G
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M;')57B".LQ!ETD40*$,3JPI<"NY=9I[Z>R"-DEP9D'*SC$[P\2+)/3G-IVL
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M;">)SV9(M*/W*9DDR3VO-A=>^K9HMSI(A IG6K><"JOS-$E.:T[K2(#74F"
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M[@I.<4+ZO.%*JS?K1?]F=PS*EB]PB86RC6ZA2VGH\QF@W"A59\?6;0V.X!C
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ME;SF'[+ZD(H"U4U4J]LA7],&OVI=R0E#<H\&05#PC9$5;IP-'"UP#4B$BCV
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M06]6:.-8BT.-S;#(D,\#48E&6"K-Q[?QJD$+X0](EZE?6^-","OQCG-^-*1
M;FYVYO2U4=6^I*OF.4+DF[Q;CFY^AV._L(EK/[KV.93\LU+^3JPI?O9X-05J
MO 906PI$!=G,=,94*K>ZRE8T/PB0I[([@(]1M"R&N?Y!A=&!P[JPB99:RL7L
M6YF@HG$093BG++H/HWF7(\R867-C^^OZ=#I*!#2%P<E.#1^XSIF?XWG08=>
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M2XQ&0=9<N-W708'[A(;RH_S1Z ^T-PJ5:=_>&/U6(:>NH*NN#'C\8>X_&[2
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M[19B1YTWQ *=5O&J$T%=#?'^B&_O -R9AT^%1*Y[X;KKPI:R[ACAM3"6=17
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M.N*0544H:.$9<VJ266[6Z)!FJSP^ #&Y5S<T'?32</LLU0LPT;M%T0TRI-N
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M<U\&*0X]BEI^/B3.KY*Z^6]&+W:AZ=H^R\=.&Y<HVX9H+#>9G'&\7X6WF^2
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M6:]NN5HDH"FI-UOH1X3=HPQV900E^D3%NSJS/,18U4LP3RI+B#K(PN44X%>
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MXSPE*E0&R,B!5J1<E0&&=]68GOEM?B<CMI/C..5/;=ABQ,R%H.5IQQ>79J\
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M+,Y6R=*FJOK?RSIV8J@PB2A/+]0*P<$G/4T=C@Y24NR3:1^D=#2;3?1P*8<
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M8SB;(DYUZ*-_VY\<FFIG;QYBLO_I'%TJY9MWHHW<J;_8P4=:[CLXH DS!&0
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MBX(8(]""_8\.;E_)@(NZGZTG@;&=**<E^A,YHHKX;ZX2JH"/SN)/V%R5TI.
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M"8^$=_JSN>9MW&67K\<L+3BS7SC]:)K*O[E*"KG5KXS6\PVV2 !/]/O7>RI
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M;"=G0NH\?ZS,O>;\4>+O\ 9N,?F7UK&R6Y87[GT2!3$J&!58AZ56_7YW*L^
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MV2VQ19 JCF)+MYS2\#WUGV?%L.,WY!]!+F&]?&X-_OINJ?>@TM?:>.X@9>&
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M98 )=W3A/$V1FQJV=N\<>!\#])^6D9&;#6^)":/K=^?R^[#A&^B4Y?*SBRL
MQT$+)QUKE\]J=188[_826U.9VTW9]]<Q_85DS7XRS>]2UI_SGZQ4Y8P>J;^!
M)QX'5F!W*XHSL;/5R(49VF73+0[>:JW^W&#TP_F7M?%M,(OMR*<'Z:'UQ4!2
M72C.&H3SKH_)').,LG@,?<J^/JPG&=+GSG6::8VII;YW<1M'5JP<*0F5Z93V
M009<O/(\J2^-3O75]F7M10WJ>J-"[CP8T"T4KEVJUD>!)\'[8SZ0_8OJ"W=V
M;'N7OP@NHVLNW,718#,5%B;)']OVJ[^Y9R*V2])%T/;!"QZR6;F;-!]XG+D+
M\!*+_G6P\Z?PK6>3U8_Y0YZ/J.;R=$6*K-2@0AT2G0$_[%?%#NX12B9S\!(M
MY0M 6OB@H<SC?JH&).7THZR/5J]WLH,@]\8(>W(<U6WPT6._>IP%*G)"U$/R
MWYN!-([8Z<Y;8C"B&EU(.+ PX;[0LK-,G([.YL0.O@&V47Q*%GNR1_#U)^-L
MHX[F$!B3O *$/^E".13@H_K&=FQ')/V>_%7X(UIF97H_2ED ("PLT?.'64XV
M#]]]G#J.7*!HKAUJY"L P5.>3Q[.\!N.E+VK3LK4C;@;R&[[&/4Y_^W';LBC
M < #%,+A7-D2'CC51;-1WY3VR:<Y-Q\\]7=ZJI>O,'9BYLVY5%NV('S*GE>0
MG;S)[8GR=F6I/8$-%U+U9#4(4K#U)#2EV$PT-.'XV#CQ[P^K4*Z55&DAN9G&
M?>T\U+[QI1C>W =Q=(F<9VEFO\R6NL,*Y)C#-[2GU)L_ 8>;:([L/$M>U8U@
MOP>MY7[:T-I767&3OEM9L%3R,O\P#J_)<5K%_GP3NUE3KW#&WEAS<B]G\GXT
MJ:4<BXSQU#@HUBV:)7]1[.^_.@%I@G#-F)0>AZ^?ICD*)QIH[A"Z<+_I]3B?
M]I+GE @5(Y$&$YE" JF\]F4Z#'H(E9;+P]:D^)&'ET@59F%G@^O]"F/_H'8_
MD#14.O&[)9#+,N6RKN>NG(&/+HBFC!NO "#_L&MA%4G<HDP-11B6K#^)%M>6
MRFVL?_9 KNQ[@K?QHPQA>M?<4,_$]+]EEN?'L55#A]!W?K VG]V8X@T3:0-@
MUD"%8GNWEU@*R? GU]C< !*R'JZ@?LO+'/<837,\E#+OTP/&_K*-APF@EG?V
MGK,=S[_*AQ"[##*12T44(V[A&",7QL4N-!?UGNQUI$S66WM/2(M1YC#4F"CY
M=(2;?JY,Z*B0[66:?V&&%B:P(#,..PYCOT[A)*6 <2<LYHFJ5X";Y.&[>Y)3
MSYHF2W<H&V.RLT-M36\FTC9WBOWD[G;@J(Y%5[WYB0]9[$*/KH(!_P=[[QG4
M=/?]BT9!0 $1I'<%1*4)TJN(-!$05! "1*6&$"+2:Q[I'0$!!2G2.U)")Z%7
MD0Z2T$)O@80:((3+\_O_SWEQY[XX,_?>-V?.3+YO]EZS9\W*WFM]/KNL!0[@
M_C4)1823:IE.5HY^<1UG2N.>6=!)R7ZD$?;LSKS1_,I[,?/6IA4C024V!+SH
M91WT-O0"8 CY?BO7[HY,M4BA&9T]I;Q($E6ES 5@.E7L[:;Y"\Y<22_@2WQ7
M2MA*7<;? 5?N9.<AJ%2E$L>G><5')Y6?HT>GX%OV%X"K\W%)X+K#QG,)>,>0
MGM9Y?@UMS.-..<[)=&_L5CIGKZ.4V8!,R\QEY-J;R)'=4TP6?R/+Q,YJI5#*
M%PZO,0QWBZ-T3.&$_W,X*-Q9:]KX236SJ)1:=NIQL-F;S@R@<UN< [3W3],_
M@-04W?-4WK4.*Z$QF61\1HIXD6/R+_V%"P!]3\$W,T$S8\\/>DK4SY2D;J]L
MF*>NM<-XB4-MZ,.4<!*DP&+S^-Y(S4'U6(:8*EK/NW- H-NB=U?@/D,HX$H(
M\QG<$CYPNEUS24I 6]Z&W>,C")Z 87#J45,YLEYZ0(*ANY;L\-6L1SF^>R&$
M\6ZEZ)X<G:&\B*[GF:Z9NGUNKBKSE#/B#&<.O:E_A56H"=$<RZ!DG8"5_=IV
MD\N97=;EI17I)N'?!-*&^<0PPRJ"-42L!#THE#@ CA#-KLVX_NKCAYB5G6LZ
M BO')9S4K8-:'9WF;.'N*C[S1I.+4\[NLR9O<>;W"[R=8HHUK]I\??;RVXRN
MO,+R<$7U-DJ/C)K<,APZK-LXAV)(<@02'Z.;2-3*6/D!9$"IK^8,)_=R>LU\
MYMD3MP^Y19NYCP1OJ9=#-(D$VU+'TP^9#%NL5CP3%6K5!_.,,X(?1G?\JHI#
MZ&PT/Y2R?'_B+#ENJKD@0=&W<!;'IJLR[@DIA]1Q-A;? 3T0U)D:<#H4&%".
M,U^LD0CTV<F4"SN S#.A9XE\'>A@G]A,:Y8(O2F'V0SV_#07XW!@<:$=^O%<
M;,D*?&IGG1.R7[=Q :#,;)NOD:F+@M7<FF.9/&@1!C8FMP^8-NT%# F-<CQF
M91F(/H&&"H"['YN#;@7P0Y!<Q.\+]-3Z(_G(,?<B\9"53N@M-)-RM/,[K=^[
M3A1?'DEY%:=*M)64B;3S,1S8C2\D&-)!!%XGO[]]K?ZEO1*S._7Q4N+YF"5#
M3#-+H5=0Y]S-R9J!+:#N@4A1QML=+)C5ZU[<0+PIF O$Y_8C^I Y'5< W[L
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MOC&,_'''=O]NJ!G-_O?^=]*1K5>]+&[Z2SPAQN5OHFB=_-S=YM^-YH^:FOQ
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MCS3-B&%X<;[PT^2LJ>,MUDQO;!#V*.;NS)8PFM7VF_T*/S/?@ZV#0E.]W0L
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MV16DY^ON1>JLWK[C+.ZO;S#B(YK,S/]FR7#)9($O \/^ZT29=/L_3V%))A>
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M%L_,U1"4E96=--+IFE/R,I'YX), X)#V?6/O!A5-J"XNX-R1--453VDIJ\A
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MP?.>!F+=TGQ@,YM8L.=I;F+:@&V+1@%:SZ,2(S>;H<'T*U9@Z,]?;EZO(N<
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M !8S&.BV8L'GQ[C:>A9"5.\@?R43-]BJU*'7FC%TS^ZO6I#R]BM=FF,0RA<
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M_L6S%4E@:$/= I%4B8@\( :8=@%@)'YVIZ7[DZ5[(^HEK1P^?AE%/>PS14T
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MM.V+__D^_F.AP,SP.^[^*^I!@R""&DX,?TFRS,/^5B BK-[;PPHSJ\ST/Y9
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M;B!D3\_DK;#^1HM()[JIMKW1?.EL(OR\2?C KF%-/KZ3$3%3=NX16+O*OYX
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MQ8L^*#78IGN)9^+L^NBA,:I4L:.N$3-C^]EX0<6#"37+#_>,%QP<VHC8IEW
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M;+KQN@6(^8)*][=7)60XRQWK.LLA;F7F2KYNU1;+;;O\;E0RGUZB*1T18@<
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M?^*RZO9T+'HE3 YJ/AZ/-R[AOB-U:AGK3)[$D%SBZ_7,FP!O 5CH49(9P8;
M9?);0+T=V7)IK(CJ@NFOK<>9VMX.2476Z\LX;?%6Y^'3;Y EY< WA;'#@AK3
M\G5V33$S:^J?@EED*EG+XU]L2]-LA,R+_E9$T'=_,]U%B(Z4RI]7W]04>_!=
M/-YP^@(:\*'\HZ5S^;;> :56I+9FEO.6?M&T_\!'W=_KC8/?N)FYYK.3U@3W
M]T+W .M)SAW5U'8<_I TZC\#YY3K/KCVMX 1US.KF<N\>IP62 &*#J_^&CYI
MI3MUX#GKNKY:O9:.."2Q"0GVM\]''/VXH5_5;'&KV&D]K^#/Z',2$*EL@]7?
MN;HGVG<:*.T']UUS)7+J?#HN<!IO.>O*)Y#Y+OE9?T HWA^%#3+SQ# Y7)1'
MEU_;;K):V2Y\BZHQ 61Z4//PF?C#*)+G*I2C!-%Z;AVY,%EYK:F]''&>"N_6
MR9JY70RDU"8+<=0G2&9.@@.DZ\PI[5\]HEJL+OYLF"+9VB" 'UW$N6GM?=)$
M,^K7,XX1!\_K?D,LW@+.7:) 7AWV@<04@CRM@U5==C8#A,?'[:D)LU#%,3D"
ML']W:TV>SX/,DZX2U4FG.:_IT4] VX//]6IQ83_[U/K O?):*-$O.UDN(38/
M,R,8J0T"W\Y[5JCEQ)+3;VX&V?0SF\[GAF.84:XG)T_/P=E 012DS97M0]ZZ
M3\SC,="TR(V0A9>,T2T ;V%9N+K]L\,OJS7+18^E6@P'^,1L*H!Y78MX3V=>
MH<K1+R)CV7F2<88[/\N31UESD^T!J8;G+8 T" _B:/+;S/&MB>YVK\Y>:W+&
MAO) $=GC.(2RQ'=:T7'F4";FU)?3ISO;4R[+AJT1A\>8M1797Z./<.*HYH,+
M'6FP2IP+I9YMYC2THB4A*\E27AN;A#L.J),@>9(SV*,UK3D2@TFT4[6)4^OS
MCLG3V+-O68O\+NS-+=>=-H4%'R==CEH7/GL/.X'SUOIC1%QC2%&L,]T:N7OZ
M&;2G\S]I0SE*:(:W!?8O8YN"GWV&6P4B4E7;D?PS=92'U:4=&SL>O@YO_,;F
M%U4_$HQ4CH!INVC[)2NRFKI(2("F&?D5%NH!<[V+^^*5Y7S?M=Z-!_9$'?SX
M0DO_WB,U*VHD=+-U!UJ35[U<DIO) T[TF]@K+8$59]9TB)Z0Q 3Q3%?ORW&4
MQ%A/E-;#/8><7 I] WY.*&G"GA'^!!P *$>#@-5(ZCXB8)=B[Y5WM:N-7,,;
M)R>YE,;!/<8]S9?6UI^1 BJ,E973&)(_IIM-T:NM_G]5,#U$6%BTOJ),,0[]
MX(BQRJ17V):!R]8$"'8BQ7OE\7:I,_+K(0][3+QXLXM3UK4#[L?\ ?3!Z:-E
MM5Z]S^'FH 7!-VD.3C0">B4,PSP2CEP_%\-^EA[+JFA=&_WF[YS?O*D;M)(?
M'!D5QO)>.!]Q,^2B,"*<7CA-J?UZY]4B_CIGST.>%+:!Q7P3T(_.*D24W0)4
M3#/[UZ48(&<GS,?.#A&X5U)CN)H=W$[4Q?P CSRR@#MGA2<8<E;M]=9INZZ)
MW_7^P_JZ%"IVK,X=6MQU2RP$_"42WG5$"Z;:ZS5]DEJZ8^1]"T D.!O->9?
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M!^W\0:#\&9Q"NU++'CLF0P$<=O*^PG>@)RN#ZD2_APU0Z95=OC8KRZ2[XEI
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MK_Q(=;QPW9W7IF2%F%><OE>E%GBD$52H6_^Y;1[AA(D<HF,*!R$J7/&M')%
M<>:Y99(CEP9UL*!="O!G?NAL@>V"JIKRA0$/SKV=7E]8"+,&DCFN08/ME9C>
M#MURF)>BOUW1KC@\6G20SY4FP^0KG9?D0")N#9C%:.D>!>F+8'UK4BD2UU=*
MT8_H=:AIV0APA&<J@#E-BZ(7R^@[%VI]J6M1C3)#PQ[UR&!7.-'A[H>_"?S2
MY55F/(=R=6N:*'5[?X)W"P@HV^:K85].14M(,-RS$G>ZVM?.BYK!T'?4):JW
M(8C.)FO"(?Y>6!9%XZN_)F]VTLW#ZFB.IHS^$!04K.ISG>J$:)#V4;MF9/O2
M_'XV:LF5!^-6;X7$0+91!$P;^OYF=^N0%XV\Z%LF(,$GP=IQ\G]3"&9:U\@Z
MWUWO$1<?!<J5;3WA%TD:8)!\G?ZPRZ,-2P+JC'HOHT:]_P>[L4)TF31>Z.1:
MZE11) CX5JMNY376YX!@X<"5>S]'@#.TE' @3^TMP"N8[;A4>WHJ$[*'V-D0
MV5^[AE@EZJUUD+4S<\:@&3D_0$5Y<UZ#@192VW.ES<DI%_OX[4-;S"F!\[65
M"8#UXK= ^8>>C Y=3-(S@IX_7415.VD=X3^ES4>;%^J%<-YBK>0MECX@Z]?4
M##HX3DKQ%E!CSRF$F<H4=3&96L>1U;O+RJ6)0O;05NC,%5%>LR'TVBU J^=2
MN/?*MI/"E<')3_X\/#&B:A51[_/31F24C\Y)B+Z0WK;Y4NN7PF*37!J1:U<N
MQ50 )Q1L9#2-VYW#V=MUZ.IBFV$A]5N]]/4'!3:[+,&G)6L]%6WO@7O/8_ ?
M/^<LQZKFS,@6>V>1(P:BAPBDG;4%WOE4RM+5BT8M=5\S1,.-5D8 M[_K>B*#
ML3EE<_,$M)/-N2P4],=TL3ZTW0';((3=AMF?M35QMK);CCGO_%TSXJ;XJY?\
M')5?\<<,C3VWENG"=XV;H%PK0,*7"VC0,5QRKF7$(^3SG0$TH!1N>+&QL6+#
M.9/?O^AVW+20<D/0UAKD@S:[T8K",)/<FP<+KPY#XP4YZQ 4073WGS;Y/#.+
M?Z\16YR>'(:?[KW_XCW^.X(KW-7A_ECVF^P9G?.? 5HWF6#/]3+!*_65H7-%
M%OD^O<$1WU'3L[PGLFT!]?.?#^:>Y9G[3>YN'CUIPS2AH78;[/N3!S>0[LL\
MJJ#1'X(HM92[5>\UE3G7*EP4C_'<<RL7.7S(YF])^RF%EJR)(?[#9NCDG1:\
MZE]E3H3W^$C],OTVSK_<K?5^TP'3?:W[CLWI%I#X.?U$^,2#NAS:\%#59Y/B
MZ'J9Z[*S$Q;_%CS?U0I)#'@6F.]LZ3R[Q%.5>(^0A6!WW8EE/9TB%P:'7M[
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M% ;D?_WC\+]"'KDRM.-LMP#H!XR&!F*@AU 7O.&@G(CI?'0I*MYM<\/(A57
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MV549_M:P7/AK00LO)#:(L VQV0@CB1$I%S'[U#E*=+7(F7*\DA-2%_];U^W
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MRY=A8KZ+7M$SCD[MPI?KJ5_GS)STRF33\Q.I*]X(9&*O.@F1U<ZY6#Q.L;]
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MZQ5 ['I*9"%M+K_:3_IX)\YN =$8<D1CK$WE+H9MTO- X-IUUN500,<F^_W
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M.M,'O]'TZBR@,$UJ:UBP1^UEYY@>/T-[ Y??#7&-KRX/W*!):@!<?_12#3P
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M-;I+.5,*E>6^_DZJB#.U)6_ +WNS4M:1T2MK!?!.Y@[FF]_?V?M7')9&!Z>
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MR_8OVW^N+?R>0'Q5<6FP5EZ,*/WIY'\!4$L#!!0    ( "PYL%2$M$\&CHL
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MWX*=)H(P,\1R1GUQ$N$6W).$WL6"&H"]'VTD,NQQ%'N^>\2Y W"_'_"R0G$
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M]'3<";T.G$,_2@]HY]4KTZ.T2X<^;%#1@IUMQ4R^P*K)A,6^%+(%M(J5R;)
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MB' B?GQ/BCK%G("H9:L.X)445A4L3,Y!3H.TO4*_,;Q96QH.EKJ,TB&)NH
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M&O7ZAYL*X\8"^T[L'I/MZ_3QWU!+ P04    "  L.;!4K[V$A8T%  "+%P
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MMY;Q-.<L@W,NL1YS/'"59;A)6Q0L^\:\#B *+-D D@S/-E;A9@?%ZNNH*NL
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M]3.S>[<^_AM02P$"% ,4    "  L.;!4R E;#W8,  # 9@  $
M    @ $     <&QX+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( "PYL%3K-G+>
M?PH  $R$   4              "  :0,  !P;'@M,C R,C S,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( "PYL%0^8E!+JQP  (B7 0 4              "  547
M  !P;'@M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( "PYL%01HR7&ZC@
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M;'@M,C R,C S,S%X,3!Q,# W+FIP9U!+ 0(4 Q0    ( "PYL%0UVXT+80@
M +,F   7              "  ?4_!0!P;'@M,C R,C S,S%X97@S,60Q+FAT
M;5!+ 0(4 Q0    ( "PYL%0A*#@?= @  !LH   7              "  8M(
M!0!P;'@M,C R,C S,S%X97@S,60R+FAT;5!+ 0(4 Q0    ( "PYL%0$W?2Q
MB@4  '$7   7              "  311!0!P;'@M,C R,C S,S%X97@S,F0Q
M+FAT;5!+ 0(4 Q0    ( "PYL%2OO82%C04  (L7   7              "
M ?-6!0!P;'@M,C R,C S,S%X97@S,F0R+FAT;5!+!08     #0 - &L#  "U
%7 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
